Best practice guidelines to monitor and prevent hearing loss related to drug resistant tuberculosis treatment by Haumba, Samson Malwa
BEST PRACTICE GUIDELINES TO MONITOR AND PREVENT 
HEARING LOSS RELATED TO DRUG RESISTANT TUBERCULOSIS 
TREATMENT 
 
by 
 
 
SAMSON MALWA HAUMBA 
 
 
submitted in accordance with the requirements for the degree of  
 
 
DOCTOR OF LITERATURE AND PHILOSOPHY  
 
in the subject 
 
HEALTH STUDIES  
 
at the 
 
UNIVERSITY OF SOUTH AFRICA 
 
 
SUPERVISOR: PROF. TMM MAJA 
 
 
 
June 2015 
 
 
 
DEDICATION 
 
 
In memory of my late father, Yutuko Manuel Haumba Malwa, wishing he could 
have been here.  I owe my beginnings, foundation and achievements to him, for 
what he stood for, and what he wanted me to achieve. He always inspired me in all 
aspects of my life. 
 
To my dear mother, Edith Mary Malwa, to Timothy Emmanuel Haumba Malwa, my 
son and his siblings Samantha Haumba, Tracey Haumba,  Ruth Haumba and to my 
beloved wife, Eunice Marion Twongyeirwe Haumba for their love, 
encouragement and relentless support in making the research project achieve its 
intended objectives. 
 
To the Almighty, my God, who has carried me through all the challenges, 
sometimes bringing a smile to my face, even in the very difficult and trying 
moments of this study.  To know Him and to know that He is able, He is good all 
the time, and that the glory is His, has been an inspiration throughout my life’s 
journey. 
  
 
 
 
                                               DECLARATION 
 
STUDENT NUMBER: 356-0280-3 
 
I declare that BEST PRACTICE GUIDELINES TO MONITOR AND PREVENT 
HEARING LOSS RELATED TO DRUG RESISTANT TUBERCULOSIS 
TREATMENT is my own work and that all sources that I have used or quoted 
have been indicated and acknowledged by means of complete references.  
 
 
 
Signature:                                                                14 June 2015 
(Mr Samson M. Haumba)                                         Date 
 
 
  
 
 
ACKNOWLEDGEMENTS 
 
This thesis would not have been possible without the guidance and support from 
many people and institutions. I want to thank the following persons for their 
respective contributions to this thesis:  
 
My wife, Eunice Haumba, for her unconditional love, support, encouragement and 
patience and my four children, Samantha, Tracey, Timothy and Ruth, for their 
support and understanding. Despite their limited understanding of what it means to 
undertake a PhD have walked the journey with me until the end. I am also grateful to 
the retired Bishop of Bukedi, Dr Nicodemus Okille, a spiritual leader, a personal 
friend, and intellectual who was always available to me and my family for counsel 
and also provided encouragement, support and prayers;  
 
Special thanks go to my supervisor, Prof Todd Maja, for her guidance, support and 
encouragement. ‗How are you coping?” became a familiar source of inspiration from 
Prof Maja. Prof Maja who always guided me with a calm and tenacious firm resolve. 
Through her encouragement, I was able to fix my eye on the prize even when the 
going got very tough. I truly appreciate.  
 
My colleagues at University Research Co., LLC (URC), Dr Munyaradzi Pasipamire, 
Dr Arnold Mafukidze, Ms. Nomcebo Fakudze, Mr. Tafuma Zanamwe, Ms. 
Makhosazana Matsebula, Ms Sphesihle Dlamini and Dr Kelly Clarke for the support 
they provided at different stages in the conduct of the study; and the URC Senior 
Vice President, Dr Neeraj Kak and the Regional Vice President, Dr Refiloe Matji, for 
their understanding and for allowing me to undertake this work while maintaining my 
work portfolio. I am also grateful to Dr Victoria Kisaakye Kanobe of UNESCO for 
editorial advice. 
 
I am also grateful to the entire Ministry of Health of Swaziland, including the Director 
of Health Services and the Deputy Directors (Clinical and Public Health), for giving 
me permission to conduct the study and also being physically present at the 
dissemination of the study results and draft guidelines. My gratitude also goes to Mr 
Themba Dlamini, the National TB control Programme Manager for endorsing and 
 
 
supporting the study and staff of the National TB Hospital especially Drs Kamal  
Mohammed, Adnan Shabangu and Semetlane for their leadership and support during 
data collection and to the Medical Officers and nurses at the national TB hospital for 
the understanding and support.  Special thanks to Sister Eunice Simelane, who 
together with Nomcebo Fakudze participated in the establishment of an audiology 
unit within the hospital making it possible for the study to be conducted and for 
participation as a research assistant. Nomsa Mabaso, Sikhumbuzo Simelane and 
Sixolelwe Hlatshwayo, the staff at the ENT department in Mbabane and Piggs Peak 
are very much appreciated as well for their participation in the development of the 
guidelines, advocacy for the services and in the dissemination and stakeholder input 
in the draft guidelines. 
 
Most sincerely, I am grateful to the patients receiving MDR-TB treatment at all the 
study sites who served as study respondents and giving me an opportunity to study 
the phenomenon of MDR-TB related hearing loss, but above all, they were my 
inspiration to conduct this study and make a contribution towards improving hearing 
health care and post treatment quality of life. 
 
Finally, I acknowledge the Africa Doctoral Dissertation Fellowship managed by 
APHRC and IDRC for the partial funding of the research work. 
 
  
 
 
 
BEST PRACTICE GUIDELINES TO MONITOR AND PREVENT HEARING LOSS 
RELATED TO DRUG RESISTANT TUBERCULOSIS TREATMENT 
 
STUDENT NUMBER:       35620803 
STUDENT:                        SAMSON MALWA HAUMBA 
DEGREE:                          DOCTOR OF LITERATURE AND PHILOSOPHY  
DEPARTMENT:                HEALTH STUDIES  
SUPERVISOR:                 PROF. TMM MAJA 
 
 
ABSTRACT 
 
The purpose of the study was to develop best practice guidelines to prevent 
permanent hearing loss associated with the management of multi-drug resistant 
tuberculosis (MDR-TB) through raised awareness and monitoring. The Human 
Immunodeficiency Virus (HIV) and MDR-TB are global public health problems 
requiring urgent scale-up of treatment services. Irreversible sensorineural hearing 
loss (SNHL) is one of the adverse drug reactions of the current World Health 
Organization (WHO) recommended MDR-TB chemotherapy fuelling another public 
health problem, that disabling hearing loss, which is the second highest contributor of 
Years Lived with Disability (YLD) according to the World Health Report (2003). 
Expansion of MDR-TB treatment threatens to increase incidence of SNHL unless 
there is urgent implementation of intervention towards preservation of hearing for 
patients on treatment. This empirical study determined and documented the 
incidence of SNHL in HIV positive and HIV negative patients on MDR-TB treatment, 
the risk factors for SNHL, from the time treatment initiation to SNHL. Based on the 
findings, developed and improved the understanding of best practice guidelines for 
monitoring and prevention of MDR-TB treatment-related SNHL.  
 
The empirical study recruited a cohort of 173 patients with normal hearing status, 
after diagnosis with MDR-TB and enrolled on MDR-TB therapy over thirteen month 
period. Patients in the cohort received monthly hearing sensitivity testing during the 
intensive MDR-TB therapy when injectable aminoglycoside antibiotics are part of the 
treatment regimen.  The three study endpoints included completion of the eight-
month intensive treatment phase without developing hearing loss, development 
incident hearing loss or loss to follow up. Data was analysed using STATA statistical 
software and summarised using frequencies, means, proportions, and rates. The 
study documented incidence of SNHL, time to hearing loss and risk factors for 
 
 
hearing loss.  Recommendations to prevent and monitor hearing loss are made 
based on the the study findings. 
 
Key concepts 
 
Sensorineural hearing loss, cochleotoxicity, multi drug resistant tuberculosis, 
aminoglycoside antibiotics, Audiometry, incidence, time-to-event, best practice 
guidelines, prevention, monitoring. 
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Neuman‘s Systems Model 
OAE Otoacoustic Emissions  
OHS Occupational Health and Safety 
ONIHL Occupational Noise-Induced Hearing Loss 
PHPs  Personal Hearing Protectors 
PLHIV People Living with HIV 
PRN 
Pro re nata (from Latin) As needed.  Decision on when 
to administer drug is left to nurse, care giver of patients 
prerogative  
PTA  Pure Tone Average  
PTB  Pulmonary Tuberculosis 
PZA Pyrazinamide 
RTC  
RNID 
Return To Clinic    
Royal National Institute for Deaf and Hard of Hearing 
People 
SAT 
SIDS 
Speech Awareness Threshold 
Swaziland Demographic and Health Survey 
SLD  Second Line Drugs [TB] 
S/N-SIFTER  Signal-to-Noise (ratio) SIFTER  
SNHL Sensorineural Hearing Loss 
SPL Sound Pressure Level 
SRT Speech Reception Threshold 
TB Tuberculosis 
TDF Tenofovir 
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Trizivir  Abacavir/Lamivudine/Zidovudine 
UCL Uncomfortable Loudness Level 
UHL  Unilateral Hearing Loss  
VT Vibrotactile Response 
WHO  World Health Organization 
WNL Within Normal Limits 
WRD  WHO Recommended rapid Diagnostics [TB] 
XDR Extensively drug resistant 
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LIST OF DEFINITIONS AND DISTINCTIONS OF TERMS USED IN THE STUDY 
 
Age-related hearing loss:  Loss of hearing that progresses with age. Also known as 
presbycusis. 
 
Assistive Device: An Assistive Device is any device that helps someone do 
something that they might not otherwise be able to do well or at all. Generally, the 
term is used for devices that help people overcome a handicap such as a mobility, 
vision, mental handicap, and dexterity or hearing loss.  
 
Audiogram: An Audiogram is a means of recording the results of a hearing test. It 
will include a table and a graph for each ear showing how well someone could hear 
sounds at various frequencies. This graph dominates the Audiogram and measures 
the lowest volume that someone can hear pure tone signals at different frequencies 
for each ear. 
 
Audiometry: A test to measure an individual‘s hearing threshold level. 
 
Auditory Brainstem Response (ABR): A test that is used to screen or to diagnose 
hearing loss. The ABR evaluates the nervous system response to sound. 
 
CD4: A glycoprotein that serves as a differentiation antigen found on the surface of T 
lymphocytes and macrophages.  The CD in CD4 stands for cluster of differentiation. 
The presence of CD4 characterises the helper/inducer cell. It also serves as HIV 
receptors where the virus binds directly with its envelope protein, gp120. 
 
Cochlea: The cochlea is the sense organ that translates sound into nerve impulses 
to be sent to the brain. Each person has two cochlea, one for each ear. The cochlea 
is a fluid-filled, snail-shaped cavern in the mastoid bone of your skull behind each 
ear. Tiny bones in the middle ear transmit sound from the eardrum across the middle 
ear and vibrate against the cochlea. Vibrations in the fluid cause tiny hair cells in the 
fluid inside the cochlea to vibrate and generate nerve impulses that then travel to the 
brain. 
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Decibel: The unit used to indicate the relative magnitude of sound pressure level and 
other acoustical quantities, abbreviated as ‗dB‘. A decibel, or dB, is an appraised 
signal strength in terms of relative loudness heard by the ear. The decibel is 1/10 of a 
bel, a unit of sound named after Alexander Graham Bell. A change of 1 dB is just 
detectable as a change in loudness under ideal conditions. The decibel is a relative 
unit.  
 
deaf (lower case “d”): In this uncapitalised form, the word "deaf" simply means 
unable to hear. It says nothing about the individual, the individual's language or 
culture. Some deaf people also consider themselves "Deaf" with a capital "D", which 
does imply a lot about their language and culture. Technically, Deaf people, some 
hard of hearing people, and all late deafened people, are deaf.  
 
Deaf (Upper Case "D"): In this capitalised form, the word "Deaf" generally implies 
that the person does not hear well enough to understand speech from their hearing 
alone, but it also means that they consider themselves part of the "Deaf Community". 
People in the "Deaf Community" typically use sign language. 
 
Frequency: The number of cycles per second (Hertz) (abbreviated as, Hz) of 
anything that oscillates is called the "frequency". The electricity of an AC wall outlet is 
said to have a frequency of 60 Hertz as it cycles negative and then positive, 60 times 
each second.  
 
Full Diagnostic Audiologic Testing: An in-depth evaluation of hearing using 
different tests to determine if a hearing loss exists. If a hearing loss is identified, the 
evaluation determines the type, degree, and configuration of the hearing loss. 
 
Hair cells: Hair cells in the cochlea are moved by the vibrations of the cochlea and of 
the fluid in the cochlea caused by sound waves. The cells at the base of the hair cells 
convert their motion into electrical signals to be sent up the acoustic nerve to be 
interpreted by the brain as sound. Actually, the hair cells are not really hair; but they 
behave somewhat like hair might. Damage to hair cells (or the lack of them) is one of 
the major causes of hearing loss. 
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Hearing aid: A hearing aid is anything that helps you to hear better than before. 
Early hearing aids were mechanical, and typically involved horns or funnels and 
tubes to direct sound into a person's ears. 
 
Hearing impairment:  Hearing loss that causes some degree of disability. 
 
Hearing loss: Reduced ability in a person to detect sound. 
 
Hearing screening: An objective screening method performed to identify who may 
have hearing loss and who need follow up or more in-depth diagnostic hearing loss 
assessment  
 
Hearing threshold level: The quietest sound a person can detect at a particular 
frequency relative to young people with normal hearing. 
 
Incidence: Number of new cases of disease or condition of interest of during a 
defined period. 
 
Intervention: A programme, strategy, or specific measure aimed at eliminating or 
minimising a risk. 
 
Noise: Any unwanted or damaging sound. 
 
Occupational noise: Noise experienced in the workplace. 
 
Organ of Corti: The spiral structure within the cochlea which contains the hair cells 
which convert the vibrations representing sound into nerve impulses. 
 
Otoacoustic emissions (OAEs): A screening method that measures sounds made 
by the sensory cells in a healthy ear that can be recorded from the ear canal. For 
screening purposes, the test is fully automated. 
 
Ototoxic drugs: Ototoxic drugs are drugs that can cause temporary or permanent 
hearing loss. They can also make an existing hearing loss worse. They may also 
cause other related problems including such things as: tinnitus, hyperacusis, 
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pressure in the ear, ceruminosis, dizziness, vertigo, ataxia, nystagmus, oscillopsia, 
ear pain, auditory hallucinations, various eye problems, or muscle pain in the neck.  
 
Presbycusis: refers to hearing loss related to age. It is also referred to as age-
induced hearing loss. Age, itself, does not cause hearing loss, but the prevalence of 
hearing loss does increase with age.  
 
Sound: Energy in the form of pressure waves that move through air and other media 
and are capable of exciting the sensation of hearing in a listener. It is an oscillating 
wave, but it has a broad range of frequencies. A low frequency sound (say, 50 Hz) 
might sound like a low rumble, while a high frequency sound (say 12,000 Hz), might 
sound more like a "sizzle". A person with normal hearing can hear all the way up to 
about 20Hz to 20,000 Hz. 
 
Sound pressure level: The relative magnitude of sound pressure expressed in 
decibels referenced to 20 micropascals. 
 
Temporary threshold shift: Temporary hearing loss, usually as a result of short-
term exposure to loud noise.  
CHAPTER 1 
 
ORIENTATION TO THE STUDY 
 
1.1. INTRODUCTION 
 
This chapter focuses on the exposition of the problem, the research objectives, 
research questions and the salient methodological and ethical considerations. It 
provides the basis for the research problem and the scope of the research, given 
that the reasons for undertaking the study link closely to the principles of the 
research problem. The chapter reflects these in the description of the problem and 
its background including the socio-economic and the policy importance of this 
investigation.  
 
Tuberculosis, or TB, is an infectious bacterial disease caused by Mycobacterium 
tuberculosis. According to World Health Organization, in 2012, worldwide, 450,000 
and 170,000 people developed and died multi drug resistant TB (MDR-TB), one of 
most serious and urgent public health challenges of the 20th century (Upshur, Singh 
& Ford 2009:481; WHO 2013). Multidrug-resistant tuberculosis (MDR-TB) is TB that 
does not respond to at least isoniazid and rifampicin, the two most powerful anti-TB 
drugs (Chiang, Centis & Migliori 2010:413). Marginal evidence shows an increase in 
the risk of MDR-TB among people with HIV infection (Mesfin, Hailemariam, 
Biadgilign & Kibret 2014). Treatment outcomes for MDR-TB are poorer than for drug 
susceptible TB and adversely affected by the longer duration of treatment, serious 
side effects and high costs (Araújo-Filho, Vasconcelos-Jr, Sousa, Silveira, Sousa, 
Severo, Vieira, Kipnis & Junqueira-Kipnis 2008:94).  Wu, Zhang, Sun, Chen, Zhou, 
Wang and Zhan (2013) report that pooled estimate of 70.4% of patients on MDR-TB 
treatment required a change in their treatment because of adverse drug reactions. 
Disabling hearing loss is one such severe drug adverse reactions affecting outcomes 
(Javadi, Abtahi, Gholami , Safari Moghadam , Tabarsi & Salamzadeh 2011:905-11; 
Modongo, Sobota, Kesenogile, Ncube, Sirugo, Williams & Zetola 2014). There is no 
other period in recent history when there was such an urgent search for new and 
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safer anti-tuberculosis medicines than in the post 2000 era (Nathan, Gold, Lin, 
Stegman, de Carvalho, Vandal, Venugopal & Bryk 2008:S25-33; Orme 2001:1943)   
 
The Agency for Healthcare Research and Quality identifies the minimisation of 
treatment-related adverse events (AEs) or harms, as patient safety practice and 
defines patient safety as: 
 
“A type of process or structure whose application reduces the probability of 
adverse events resulting from exposure to the health care system across a 
range of diseases and procedures‖  
 
-(Shojania, Duncan, McDonald, Wachter & Markowitz July 2001:1998-2005).  
 
To this end, a proportion of patients treated for MDR-TB have to contend with the 
consequences of an irreversible toxicity, literally ―separating them from their loved 
ones and from their communities‖ because of a new identify as hearing-impaired.   
 
“Blindness separates people from things; deafness separates people from people.” 
 
― Helen Keller (Keller, [Sa]) 
 
The status quo prevails because:  
 Injectable aminoglycoside antibiotics are a backbone in the MDR-TB 
treatment regimen and increased duration of the injectable aminoglycoside is 
associated with improved treatment outcomes  (Caminero, Sotgiu, Zumla & 
Migliori, 2010:621-9; Modongo et al 2014; World Health Organization, 
2011b:6, 16-22).  
 The second line anti-tuberculosis treatment (ATT) available for treatment of 
MDR-TB are limited in number (Caminero et al 2010:621).  
 The serious adverse reactions of MDR-TB treatment like ototoxicity 
(comprised of vestibulotoxicity and cochleotoxicity) and specifically the 
irreversible sensorineural hearing loss (cochleotoxicity) have not been 
investigated adequately, there is lack of high quality clinical data to inform 
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guidelines and  modifiable risk factors are largely unknown, or seldom 
reported in studies (Bloss, Kuksa, Holtz, Riekstina, Skripconoka, Kammerer & 
Leimane 2010:275-81; Javadi et al 2011:906-10; Sturdy, Goodman, Jose, 
Loyse, O'Donoghue, Kon, Dedicoat, Harrison, John, Lipman & Cooke 
2011:1815).  
 Cutting prevalence and death rates due to MDR-TB through expansion of 
treatment is arguably a more important goal in the short-term (World Health 
Organization 2011b:5).  
 
Given that universal treatment of MDR-TB patients is critical and, will most likely, 
escalate the burden of SNHL in the country in the absence of better drugs, 
interventions aiming at prevention and hearing conservation are critical contributions 
in improving quality of life of MDR-TB patients and their families. The WHO has 
heighted awareness about disabling hearing impairment in the past, as is still doing 
so today. In 1995 through a World Health Assembly resolution, WHA48.9, disabling 
hearing loss was tagged as a new public health problem (Resolution 1995). 
According to the WHO, the number of people with such impairment increased from 
42 million in 1985, to about 420 million in 2011 (Olusanya, Neumann & Saunders 
2014b).  The cost of rehabilitative services is so high and primary prevention is 
emphasised. Deliberate effort is required to stop the silent progress of hearing loss 
associated with MDR-TB treatment through monitoring any deterioration in hearing 
sensitivity and implementation of interventions that preserve hearing and 
communication functionality. Public health actions are early detection and prompt 
action (Ahmad & Mokaddas 2009:1777; Guthrie 2008:91; Wu et al 2013;Yew 
2011:9).  
 
The sense of hearing is essential for enabling us to live and participate in life more 
fully, first and far most.  Good hearing also helps to keep us safe, by warning us of 
potential danger.  Therefore, post lingual and adult onset loss of hearing can be a 
very devastating and life-changing experience for patients, affecting the way they 
communicate, relate, perceive self, earn a living and/or are perceived (Ask, Krog & 
Tambs 2010:271-275; Morris, Quezada, Bhat, Moser, Smith, Perez, Laniado-
Laborin, Estrada-Guzman & Rodwell 2013:954; Wallhagen 2004:S190-119; 
Wallhagen 2010:66-75).  The impact of adult onset hearing loss can also have 
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profound effects on the victim and the family members. Shannon describes her 
personal experience with hearing loss: 
“Deafness, however, left me and those around me at a loss. I had always taken 
hearing for granted. I was a musician and my training, my dreams and my life, 
revolved around music. Now all I had left was a distorted form of inner noise...” 
 
- Shannon (2006:6) 
 
In Swaziland, Groce, Yousafzai, Dlamini, Zalud and Wirz (2006) and Groce (2003) 
found that the majority, (99%) of deaf people, report difficulties in communicating 
with healthcare facility staff affecting their utilisation of health preventive and curative 
services. In another study, the deaf population in Swaziland was more likely to 
believe in incorrect modes of HIV transmission than the normal hearing population 
(Groce, Yousafzai, Dlamini, Zalud & Wirz 2006:319-324; Groce 2003:1401-1402). 
Yet hearing preservation, and if possible restoration of hearing in affected MDR-TB 
patients, can mean a big change in the quality of life of the individual and their 
families (Ask et al 2010:271-5; Lotfi, Mehrkian, Moossavi & Faghih-Zadeh 2009:265-
70; Newberry 2011:S24-6).   
 
1.2 BACKGROUND INFORMATION ABOUT THE RESEARCH PROBLEM  
 
1.2.1 Source of the Problem 
 
Swaziland has a population of about 1.2 million inhabitants and a very high per 
capita burden of HIV and TB.  Recent statistics show that about 31% of the adults 
aged 18-49 years are living with HIV infection. Coupled with the high HIV rate is the 
high HIV related TB incidence. About 13 people in 1000 develop tuberculosis 
disease every year, and 80% of those developing TB are HIV infected (Bicego, 
Nkambule, Peterson,  Reed, Donnell, Ginindza, Duong, Patel, Bock, Philip, Mao & 
Justman 2013; Central Statistics Office (CSO) [Swaziland] and Macro Inc, 2008:221-
222; World Health Organization 2012). Closely linked with the high HIV and TB per 
capita burden is the country‘s MDR-TB rate which is 7.7% in new TB patients (higher 
than the global average of 3.5% among new TB patients) and 33.9% among 
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previously treated TB patients (Sanchez-Padilla, Dlamini, Ascorra, Rusch-Gerdes, 
Tefera, Calain, de la Tour, Jochims, Richter & Bonnet 2012:29-37; World Health 
Organization 2014b). Hedt, van Leth, Zignol, Cobelens, van Gemert, Nhung, 
Lyepshina, Egwaga & Cohen (2012:293-300) define thresholds for low and high 
prevalence of MDR TB as 2% or less and 10% or higher among new cases, 
respectively. According to the Swaziland Ministry of Health annual report of 2013, 
the annual number of cases initiated on MDR-TB treatment increased from 54 cases 
in 2007 to 562 in 2012. The incidence of MDR-TB is likely to continue increasing, an 
indication that more and more patients will be exposed to potentially cochleotoxic 
medications resulting in more cases of MDR-TB related sensorineural hearing loss 
(NTCP 2013). 
 
Cure, prompt initiation of treatment, avoiding acquisition of resistance and survival 
are the top four priorities for MDR-TB control (World Health Organization, 2011b:5).  
However, the long-term aim of MDR-TB control is to eliminate new cases (Gandhi, 
Nunn, Dheda, Schaaf, Zignol, van Soolingen, Jensen & Bayona 2010:1830-43). To 
that end, the WHO guideline development group ranks avoiding toxicity and adverse 
drug reactions associated with MDR-TB as a number 14 priority in the 
recommendations for a treatment regimen (World Health Organization 2011b:5). 
While WHO also recommends pharmacovigilance, monitoring adverse events 
among MDR-TB patients as a safety prerequisite, most MDR-TB treatment 
programmes lack hearing status monitoring equipment and personnel and there is 
no high quality data to inform guidelines (Sturdy et al 2011:1815).  
 
1.2.2 Background to the research problem 
 
Research and anecdotal evidence suggest that treatment of MDR-TB is be 
associated with significant adverse drug reactions (ADRs) as elaborated in section 
1.1. Yet ADRs to treatment are inadequately reported by patients and health care 
workers (Lopez-Gonzalez, Herdeiro & Figueiras 2009b:19-31). The main barriers for 
reporting ADRs are ignorance about ADRs, indifference about reporting ADRs, 
complacency, and lack of guidelines and structures (Lopez-Gonzalez et al 2009b:19-
31; Sturdy et al 2011:1815).  Lack of recognition of sensorineural hearing loss during 
MDR-TB treatment due to the high cost of audiometry equipment and lack of skilled 
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personnel to conduct audiometry is a major contributor for underreporting SNHL 
(Fausti, Wilmington, Helt, Helt & Konrad-Martin 2005; Jacob, Aguiar, Tomiasi, 
Tschoeke & Bitencourt 2006:836-44; Javadi et al 2011:906; Merriam-Webster 
Medical dictionary [Sa], Sturdy et al 2011:1815-1820). Coleman, Ferner and Evans 
(2006:371-372) underscore the importance of a systematic monitoring health status 
and reporting any ADRs during treatment as the process of proactive targeted 
observation, analysis and action in order to avoid or mitigate harm from adverse drug 
reactions. 
 
1.3 THE RESEARCH PROBLEM  
 
The analysis of the research problem deals with becoming aware of the problem, a 
preliminary literature study to investigate the problem and finally, formulation of the 
research problem statement.   
 
1.3.1 Awareness of the Problem 
 
The researcher become aware of the problem because of his involvement in the 
management of MDR-TB patients since 2006. As a public health physician involved 
in the management of patients with multi drug resistant tuberculosis, the researcher 
interacted with many patients who developed hearing loss while on MDR-TB 
treatment. Each patient, with a heart-breaking story. Relatives expressed concerns 
about the changed identity of their loved ones.  Linda is one of the MDR-TB patients. 
She notes..:  
 
“Losing my hearing was very difficult for me…but I tried to be positive about it, 
telling myself that the doctors knew what they were doing. Eventually I 
accepted that this was the price I had to pay for my health”  
 
-Linda (MSF, August, 2013). 
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1.3.2 Preliminary questions 
 
The awareness increased the sentience of the following questions about hearing 
loss related to MDR-TB treatment: 
 
 What is the incidence of sensorineural hearing loss among MDR-TB patients 
receiving MDR-TB treatment in Swaziland and who is affected, when are they 
affected, what factors are associated with development of SNHL?  
 What are best practices for monitoring and prevention of MDR-TB treatment 
related hearing loss?  
 
1.3.3 Policy Relevance of the Research  
 
The detection of preventable adverse events is a primary step in achieving a safe 
healthcare system (Forster, Worthington, Hawken, Bourke, Rubens, Shojania & van 
Walraven 2011:756; Steinman, Handler, Gurwitz, Schiff & Covinsky 2011:1513-20; 
World  Health Organization 2005, 2010b). Many settings including Swaziland lack 
local evidence to address the questions in section 1.3.2. The research findings can 
play a catalytic role in increasing awareness of MDR-TB treatment related hearing 
loss among the key decision and policy makers. Among others, key policy makers 
include the directors and managers in the Ministry of Health, in the Ministry of 
Education, in the department of Social welfare in the Prime Minister‘s office, in the 
relevant health care service organisations as well as members of the legislature and 
sectoral committee on health.  Other stakeholders involved in guideline development 
and policy formulation are the clinicians and health management committees. The 
aforementioned policy makers are responsible for making, laws, creating a 
conducive environment for policy dialogue and legislation as recommended by the 
World Health Assembly resolution WHA.48.9 of 1995. 
 
Policy makers engage in a wide range of health care concerns such as health care 
costs, disease burden and treatment effectiveness. They can effectively address the 
concerns aforesaid concerns if there is contemporary data to drive the public health 
urgency to do something. (Armstrong,  Waters, Dobbins, Anderson, Moore, 
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Petticrew, Clark, Pettman, Burns, Moodie, Conning & Swinburn, 2013; Atun, de 
Jongh, Secci, Ohiri & Adeyi 2010:104-11).  
 
The absence of programmatic and research data on the social, economic, morbidity 
and disabling disability burden as evidence for planning decisions may hamper the 
desired and appropriate response by policy makers to do something about MDR-TB 
treatment related hearing loss. From the social perspective hearing impaired persons 
require specialised educational, social services and other resources in order to 
function in society (Mohr, Feldman, Dunbar, McConkey-Robbins, Niparko, 
Rittenhouse & Skinner 2000). From the economic perspective the costs for hearing 
aids can put a strain on the Ministry of Health budget given the costs about $1800-$ 
6800 per hearing aid which lasts for only 4-6 years and maximum benefit occurs if 
the hearing aids are introduced when the hearing impairment is mild to moderate 
(Donahue, Dubno & Beck 2010:3-4). While from a health care access perspective, a 
number of studies suggest that barriers for prevention of MDR-TB related hearing 
loss result from of lack of conducive policy environment, guidelines, equipment and 
skilled personnel (Javadi et al 2011:906; Seddon, Godfrey-Faussett, Jacobs, 
Ebrahim, Hesseling & Schaa, 2012).  
 
While hearing health care access is not universal even in the most developed 
countries, anecdotal evidence suggests that in Swaziland, the burden of MDR-TB 
treatment related hearing loss is unknown to the policy makers and neither are the 
resources needed to increase accessibility and affordability of hearing preservation 
(Donahue et al 2010:2-6; Sturdy et al 2011:1815). Research evidence is a powerful 
tool for advocacy with policy makers because it enables them to make the right 
policy decisions and the desired resource allocations to address the existing health 
systems challenges. Best practice research evidence also occupies the moral high 
ground because its practitioners do ―what works‖ and generates contemporary data 
to drive clinical practice (Murthy, Shepperd, Clarke, Garner, Lavis, Perrier, Roberts & 
Straus 2012). 
 
This study developed a technical briefing report and best practice guidelines. Among 
the most frequent sources was advice from an expert and consulting technical 
reports. Summaries from systematic reviews and technical documents also enable 
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ease with which the policy makers access evidence (Dobbins, Jack, Thomas & 
Kothari 2007; Zardo & Collie 2014). The presentation of a technical report and 
guidelines is one way to encourage policy makers‘ access research evidence about 
hearing loss and encouraging greater use of this evidence to do something about 
hearing preservation in MDR-TB patients.  
 
1.3.4 Statement of the Problem 
 
Every year, MDR-TB and HIV contribute significantly to mortality and morbidity in 
Swaziland. Anecdotal evidence suggests that the role out of MDR-TB treatment as a 
response to the threat MDR-TB poses of public health is also associated with a rising 
incidence of MDR-TB treatment related hearing loss. Numerous studies conducted in 
other parts of the world confirm the association of hearing loss and the 
aminoglycoside antibiotics used in the intensive phase of MDR-TB treatment. A 
closer examination of the situation reveals that the while the current MDR-TB 
guidelines mention performance of audiometry of patients presenting with hearing 
loss, they provide little guidance on how to detect ototoxicity before overt hearing 
loss and how to prevent or minimise development of hearing loss associated MDR-
TB treatment in the first place.   
 
There is a clear gap in the knowledge of the burden of MDR-TB treatment related 
hearing loss and the associated factors.  The lack of local studies on hearing loss in 
the context of the dual epidemic of MDR-TB and HIV further exacerbates the 
knowledge gap. For instance, the unknown impact of HIV infection on the incidence 
of hearing loss related to MDR-TB treatment exposes a major gap in the evidence 
base for guidelines development (Seddon et al 2012; Sturdy et al 2011:1815; World 
Health Organization 2011c). The generation and use of high quality data to 
recommend guidelines and for advocacy with policy makers and donors has the 
potential for catalyst action for additional investments in hearing health and quality of 
life for MDR-TB patients.  
 
The design of the study contributes to a deeper and clearer understanding of the 
situation regarding MDR-TB treatment related hearing loss and the risk factors, so 
that health care workers and stakeholders are in a better position to initiate remedial 
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measures. This research addresses both the gap in clinical data and evidence for 
the urgent call to action on monitoring hearing loss and provides best practice 
guidelines to guide establishing an ototoxicity program. It also provides an empirical 
framework for integrating hearing loss monitoring and hearing preservation actions 
within the health system in Swaziland (Atun et al 2010:104; Geib 2002:235; Sturdy et 
al 2011:1815).  
 
1.4 AIM OF THE STUDY 
 
1.4.1 Research Purpose 
 
The purpose of the research was determine the incidence of  sensorineural hearing 
loss associated with MDR-TB treatment, the risk factors for hearing, time from 
treatment initiation to development of hearing loss and to develop best practice 
guidelines for prevention and monitoring hearing loss associated with MDR-TB 
treatment in Swaziland. The aim of the best practice guidelines is to contribute to 
strengthening institutional capacity for prevention of hearing loss, ototoxicity 
monitoring and early identification of SNHL to facilitate of timely remedial actions 
aimed at preservation of communication. 
 
1.4.2 Study Objectives  
 
The specific objectives of the study were to: 
 
 Establish the incidence of sensorineural hearing loss among MDR-TB patients 
during the intensive phase of MDR-TB treatment in Swaziland. 
 Identify risk factors for sensorineural hearing loss during the intensive phase 
of MDR-TB treatment in Swaziland. 
 Determine the impact of HIV/AIDS influences the incidence of sensorineural 
hearing loss in MDR-TB patients in Swaziland. 
 Assess the time it takes from start of intensive MDR-TB treatment to the 
development of hearing loss and recommend the optimal frequency for 
audiometric monitoring of patients on MDR-TB treatment in Swaziland. 
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 Develop best practice guidelines for prevention and monitoring MDR-TB 
related hearing loss in Swaziland. 
 
1.4.3 Study Hypotheses 
 
In the study, it is hypothesised that: 
 
Study hypothesis 1: 
 
The incidence ratio of sensorineural hearing loss during the intensive 
phase of MDR-TB treatment increases proportionally with the duration 
of treatment. 
 
Study hypothesis 2 
 
MDR-TB patients living with HIV infection have a higher incidence ratio 
of sensorineural hearing loss than HIV negative MDR-TB patients 
during the intensive phase of MDR-TB treatment. 
 
 
1.5 SIGNIFICANCE OF THE STUDY 
 
The rapid scale up of current treatments for DR-TB, accompanied by an increasing 
challenge of post lingual SNHL associated with MDR-TB treatment poses a new 
dilemma for health professionals, patients, and families, most importantly, the 
psycho-socio-economic impact. The knowledge generated has many potential 
applications for advocacy, community sensitisation, and clinical practice to mitigate 
the many psychological, physical, social, and economic consequences of a silent, 
but destructive, condition and contribute to the alleviation of human suffering related 
to this condition.  Thus, the expected benefits of the study are the contributions to 
clinical practice, contributions to public health and policy dialogue and contributions 
to knowledge.  
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The main contribution of this study is the advancement of science. As this is a case 
study of the local value, the study will increase awareness about hearing health and 
actions for hearing preservation, and could bring about change and improvement in 
the way health care workers manage their patients because of the guidelines 
developed as part of this study.  The study responds to the World Health Assembly 
resolution WHA48.9 of May 1995, that requested the Director General ―to promote 
and support, to the extent feasible applied and operations research for the optimal 
prevention and treatment of the major causes of hearing impairment‖ (World Health 
Assembly 1995).  
 
In so doing, the study directly contributes to the needs of the secondary beneficiaries 
who are the clinicians, the policy makers, as well as the community and families as 
follows: 
 
1. Improving clinical practice and patient care through systematic practice 
improves quality of life. 
 
The study responds to a call from other researchers for better clinical 
data to inform guidelines for monitoring hearing loss related to MDR-TB 
treatment by providing robust data and best practice guidelines (Sturdy 
et al 2011:1815). Davies et al (2008:29), Dulko (2007:29), Herdeiro, 
Polonia et al (2004:483-9), Ploeg, Davies et al (2007:201-9) and 
Tanenbaum (2005:163-73) contend that the goal of research evidence 
is to change practitioners‘ behaviour by bridging the distance from 
research to practice and securing a central place for research in the 
consulting room. Synthesis of the results of the study and the 
development of guidelines is a positive step in the implementation of 
interventions to mitigate the impact of hearing loss among MDR-TB 
patients. The study provides a basis for implementation of standardised 
monitoring practices to improve quality of patient care and minimise 
variations in service delivery and plays a catalytic role in the renewal of 
interest in pharmacovigilance (Eccles & Mason 2001).  
 
 
13 
 
2. Increasing services to support patients and families. 
 
The best practice guidelines, a product of this study provides 
standardised recommendations for hearing preservation and 
engagement of patients and their families. The principles and tools 
suggested for monitoring ototoxicity are a potential catalyst for 
establishment of systems for monitoring all the ADRs associated with 
MDR-TB treatment. For the patients who develop hearing loss and 
their families and communities, the guidelines provide minimum 
standards for counselling services, establishment of communication 
skills for patients, provision of hearing aids and training in sign 
language. Collaboration with sign language organisations, the 
guidelines call for the training of staff at the MDR-TB treatment sites on 
an essential package of hearing health care and its integration the 
community linkages component of MDR-TB care to assist patients with 
hearing loss to preserve communication with family and community. 
 
3. Advocacy and guidance to policy makers and health planners to 
investment opportunities in public health and hearing health care. 
 
This research documents the quantifiable outcomes of a standardised 
intervention and enables evidence based planning and a basis for 
construction of a hearing health policy for MDR-TB patients. Policy 
makers and health planners can use the evidence to create an 
enabling environment for early preventive interventions and use the 
data for planning procurement of hearing aid services/ assisted 
listening devices, rehabilitation, and reintegration for patients who do 
not benefit from prevention and develop hearing impairment. Policy 
makers can also promote family counselling and education, and 
legislation concerning use of ototoxic medicines or introduction of safer 
medicines in the health systems such as the new and old repurposed 
drugs for MDR-TB through the use of informed data for informed 
decisions (Atun et al 2010:104; Chasin & Russo 2004:35-47; Rogers 
2003).  
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1.6 DEFINITION OF TERMS 
 
1.6.1 Adverse drug reactions 
 
An adverse drug reaction as ―an appreciably harmful or unpleasant reaction, 
resulting from an intervention related to the use of a medicinal product, which 
predicts hazard from future administration and warrants prevention or specific 
treatment, or alteration of the dosage regimen, or withdrawal of the product‖ 
(Davies, Green, Taylor, Williamson, Mottram & al., 2009; Edwards & Aronson 
2000:1255-59). The WHO defines an adverse drug reaction as a ―response to 
a drug which is noxious and unintended and which occurs at doses normally 
used in man for prophylaxis, diagnosis, or therapy of disease or for the 
modification of physiologic function(World Health Organization, 1969).‖ The 
definition excludes therapeutic failures, intentional or accidental poisoning, 
and drug abuse (Naranjo, Busto, Sellers, Sandor, Ruiz, Roberts, Janecek, 
Domecq & Greenblatt 1981:240; World Health Organization 1969). Of note is 
that adverse drug reaction is harm caused directly by the drug at normal 
doses, during normal use. There are six types of ADRs: dose-related 
(Augmented), non-dose-related (idiosyncratic, bizarre), dose-related and time-
related (Chronic), time-related (Delayed), withdrawal (End of use), and failure 
of therapy (Failure).  Suspected ADRs can also be classified in terms of 
causality and avoidability according to validated algorithms (Davies et al 
2009). Included in this definition, is the term ADE, which refers to harm 
caused by the drug (adverse drug reactions and overdoses) and harm from 
the use of the drug (including dose reductions and discontinuations of drug 
therapy) (Nebeker, Barach & Samore 2004b:795-801).  
 
1.6.2 Audiogram 
 
An audiogram is a graph that shows the softest sounds a person can hear at 
different pitches or frequencies. An ―O‖ represents responses for the right ear 
and an ―X‖ for responses of the left ear. An audiogram shows the audible 
threshold for standardised frequencies as measured by an audiometer, which 
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is an instrument used to obtain air conduction thresholds on all examinees. 
The Y-axis represents intensity measured in decibels and the X-axis 
represents frequency measured in Hertz. The threshold of hearing plotted is 
relative to a standardised curve that represents 'normal' hearing, in dB (HL). 
Audiograms are set out with frequency in hertz (Hz) on the horizontal axis, 
most commonly on a logarithmic scale, and a linear dBHL scale on the 
vertical axis. Frequency is cycles per second and pitch is the perceptual 
correlate of frequency and measured in hertz. The intensity is the level of 
sound power measured in decibels and loudness is the perceptual correlate of 
intensity (Gelfand 2009:144; Wikidepia, ibid-a). 
 
1.6.3 Best Practice guidelines 
 
A best practice is a method or technique that has consistently shown results 
superior to those achieved with other means, and used as a benchmark. In 
addition, a "best" practice can evolve to become better as improvements are 
discovered. Best practices are used to maintain quality as an alternative to 
mandatory legislated standards and can be based on self-assessment or 
benchmarking (Bogan & English 1994). However, in clinical practice, this 
refers to clinical practice guidelines, which is a document with the aim of 
guiding decisions and criteria regarding diagnosis, management, and 
treatment in specific areas of healthcare. It contains professional procedures 
and systematically developed statements that are accepted or prescribed as 
being correct or most effective, and assists both practitioner and patient 
decisions in specific circumstances. Best practice guidelines are based on an 
examination of current evidence within the paradigm of evidence-based 
medicine (Medicine 2011; The Agree Collaboration 2003, Wikidepia.). 
Guidelines are viewed as useful tools for making care more consistent and 
efficient and for closing the gap between what clinicians do and what scientific 
evidence supports (Burgers, Grol, Klazinga, Mäkelä & Collaboration 2003). 
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1.6.4 Hearing loss/Hearing impairment/Deafness 
 
Hearing loss refers to any reduction of, or difficulties with, hearing and there 
are three aspects for describing hearing loss: type of hearing loss, degree of 
hearing loss, and configuration of hearing loss. The basic types of hearing 
loss are the conductive, SNHL, and mixed hearing loss. The degree of 
hearing loss refers to the severity of the loss, and WHO (WHO 2013) defines 
a person who is not able to hear the hearing thresholds of 25dB or better in 
both ears as having hearing loss, which may be mild, moderate, severe, or 
profound. While configuration, or shape, of the hearing loss refers to the 
degree and pattern of hearing loss across frequencies (tones) as illustrated in 
a graph called an audiogram as described above in section 1.6.2 (ASHA 
2011).  On the other hand, ‗Hard of hearing‘ refers to people with hearing loss 
ranging from mild to severe. They usually communicate through spoken 
language and can benefit from hearing aids, captioning, and assistive 
listening devices. People with more significant hearing losses may benefit 
from cochlear implants. ‗Deaf‘ people mostly have profound hearing loss, 
which implies very little or no hearing. They often use sign language for 
communication. 
 
1.6.5 Multi-Drug Resistant Tuberculosis 
 
Multi-drug resistant TB is defined as tuberculosis strains with resistance to at 
least two anti-tubercular drugs, Isoniazid and Rifampicin (Gandhi et al., 2010). 
A subcategory of extensively drug-resistant TB (XDR TB), has additional 
resistance to Fluoroquinolone and to at least one of three injectable anti-TB 
drugs; namely, Kanamycin, Capreomycin, or Amikacin (Chiang et al., 2010). It 
excludes mono resistant and poly resistant tuberculosis(WHO 2011b) (World 
Health Organization 2011b). 
 
1.6.6 Pure Tone Audiometry 
 
Pure tone audiometry is an air conduction behavioural test that tests the 
hearing sensitivity of the entire auditory system by presenting pure tone 
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signals to the ear through earphones, and varying the intensity of the signals 
until the level is identified at which the person is just able to hear the sound. 
This level is known as the person‘s threshold; clinically, threshold is usually 
defined as the level at which the subject will be able to detect the signal 50 % 
of the times that it is presented. Pure tones are presented at different 
frequencies across the range of human hearing and this type of testing 
evaluates the auditory system as a whole, and is capable of identifying 
hearing problems at almost any level within the auditory system (Gelfand 
2009:139; National Center for Health Statistics &Centers for Disease Control 
and Prevention 2005). 
 
1.6.7 Ototoxicity Monitoring 
 
Ototoxicity is the property of being toxic to the ear, specifically the cochlea or 
auditory nerve, and sometimes the vestibular system (Medical dictionary, Sa). 
Ototoxicity causes hearing loss. The term ―ototoxicity monitoring‖ therefore 
refers to the steps takes for early identification changes to hearing status, 
presumably attributed to a drug/treatment as well as early intervention 
audiologic intervention when handicapping hearing impairment has occurred 
(American Academy of Audiology 2009:3).  
 
1.6.8 Threshold shift 
 
The smallest intensity of sound that a person requires to detect its presence is  
a threshold. Therefore, the threshold shift refers to the degree of hearing loss 
or impairment in terms of a decibel shift from a patient's previous audiogram. 
Audiometric monitoring programmes will encounter two types of changes in 
hearing sensitivity, that is, threshold shifts: permanent threshold shift (PTS) 
and temporary threshold shift (TTS). As the names imply, any change in 
hearing sensitivity, which is persistent, is a PTS. Persistence is assumed if the 
change is observed on a 30-day follow-up exam (Gelfand 2009:139). 
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1.7 THEORETICAL FOUNDATIONS OF THE STUDY 
 
1.7.1 Research paradigm 
 
Ideological positions called paradigms or ―worldviews‖, guide research activity. Each 
of the paradigms is organised around concepts, theories, assumptions, beliefs, and 
principles that form a way that a discipline interprets the subject matter. All 
researchers work from these frameworks, ―worldviews‖ underpinning philosophical 
assumptions. The paradigms or worldviews refer to a basic set of beliefs 
(assumptions) that guide action and have been described as ontological (beliefs 
about the nature of reality and humanity), epistemological (the nature of knowledge 
that informs the research), and methodological (how that knowledge may be gained) 
premises (Creswell 2014a:6; Curtis & Drennan 2013b:20).  In the execution of the 
current study, the post-positivist/ quantitative paradigm was utilised. The quantitative 
approach is associated with an objectivist ontology, a positivist epistemology, and 
uses quantitative methods that aim to produce findings that are objective, reliable, 
valid and reproducible (Curtis & Drennan 2013a:133).  The implications these 
assumptions have on the study to hold true to the paradigm are:   
 
 Data collection instruments completed by the respondents and /or 
observations recorded by the researcher; 
 Standards of validity and reliability examine the methods and conclusions for 
bias; 
 Statements that explain causal relationships of SNHL related to MDR-TB 
treatment use quantitative terms such: the number (and proportion) of 
respondents developing SNHL, time to  hearing loss, incidence ratios, hazard 
ratios and cumulative incidence; and 
 Inferential statistics generalise the results from the sample to match those of 
the population under study, knowing that the absolute truth can never be 
found and that evidence established by research is imperfect and fallible.  
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1.7.2 Meta-theoretical assumptions of the study  
 
This study is based on the general philosophical orientation about the world and the 
nature of the quantitative research and numeric measures of observations, and is 
linked to study outcomes (Creswell 2014a:6). Mouton ad Marais (1994:192) contend 
that no scientific findings can be conclusively proved based on empirical research 
data and the researchers are compelled to make assumptions justifying specific 
theories and methodological strategies. A brief discussion of this perspective in the 
subsections below reveals that the epistemology, ontological and methodological 
assumptions guided this study and are summarised in Table 1-1. 
 
1.7.2.1 Epistemological assumptions 
 
Epistemology is an underpinning philosophical assumption about the nature of 
knowledge or how we come to know (Curtis & Drennan 2013b:19-21). Epistemology 
poses the question on the relationship between the knower/inquirer and those being 
studied, what is known, and how do we know what we know (Krauss 2005:759; Polit 
& Beck 2008:11). The epistemological assumptions in this study contend that the 
MDR-TB treatment related hearing loss is a phenomenon that occurs in individuals 
receiving a certain regimen of MDR-TB treatment. Direct observations of 
measurements of the phenomena are the basis for the discovery and verification of 
the knowledge of MDR-TB treatment related hearing loss. Central to this positivist 
epistemology is the assumption that observation and measurement are at the core of 
scientific endeavour; and perspective seeks to explain and predict what happens in 
the social world by searching for regularities and casual relationships between MDR-
TB related hearing loss constituent elements related to its occurrence (Krauss 
2005:759). The axiological assumptions that flow from this perspective is that the 
research is value neutral and the researcher‘s values do not bias the research. 
 
1.7.2.2 Ontological assumptions 
 
This research assumes that there is a single unitary reality apart from our 
perceptions about hearing loss associated with MDR-TB treatment. The ontological 
assumption is that each researcher‘s individual cannot bias research, being objective 
20 
 
is an essential aspect of competent inquiry, and hence the researchers must 
examine the methods and conclusions for bias. It is therefore very important that we 
―establish validity‖ in an external and objective sense (Creswell 2014a:7; Krauss 
2005:759). See Table 1.1 
 
1.7.2.3 Methodological assumptions 
 
Methodology identifies the particular practices used to attain knowledge by the 
inquirer (Krauss 2005:759). This study uses quantitative methods associated with 
positivism to obtain knowledge on the incidence, risk factors and hazard rate ratios 
of MDR-TB treatment related hearing impairment. Numeric information is collected 
and analysed within the traditional scientific method based on what was observed 
and what was measured(Polit & Beck 2008). Another methodological assumption of 
quantitative studies is that the empirical findings are generalisable beyond the single 
setting. Postulation of theories that are to be tested use deductive reasoning and, 
based on the results of studies, we may learn that a theory does not fit the facts well 
and so the theory must be revised to better predict reality (Creswell 2014a:5-8; 
Krauss 2005:760; Phillips & Burbules 2000:8-26).  
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Table 1.1: Ontological, Epistemological and Methodological assumptions under the 
research paradigm 
 
Feature Description 
Purpose of research 
 
- The empirical study determines incidence, risk factors, and 
hazard rate ratios of hearing loss in HIV positive and HIV 
negative patients on MDR-TB treatment in Swaziland  
- Develop of best practice guidelines for prevention and 
monitoring hearing loss related to MDR-TB treatment.  
Ontology (Objectivist) - There are laws or theories that govern the world.  
- Laws and theories need to be tested or verified and refined so 
that we can understand the world.  
- Researchers advance the relationship among variables and 
pose this in terms of questions or hypotheses. 
- Researcher begins with a theory or hypothesis, collects data 
that either supports or refutes the theory, and then makes 
necessary revisions and conducts additional tests.  
- Researchers do not prove a hypothesis; instead, they indicate a 
failure to reject the hypothesis because evidence established in 
research is always imperfect and fallible.  
Epistemology (Positivist) - Knowledge is based on careful observation and measurement of 
the objective reality that exists ―out there‖ in the world. 
- Data, evidence, and rational considerations shape knowledge.  
- Research seeks to develop relevant, true statements; ones that 
can serve to explain the situation of concern or that describe the 
causal relationships of interest. 
Methodology - The researcher collects information on instruments based on 
measures completed by the respondents or by observations 
recorded by the researcher. 
- Being objective is an essential aspect of competent inquiry; 
researchers must examine methods and conclusions for bias.  
- For example, standard of validity and reliability are important in 
quantitative research. 
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1.7.3 Theoretical framework 
 
1.7.3.1 Neuman Systems Model Nursing Theory 
 
In the formulation of a theoretical perspective for studying hearing loss related to 
MDR-TB treatment, Neuman Systems Model (NSM) provided a useful theoretical 
prototype. Neuman Systems Model focus is on the client as a system (which maybe 
an individual, family group or community) and on the client‘s response to stressors 
(Freese & Lawson 2010:311-15).  The medicines used in the treatment of MDR-TB 
affect the internal environment of the patient (physiological and pathophysiological) 
and treatment affects the external environment of the client (patient) system 
(perceptual, operational, and conceptual). The conceptual environment can be 
viewed as hearing, language and expression of emotion (Levine 1990:189; Schaefer 
2010:227-229).  
 
The client system includes physiological, psychological, sociocultural, 
developmental, and spiritual aspects. The client system is conceptualised as having 
an inner core or basic structure (basic energy resources) that is protected by 
concentric circles representing a normal line of defence and flexible line of defence. 
The normal line of defence represents the usual level of health that also, in turn, is 
protected by a flexible line of defence.  Tension-producing intrapersonal, 
interpersonal and extra-personal stressors, which arise from the internal, external, 
and created environment, affected these lines of defence (Freese & Lawson 
2010:309-334). When stressors break through the flexible line of defence, the client 
system is invaded and the lines of resistance are activated with the client system 
moving into illness on a wellness-illness continuum. If adequate energy is available, 
the system will be reconstituted with the normal line of defence restored at below, or 
above its previous level (Freese & Lawson 2010:315-323).  
 
According to NSM, nurses and doctors treating patients with MDR-TB facilitate 
conservation of hearing as part of preservation of the wholeness of the individual so 
that his or her participation and place in the family, community, and society can be 
preserved using prevention as an intervention (three levels). Primary prevention of 
SNHL starts at the client‘s baseline assessment to identify risks and address 
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preventable ones prior to the administration of injectable anti-TB medicines. 
Secondary prevention starts once there is detection of signs of hearing impairment. 
In order to implement secondary prevention, regular monitoring of hearing status is 
critical to identify those at risk for secondary prevention. The purpose of secondary 
prevention is to slow worsening of the impairment to preserve hearing.  Tertiary 
prevention is part of restoration of hearing and/or to prevent consequences of 
hearing loss through maintenance of communication. The three levels are used for 
retention, attainment, and maintenance of optimal client system wellness (Freese & 
Lawson 2010:311-314; Neuman 2001:321-9).  
 
1.7.3.2 Conceptual framework for the best practice guidelines 
 
Based on Neuman Systems Model, the stages of the medical process form a 
continuum:  
 
 At diagnosis, the identification and diagnosis of stressors is done, as well as 
the cognisance of the dynamic interaction with the five variables; 
 At enrolment, treatment goals negotiated with the patient, taking into account 
the patient‘s and nurse‘s perceptions of variance from wellness.  
 
The conceptual framework is presented in Chapter 2 of this thesis. 
 
1.8 RESEARCH DESIGN AND METHODS 
 
1.8.1 Research Design 
 
Research design refers to the broader plan for management of the study, 
encompassing the plan for data collection, utilisation, measurement and analysis. 
The research methods refer to data collection using the specific instruments and 
techniques to achieve the outcomes of the study (Curtis & Drennan 2013a:131; 
Mouton 2001:55-56). This study was an observational prospective cohort with a 
nested case-cohort approach. The cohort involved normal hearing HIV negative and 
HIV positive patients initiating MDR-TB treatment, followed up until hearing loss 
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developed, completed 8 months of the injectable intensive phase of DR-TB 
treatment, or were lost to follow up. Analysis of incident hearing loss involved 
calculation of incidence, association exposure to various risk factors and time to 
development of hearing loss (Creswell 2014a:11-17; Duggal & Sarkar 2007; Krauss 
2005:759-60). The Cohort design allowed for the determination of population-based 
incidence; accurate relative risk (risk ratio) estimation; inference to the temporal 
relationship; time-to-hearing loss analysis (Pfeiffer, Ryan, Litonjua & Pee 2005:982-
91). 
 
1.8.2 Research Methods 
 
Research methods involve the forms of data collection, analysis and interpretation 
that the research utilises for the studies (Creswell 2014a:16-17). Longitudinal data 
collection methods were utilised for the study. 
 
1.8.2.1 Population, Sampling and Research sites  
 
A two-stage multi stage sampling was done in order to study the target population, 
which comprised of patients diagnosed (confirmed and suspected) with DR-TB 
patients enrolled into an MDR-TB treatment regimen. The first stage was 
identification of study sites from a list of six MDR-TB treatment sites in the country. 
The second stage of sampling was selection of patients who eventually enrolled into 
the study.  The study setting was in a high per capita burden of DR TB and HIV co-
infection setting. Patients attending DR-TB treatment sites were the accessible 
population and the study sample comprised MDR-TB patients enrolled onto MDR-TB 
treatment at two centres in Swaziland, namely National TB Hospital, and Pigg‘s Peak 
Hospital. Referrals from other treatment sites, such as Manzini Comprehensive 
Clinic and Good Shepherd hospital were also attended to as long as they fulfilled the 
including criteria.  
 
Before establishment of their own audiometry services, patients from Pigg‘s Peak 
Hospital were referred to the National TB Hospital for audiometry testing. The criteria 
for inclusion in the study were: i) have a diagnosis of DR-TB; ii) normal pre-treatment 
hearing level, (iii) normal hearing level for those on treatment for no more than 72 
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hours; (iv) aged 15-65 years; (v) clinically stable; and (vi) provide informed consent 
to participate in the study. Excluded from the study were the following: (i) patients 
with extensive resistant tuberculosis strains, (ii) patients with exhibited psychiatric 
conditions, (iii) pre-treatment clinical assessment of infective pathology in the ear, 
and (iv) pre-existing hearing loss. All consecutive patients who fulfilled the inclusion 
criteria and consented to participate were enrolled into the study.  
 
1.8.2.2 Ethical Considerations 
 
The Research Ethics Committee of the Department of Health Studies Higher 
Degrees Committee (DHSHDC) of University of South Africa and the Scientific and 
Ethics Committee of the Ministry of Health in Swaziland granted ethical clearance 
and approval for the study.  Institutional approvals was also provided by the National 
tuberculosis programme and National TB Hospital and participating MDR-TB 
treatment centre. Ethical considerations during sampling and during data collection 
are of this study are presented in sections see section 3.3.1.4 and 3.3.2.5. As part of 
the design of the study, the principles of ―do good‖ (beneficence) and ―do no harm‖ 
(non-maleficence) were some ethical considerations made in the design and plan for 
data collection in the study. Information was the purpose of the study, study 
procedures rights, risks, discomforts, as well as the constraints of participation. 
Patients‘ autonomy, informed consent, right to withdraw from the study at any time, 
assurance of confidentiality, anonymity, and privacy were the other of the ethical 
considerations under the respect for the human subjects involved in research. 
 
1.8.2.3 Data collection  
 
An interviewer-administered questionnaire was used to capture: socio-demographic 
data, medical history, lifestyle characteristics, biometric and physical measurements; 
medical and laboratory results abstracted from laboratory and medical records; 
medical and family history of hearing; results of screening examinations that included 
otoscopy and tympanometry for identification of ear canal abnormality or cerumen 
impaction conducted; and the baseline and continuing audiology results. Referral for 
immediate medical cerumen management was done, as appropriate (ASHA 1997) 
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1.8.2.4 Instrumentation 
 
Data collection instruments were the face-to-face interviewer-administered 
questionnaire and an audiometry protocol and equipment used to collect and test the 
respondents‘ hearing threshold (in decibels, dB) at six frequencies, collected in a 
soundproof room. For each ear tested, results of the hearing threshold (in decibels) 
at frequencies of: 250 hertz; 500 hertz; 1 000 hertz; 2 000 hertz; 4 000 hertz; 8 000 
hertz were recorded using standard symbols in an audiogram(ASHA 1990:32-35) . 
 
1.8.2.5 Case definition 
 
Hearing loss was graded according to the WHO criteria using audiometric ISO 
values that are averages of pure tone values at 250, 500, 1 000,  
2 000 and 4 000hz as: 0-25 dB Normal hearing; 26-40 dB Mild hearing loss; 41-60 
dB Moderate hearing loss; 61-80 dB severe hearing loss; 81+ dB Profound hearing 
loss. It should be noted, however, that given that different frequencies may be 
affected in a given person, averaging across all frequencies tested may wash out 
ototoxic change (Dobie, 2005b:62-63, Gordon , Konrad-Martin , Reavis , Wilmington 
, Bratt &Fausti).  
 
Some studies however, have validated that use of pure tone average (PTA) or any 
frequency (AF) criteria depends on the choice and whether the genuine threshold 
shift has occurred at a single frequency or across a range of frequencies (Dobie, 
2005b:62-67). For that reason, additional criteria for defining hearing loss included 
consideration of significant threshold shift compared to baseline measurements if: 1) 
a 20 dB decrease at any one frequency or 2) a 10 dB decrease at any two adjacent 
frequencies (American Speech-Language-Hearing Association 1994). 
 
1.8.2.6 Data Analysis 
 
Before detailed statistical analysis, the nature of the data available and questions of 
interest were reviewed using exploratory analysis and preliminary tabulations to 
clean up the data and resolve any inconsistences in the data. This study design 
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allows for three major analytic approaches, namely, analysis as a cohort study, a 
case-cohort study and a nested case control. Analysis as a cohort study is the main 
approach that is utilised given that baseline data was retrieved on all respondents. 
Given that the time-to-event outcome is binary in nature, non-standard statistical 
analyses were not required for the case cohort (Barlow, Ichikawa, Rosner & Izumi 
1999:1165-70; Pasupathy, Dacey, Cook, Charnock-Jones, White & Smith 
2008:1165).  
 
a. Descriptive analysis 
 
Objective 1 and 4: descriptive data analysis was done to address each sub problem 
statistically, using measures of central tendency (mean, standard deviation and 
median) calculated from the continuous data, analysis of time-to-event data and 
using epidemiological estimates (rates, proportions, and ratios). 
 
b. Explanatory analysis 
 
Objectives 2 and 3: analysis tests the study hypotheses and establishes the risk 
factors and determinants that are responsible for producing the state of hearing 
impairment details, and this is provided in Chapter 3 of this thesis. Logistic 
regression and the proportional hazards regression are used to study the effect of 
HIV status.   
 
c. Predictive analysis 
 
Objective 4, to assess the time-to-hearing loss and hence the optimal frequency for 
audiologic testing for monitoring of patients on MDR-TB treatment, utilised the 
proportional hazards regression and hazard function to predict the probability that if a 
person survives to t, they will experience the event in the next instant.  
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d. Literature review of existing guidelines and synthesis of results of the 
empirical study 
 
To achieve Objective 5 that aims to develop best practice guidelines, data from the 
empirical research and relevant literature were used to make recommendations and 
guidelines for monitoring and prevention of hearing loss associated with MDR-TB 
treatment in Swaziland based on internationally recommended hierarchy and 
methods for grading the evidence (Ansari & Rashidian 2012; Curtis & Drennan 
2013b:18). 
 
1.8.2.7 Internal and external validity of the study 
 
To ensure the internal and external validity, and reliability of the study, methods and 
techniques used included the following: 
i) Standardisation of conditions, controlling for quality of procedures and 
techniques and execution of pilot test of procedures, equipment, and 
questionnaires.  The procedure manuals provided details of each step, 
including regular calibration of audiometry equipment according to 
international standards, staff training on details of study procedures, data 
collection techniques and data entry, standardised tools for data collection. 
These methods ensured reliability of the audiology test results as well as 
accurate and complete entry of questionnaires. The researchers also had a 
written schedule for progress meetings and review reports, and timely trouble 
shooting was implemented to ensure that the findings match reality and what 
is captured or measured is what is supposed to be measured or captured;  
ii) Making adjustments for confounders through identification of a priori potential 
confounders, dealing with those discovered later during the data collection; 
restriction to participation in the study; stratified analysis within strata of the 
confounding variable (for example, age, gender) and; intent-to treat analysis 
addresses drop out and non-compliance ensures translation of the measured 
constructs into functioning reality; 
iii) Selection bias and error were addressed in accordance with the 
recommendations in (Enarson, Kennedy, Miller & Bakke 2001:97-104). where 
the researchers employed rigor in defining the target population, collecting 
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and reporting demographic characteristics of respondents, inclusion of all 
cases meeting the eligibility criteria and not omitting ―hard to find‖ persons. 
Skills to ensure high acceptance rate and lower dropout rate were imparted; 
iv) Information Bias (Error or bias in measurements) was minimised by strict 
observance of diagnostic criteria; testing for inter- and intra-observer 
variability; and implementing regular quality assurance procedures to ensure 
that there is no ―drift‖ in the precision of the results;  
v) Blinding: The respondents and the research assistants are ―blinded‖ on the 
hypothesis being tested in order to avoid the risk that personal expectations 
might influence, bias the result, and reduce reliability and validity; and 
vi) Oversampling of HIV negative patients to increase proportion of HIV negative 
respondents in the cohort to at least one third, given the very high HIV 
prevalence (75%) among the MDR-TB patients. 
 
1.9 THE SCOPE OF THE STUDY 
 
The study falls within the field of health studies encompassing fields of health 
systems research, quality of patient care and translation of evidence into practice 
through the development of guidelines for monitoring and prevention of adverse drug 
events. The study evaluated the incidence, risk factors and time-to-hearing loss in a 
setting with a very high per capita burden of high HIV and MDR-TB. The population 
accessed for the study was a cohort of 173 MDR-TB patients enrolled from 
November 2012 and December 2013 at three health facilities managing MDR-TB in 
Swaziland. During the same period, 353 MDR-TB patients were enrolled into 
treatment nationally. Data collected during the study indicates the need for 
guidelines for monitoring and prevention of SNHL for MDR-TB patients of injectable 
second-line anti-tuberculosis treatment. 
 
The study might have the following limitations:  
 
i) This study was an observational study with a main weakness of confounding, 
given that the researcher did not allocate which study respondent was 
exposed or not exposed to HIV (exposure) (Harris, Bardien, Schaaf, Petersen, 
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De Jong & Faga, 2012; Seddon, Thee, Jacobs, Ebrahim, Hesseling & Schaaf 
2013). Specific measures to minimise confounding included a priori 
identification of potential confounders and dealing with those discovered later 
during the data collection. Restriction to participation in the study, stratified 
analysis within strata of the cofounding variable (for example, age) and intent-
to-treat analysis were used to address drop out and non-compliance at 
analysis stage; 
ii) The study reports incidence at 8 months, although some studies show that 
progressive ototoxic effects on hearing by MDR-TB treatment may continue 
even after the stoppage of the offending drug; 
iii) The frequency of audiometry was limited to intervals of two-weekly, four- 
weekly and eight-weekly because the patients and doctors, and not the 
researcher, decided the follow-up appointment dates; 
iv) Repeated testing of respondents over time can also lead to confounding due 
to learning effects. Where indicated, ABR studies were conducted to negate 
this effect; and 
v) Increased possibility of missing data common for longitudinal research could 
affect results. Some patients could fail to honour their appointments for 
audiometry.  Patient phone reminders were used to minimise loss to follow up 
as well as using thorough training of study assistants with the skills to ensure 
high acceptance rate and lower dropout rate and provision.   
 
1.10 STRUCTURE OF THE THESIS 
 
Chapter 1:  Serves as an introductory chapter. It contains the problem, background 
to the research problem/preliminary literature study, statement of the 
problem, research aims, definitions of terms, theoretical frameworks 
and its limitations, significance of the research, conceptual framework, 
research methodology, scope and limitations of the study, and 
programme of the study. 
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Chapter 2:   Provides reviewed literature and summarises the investigation into the 
phenomenon of hearing loss related to MDR-TB treatment, exposition 
of prevention and support services.  
 
Chapter 3:  Discusses the research design and methods. It includes; sources of 
data indicating the locale of the study, population, and sampling; 
instrumentation and data collection; and tools for data analysis. 
 
Chapter 4:  Presents the results of the empirical research in form of analyses, 
presentation, and interpretation of the data. The results are presented 
in the form of text, tabular presentations, pie charts, and/or any other 
analysis suitable for the collected data.  
  
Chapter 5:  Presents and independent reflection of the researcher on the entire 
research process and findings and summarises the whole research 
process (describes the problem, research design, and the findings 
(answers to the questions raised), and discussion of research results. 
 
Chapter 6: Presents the process to develop and validate the best practice guidelines 
to monitor and prevent hearing loss associated with MDR-TB 
treatment. 
 
Chapter 7:  Presents the conclusions of the study, describes its limitation, and makes 
recommendations for practice and for further research. 
 
1.11 CONCLUSION 
 
This chapter introduced the study. It provided a background describing the problem 
of MDR-TB and cochleotoxicity resulting in permanent SNHL in a proportion of 
patients on MDR-TB treatment. Despite evidence supporting the importance of early 
identification of ototoxicity, lack of guidelines, tools and experts hamper the routine 
practice of ADR monitoring programmes in the country. The purpose, the objectives 
and the theoretical foundations of the study are stated. Key concepts are defined as 
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well as the ethical considerations and measures to ensure validity and reliability of 
the study findings. 
 
Chapter 2 discusses the literature review. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
This chapter presents the review of the literature on the concepts of sound, hearing 
and hearing loss associated with MDR-TB, with special focus on aminoglycoside 
cochleotoxicity, mechanisms for the hearing loss, impact of hearing impairment and 
best practices for ototoxicity monitoring and prevention. The chapter describes 
Neuman Systems model and the application of the model in prevention and 
monitoring hearing loss and hearing preservation.  
 
While the emergence and spread of MDR-TB threatens global ability to treat 
infectious diseases, and the costs related treatments are draining available meagre 
resources in developing countries, the use of ototoxic medications in the current 
MDR-TB treatment regimens contributes to an escalating incidence of SNHL hearing 
loss (Laxminarayan, Bhutta, Duse & al 2006:1031; World Health Assembly 1995; 
World Health Organization 2008, 2011b). In 1994, the WHO reported a median 
prevalence of primary and acquired MDR-TB as 1.4% and 13% respectively (Prasad, 
2010:180). However, by the end of 2013, the median prevalence of MDR-TB had 
risen to 3.5% among new TB cases and 20.5% among previously treated cases 
(Chiang, Van Weezenbeek, Mori & Enarson 2013:596; World Health Organization 
2014b). The critical, urgent, and necessary expansion of MDR-TB treatment as a 
measure to curb the scourge of MDR-TB directly contributes to increased MDR-TB 
treatment related to hearing loss. Sensorineural hearing loss is sometimes referred 
to as the ―invisible‖ impairment because usually, no obvious external signs of the 
damage are exhibited (Chiang et al 2010:413; Chiang et al 2013:596; Prasad 
2010:180).  
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2.2 THE EAR, SOUND AND HEARING IMPAIRMENT 
 
This section provides a brief background of the anatomy of the ear and the auditory 
system, the mechanism of sound, and the mechanism of hearing as a preamble to 
the discussion on hearing impairment.  
 
2.2.1 Anatomy of the Ear and Auditory System  
 
Three parts form the ear and they are described and shown schematically in Figure 
2.1.  
 
i) The outer ear, which is made up of the pinna (auricle) and ear canal (external 
auditory meatus). The pinna is made up of folds of cartilage surrounding the 
ear canal and the pinna plays an important role in trapping sound waves. 
ii) The middle ear, which consists of the tympanic (middle ear) cavity; the 
ossicular chain (malleus, incus, stapes) with its associated muscles, tendons, 
and ligaments; and the eustachian (auditory) tube. The middle ear begins at 
the eardrum (tympanic membrane), the membrane that separates the outer 
and middle ear. 
iii) The inner ear is made up of the sensory organs of hearing (the cochlea) and 
of balance (the semi-circular canals, utricle, and saccule) and begins at the 
oval window.  
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Figure 2.1: Anatomy of the ear showing the outer ear, the middle ear and the inner ear. The 
Cochlear and semi-circular canals are shown as the snail line structure in the inner ear and are 
connected to the cranial nerves. 
Source:(Chelsea 2013) https://www.studyblue.com/notes/note/n/anatomy-of-the-ear-
oral-cavity-pharynx--nasal-cavities/deck/7162701 Accessed on 31 May 2015. 
 
2.2.1.1 The Cochlea 
 
The auditory nerve connects the organ of hearing (the cochlea) to, and within, the 
central nervous system (Gelfand 2007:20). The cochlea sits within the inner ear and 
it is a snail-shaped organ and enables sound transmission via a sensorineural route 
(Figure 2.4). Three layers of fluid make up the cochlea, namely: the scala vestibuli 
separated by Reissner‘s Membrane from the scala media, which in turn is separated 
from scala tympani by the basilar membrane. The scala vestibuli and scala tympani 
are filled with perilymph-filled and are above and below the endolymph-filled scala 
media respectively. The scala media contains the organ of Corti, which is further 
described in Section 2.2.1.2.  Figure 2.2 shows a schematic that illustrates the 
complex layout of the compartments and their divisions: 
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Figure 2.2: Schematic of Inner ear showing the cochlea and its components  
 
2.2.1.2  The organ of Corti 
 
The organ of Corti has the hair cells that are the sensory receptors for hearing and is 
supported by the basilar membrane (Gelfand 2009). There are approximately 
between 15 000 and 16 000 of these hair cells in one ear (Plewes 2006).  Figure 2.3 
shows the position of the organ of Corti and the composition. 
 
 
Figure 2.3 Position of Organ of Corti and the hair cells within the Cochlear 
 
Inner hair cells are the mechanoreceptors for hearing: they transduce the vibration of 
sound into electrical activity in nerve fibres, which is transmitted to the brain 
(Furness, Hackney & Evans 2010:765). Outer hair cells are a motor structure. The 
organ of Corti forms a ribbon of sensory epithelium, which runs lengthwise down the 
cochlea's entire scala media (Gelfand 2009). The basilar membrane widens as it 
progresses from base to apex.  Hence the amplitude of a sound wave travelling 
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through the basilar membrane varies as it travels through the cochlea, responding in 
a wave-like manner as the a vibration is carried through the fluid within the three 
compartments and causes the basilar membrane to move. 
 
Afferent neurons innervate cochlear inner hair cells, at synapses where the 
neurotransmitter glutamate communicates signals from the hair cells to the dendrites 
of the primary auditory neurons. There are far fewer inner hair cells in the cochlea 
than afferent nerve fibres – many auditory nerve fibres innervate each hair cell. The 
neural dendrites belong to neurons of the auditory nerve, which in turn joins the 
vestibular nerve to form the vestibulocochlear nerve, or cranial nerve number VIII. 
Sound information, now re-encoded, travels down the vestibulocochlear nerve 
followed by processing in the brain through intermediate stations such as the 
cochlear nuclei and superior olivary complex of the brainstem and the inferior 
colliculus of the midbrain, being further processed at each waypoint. The information 
eventually reaches the thalamus and relayed to the cortex. The primary auditory 
cortex is the first region of cerebral cortex to receive auditory input, and is 
responsible for the sensation of basic characteristics of sound such as pitch and 
rhythm and is located in the temporal lobe (Lincoln, [Sa]b). 
 
2.2.2 Physiology of the Ear and Auditory System  
 
The auditory periphery and the central auditory system make up the functioning of 
the auditory system. The auditory system changes a wide range of weak mechanical 
signals into a complex series of electrical signals in the central nervous system 
(Furness et al 2010:765). Sound is a series of pressure changes in the air. Sounds 
often vary in frequency and intensity over time and, in man, the first stage of 
transduction is the ear (Lincoln, [Sa]a). While not part of the nervous system, its 
components feed directly into the nervous system, performing mechanoelectrical 
transduction of sound pressure-waves into neural action potentials (Lincoln, [Sa]b).  
 
Reflection and attenuation of sound waves occur when they hit the pinna.  These 
changes provide information to the brain to determine the direction from which the 
sounds came. This is followed by amplification of the sound in the ear canal before 
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hitting the tympanic membrane of the middle ear. The sound wave hitting the 
eardrum causes wave information to travel across the air-filled middle ear cavity via 
a series of delicate bones: the malleus, incus, and stapes. These ossicles act as a 
lever, converting the lower-pressure eardrum sound vibrations into higher-pressure 
sound vibrations at another, and smaller membrane called the oval (or elliptical) 
window. Higher pressure is necessary at the oval window than at the tympanic 
membrane because the inner ear beyond the oval window contains liquid rather than 
air. The stapedius reflex of the middle ear muscles helps protect the inner ear from 
damage by reducing the transmission of sound energy when the stapedius muscle is 
activated in response to sound. While the middle ear still contains the sound 
information in wave form, it is converted to nerve impulses in the cochlea in the inner 
ear (Plewes 2006).   
 
A sound presented to the human ear will travel through the cochlea in only 5 
milliseconds (Plewes 2006). The placement of vibration on the cochlea depends 
upon the frequency of the presented stimuli: the lower frequencies mostly stimulate 
the apex and higher frequencies stimulate the base of the cochlea. When stimulated 
by sound energy, hair cells change in the shape, which serves to amplify sound 
vibrations in a frequency specific manner in order to initiate activity in the auditory 
nerve fibres with which they are in contact. Outer hair cells have stereo cilia 
projecting towards the tectorial membrane, which sits above the organ of Corti. 
Stereocilia respond to movement of the tectorial membrane when a sound causes 
vibration through the cochlea as shown in Figures 2.2 and 2.4. When this occurs, the 
stereocilia separate and a channel is formed that allows chemical processes to take 
place (Fettiplace &Kim, 2014:951). A signal travels to reach the auditory nerve. The 
auditory nerve leaves the inner ear through the vestibulocochlear nerve, through the 
internal auditory canal, to enter the brain at the angle of the pons and cerebellum, 
and terminates in the brainstem at the cochlear nuclei in the central auditory system 
(Gelfand 2009; Lincoln, [Sa]b; Plewes 2006). 
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Figure 2.4: The human cochlea and sound transmission.  
A classic anatomical drawing from Frank Netter of a mid-modiolar crosssection through the human 
cochlea showing the centrally located cochlear spiral ganglion and the various coils of the cochlear 
duct. The higher magnification drawing on the left represents a cross-section through an individual 
turn and shows the location of the organ of Corti, the three scalae and the peripheral process of the 
cochlear nerve cells 
Source: (Cotanche 2008:422) 
 
2.2.3 Development of the auditory system 
 
The auditory system is complete and possesses normal adult sensory function 
approximately halfway through prenatal development (Whitfield 2015:116). However, 
the advancement of the auditory neural system capacity to process signals continues 
for several years. Frequency, intensity, and type of stimulus help babies to 
differentiate sounds but, over the first few months, they learn to localise, associate 
hearing with their own vocal productions, and gradually to better imitate the vocal 
sounds of others. By one year of age, they are able to process the meaning of 
approximately 50 words. By age four, children can process and understand just 
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about everything they hear. Auditory sensitivity reaches its peak at adolescence and 
then begins a very gradual decline (Litovsky 2015:55).  
 
Barring any insult that would accelerate the decline (such as noise, drugs or 
disease), the reduction in sensitivity is not generally clinically measurable until at 
least the third decade of life. After about age 60, hearing sensitivity decreases by an 
average of about 10 dB per decade. The decrease in hearing sensitivity begins at 
the highest frequencies and gradually progresses to include the middle and low 
frequencies. Hearing loss due to age-related changes is known as presbycusis 
(Mitchell, Gopinath  Wang, McMahon, Schneider, Rochtchina &  Leeder 2011:251). 
 
2.2.4 Sound Evaluation/Characterisation 
 
Sound may be characterised along three main parameters: frequency, intensity, and 
complexity (Fausti et al 2005:49). 
 
2.2.4.1 Frequency 
 
Frequency is the rate of the sound pressure waves, or how often the molecules are 
displaced in a given period. Frequency is measured in Hertz (Hz), or cycles per 
second, and is perceived as pitch. Lower-pitched sounds (such as the rumble of 
traffic or a man‘s speaking voice) are lower in frequency; higher-pitched sounds 
(such as a whistle or a baby‘s cry) have higher frequencies (Berke 2014).  
 
Humans can hear sounds waves with frequencies between 20 and 20 000 Hz. The 
ears contain structures for both the sense of hearing and the sense of balance.   
Table 2.1 compares frequencies heard by different animals.  
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Table 2.1 Hearing range frequencies for different animals 
 
Hearing Ranges (Hertz) 
Animal Lowest frequency limit Highest frequency limit 
Elephant 17 10 000 
Human 20 20 000  
Cow 23 35 000 
Horse 55 33 500 
Dog 60 45 000 
Monkey 110 45 000 
Rat 650 60 000 
Mouse 1 000 90 000 
Bat 3 000 120 000 
 
Source: Schiffman, H.R., Sensation and Perception. An Integrated Approach, New York: 
John Wiley and Sons, Inc., 2001) 
 
2.2.4.2 Intensity 
 
The pressure of a sound that is just barely audible to a young, normal-hearing 
listener is approximately 20 μPa (the μPa—micropascal—is a unit for measuring 
pressure). The pressure of a sound that is painfully loud could be about 200 000 000 
μPa. The pressure measurements are converted to a logarithmic scale decibel (dB). 
In decibels, the human ear is responsive to intensities from 0 dB to 140 dB (Gelfand 
2007:5). Intensity refers to the amplitude of the pressure waves, or how far the 
molecules are displaced from their original position. Amplitude is measured in 
decibels and is perceived as volume, or loudness. Low amplitude sounds (in which 
the molecules are displaced only a little bit) are perceived as ―quiet‖ and high 
amplitude sounds (in which the displacements are larger) are perceived as ―loud.‖  
Loudness is measured in decibels (dB), which is the force of sound waves against 
the ear. The louder the sound, the more decibels intensity level the sound will be.  
 
Intensity expressed in decibels is called intensity level (IL), and sound pressure in 
decibels is called sound pressure level (SPL) (Gelfand 2007:5). When measuring an 
individual‘s hearing thresholds, the hearing level scale is used; results are recorded 
in dB HL.  Just like temperature of 0◦C, a measurement of 0 dB does not mean that 
there is no sound at all, just as if a temperature of 0◦F does not mean that there is no 
heat at all. There are sounds that are quieter than 0 dB, and these sounds are 
measured in negative decibels in the same way that temperatures colder than 0◦ are 
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measured in negative degrees.  Table 2.2 provides approximate decibel levels for 
some everyday sounds (National Institute on Deafness and Other Communication 
Disorders, [Sa]). 
 
Table 2.2  Sound decibel level for some every day sounds 
 
 
 
 
 
 
 
 
 
Source: Adopted from: http://www.asha.org/public/hearing/noise/ (retrieved Feb 16, 
2012) 
 
2.2.4.3 Complexity 
 
Complexity refers to the interaction of the various frequencies and intensities that 
make up a sound; for example, a pure tone is a sound that is made up of only one 
frequency and one intensity. Most sounds are made up of many frequencies at 
different intensities combined, to make a very complex signal. Complexity is 
perceived as sound quality or timbre. If a flute and violin are playing the same note at 
the same volume, complexity is the parameter of sound that allows us to distinguish 
between the two instruments.   
 
2.2.5 Hearing 
 
According to the Merriam-Webster Dictionary hearing is defined as ‖the process, 
function, or power of perceiving sound: specifically, the special sense by which 
noises and tones are received as stimuli‖ (Merriam-Webster Medical dictionary, 
[Sa]). As described above, the sound of characteristics of frequency, intensity, and 
complexity determine hearing (Fausti et al 2005:49) A hearing person is one who 
Sound  Intensity (dB) 
Ticking of a Watch 20 
Whisper 30 
Normal Speech 50-60 
Car Traffic 70 
Alarm Clock 80 
Lawn Mower 95 
Chain Saw 110 
Jackhammer 120 
Jet Engine 130 
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can perceive sounds that have frequencies between 20 and 20 000 Hz, with the 
most important frequencies being the 250–6 000 Hz range. On the other hand, 
speech includes a mix of low- and high-frequency sounds (Patel & Merrick 2011:8). 
The Webster Dictionary‘s medical definition of hearing is ―the act or power of 
apprehending sound‖ (Merriman-Webster [Sa]). 
 
2.2.6 Hearing impairment/loss 
 
Hearing loss exists when there is diminished sensitivity to the sounds normally heard 
at appropriate intensity (Patel & Merrick 2011:8-9). The severity of a hearing loss is 
categorised according to the increase in volume above the usual level necessary 
before the listener can detect it (Feldman, Salinas & Tang 2012:602). The term ―hard 
of hearing‖ refers to people with hearing loss ranging from mild to severe/pro-found, 
who mostly communicate through spoken language. Quite often, these people lost 
hearing gradually. Such people often benefit from hearing aids and cochlear implants 
(Action on hearing loss 2015; World Health Organization 2012a). Conversely, 
deafness is defined as a degree of impairment that is so severe such that a person is 
unable to process or understand speech even in the presence of amplification. In 
profound deafness, even the loudest sounds produced may not be detected. In total 
deafness, no sounds at all, regardless of amplification or method of production, are 
heard (Feldman et al 2012:602; Mackenzie & Smith 2009:565-71; World Health 
Organization 2012a:8). 
 
Hearing impairment can be characterised in many ways: i) based on the source of 
the dysfunctions along the auditory pathway can cause hearing loss. Hearing losses 
may be divided into several categories based on where in the ear the impairment is 
located (the type of hearing loss); ii) based on how severely the impairment affects a 
person‘s hearing sensitivity (the degree of hearing loss); and iii) may be based on 
which ears are affected (the laterality of the hearing loss). Other considerations 
include the nature of the hearing impairment, especially onset; association with other 
conditions; or duration and reversibility of hearing loss (Feldman et al 2012; 
Mackenzie & Smith 2009:565-71; Shield 2006:10-12). 
 
44 
 
2.2.6.1 Characterisation according to where impairment is located (type of 
hearing loss) 
 
Hearing loss could be conductive, sensorineural, or mixed. The schematic in Figure 
2.5 illustrates the mechanism for the main categories of hearing loss. 
 
 
 
Figure 2.5: Schematic showing main types and cause of hearing loss.  
(Source: Harrison, RV. 2008. Noise-induced hearing loss in children: A 'less than silent' 
environmental danger. Paediatric Child Health, 13(5): 377-382). 
 
2.2.6.1.1 Conductive hearing loss 
 
This type of hearing loss occurs when there is a problem in the outer or middle ear. 
Sound is not able to travel properly through the ear canal to the eardrum and 
ossicles and the difficulty lies in the conduction of sound to the cochlea. One of the 
most common causes of conductive hearing loss is excessive wax in the ear canal, 
fluid in the middle ear brought on by an infection, or a discontinuity between the 
ossicles, which prevents sounds from reaching the inner ear efficiently. These may 
lead to a temporary hearing loss that can be treated medically or surgically.  
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2.2.6.1.2 Sensorineural hearing loss 
 
Sensorineural hearing losses occurs when there is a problem in the inner ear or 
along the auditory nerve, because the difficulty lies in the ability of the cochlea to 
sense the sound or the ability of the nerve to carry the signal to the brain. Patients 
with SNHL can have a varying amount of hearing loss (slight to profound) and may 
have difficulty hearing and understanding speech clearly. Sensorineural hearing loss 
is typically treated with the use of hearing aids or other hearing technologies; it 
cannot be medically or surgically corrected.  
 
2.2.6.1.3 Mixed hearing loss 
 
This type of hearing loss occurs when a person has both conductive hearing loss 
and SNHL. People with mixed hearing loss may have damage to the outer ear, the 
middle ear, the inner ear, and/or the nerve that connects the inner ear and the brain 
(Smith, Bale & White 2005:880). 
 
2.2.6.2 Characterisation of hearing loss according to severity (grade of 
hearing loss) 
 
Severity of hearing impairment is categorised differently by different organisations 
(Shield 2006:10; World Health Organization 2012a). One hearing scale used a 
qualitative self-rated scale (SRS), and people rate the hearing ability of each ear 
without the use of hearing aids on a four-point scale, ranging from ―good‖ to ―deaf.‖ 
Another qualitative scale is the Gallaudet Hearing Scale (GHS). This is a five-point or 
eight-point scale that rates how well a person can usually hear and understand 
speech without the use of hearing aids, and it ranges from the ―ability to hear and 
understand whispered speech‖ to the ―inability to hear or understand any speech‖ 
(Barnett & Franks 2002:106; Kochkin 2007:3-4).  
 
An eight-point scale was used in which the respondent indicates whether they can 
understand speech under the following conditions: 
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1. whisper across a quiet room;  
2. normal voices across a quiet room;  
3. shouts across a quiet room; 
4. loud speech spoken into their better ear; 
5. not able to understand loud speech in their better ear;  
6. tell noises from each other; 
7. hear loud noises at all; 
8. Hear any sound or any noise.  
 
While an individual‘s score ranges from 1-8, typically the scores are classified into 
one of five groups:  
 
1. hear whisper;  
2. hear normal voice; 
3. hear shouts; 
4. hear speech in loud ear; 
5. cannot hear speech (Kochkin 2007:3-4).  
 
From the quantitative point of view, below are examples of the grading of hearing 
impairment by individual institutions. 
 
2.2.6.2.1 World Health Organization Grading system  
 
The WHO defines disabling hearing impairment in adults as a permanent unaided 
hearing threshold level (average for frequencies 0.5, 1, 2, 4 kHz) for the better ear of 
41 dB or greater (World Health Organization 2013). In children under 15 years of 
age, disabling hearing impairment is defined as permanent unaided hearing 
threshold level (average for frequencies 0.5, 1, 2, 4 kHz) for the better ear of 31 dB 
or greater.   
 
The WHO grades hearing impairment into four grades in better ear and provides 
qualitative description:  
 
47 
 
 Grade 0 is no impairment; 25 dB or better refers to no or very slight hearing 
problems.  
 Grade 1 refers to slight impairment, and 26 - 40 dB the person is able to hear 
and repeat words spoken in normal voice at 1 metre.  
 Grade 2 is moderate impairment with a 41 - 60 dB range and the person is 
able to hear and repeat words using raised voice at 1 metre.  
 Grade 3 is severe impairment with a threshold of 61 - 80 dB and the person is 
able to hear some words when shouted into better ear.  
 Grade 4 is profound impairment including deafness and a threshold of 81 dB 
or greater. The person is unable to hear and understand even a shouted 
voice.  
 
2.2.6.2.2 European Commission Grading system 
 
The European Commission proposed definitions of grades of hearing impairment for 
use in Europe (European Group on genetics of hearing impairment, 1996) as cited in 
Shield (2006). In these definitions, the better ear hearing loss (BEHL) is defined as 
the pure tone average of the four frequencies 0.5, 1, 2 and 4 kHz for the better ear 
as follows:  
 
 Normal -20dB(BEHL); 
 Mild-21-39 dB (BEHL);  
 Moderate-40-69dB (BEHL); 
 Severe-70-94 dB (BEHL); and  
 Profound-95 or more dB (BEHL)  
 
A reason for including the frequency 4 kHz was that it is often a significant frequency 
in noise induced hearing loss and age related loss (Shield 2006:12) 
 
2.2.6.2.3 American National Standards Institute Grading system 
 
The American National Standards Institute (ANSI) defines 5 categories of hearing 
impairment, starting at a hearing level of 27 dB (Shield 2006:12):  
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 Normal hearing level - less than 27 dB;  
 Mild hearing loss is 27 - 40 dB hearing level;  
 Moderate hearing loss is 41 - 55 dB hearing level;  
 Moderate-severe   hearing loss 56 - 70 dB hearing level;  
 Severe hearing loss is 71 - 90 dB hearing level; and  
 Profound hearing loss is 91 dB and above. 
 
2.2.6.2.4 The Royal National Institute for Deaf and Hard of Hearing People Grading 
system (RNID) 
 
The Royal National Institute for Deaf and Hard of Hearing People (RNID) on the 
other hand has defined deafness in four categories (Action on hearing loss, 2015) 
which relate to the quietest sound that can be heard in the better ear as follows: 
 
 Normal hearing is below 25dB; 
 Mild hearing loss is 25 - 39 dB and there is difficulty in following speech;  
 Moderate hearing loss is 40 - 69 dB and there is difficulty in following speech 
without a hearing aid; 
 Severe hearing loss is 70 - 94 dB with great reliability on lip reading, even with 
a hearing aid;  
 Profound hearing loss is 95 dB or greater and communication is by lip 
reading, the British Sign Language or the preferred language.  
 
The RNID defines ‗deafened‘ people as people who are not pre-lingual deaf but 
become profoundly deaf later in life because of trauma, infection or ototoxic drugs. 
 
 
2.2.6.2.5 The British Society of Audiology (BSA) grading system 
 
In the United Kingdom, four audiometric descriptors used are based on the average 
pure tone thresholds at 0.25, 0.5, 1, 2 and 4 kHz. Averages do not imply any 
particular configuration of hearing loss and do not exclude additional terms (e.g. 
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profound high frequency hearing loss) (British Society of Audiology 2011:22). 
According to the BSA:  
 
 Mild hearing loss is 20 - 40 dB;  
 Moderate hearing loss is 41 - 70 dB;  
 Severe hearing loss is 71 - 95 dB; and 
 Profound hearing loss is in excess of 95 dB.  
 
2.2.6.2.6 The National Institute on Deafness and Other Communication Disorders 
Grading System 
 
The National Institute on Deafness and Other Communication Disorders (NIDCD) in 
the US defines hearing handicap in terms of the pure tone average hearing loss at 
speech frequencies 0.5, 1, 2, and 3 kHz: 
 Normal hearing is 25 dB or less; 
 Functional handicap is around 40 dB and some form of amplification is 
beneficial; 
 Severe to profound hearing loss is 75 dB or greater and hearing aids provide 
limited benefit. 
 
From the above descriptions, it is clear that there is no global consensus on the 
standards used to determine the   thresholds of hearing loss. Each institutions has 
made their own recommendations for grading severity of hearing loss as 
summarised in Table 2.3.  
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Table 2.3 Summary of hearing status grading by different institutions 
 
  
 
2.2.6.3 Characterisation of hearing loss by the laterality of the hearing loss 
 
Hearing losses may be classified as either unilateral (affecting only one ear) or 
bilateral (affecting both ears). Bilateral hearing losses may be symmetric 
(approximately the same in each ear) or asymmetric (worse in one ear than the 
other). Hearing losses from environmental causes (such as noise, ototoxic 
chemicals, and ageing) are generally bilateral and symmetric. Hearing losses from 
medical causes (such as ear infections, mumps, and acoustic tumours) are often 
unilateral or asymmetric. A substantial difference in hearing sensitivity between ears 
can be indicative of a medically significant condition. 
 
2.3 IMPACT OF HEARING LOSS 
 
The loss of hearing can be very devastating and a life-changing experience. It has 
far- reaching consequences that may encompass the way one communicates, 
relates, perceives self, earns a living and and/or is perceived (Ask et al 2010:271-
275; Morris et al 2013:954; Wallhagen 2004:S190-119; Wallhagen 2010:66-75). 
Groce, Yousafzai, Dlamini, Zalud and Wirz (2006: 319) found that in Swaziland, the 
majority (99%) of the deaf report difficulties in communicating with healthcare facility 
staff affecting their utilisation of health preventive and curative services. In another 
study, the deaf population in Swaziland was reported to be significantly more likely 
(p<0.05) to believe in incorrect modes of HIV transmission than the normal hearing 
(Groce et al 2006:319-324; Groce 2003:1401-1402). 
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2.3.1 Impact of diagnosis on the patient 
 
If hearing loss develops in the young, it impedes speech and language development 
and could affect the educational and vocational attainment, including an increase in 
physical, emotional and psychological abuse (Mason & Mason 2007:407-26; 
Olusanya 2008:S3-13; Olusanya, Neumann & Saunders 2014a). Increased mental 
problems have been reported among deaf people (Fellinger, Holzinger & Pollard 
2012:1037-38). After adjusting for confounding factors, hearing impairment 
negatively impacted on the independence of the affected by increasing reliance on 
community or family support (Schneider, Gopinath, Karpa, McMahon, Rochtchina, 
Leeder & Mitchell 2010:458-60). Hearing-impaired persons had a 3-fold higher risk of 
developing social and emotional deficits in everyday life (Gopinath, Hickson, 
Schneider, McMahon, Burlutsky, Leeder & Mitchell 2012:618-23). Hearing loss 
causes impairment of the exchange of information, thus significantly impacting 
everyday life, causing loneliness, isolation, dependence, and frustration (Ciorba, 
Bianchini, Pelucchi & Pastore 2012:159-63). People with hearing impairment have 
barriers to health care (Groce et al 2006:319-24; Scheier 2009:4-10). In principle, 
persons with MDR-TB treatment related hearing loss have the same right on 
diagnosis and treatment of sensory loss as other people have to other medical and 
surgical conditions. 
 
2.3.2 Effects of hearing loss on the family  
 
Hearing disabilities, due to their interactive nature, strongly affect intimate 
relationships (Hetu, Jones & Getty 1993-81), placing a considerable strain on 
relationships and increasing their vulnerability to failure (Hallam, Ashton, Sherbourne 
& Gailey 2008:369-88). Hearing loss affects the whole family, as communication is a 
key part of maintaining healthy relationships with family members. Failure to 
communicate, or when people with hearing loss fail to correctly guess the words, 
they miss a range of reactions, ranging from laughter, to confusion, to anger, and 
social withdrawal.  Ultimately, the whole family misses out, including children and 
adolescents (Mason & Mason 2007:407-26). Spousal impact is high and ranges from 
the effects of the  hearing impairment on the spouses' everyday lives; the spouses' 
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need to constantly adapt to their partners' hearing impairment; and the effect of 
acceptance of the hearing impairment on the spouse (Scarinci, Worrall & Hickson 
2008:141-50). Spouse hearing loss increases the likelihood of subsequent poorer 
physical, psychological, and social wellbeing in partners, although the negative 
impact of husbands' hearing loss on wives' wellbeing appears stronger than the 
reverse (Wallhagen, Strawbridge, Shema & Kaplan 2004:S190-6). Mental health of 
the spouse could be affected (Ask et al 2010:271-5). 
 
2.3.3 Impact on informal and professional networks 
 
Most work places rely on verbal communication and hence hearing is a critical sense 
for effective communication in the work force. The quality of life of people with 
hearing loss is significantly affected in the following ways: reduced earning power 
(especially the more severe hearing losses); reduced interpersonal relationships 
(especially for mild-to-moderate losses), including lesser intimacy and increasing of 
negative dysfunctional communication in the informal and professional networks and 
the hearing impaired may be unintentionally left out. The hearing impaired are also 
challenged by the physical aspects of the work environment, the need to use 
telephones or videoconferencing, the difficulty of group communication situations, 
and difficulties presented by various speaker characteristics.  Employer attitudes 
could be another barrier and unsupportive supervisors could be among the 
difficulties encountered by many deaf and hard-of-hearing workers causing them to 
make mistakes on the job, which may negatively impact job performance (Dobie & 
Van Hemel 2004). 
 
2.3.4 Hearing Loss and self-esteem, self-image and communication 
 
Positive self-concept is associated with higher levels of positive adjustment and 
lower levels of psychosocial problems, especially internalizing problems. 
Communicative deprivation amongst the hearing impaired, and sometimes, even 
isolation, may be particularly troublesome during adolescence. Intimate attachments 
with parents and peers are especially important for the development of a sense of 
competence and for identity or ego development (van Gent, Goedhard, Knoors, 
Westenberg &Treffers 2012:331-51). Increased self-criticism; and reduced cognitive 
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functioning (primarily severe-to-profound hearing loss) could result because of 
isolation and being misunderstood, with a severe blow to self-concept in the social 
domains (van Gent et al 2012:333-351). Hearing loss can also cause decreased 
health status and more incidence of pain, and reduced group social activity because 
of a negative self-image (Olusanya et al 2014a:367-73). Hearing loss also 
associated with increase in the incidence of depression and depressive symptoms; 
reduced emotional stability; increase in paranoid feelings and increased anxiety 
symptoms as well as increased social phobias (primarily severely impaired 
respondents); and reduced belief that the subject is in control of their lives (locus of 
control). 
 
 
2.3.5 Economic and social costs 
 
While no studies have been undertaken in Swaziland to assess the economic and 
societal costs of SNHL, anecdotal evidence suggests that MDR-TB patients who 
develop hearing loss lose their jobs because of the permanent loss of hearing. 
Consequently, if they are the breadwinners, the family loses income. Based on 
report on hearing loss, Shield (2006:140) posits that the socio-economic costs of 
hearing impairment arise from loss of earnings and medical costs related to hearing 
health, either on an individual or total population basis.  Jung and Bhattacharyya 
(2012:771-5) states that adults with hearing loss are more likely to be unemployed 
and on average earn significantly less wage income than adults without hearing loss. 
(Jung & Bhattacharyya 2012).  Kochkin (2005) shows that hearing loss negatively 
impact household income on average up to US $12 000 per year in the US 
depending on the degree of hearing loss and it can projected some degree of 
household income is affected in Swaziland too.. Emmett &Francis (Emmett & Francis 
2015) affirm that that although hearing loss is also associated with low educational 
attainment, even after controlling for education and important demographic factors, 
hearing loss is independently associated with economic hardship, including both low 
income and unemployment/underemployment. 
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2.4 DRUG RESISTANT TUBERCULOSIS  
 
Multi-drug resistant tuberculosis (MDR-TB) is caused by Mycobacterium tuberculosis 
that is resistant at least to Isoniazid and Rifampicin, the main first-line drugs in the 
treatment of tuberculosis. On the other hand, extensive drug resistant tuberculosis 
(XDR-TB) by mycobacteria is resistant to Rifampicin and Isoniazid, any 
fluoroquinolone, and one of the three injectable drugs, Capreomycin, Kanamycin, 
and Amikacin (Ahmad & Mokaddas 2013:1-5, Gandhi et al 2010:1830; WHO 2013, 
World Health Organization 2011c, 2012). While DR-TB is a global emergency and 
poses a major threat to control of TB worldwide, more than 50% of the estimated 
cases are in India and China (Chiang et al 2010:413). Globally, however, major 
diagnostic and treatment gaps of MDR-TB exist: 55% of reported TB patients 
estimated to have MDR-TB were not detected.  Of those detected, less  than 60% 
were in 10 high MDR-TB burden countries in 2013 with the lowest in Myanmar 
(34%), South Africa (41%), and Tajikistan (30%) who were started on treatment: 136 
000 MDR-TB patients were diagnosed and notified and 97 000 MDR-TB patients 
were started on treatment out of the estimated 480 000 cases globally (World Health 
Organization 2014).  
 
2.4.1 Global Control of Multi-drug resistant tuberculosis 
 
The WHO has characterised MDR-TB as a public health crisis, synonymous with a 
global health security risk and with grave consequences for those affected. The five 
prioritised global control priority actions to accelerate the response against the MDR-
TB epidemic are: i) Prevent MDR-TB as a first priority; ii) Scale-up rapid testing and 
detection of all MDR-TB cases; iii) Ensure prompt access to appropriate MDR-TB 
care, including adequate supplies of quality drugs and scaled-up country capacity to 
deliver services; iv) Prevent transmission of MDR-TB through appropriate infection 
control; and v) High level political commitment, strong leadership across multiple 
governmental sectors, ever-broadening partnerships, and financing for care and 
research (Chiang et al 2010:413; Chiang et al 2013-604; Gandhi et al 2010:1830-43; 
World Health Organization 2014b).  
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2.4.2 Burden of MDR-TB in Swaziland 
 
In Swaziland, 7.7% of the new TB patients have MDR-TB and 33.4% of the 
previously treated patients are estimated to have MDR-TB (Sanchez-Padilla et al 
2012:29-37). In 2013, Swaziland had 491 laboratory confirmed MDR-TB cases but 
only initiated 199 cases on treatment (WHO 2013).  
 
2.4.3 Mechanism for development drug resistant tuberculosis 
 
Resistance to anti-tuberculosis drugs can be primary or acquired (Laxminarayan et 
al., 2006). Drug resistance primarily arises because of spontaneous mutations in the 
genome of M tuberculosis. These resistant-conferring mutations occur at predictable 
rates for each antituberculosis drug (for example, Isoniazid 10–6, Rifampicin 10–8) 
(Gandhi et al 2010:1830-43). Thence, subpopulations of resistant mycobacteria arise 
spontaneously, and can emerge as the dominant strain in the presence of drug-
selection pressure (Ahmad & Mokaddas 2009:1777). Many activities of the health 
care workers, patients and health system in the management of tuberculosis and 
anti-tuberculosis medicines may be responsible for sub-therapeutic serum 
concentrations, hence a cause of the current predicament of DR-TB. Isoniazid mono-
therapy selects for Isoniazid-resistant mutants and allows them to multiply (Figure 
2.5) and become the dominant strain.  
 
Resistance to additional tuberculosis drugs can be added in a step-wise manner to 
create tuberculosis strains that are resistant to several drugs; for example, treatment 
of Isoniazid mono-resistant tuberculosis with Isoniazid and Rifampicin selects for 
spontaneous Rifampicin-resistant mutants (Gandhi et al 2010:1830-43). This 
process is referred to as acquired resistance. Once created, drug-resistant strains 
can be transmitted giving rise to DR-TB in individuals never previously exposed to 
anti-tuberculosis drugs (primary resistance) (Gandhi et al 2006:1575–80) 
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2.4.4 Treatment of MDR-TB 
 
MDR-TB is treated with combination chemotherapy. In 2011, the WHO released an 
update of the programmatic guidelines (Falzon, Jaramillo, Schunemann, Arentz, 
Bauer, Bayona, Blanc, Caminero, Daley, Duncombe, Fitzpatrick, Gebhard, Getahun, 
Henkens, Holt, Keravec, Keshavjee, Khan, Kulier, Leimane, Lienhardt, Lu, 
Mariandyshev, Migliori, Mirzayev, Mitnick, Nunn, Nwagboniwe, Oxlade, Palmero, 
Pavlinac, Quelapio, Raviglione, Rich, Royce, Rusch-Gerdes, Salakaia, Sarin, 
Sculier, Varaine, Vitoria, Walson, Wares , Weyer, White & Zignol 2011:516-28) 
recommending that the intensive phase of MDR-TB treatment should consist of at 
least 8 months of injectable second-line anti-tuberculosis drugs (TB SLD) and total 
treatment duration of a minimum of 20 months. Hence, treatment of MDR-TB may 
require at least 2 years or more to treat (Ahmad & Mokaddas 2013). Shorter 
treatment regimens are currently being explored but these two require injectable TB 
SLDs (Piubello, Harouna, Souleymane, Boukary, Morou, Daouda, Hanki & Van Deun 
2014:1188-94). 
 
The drugs used in the treatment of MDR-TB are referred second-line drugs and are 
generally more toxic than the first-line drugs (Bardien, de Jong, Schaaf, Harris, 
Fagan & Petersen 2009a; Bardien, Human, Harris, Hfke, Veikondis, Schaaf, van der 
Merwe, Greinwald, Fagan & de Jong 2009). Aminoglycosides constitute one of the 
oldest classes of antimicrobials. Despite their toxicity, mainly nephrotoxicity and 
ototoxicity, aminoglycosides are valuable in current clinical practice, since they retain 
good activity against multidrug-resistant Gram-negative pathogens, such as 
Pseudomonas aeruginosa and Acinetobacter species (Arbex, Varella Mde, Siqueira 
& Mello 2010:626-640; Pagkalis, Mantadaki, Mavros, Ammari & Falagas 2011:2277-
94).  
 
In Swaziland, MDR-TB treatment consists of a backbone of an injectable agent 
Kanamycin (Amikacin or Capreomycin) and oral second-line medicines. Formulation 
of an MDR-TB treatment regimen in based on the following principles: 
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1. The recommended regimen in the treatment of MDR-TB is the combination of 
at least four drugs to which the Mycobacterium tuberculosis isolate is likely to 
be susceptible.  
 
2. Drugs are chosen with a stepwise selection process through five groups 
based on efficacy, safety, and cost and the injectable medicines form the 
backbone of MDR-TB treatment (Caminero et al 2010:621): 
 
a) Group 1:  the oral first-line drugs including high-dose Isoniazid, 
Pyrazinamide, and Ethambutol are adjunct for the treatment of MDR and 
XDR tuberculosis.  
b) Group 2: the fluoroquinolones including Moxifloxacin and high-dose 
Levofloxacin.  
c) Group 3: the injectable drugs: Capreomycin, Kanamycin, and Amikacin.  
d) Group 4: the second-line drugs should be used in the following order: 
Thioamides, Cycloserine, and then Aminosalicylic acid.  
e) Group 5: includes drugs that are not very effective, or for which there are 
sparse clinical data, should be used in the following order: Clofazimine, 
Amoxicillin with Clavulanate, Linezolid, Carbapenems, Thioacetazone, and 
then Clarithromycin. 
 
The full treatment regimen used is recommended by the Swaziland National 
Tuberculosis Control Programme and abbreviated as Km-Lfx-Eto-Cs (Trd)-PAS-Z; in 
full the abbreviation stands for: Kanamycin, Levofloxacin, Ethionamide, Cycloserine, 
Para Amino-Salicylate, and Pyrazinamide).  The injectable agents are used for the 
first 8 months before a continuation treatment of 12 months on oral medicines giving 
a total treatment duration of 24 months (Kingdom of Swaziland Ministry of Health 
2012). 
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2.4.5 Adverse drug reactions: definition, grading and monitoring 
 
2.4.5.1 Definitions related to adverse drug reactions 
 
In section 1.6.1, the term adverse drug reaction (ADR) is defined as ―an appreciably 
harmful or unpleasant reaction, resulting from an intervention related to the use of a 
medicinal product, which predicts hazard from future administration and warrants 
prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of 
the product‖ (Davies et al 2009; Edwards & Aronson 2000:1255-59; Mammi, Citraro, 
Torcasio, Cusato, Palleria & di Paola 2013:S33-7). However, WHO (1969) provides 
a more precise definition stating intention and dosage as important components of 
the definitions:  an ADR is a ―response to a drug which is noxious and unintended 
and which occurs at doses normally used in man for prophylaxis, diagnosis, or 
therapy of disease or for the modification of physiologic function.‖  The European 
Union, however, further clarifies that all noxious and unintended effects may be due 
to: i) the use of medicines according to the marketing authorisation instructions; uses 
not complying with the wording marketing authorisation: ii) authorised use of 
medication (off-label use), abuse, misuse, medication errors, overdose and adverse 
reactions associated with occupational exposure. 
 
The terms adverse drug reaction (ADR) or adverse drug effect (ADE), sometimes 
referred to only as adverse events (AEs), are used synonymously and are broad 
terms referring to unwanted, uncomfortable, or dangerous effects that a drug may 
have (Forster et al 2011:576; Nebeker, Barach & Samore 2004a:975; Thomas & 
Petersen 2003:61). Nebeker et al (2004:795) delineates these terminologies. In that 
regard, an ADR (as defined above) is part of a bigger term, adverse drug event. An 
adverse drug event (ADE) is an injury resulting from the use of a drug. Under this 
definition, the term ADE includes harm caused by the drug (adverse drug reactions 
and overdoses) and harm from the use of the drug (including dose reductions and 
discontinuations of drug therapy). About 25% of adverse drug events are due to 
medication errors as shown in Figure 2.8 (Nebeker et al 2004b-801). 
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Figure 2.6: Relation between adverse drug reaction, adverse drug events, and medical errors.  
(Source: Nebeker et al. Ann Intern Med 2004; 140: 795-801). 
 
While adverse drug reactions result from intended use, adverse drug events may 
result from medication errors. Medication errors are mishaps that occur during 
prescribing, transcribing, dispensing, administering, adherence, or monitoring a drug. 
Examples of medication errors include misreading or miswriting a prescription. 
Medication errors that are stopped before harm can occur are sometimes called 
―near misses‖ or ―close calls‖ or more formally, a potential adverse drug event 
(Naranjo et al 1981:240-245; Nebeker et al 2004b:795).  
 
On the other hand, a side effect is an expected and known effect of a drug that is not 
the intended therapeutic outcome of medication.  The term ―side effect‖ tends to 
normalise the concept of injury from drugs and adverse drug reaction is a more 
accurate expression. Medication errors are more common than adverse drug events, 
but less than 1% of the time result in harm (Naranjo et al 1981:240). 
 
2.4.5.2 Grading of adverse drug reactions  
 
Adverse reactions can be graded as mild, moderate or severe or grades 1-5, each 
with a unique clinical description of severity (US Deaprtment of Health and Human 
Services 2010:1): 
 
 Mild ADRs require minimal therapeutic intervention such as discontinuation of 
drug(s);  
 Moderate ADR requires active treatment of adverse reaction, or further testing 
or evaluation to assess extent of non-serious outcome.  
60 
 
 Severe ADRs include any serious outcome, resulting in a life- or organ-
threatening situation, significant or permanent disability, requiring intervention 
to prevent permanent impairment or damage, or requiring/prolonging 
hospitalisation. MDR-TB related hearing loss falls in this category. 
 Death related to the ADR. 
 
2.4.5.3 Adverse drug reactions monitoring 
 
Pharmacovigillance is the term used for routine monitoring of adverse drug 
reactions. It is defined as the science and activities relating to the detection, 
assessment, understanding and prevention of adverse effects or any other drug-
related problems.  It can be linked to the risk reduction strategies for adverse drug 
reactions that require a reporting system that enables reporting on the frequency, 
magnitude, and impact of adverse events (WHO 2005:7).  
 
However, in general, in spite of spontaneous adverse drug reaction reporting being 
the cornerstone of PV, adverse drug reactions are inadequately reported (Lopez-
Gonzalez, Herdeiro & Figueiras 2009a:19-31). Below are some illustrations in 
literature that implicate potential under-reporting of ototoxic hearing loss, which can 
be a ―silent‖ condition. In Nigeria, Ohaju-obodo and Iribhogbe (2010:191) report that 
although 92.6% of medical doctors had observed adverse drug reactions at the four 
large teaching hospitals, only 25.5% had reported them. Inadequate knowledge 
about adverse drug reaction reporting (73.1%) among the doctors was the 
commonest reason. However, in Oshikoya and Awobusuyi (2009), ADR reporting 
was encouraged if the reaction was serious (77, 77.8%) and unusual (70, 70.7%) 
and education and training was the most recognised means of improving ADR 
reporting. Voluntary reporting (41.66%) was the most preferred form of reporting 
ADRs in India (Pimpalkhute, Jaiswal, Sontakk, Bajait & Gaikwad 2012:55-61).  
 
2.4.5.4 Adverse drug reactions associated with MDRTB treatment 
 
Many studies have documented adverse drug reactions (ADRs) associated with 
MDRTB treatment (Bloss et al 2010:275-81; Furin, Mitnick, Shin, Bayona, Beccerra, 
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Singler, Alcantara, Casteneda, Sanchez, Acha, Farmer & Kim 2001:648-55; Törün, 
Güngör, Özmen, Bölükbaşi, Maden, Biçakçi, Ataç, Sevim & Tahaoğlu 2005:1373-77) 
may include the following:  
 
 psychiatric disorders manifesting as depression, anxiety, nightmares or 
psychotic symptoms;  
 gastrointestinal effects consisting of nausea, vomiting, abdominal pain, 
hematemesis, melena, diarrhoea and positive endoscopic findings;  
 skeletal effects like arthralgia, arthritis with pain or swelling in the joints and 
limitation of movement;  
 central nervous system disorders like seizure activity of any type as reported 
by the patient or witnessed by another individual;  
 hepatitis evidenced by any elevation of serum transaminases in the presence 
of symptoms or elevation of serum transaminases to five times normal values 
without any symptoms;  
 peripheral neuropathy manifesting as numbness, tingling or burning in the 
trunk or extremities; diminished or absent reflexes; and  
 Ototoxicity manifesting as cochleotoxicity and/or vestibulotoxicity. Symptoms 
of ototoxicity include partial or profound hearing loss, vertigo, and tinnitus. 
  
2.5 AMINOGLYCOSIDE RELATED HEARING LOSS AND OTOTOXICITY 
 
2.5.1 Structure and Chemistry 
 
Aminoglycosides are a class of antibiotics, discovered in 1944 by Selman Waksman 
and, because they are cost effective, they are widely used in the treatment of 
tuberculosis.  Aminoglycosides are naturally occurring compounds produced by the 
soil actinomycetes and their semi synthetic derivatives. Streptomycin, Neomycin, 
Gentamycin, Kanamycin, Tobramycin and Amikacin are all examples of 
aminoglycosides.  They were part of the miracle drugs in treatment of tuberculosis.  
Although Streptomycin was abandoned as a first-line drug for treating new TB 
patients, it plays an important role in the re-treatment regimen for previously treated 
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patients. The other aminoglycosides, Kanamycin and Amikacin are used in the 
treatment of DR- TB (Arbex et al 2010:641; Guthrie 2008:91).  
 
2.5.2 Antibacterial activity of aminoglycosides 
 
Aminoglycosides inhibit protein synthesis by irreversibly binding to the 30S ribosomal 
sub-unit of M. tuberculosis, interfering with the integrity of the cell membrane. The 
aminoglycosides are bactericidal antibiotics that bind to the 30S ribosome and inhibit 
bacterial protein synthesis (Arbex et al 2010:642). Resistance is due to mutations in 
the rrs gene, which encodes 16S ribosomal RNA, and in the rpsL gene, which 
encodes the S12 ribosomal protein gene. 
 
2.5.3 Pharmacokinetics of aminoglycosides 
 
Oral absorption of aminoglycosides is minimal, and the drugs are administered 
parenterally. Absorption is complete when aminoglycosides are administered 
intramuscularly and the serum levels of the drugs peak within 30-90 minutes after 
their administration; however, intramuscular absorption can be slower, requiring 
successive injections at the same site. It is recommended that intravenous 
administration of aminoglycosides be carried out over a period of 15-30 minutes in 
order to reduce the risk of adverse effects, such as neuromuscular blockade. The 
binding of aminoglycosides to plasma proteins is low (approximately 10%). Over a 
24-hour period, 80-98% of the drug is excreted, unaltered, by the kidneys 
(glomerular filtration), 1% is excreted in bile, and 1% is excreted in faeces. The half-
life of Streptomycin is 2-3 hours, and the half-life of Amikacin is 2 hours, although the 
latter can be as long as 86 hours in patients with kidney failure (Arbex et al 
2010:642). 
 
2.5.4 Aminoglycoside Ototoxicity 
 
Ototoxicity refers to poisoning of the inner ear by medication, by a toxin or a 
poisonous reaction damaging the cochlea, vestibule, semi-circular canals, or the 
auditory/ vestibulocochlear nerve. Symptoms of ototoxicity include partial or profound 
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hearing loss, vertigo, and tinnitus (Roland 2004). The damaged structure then 
produces the symptoms the patient presents with and ototoxicity defined as a) 20dB 
or greater decrease in pure tone threshold at one frequency, b)10dB or greater 
decreased at 2 adjacent frequencies, or c) loss of three consecutive test frequencies 
in which responses were previously obtained when OAR or Auditory Brainstem 
Responses (ABR) is used ((American Speech-Language-Hearing Association 1994).  
 
Aminoglycoside antibiotics used in MDR-TB treatment may cause hearing loss 
resulting from cochlear toxicity. Cochlear toxicity usually begins in the high 
frequencies and is secondary to irreversible destruction of outer hair cells in the 
organ of Corti, predominantly at the basal turn of the cochlea (Rybak & Ramkumar 
2007). This type of hearing loss is induced by selective inner ear sensory hair cell 
death caused by the aminoglycoside cleared more slowly from inner ear fluids than 
from serum, and therefore latency exists to the ototoxic effects of aminoglycosides 
(Alharazneh, Luk, Huth, Monfare, Steyger, Cheng & Ricci 2011). This latency can 
result in progression of hearing loss or onset of hearing loss after cessation of 
aminoglycoside treatment. Continuing to monitor the patient for cochleotoxic and 
vestibulotoxic effects up to 6 months after cessation of aminoglycoside treatment is 
recommended (Fausti et al 2005:52). 
 
2.5.5 Mechanism of aminoglycoside ototoxicity  
 
The cellular basis for aminoglycoside hearing loss is a destruction of cochlear hair 
cells, specifically the outer hair cells, and ototoxicity is mediated by disruption of 
mitochondrial protein synthesis and the formation of free oxygen radicals. 
Aminoglycoside uptake is mediated through the mechanotransducer (MET) 
Channels (Alharazneh et al 2011). Damage to the hair cells progresses from the 
base of the cochlea that is an area for high frequency sound detection to the apex 
and low frequency sound detection (Chen et al 2007:178). Sha, Taylor, Forge and 
Schacht (2001) have suggested that the base is more vulnerable than the apex  
which could be due to an intrinsic difference in sensitivity to damage along the 
cochlear spiral.  Since hair cells do not regenerate in the mammalian cochlea, their 
losses are irreversible and cumulative, and result in permanent damage to sensory 
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cells and neurons. Coupled with damage to sensory cells and neurons is the 
retrograde damage to the auditory nerve.  
 
2.5.6 Characteristics of individual aminoglycosides 
 
Ototoxicity is a grade 4 ADR and is one of the most severe ADR of MDR-TB 
treatments because it causes permanent disability (US Deaprtment of Health and 
Human Services 2010:17). Ototoxicity consists of one, or a combination of tinnitus, 
hearing loss and presence of disequilibrium. The anti-TB aminoglycosides vary 
greatly in their differential effects on the vestibular and cochlear systems. 
Kanamycin, Amikacin, Neomycin, and Dihydrostreptomycin are preferentially 
cochleotoxic. Gentamicin affects both cochlear and vestibular systems. 
Streptomycin, Tobramycin, and Netilmicin are primarily vestibulotoxic (Guan 
2011:237; Guthrie 2008:91-6; Huth, Ricci & Cheng 2011:1-6).  
 
2.5.6.1 Streptomycin 
 
Streptomycin was the first clinically applied aminoglycoside and was used 
successfully against tuberculosis. Streptomycin preferentially affects the vestibular 
system rather than the auditory system. Vestibular damage due to Streptomycin is 
common with prolonged use and in patients with impaired renal function. However, 
Streptomycin use has risen for treatment of tuberculosis (Arbex et al 2010:626-40). 
 
2.5.6.2 Kanamycin 
 
Kanamycin is quite ototoxic. Kanamycin has a propensity to cause profound cochlear 
hair cell damage, marked high-frequency hearing loss, and complete deafness 
(Brennan & Young 2008:89-169; Perletti, Vral, Patrosso, Marras, Ceriani, Willems, 
Fasano & Magr 2008:3-13). The damaging effect is primarily to the cochlea, while 
the vestibular system is usually spared injury (Perletti et al 2008:3-13; Zhang, Yu, 
Liu, Tian, Wang, Lai & Zhou 2011:171-6).  
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2.5.6.3 Amikacin  
 
Amikacin is a derivative of Kanamycin and has very little vestibular toxicity. Its 
adverse effects primarily involve the auditory system; however, it is considered less 
ototoxic than Gentamicin (Brennan & Young 2008:89-169; Perletti et al 2008:3-13). 
 
2.5.6.4 Polypeptides (Capreomycin) 
 
Capreomycin is a cyclic polypeptide antimicrobial and not an aminoglycoside and the 
chemical structure of Capreomycin is different from that of aminoglycosides. 
Capreomycin is obtained from Streptomyces capreolus and has been used as an 
anti-tuberculosis drug since 1959 (Akbergenov, Shcherbakov, Matt, Duscha, Meyer, 
Wilson & Bottger 2011:4712-7; Arbex et al 2010:626-40). The MIC of Capreomycin 
for M. tuberculosis is 10 μg/mL. However, Capreomycin and aminoglycosides are 
quite similar in terms of their antibacterial activity and adverse effects (Akbergenov et 
al 2011:4712). Resistance is associated with ribosomal changes in the 16S rRNA. 
There is cross-resistance between Capreomycin and Streptomycin and certain 
strains resistant to Amikacin and Kanamycin (Brennan & Young,2008:89). The 
mechanism of action of Capreomycin has yet to be fully understood. It is believed 
that the drug is active because it interferes with bacterial protein synthesis.  
 
Capreomycin is not absorbed when taken orally. Capreomycin is administered by 
intramuscular injection and absorption can be delayed in cases in which the same 
site of application is used repeatedly. Tissue distribution has yet to be fully 
understood. After the administration of the drug, the serum levels of Capreomycin 
peak within 1-2 hours. The plasma half-life of Capreomycin is 4-6 hours in patients 
with normal renal function, and it can be as long as 55 hours in patients with kidney 
failure. Most of the dose (50-60%) is excreted through glomerular filtration 12 hours 
after administration and a small proportion is excreted via the biliary tract (Brennan & 
Young 2008:88-90).  
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2.6 STUDIES ON INCIDENCE AND RISK FACTORS FOR MONITORING 
MULTI DRUG RESISTANT TB RELATED HEARING LOSS 
 
2.6.1 Global incidence of hearing loss related to MDR-TB treatment 
 
The incidence of ototoxicity among patients receiving the standard MDR-TB 
treatment varies greatly, according to some of the studies reviewed. Refer to Table 
2.4.  
 
Table 2.4 Studies on the incidence of MDR-TB treatment induced hearing impairment 
 
Year  Country  Prevalence/ 
incidence 
Rate Source Comments 
1994 India  incidence 52.9% WHO (1995:4) Patients treated 
with Streptomycin 
2001 Peru  incidence 6.7 Furin (2001:650) Community based 
study 
2002 Netherlands  incidence 18.5% de Jager 
(2002:622-7) 
Investigated 
ototoxic and 
nephrotoxic effects  
2005 Turkey  incidence: 
record 
review 1992-
2004 
41.8% Torun 
(2005:1375) 
Tinnitus, hearing 
loss,disequilibibrium 
2007 India  incidence 18.75% Duggal (2007:1-
9) 
Group I, 34 
(Amikacin), group II, 
26 (Kanamycin) 
group III, 4 
(Capreomycin)  
 
(*Sources: Brummett and Fox, 1989:797-798; Duggal, 2007:1-9; de Jager, 2002:622-7; Furin, et al, 
2001: 648-655; Torun, et al, 2005:1375; WHO, 1995:1-4) 
 
2.6.2 Incidence of hearing loss related to MDR-TB treatment by 
continent 
 
2.6.2.1 Europe 
 
In the Netherlands, de Jager (2002:622-7) found that 18% of the patients treated 
with injectable aminoglycoside developed hearing loss, while Bloss et al (2010:275) 
reported the hearing loss incidence of 19% in Latvia among 1 027 patients, while 
other researchers in Latvia found an incidence of 28.4% among 204 patients 
67 
 
(Leimane, Riekstina, Holtz, Zarovska, Skripconoka, Thorpe, Laserson & Wells 
2005:318). Shin, Pasechniko, Gelmanova, Peremitin and Strelis (2007:1317) in 
Tomsk, Russia, report hearing loss incidence of 15.6%.  Sturdy et al (2011:1815-20) 
reported an incidence rate of hearing loss of 18% in the United Kingdom, and Törün 
et al (2005:1373-77) reported a rate of 41.8%, which is the highest reported in 
Eastern Europe.   
 
2.6.2.2 Latin America 
 
Furin, et al (2001:648-655) found lower incidence of hearing loss of 6.7% in Peru.  
 
2.6.2.3 Middle East and Asia 
 
Masjedi, Baghaei, Mirsaeidi, Farnia, Javanmad, Mansoiri and Velayati (2011:752) in 
Iran, reported a hearing loss incidence of 46% and Duggal and Sarkar (2007:1) 
reported a hearing loss incidence rate of 18.75% in India which compares closely 
with the incidence of 14% in another study in India (Singla, Sarin, Khalid, Mathuria  
2009:976). 
 
2.6.2.4 Sub-Saharan Africa 
 
Among children in South Africa, the incidence of hearing loss was 24% (Seddon et al 
2013:320-9). Van der Walt et al documented a hearing loss incidence of 38% among 
ART naïve HIV positive patients (Van der Walt, Lancaster, Odendaal, Davis, Shean 
& Farley 2013:[1]), while Harries et al (2012:363-6) documented a hearing loss 
incidence of 37.8%.Ramma and Ibekwe (2012) found a prevalence of 47%.  
 
2.6.2.5 North America 
 
Peloquin found a hearing loss incidence of 37% among patients on aminoglycosides 
in the USA (Peloquin, Berning, Nitta, Simone, Goble, Huitt, Iseman, Cook & Curran-
Everett 2004:1538-44). 
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2.6.3 Risk Factors and Determinants of Aminoglycoside Related 
Ototoxicity 
 
A risk factor as any attribute, characteristic or exposure of an individual that 
increases the likelihood of developing a disease or injury, (adverse health out-
comes) (World Health Organization 2004). On the other hand, a determinant is a 
variable associated with either increased or decreased risk. Risk factors and 
determinants are correlational and not necessarily causal, because correlation does 
not prove causation. In this section, risk factors for developing ototoxicity are 
grouped as health system related or patient related.  
 
2.6.4 Health system related risk factors 
 
There are a number of health system related risk factors for MDR-TB treatment 
related ototoxicity such as type of drug, dose, frequency and administration route, 
treatment duration, dosage, co administration with other drugs and bioavailability, 
and so on. 
 
2.6.4.1 Dose of aminoglycoside drug 
 
Some studies show that the dose is a risk factor for MDR-TB treatment ototoxicity. 
Gatell, Ferran, Araujo, Bonet, Soriano, Traserra and SanMiguel (1987:1387) showed 
that patients enrolled in three prospective randomised trials patients who developed 
auditory toxicity,  had a significantly higher (P = 0.04) percentage of trough levels 
Amikacin above 5 mg/liter on univariate analysis. Rybak and Ramkumar (2007:933) 
contend that the degree of hair cell damage and hearing loss is directly proportional 
to the dose of the drug to which the hair cells are exposed. However, de Jager and 
Alterna (2002:622) found that factors such treatment duration, total aminoglycoside 
doses or first serum creatinine concentration were not associated with hearing loss. 
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2.6.4.2 Frequency of dosing 
 
One meta-analysis of once-daily versus multiple-daily dosing rates of clinically 
reported hearing loss were 0.4% for once-daily dosing and 0% for multiple daily 
dosing. Hearing loss rates determined audiometrically were 5.1% and 7.8%, 
respectively (Turnidge 2003:503). According to Barclay, Kirkpatrick and Begg 
(1999:89), at least 30 controlled clinical trials have compared once daily dose versus 
conventional multiple daily dose administration and it appears that aminoglycoside 
regimens that use the same total daily dose have the same incidence of ototoxicity 
as multiple dosing. Aminoglycosides appear to rapidly enter the cochlea after 
systemic administration, but the distribution within inner ear tissues does not 
correlate with their preferential toxicity to particular cells in the cochlea and vestibular 
system (Dulon, Aran, Zijic et al 1968:96). Perletti (2008:13) questioned what seems 
to be paradoxical.  Although single dose drugs induce higher peak serum 
concentrations, lower ototoxicity was observed when compared to multiple dose 
drugs. The inner ear uptake of AGs is a saturation process. Single dose drugs inner 
ear cells are saturated only once, whereas with multiple drug saturation occurs 2-3 
times within 24 hours thus increasing the cellular aminoglycoside load. 
 
2.6.4.3 Duration of exposure and previous exposure 
 
MDR-TB patients with previous exposure to Streptomycin could be prone to hearing 
loss. Repeated exposure to aminoglycosides leads to an additive damage to hair 
cells and other structures, and subsequently to deafness (Rybak & Ramkumar 
2007:933). It appears that the aminoglycosides persist in the inner ear tissues for 6 
months or longer after administration, and is the main cause for enhanced 
susceptibility of patients to the ototoxicity of aminoglycosides when they have a 
history of previous aminoglycoside treatment. The susceptibility does not seem to 
arise from drug accumulation within the inner ear, given that the inner ear 
concentration of aminoglycosides does not exceed that of the plasma. 
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2.6.4.4 Concurrent exposure to ototoxic drugs 
 
Prescription of ototoxic drugs concomitantly, especially loop diuretics, platinum-
based antineoplastic drugs, salicylates and NSAID, anti-malarial drugs (especially 
Quinine), HIV protease inhibitors and NRTI may be associated with increased MDR-
TB treatment hearing impairment. Antineoplastic agents most commonly associated 
with ototoxicity are the platinum-based compounds cisplatin and, to a lesser degree, 
carboplatin (Xia, Chen, Su, Yin & Wang 2014:376-85). These agents are widely used 
in gynaecologic, lung, central nervous system, head and neck, and testicular cancers 
(Yasui, Adachi, Kato, Koh, Asanuma, Sakata & Hanada 2014:1).  
 
Platinum compounds damage the stria vascularis in the scala media and cause outer 
hair cell death beginning at the basal turn of the cochlea (Xia et al 2014). The 
mechanism of platinum ototoxicity is mediated by free-radical production and the free 
radicals generated by this mechanism then lead to mitochondria-mediated and 
caspase-mediated apoptotic cell death, and ultimately permanent hearing loss. The 
following risk factors have been identified for development and potentiation of 
platinum-induced ototoxicity: (1) high dose and increasing number of cycles, (2) 
concurrent or past cranial irradiation, (3) age extremes, (4) dehydration, (5) co-
administration of other ototoxic agents, and (6) renal failure (Langer, am Zehnhoff-
Dinnesen, Radtke, Meitert & Zolk 2013:558-69; Mudd 2012). 
 
Loop diuretics are a class of medications used to treat congestive heart failure, renal 
failure, cirrhosis, and hypertension.  These include several different chemical groups, 
including sulfonamides, phenoxyacetic acid derivatives, and heterocyclic 
compounds. The most effective and frequently used diuretics; ethacrynic acid, 
furosemide, bumetanide can cause ototoxicity (Vilayur, Gopinath, Harris, Burlutsky, 
McMahon & Mitchell 2010:661-9).  The ototoxic effects of loop diuretics seem to be 
associated with the stria vascularis, which is affected by changes in the ionic 
gradients between the perilymph and endolymph (Xia et al 2014:376-85). These 
changes cause oedema of the epithelium of the stria vascularis. Overall, ototoxicity 
attributed to this group of medications is usually self-limited and reversible in adult 
patients, although irreversible hearing loss has been reported in neonates.   
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Ototoxicity is estimated to occur in 6-7 % of patients taking loop diuretics. 
Occurrence of loop diuretic ototoxicity depends on several factors, including dose, 
infusion rate, history of renal failure, and co-administration of other ototoxic agents 
like those used in treatment of MDR-TB (Sinxadi 2009:372-73). Potentiation and 
synergism of ototoxic effects of aminoglycosides and loop diuretics is well 
documented, and co-prescription of these drugs is not recommended (Hirose & Sato 
2011:108-18; Xiong, Chu, Huang, Cui, Zhou ,Chen, Li, Wang, Chen & Li 2010:222-
8).  If used, the lowest doses of loop diuretics is possible to achieve desired effects, 
avoiding rapid infusion rates and use in renal failure.  
 
2.6.5 The patient related risk factors  
 
From the literature reviewed, patient characteristics include age, sex, ethnicity, 
coexisting disorders, and genetic or geographic factors. 
 
2.6.5.1 Age above 60 years  
 
Gatell, Ferran, Araujo, Bonet, Soriano, Traserra, and SanMiguel (1987:1387) studied 
records of 187 patients enrolled in three prospective randomised trials. The patients 
who developed auditory toxicity were significantly older (P = 0.01) and only age was 
retained as independently influencing the development of auditory toxicity on logistic 
regression. It appears that damage is more significant in the elderly who may have 
fewer hair cells at the beginning of treatment or lower endogenous protective 
mechanisms than other individuals with compromised auditory function (Rybak 
2007:364-9; Rybak & Whitworth 2005:1313-21); Rybak & Ramkumar 2007:933). On 
the converse, de Jager and Alterna (2002:622-7) did not find that factors such as sex 
or age were associated with hearing loss in a prospective study. These findings are 
also corroborated in Moore, Smith and Lietman (1984:30) who analyzed risk factors 
for the development of auditory toxicity in patients receiving aminoglycosides from 
patients enrolled in three prospective randomised double-blind clinical trials of 
Gentamicin, Tobramycin and Amikacin, found that age and sex did not increase risk 
for hearing loss among the patients.  
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2.6.5.2 Renal impairment and/or hepatic impairment  
 
Individuals with renal insufficiency are more susceptible to aminoglycoside 
ototoxicity, because of reduced renal excretion that can result in higher serum levels 
and prolonged half-life. This could lead to increased exposure of the inner ear to 
toxic concentrations of aminoglycosides resulting in more severe hearing loss 
(Meena, Aseri, Singh & Verma 2012:356). Vilayur, Gopinath, Harris, Burlutsky, 
McMahon and Mitchell (2010:661-69) and(Vilayur et al 2010:661) show that 
moderate and severe grades of chronic kidney disease (CKD) are significant risk 
factors even after adjusting for age; sex; noise exposure; education; diabetes, 
hypertension, and stroke histories; and smoking. Respondents with eGFR 45 
mL/min/1.73 m2 had the highest prevalence of hearing loss (73%) compared with 
those with eGFR 90 mL/min/1.73 m2 (19%). Pandey, Gore, Valame and Mehta 
(2011:131-6) demonstrated that hearing loss in patients with CRF has a distinct 
audiologic pattern and significant differences in the degree of hearing loss were 
observed among patients with different stages of CRF  
 
2.6.5.3 Smoking and Alcohol abuse 
 
Current smoking status is significantly associated with the prevalence of hearing loss 
(Gopinath, Flood, McMahon, Burlutsky, Smith & Mitchell 2010:277-82) and noise 
induced hearing loss (Agrawal, Platz & Niparko 2008:1522-30).  Teens who are 
regularly exposed to second-hand smoke are nearly twice as likely to have hearing 
loss as teens who live in smoke-free environments (Lalwani, Liu & Weitzman 
2011a:655-662). Lalwani, Liu and Weitzman (2011:655) postulate that nicotine is 
neurotoxic. Conversely, cross-sectional analysis also demonstrated a significant 
protective association between the moderate consumption of alcohol (1 - 2 
drinks/day) and hearing function in older adults (compared with non-drinkers), OR 
0.75 (95% CI, 0.57 to 0.98).  
 
2.6.5.4 Genetic predisposition and family history of ototoxicity 
 
Genetic variations, including mitochondrial mutations and inherited haemoglobin 
gene disorders are important contributors to hearing loss, especially in children, and 
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newborn genetic screens for hearing loss mutations and gene disorders could be 
useful.  
 
Mitochondrial mutations have been linked with ototoxic responses to common 
antibiotics, therefore understanding the association of these mutations with hearing 
loss is of special importance (Jing, Zongjie, Denggang, Na, Bin, Aifen, Xijiang, Cong, 
Yunping, Ring & Ring 2014:1-4). Genetic predisposition where some mutations of 
genes coding for mitochondrial 12S r RNA confer higher susceptibility to 
aminoglycoside-induced ototoxicity and such mutations are transmitted to all children 
by maternal lineage and recessive SCD gene. Mutations in the mitochondrial 12S 
ribosomal rRNA renders patients highly susceptible to aminoglycoside ototoxicity. 
The first described mutation was an A1555G mutation in the 12S rRNA. There are at 
least six mutations described to date (A1555G, T1095C, C1494T, A827G, 961delT, 
and T1291C). The A1555G mutation has been described in numerous populations 
worldwide, including Chinese, Spanish, and Arab-Israeli (Peng, Zheng, Fang, Wu, 
Liang, Zheng, Nan, Yu, Tang, Zhu, Lu, Chen & Guan 2013:62). This mutation has 
also been found in a South African family in which 11 family members were 
diagnosed with aminoglycoside-induced hearing loss following Streptomycin 
treatment for TB. Persons with this mutation may incur hearing loss after a single 
dose of aminoglycoside. However, one case has been reported who did not develop 
hearing loss after repeated aminoglycoside exposure (Al-Malky, Suri, Sirimanna & 
Dawson 2014-73). Since these are mitochondrial DNA mutations, all maternal 
relatives harbour the mutation, and mutation-positive mothers will transmit the 
mutation to all of their children (Bardien et al 2009a:1).  
 
Sickle cell disease also predisposes to a significant incidence of SNHL in SCD 
patients (36.95%), although the patients maybe clinically asymptomatic (Al Okbi, 
Alkindi, Al Abri, Mathew, Nagwa & Pathare 2011:392-6). According to the study by Al 
Okbi et al (2011:392-6) the hearing loss was worse in the right ears and had a 
female preponderance. Also, the hearing loss was more severe at the higher 
frequencies, 2,000-8,000 Hz in SCD patients. HbS, HbF, or low haemoglobin levels 
did not discriminate SCD patients with SNHL, and the role of haemoglobin F in the 
cochlea is still not clear.  
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2.6.5.5 Work or environment exposure to noise 
 
Excessive sound (unprotected exposure above 95dBA) damages the hair cells and 
the blood supply in the cochlea (Dobie 2008:565,  2005a:630; Rabinowtz 2012:14, 
Thurston 2013:367). The damage may directly result from the noise, or indirectly 
from very high levels of continuous sound, that causes vasoconstriction of the 
vessels of the stria vascularis in the cochlea blood supply. This renders the hair cells 
relatively anoxic and thus secondarily damaged. The amount and type of direct hair 
cell damage depends on the intensity of the sound. Noise exposure increases 
hearing thresholds, resulting in threshold shifts toward higher values (poorer 
hearing).  
 
During each overexposure to noise, the ear develops a temporary reduction in 
sensitivity called temporary threshold shift. This shift reverses over a period of hours 
or days if the ear is allowed to rest in a quieter environment. However, if the 
exposure is high enough, or if exposures are repeated, the temporary threshold shift 
may not reverse completely, and a permanent threshold shift begins to develop. 
Hearing losses from different causes are additive and interaction can occur between 
noise exposure and chemicals such as toluene, or antibiotics such as the 
aminoglycosides (Li & Steyger 2009a:26-32).   Whenever hazardous noise exists in 
the workplace, patients on MDR-TB treatment are vulnerable to the additive effect 
and measures should be taken to reduce noise levels as much as possible to protect 
exposed workers and to monitor the effectiveness of hearing loss prevention 
programmes at the workplace. Noisy environments potentiate susceptibility to noise 
induced cochlear damage (Fausti et al 2005). 
 
2.6.5.6 Co-Morbid conditions 
 
In co-morbid conditions like diabetes mellitus, neuromas, hypertension and 
cardiovascular diseases, Bainbridge and Cowie (2009) found a six-fold increased 
risk of high-frequency hearing loss associated with both peripheral neuropathy and 
coronary heart disease. Suboptimal glycemic control was also associated with a 
nearly threefold increased risk of high-frequency hearing impairment (Akinpelu, 
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Mujica-Mota & Daniel 2014:767-76; Bainbridge & Cowie 2009; Oh, Lee, Park, Kim, 
Chung, Kim & Yeo 2014; Sogebi 2013:244-9).   
It is postulated that some of the mechanisms by which hearing is affected in diabetic 
patients include thickened vessels of the stria vascularis and the internal auditory 
artery, as well as demyelination of the eighth cranial nerve (Carrasco, Prazma, 
Faber, Triana & Pillsbury 1990:411-7; de Moraes Marchiori, de Almeida Rego Filho 
& Matsuo 2006:533-40). Evidence about hypertension as a risk factor for hearing 
loss is not as definitive. Agrawal et al posit that hypertension is an independent risk 
factor, mainly due to age (Agarwal, Mishra, Jagade, Kasbekar & Nagle 2013:614-8), 
Oh et al (2014) showed that on multivariate analysis, diabetes mellitus (DM) was an 
independent predictor of hearing loss (p<0.05). 
  
2.6.5.7 Acoustic neuromas 
 
Acoustic neuromas are intracranial, extra-axial tumours that arise from the Schwann 
cell sheath investing either the vestibular or cochlear nerve. Unilateral hearing loss is 
overwhelmingly the most common symptom present at the time of diagnosis and is 
generally the symptom that leads to diagnosis (Walsh, Bath, Bance, Keller, Tator & 
Rutka 2000:21-6). The tumour can produce hearing loss through at least two 
mechanisms, direct injury to the cochlear nerve or interruption of cochlear blood 
supply. Progressive injury to cochlear fibers probably accounts for slow progressive 
neurosensory hearing loss observed in a significant number of patients with acoustic 
neuromas (Gonzalez-Orus Alvarez-Morujo, Alvarez-Palacios, Martin-Oviedo, Scola-
Yurrita & Aristegui-Ruiz 2014:275-82). Sudden and fluctuating hearing losses are 
more easily explained on the basis of disruption of cochlear blood supply (Kutz 
2012).  
 
2.6.6 HIV/AIDS and Hearing loss 
 
Evidence of HIV as a cause of hearing loss has been scanty and so there is no 
consensus on the role of HIV and the role of anti-retroviral medicines in the 
causation of hearing loss among people living with HIV (Assuiti , Lanzoni , Santos , 
Erdmann & Meirelles 2013:448; Kakuda 2000a:685; Schouten, Lockhart, Rees, 
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Collier & Marra 2006:1-4). Schouten et al (2006) found no association between 
hearing loss with treatment with AZT.  Another study did not find a clear association 
nucleoside analogue therapy and hearing loss, and posited that the pathophysiology 
of less common adverse effects of nucleoside analogue therapy, such as diabetes, 
ototoxicity, and retinal lesions, may be related to mitochondrial dysfunction cause by 
NRTIs (Kakuda 2000b:685-708).  
 
Direct action of the virus on the central hearing systems has been muted. This is in 
way to undermine the potential action of ARV medications on the ear, which may 
have potential ototoxic effects and cause hearing loss. The possible association with 
hearing loss in the central hearing system caused by the direct action of the virus, is 
suggested by the fact that in many cases there are otoneurological signs and 
symptoms presented by or reported by the patients, such as hearing loss, tinnitus 
and dizziness (Khoza-Shangase 2011; Schouten et al 2006). Recent studies in 
South Africa that included PLHIV showed high rates of hearing loss associated with 
MDR-TB treatment among PLHIV but did provide direct evidence on the role of HIV 
and ARV in the hearing loss (Harris et al 2012:363-6; Seddon et al 2013:320-9). 
 
2.6.7 Time to hearing loss 
 
No studies reporting on time-to-hearing loss in MDR-TB patients were found during 
the literature search. 
 
 
2.7 PREVENTION, TREATMENT AND MANAGEMENT OF HEARING 
LOSS 
 
2.7.1 Basic concepts of natural history of disease occurrence 
 
Primary, secondary, and tertiary prevention programmes focus on different aspects 
of the natural history of disease. The concepts of primary, secondary, and tertiary 
prevention make use of these prevention concepts. Primary prevention aims at 
inhibiting the development of disease before it occurs. Secondary prevention aims to 
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identify and detect disease in its earliest stages before it is noticeable, when it is 
possible to prevent progression or minimise complications (sometimes referred to as 
―screening‖). The purpose of tertiary prevention is to improve the quality of life for 
people by rehabilitation (therapy to restore functionality and self-sufficiency) among 
people already affected by a disease in order to mitigate catastrophic outcomes 
(Figure 2.11 shows key milestones in natural disease progression).   
 
 
 
Figure 2.7: Natural disease progression and the milestones of detection.  
 
(Source: Gordis L. Epidemiology. Philadelphia: Saunders and Company, 2000: 83-100) 
 
From the onset of disease, until clinical symptoms occur, there is a pre-clinical phase 
without overt symptoms and the individual who has the disease may not know it. 
Within the preclinical phase, there may be an interval between the onset of the 
disease and the occurrence of clinical symptoms during which disease can be 
detected with certain tests. This is called a detectable pre-clinical phase. If treatment 
(and/or preventive action) is more effective when disease is in the preclinical stage, 
screening for disease during the detectable pre-clinical phase offers an advantage. 
See Figure 2.12. 
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Figure 2.8 Natural disease progression and the lead-time between diagnosis and ability to 
detect by screening.  
(Source: Gordis L. Epidemiology. Philadelphia: Saunders and Company, 2000: 83-100) 
 
2.7.2 Basic concepts of Years lived with Disability 
 
According to the World Health Report of 2003, adult onset hearing loss was the 
second leading cause of years of lived with disability (YLDs) in 2000 (Mathers, Smith 
& Concha 2010). Early detection may prevent hearing loss that requires 
rehabilitation and hence, YLDs as illustrated in Figure 2.11. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: Model for adult onset hearing loss.  
(Source: Mathers, Smith & Concha. (2010).Global burden of hearing loss in the year 2000) 
 
Incidence of HI 
(Hearing 
Impairment) 
Death 
 Years lived with disability (YLDs) are calculated for the box shredded in grey 
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2.7.3 Application of the prevention concepts to MDR-TB treatment 
hearing loss 
 
Primary prevention involves avoidance of the ototoxic drugs and hence prevention of 
MDR-TB, and rational prescription of aminoglycosides and polypeptides.  
 
Effective management by secondary prevention includes the early detection and 
treatment.  Early detection and monitoring of ototoxicity as a standard of care can 
reduce the impact of ototoxic-induced hearing loss, ultimately improving treatment 
options for patients and preserving post treatment quality of life (Wilmington, Konrad-
Martin, Helt, Dille, Gordon & Fausti 2011:248). That can be achieved through 
pharmacovigilance (PV) which is responsible for monitoring the safety of medicines 
in normal clinical use and during clinical trials (Mammi et al 2013:S33-4).  
 
Tertiary prevention refers to the management and rehabilitation of hearing loss and 
includes the provision of good-quality, appropriate hearing aids, essential support 
services, access to appropriate communication, improvements in the acoustic 
environment, special education and social integration at all levels (Smith, 2002, 
World Health Organization 1996). 
 
2.7.4 Monitoring hearing loss as part of a MDR-TB treatment related 
hearing loss prevention strategy 
 
The main purpose for monitoring is to enable early identification and prevention.  
 
“Should we care about early changes enough to take the time to measure 
them?”  
- Campbell (2007) 
 
The answer is yes.  Reasons to monitor cochlear and vestibular function are 
enumerated as: 
 
i) cochlear function is affected by almost all aminoglycosides;  
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ii) even slight ototoxic cochlear dysfunction is noticeable, particularly via high 
frequency audiometry and otoacoustic emissions; and  
iii) slowly progressive vestibular dysfunction may go undetected for some time. 
Cochlear and vestibular ototoxicity may be variable in terms of onset and 
progression. 
 
The American Speech-Language-Hearing Association (1997) states that:  
 
“Audiologic screening serves a secondary prevention function; that is, if a 
hearing disorder, impairment, or disability is detected and treated early, 
potential hearing-related problems can be prevented or ameliorated”. 
 
The benefits of monitoring include early detection may prevent hearing damage that 
requires amplification/rehabilitation; if change is observed, treatment modification 
can prevent further hearing loss. However, if no change is observed, continued 
treatment is warranted, monitoring provides an opportunity for counselling and 
rehabilitation during and post treatment, and finally, monitoring provides the basis for 
informed medical decision-making.  
 
2.7.5 Establishing an ototoxicity monitoring programme 
 
According to the ASHA recommendations (1997), a basic audiological ototoxicity-
monitoring programme requires: 
 
a. specific criteria for identification of toxicity; 
b. timely identification of at-risk patients; 
c. pre-treatment counselling regarding potential cochleotoxic effects; 
d. valid baseline measures (pre-treatment or early in treatment); 
e. monitoring evaluations at sufficient intervals to document progression of 
hearing loss or fluctuation in sensitivity; and  
f. follow-up evaluations to determine post-treatment effects. 
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2.8 APPLICATION OF THE NEUMAN SYSTEMS MODEL FOR HEARING 
PRESERVATION IN PATIENTS ON MDR-TB TREATMENT 
 
The model provides a comprehensive flexible holistic and system based perspective 
for nursing and health care. Developed by Betty Neuman, the Neuman System 
Model (NSM) is a nursing theory based on following key concepts:  
 
i) the client system (which maybe an individual, family group or community); 
ii) interacting variables of the client system which are the physiological, 
psychological, spiritual, developmental and sociocultural; 
iii) client‘s response to actual or potential environmental stressors (internal, 
external and created environments), the reaction to it, and reconstitution 
factors that are dynamic in nature (Freese & Lawson 2010:309-33; Geib 
2002:237);   
iv) emphasis on prevention, as intervention for retention, attainment, and 
maintenance of optimal client system wellness; and  
v) the purpose of the nurse is to retain of the client system's stability through the 
three levels of prevention; which are: 
 
 Primary prevention to protect the normal line and strengthen the flexible 
line of defence. Primary prevention relates to good clinical practice that is 
applied in client assessment and intervention, in identification and 
reduction of possible or actual risk factors. 
 Secondary prevention to strengthen internal lines of resistance, reducing 
the reaction, and increasing resistance factors. Secondary prevention also 
relates to symptomatology following a reaction to stressor, appropriate 
ranking of intervention priorities and treatment to reduce their noxious 
effects. 
Tertiary prevention to re-adapt and stabilise and protect reconstitution or 
return to wellness following treatment. Tertiary prevention also relates to 
adjustive processes taking place as reconstitution begins. 
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2.8.1 The Client system in Neuman Systems Model 
 
The client system includes physiological, psychological, sociocultural, 
developmental, and spiritual aspects as variables. The central core of the model 
consists of energy resources (normal temperature range, genetic structure, response 
pattern, organ strength or weakness, ego structure, and known or commonalities) 
that are surrounded by several lines of resistance, the normal line of defence, and 
the flexible line of defence. The lines of resistance represent the internal factors that 
help the patient defend against a stressor, the normal line of defence represents the 
person's state of equilibrium, and the flexible line of defence depicts the dynamic 
nature that can rapidly alter over a short period. 
 
NSM provides a comprehensive, flexible, holistic, and system-based perspective for 
medical practice including monitoring and prevention of hearing loss for patients on 
MDR-TB treatment. It also provides a structure for critical thinking (an active process 
that guides action). The review of literature is cognizant of the four paradigms of  
Neuman‘s System model. 
 
i) The person 
 
The model views the human being as a total person, as a client system, and 
the person is a layered multidimensional being physiological (physicochemical 
structure and function of the body); psychological (has mental processes and 
emotions); has relationships and social/cultural expectations and activities; 
has spiritual beliefs and undergoes processes related to development over 
the lifespan; 
 
ii) The environment: 
 
The model considers the environment with the totality of the internal and 
external forces (intrapersonal, interpersonal, and extra-personal stressors) 
which surround a person and with which they interact at any given time);  
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iii) Health:  
The model equates health to wellness where the condition in which all parts 
and subparts (variables) are in harmony with the whole of the client and the 
client system moves toward illness and death when more energy is needed 
than is available;  
 
iv) Medical practice/nursing: 
 
The Medical/ Nursing profession is a unique profession that is concerned with 
all of the variables, which influence the response a person might have to a 
stressor. While a person is seen as a whole, it is the task of nursing to 
address the needs of whole person through actions, which assist individuals, 
families and groups to maintain a maximum level of wellness. The primary 
aim for wholist action is stability of the patient/client system, through nursing 
interventions to reduce stressors by the use of primary, secondary, and 
tertiary interventions. 
 
2.8.2 Nursing Diagnosis, Goals and Outcomes 
 
Neuman‘s System model guides a framework for the development of comprehensive 
diagnoses, determination of appropriate interventions and evaluation of outcomes. 
We can apply the nurse-client partnership to identify a stressor(s) that may penetrate 
the flexible defence and lead to variance from wellness as in the case of MDR-TB 
treatment related hearing loss. The variation from wellness is of interest in the study 
of hearing loss.  
 
2.8.2.1 Nursing diagnosis 
 
According to Neuman‘s System model, clinical care of MDR-TB starts with 
assessment of the physiological, psychological, developmental, sociocultural and 
spiritual dimensions for the following components of the client‘s system (MDR-TB 
patient) in order to conceptualise and analyse the client‘s system (Gei, 2002:345-
357):  
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 Basic structure and function:  the central or core structure consists of basic 
survival factors (normal temp range, genetic structure, response pattern, 
organ strength/weakness (and this includes hearing health assessment) and 
ego structure (Geib 2002:235-259).  
 
 Potential or actual environmental stressors (interpersonal, intrapersonal and 
extra personal stressors) to help in identifying the majors areas of stress, 
changes in the patterns of living, previous coping behaviours, anticipated 
consequences and expectations for self, from health care systems and from 
others. Early signs of hearing loss, fears, and worry about potential hearing 
loss with MDR-TB treatment and pre-existing risk factors for hearing loss from 
various aspects are assessed according to the five interacting variables. 
 
 Characteristics of the cleanest flexible line and normal lines of defence, lines 
of resistance, degree of potential and actual reaction and reconstitutions. This 
model is used in defining parameters that enable provision of care in a 
comprehensive manner.  
 
2.8.2.2 Nursing Goals 
 
After diagnosis, the next step is synthesis. Reasoning is applied to the findings, the 
variances from wellness identified, and applicable and nursing theories appraised. 
The identified diagnosis based on the data from the client system, level of the 
system or subpart of the response, variables, stressor source. The healthcare 
specific outcome goal prioritised as and primary, secondary and tertiary prevention-
as-intervention modalities is done based on the related risk factors found, client 
perceptions, and resources to promote optimal stability, that is, hearing preservation. 
 
2.8.2.3 Nursing Outcomes 
 
In the development of the nursing outcomes, the synthesis, analysis, and evaluation 
of the prevention-as-intervention modalities and perceived efficacy are processed in 
partnership and with the validation of the client. 
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2.8.2.4 Optimal Wellness Stability 
 
Optimal wellness is the greater possible degree of system stability at a given point in 
time and the optimal client system stability means the highest possible health 
condition achievable at a given point in time (Neuman 2002).  
 
2.8.3 The Lines of defence in Neuman systems model 
 
The client is also conceptualised as having an inner core or basic structure (basic 
energy resources) that is protected by concentric circles representing a normal line 
of defence and a flexible line of defence. The usual level of health is identified as the 
normal line of defence that is protected by a flexible line of defence and it can be 
affected by tension producing intrapersonal, interpersonal, and extrapersonal 
stressors, which arise from the internal, external, and created environments 
respectively.  
 
When stressors break through the flexible line of defence, the client system is 
invaded and the lines of resistance are activated with the client system moving into 
illness on a wellness-illness continuum. If adequate energy is available, the system 
will be reconstituted with the normal line of defence restored at, below, or above its 
previous level (Freese & Lawson 2010:315-323).  
 
2.8.4 Critical thinking and Neuman Systems Model of Clinical Practice 
 
The healthcare model adapted in the theoretical framework in the study of MDR-TB 
treatment related hearing impairment is the Neuman System‘s model of nursing and 
table (Neuman 2002:10-12). See Table 2.5. 
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2.8.5 Critical thinking and Neuman Systems Model of Prevention-as- 
Intervention 
 
From a hearing preservation perspective, the model suggests that clinical and 
nursing care interventions occur through three prevention modalities based on 
Caplan‘s concept of level of prevention (Caplan, 1964). Primary prevention occurs 
before the stressor invades the system; secondary prevention occurs after the 
system has reacted to an invading stressor; and tertiary prevention occurs after the 
system has reacted to an invading stressor.  
 
Table 2.5: Application of the theoretical framework (Neuman's model) to hearing loss 
related to MDR-TB treatment 
 
Model component  Application to MDR-TB treatment related hearing impairment 
Health Care 
worker/client 
relationship 
Mutual partnership developed during the initial assessment with baseline 
tests and audiology. The HCW perceives the physiological stressors 
(injectable MDR-TB drugs and hearing impairment) as very important. 
Throughout the process of care, planning the HCW team assesses 
possible discrepancies in perception. 
Physiological Stressors: Intrapersonal: - (injectable aminoglycoside antibiotics and 
other medicines, adverse drug reactions, compromised hearing); 
Interpersonal: - (role of family support, perceptions of the caregiver); 
Extra-personal:- (nutrition and strong medications and home situation 
during the long treatment duration). 
Psychological Stressors: Intrapersonal: - (fear of the future, fear of hearing impairment 
and the serious impact on communication and self-esteem); 
Interpersonal: - (fear about children‘s future, lack of support from family 
and relatives); Extra-personal :-( Isolation during MDR-TB treatment, 
effect of the situational stress such as finances and job security during the 
long treatment duration). 
Developmental Stressors: Intrapersonal: - (productive life); Interpersonal: - (roles as 
parent, husband, wife and so on). 
Sociocultural Stressors: Intrapersonal: - (image of self); Intrapersonal: - unsupportive 
family); Extra-personal:- (reduced income).  
Spiritual 
 
Affected 
boundaries 
 
Stressors: Interpersonal:- (fears illness is punishment) 
The client‘s flexible lines of resistance have been penetrated by the 
injectable MDR-TB antibiotics and lines of defence activated. Defence 
lines are augmented by all the primary prevention (proper hydration 
while on MDR-TB treatment, temperature control, good nutrition, use of 
medical techniques to identify and prevent of risk factors for HL in the 
client, information of TB medications and ototoxicity, and baseline hearing 
screening).  The secondary prevention - regular monitoring of hearing 
status, blood chemistry while on treatment,  dose and drug change 
modifications when risk is discovered) and the tertiary prevention 
(provision of assistive hearing aids, training for sign language, family 
87 
 
counselling and support for the hearing impaired) modes of prevention-as-
interventions should be implemented to meet the client‘s needs.  
Health/ Nursing 
Goals and 
outcomes 
Promote hearing conservation; promote wellness; prevention as 
intervention is evaluated for the defensive enhancement; as needed goal 
reformulation. 
 
 
Clients have lines of resistance that protect their client‘s basic core structure energy 
resources of the client (described in 2.8.1 (i) and 2.8.2.1). Ineffective lines of defence 
can be seen when an individual receives extensive MDR-TB chemotherapy (external 
stressor) with a result that the hearing system is severely compromised. The hearing 
loss is an example of the system energy being depleted and this disrupts optimum 
health.  Mobilisation of external resources (assisted hearing aids) helps the client‘s 
internal resources and strengthens the lines of resistance. The outcome is a more 
physiologically and psychologically stable client (Alligood 2010:240). 
 
Accordingly, the health professional plays an important role in creating connections 
among the client, environment, health and health care service that lead to system 
stability (Freese & Lawson 2010:309-334). Neuman considers a ―client‖ as an 
individual, group, family, or community system, and each client has five variables 
that act synergistically to each other (physiological, psychological, developmental, 
socio-cultural, and spiritual) and reciprocally with the internal, external, and created 
environment in which the client exists.  Multi-drug resistant TB exists in the external 
environment and the sufferer develops MDR-TB through the mechanisms explained 
in Chapter 2, section 2.2. The treatment of MDR-TB also exists in the external 
environment and is categorised as a ―stressor‖ to the client, which the client reacts 
to.  
 
Neuman‘s model regards the normal line of defence as the usual or standard client 
level of wellness that protects the basic structure as the client reacts to the stressors.  
However, beyond, and in addition to the normal line of defensive, the Neuman‘s 
model points out a flexible line of defence that expands protection to the client. The 
paragraphs highlight the application of the lines of defence to MDR-TB: 
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 the flexible line of defence may include healthy life styles such as a diet free 
from saturated fats where Rosen, Olin and Rosen (1970:242) demonstrated 
that low saturated fat diet prevents coronary heart disease and may arrest 
progression of hearing loss. 
 
 minimizing modifiable risk factors for hearing loss such as voluntary exposure 
to loud noise, failure to use hearing protection when necessary, smoking, lack 
of exercise, and failure to avoid tooth decay/tooth loss (Daniel 2007:225);  
 
 a lifestyle that avoids diabetes and cardiovascular disease may buffer the 
client from the stressors that invade the client, thereby freeing the client from 
reactions to those stressors (Daniel 2007:225)  
 
Client system stability and normal health are affected by the internal and external 
environmental and the created environment, the third distinct aspect of the 
environment (made up of factors in the environment) and are defined as stressors in 
the Neuman‘s System model. 
 
When the stressors penetrate the flexible and normal lines of defence and the lines 
of resistance are activated, energy depletion and system instability occurs. When 
applying MDR-TB and MDR-TB treatment on the one hand and resultant MDR-TB 
treatment related hearing loss on the other hand to the model, as the stressors and 
system instability respectively, MDR-TB treatment can influence the client in three 
ways: intrapersonal, interpersonal, and extrapersonal dimensions. 
 
First, intrapersonal stressors are internal stressors that will occur within the patient 
system boundary such as atherosclerosis, hypertension, diabetes mellitus, Human 
immune deficiency syndrome, and Acquired immune deficiency syndrome (HIV and 
AIDS).  
 
Second, interpersonal stressors are external stressors that occur in the external 
environment outside but proximal to the client system boundaries. The client‘s role in 
89 
 
the family as a breadwinner, perceptions of the caregiver, and friend relationships 
are examples of these forces.  
 
Third, extrapersonal stressors occur distally to the client boundary and examples 
include employment of the individual client, and financial status. 
 
All the three stressors may be exhibited and observed by health professionals in the 
management of MDR-TB. Data should be collected, analysed during diagnosis and 
goals, outcomes and interventions, in conjunction with the client. Monitoring of 
hearing loss during MDR-TB treatment provides an opportunity for prevention of 
hearing loss as an intervention jointly agreed upon by the health professional and the 
client.  
 
Primary prevention for hearing loss occurs before the client system reacts to a 
stressor, which is MDR-TB disease and MDR-TB treatment as below:  
 
 MDR-TB (individual is free from potential need for MDR-TB treatment),  
 Second line anti-tuberculosis drugs (MDR-TB treatment after the stressor 
invasion-MDR-TB disease). 
 
Health professional actions implemented as primary prevention interventions of 
hearing loss aims at strengthening the flexible lines of defence. The pre-emptive 
actions promote the retention of the client‘s wellness to enable the person to better 
deal with stressors that make the client susceptible to hearing loss.  
 
Prevention interventions against stressor invasion (MDR-TB) include promotion of 
health, maintenance of wellness, preventing acquired drug resistance among 
patients on first line TB treatment (―turning off the tap‖) and prevention of MDR-TB 
transmission at household, in health care settings, and congregate settings. Once 
created, drug-resistant strains can be transmitted, giving rise to DR-TB  in individuals 
never previously exposed to anti-tuberculosis drugs (Gandhi 2010). Patients with 
tuberculosis, with and without HIV co-infection, can be infected with MDR-TB strains, 
but those co-infected with HIV are much more likely than are their counterparts to 
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progress to active tuberculosis disease after initial infection (Selwyn, Hartel, Lewis et 
al, 1989:545). Hence, prevention of HIV is an indirect primary prevention intervention 
for hearing loss.  
 
On the contrary, primary prevention-as-interventions for hearing loss occurs before 
the client system reacts to a stressor (MDR-TB treatment) and include dealing with 
the risk factors and determinants for MDR-TB related hearing loss outlined in section 
2.6  
Primary prevention-as-interventions for MDR-TB related hearing loss includes 
actions such as: 
 
 careful aminoglycoside dosing,  
 judicious use of aminoglycosides in high risk patients such as 
o  the elderly,  
o those with pre-existing renal insufficiency, 
o those with pre-existing hearing problems, 
o those with family history of ototoxicity,  
o those receiving loop diuretics or other ototoxic or nephrotoxic 
medications, and  
 Lifestyle measures to avoid noisy environments that potentiate susceptibility 
to noise induced cochlear damage, and healthy diets for prevention of hearing 
loss (Rosen, Olin & Rosen 1970:242-7).  
 
Secondary prevention-as an-intervention is implemented as a prevention of 
ototoxicity once a patient who develops MDR-TB is initiated on MDR-TB treatment 
and his system (client system) has reacted to a stressor (MDR-TB treatment). While 
primary prevention refers to inhibiting development of hearing loss, secondary 
prevention, also known as screening, refers to measures that detect the disease 
before it is symptomatic and attempt to reduce the resultant hearing loss (disability 
and restore functionality).  
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Secondary prevention entails early detection of ototoxicity by detecting the earliest 
signs of hearing impairment and effective management to stop further deterioration 
through treatment and clinical interventions.  
 
According to Neuman‘s System model, the focus of intervention is for the client 
system to attain restabilisation (reconstitution) through use of internal and external 
resources. Re-stabilisation prevents further damage to the basic structure of the 
client system, and strengthens the internal lines of resistance (against hearing loss) 
and/or removing the stressor (offending MDR-TB treatment) (Freese & Lawson 
2010:243).  Management of early hearing loss involves removing offending drug and 
risk factors as an example of secondary prevention. Monitoring hearing status during 
MDR-TB treatment is one of the interventions that assists in detecting hearing 
impairment early, hence enabling change in the offending drugs.  Monitoring of 
hearing status during treatment provides an opportunity to identify and provide 
interventions such as use of assistive hearing devices in order to preserve hearing 
and communication.   
  
Tertiary prevention-as-intervention occurs after the system has developed hearing 
loss (been treated through secondary prevention strategies) and offers support to the 
client and attempts to add energy to the system or reduce energy needed in order to 
facilitate reconstitution (Freese & Lawson 2010:243; Neuman 2002). Such 
interventions include use of hearing aids, and cochlear implants.  
 
 
2.9 CONCEPTUAL FRAMEWORK 
 
The overarching goal of clinical management of the MDR-TB patients is highest level 
of care and best treatment outcomes for the patients. The national goal of universal 
treatment and prevention coverage can be achieved through improving the 
processes of nursing care; medical care and treatment; monitoring and timely 
management of and prevention of adverse drug reactions. However, availability and 
compliance with the appropriate guidelines, policies, and protocols for the allied 
professionals, nurses and doctors enables standardised care.  
92 
 
 
Neuman Systems model provides a framework that outlines the stages of the 
medical process as a continuum:  
 
 at diagnosis, the diagnosis of stressors is done as well as the dynamic 
interaction with the five variables (physiological, psychological, 
developmental, socio-cultural and spiritual);  
 at enrolment, treatment goals are negotiated with the patient, taking into 
account of patient‘s and nurse‘s perceptions of variance from wellness (Table 
2.5); 
 during care, continuous monitoring of wellness ensures timely interventions to 
promote attainment of the treatment goals. 
 
The conceptual framework for the monitoring and prevention of hearing loss related 
to MDR-TB treatment adopted by the current study, is, in addition to NSM, enriched 
by the conceptual model on medication monitoring and adverse event proposed by 
Steinman et al (2011). According to the authors, the uncertainty in how adverse drug 
events will happen needs to be addressed, not only by the appropriateness of the 
initial prescription, but also on detecting and mitigating the adverse events once they 
have started to occur, requiring a framework of team-based approaches for patient 
management. The enhanced monitoring framework proposes integrating monitoring 
in clinical practice, use of health information technology, systems redesign including 
tracking laboratory tests and timely notification of physician, and use of risk 
assessment tools for enhanced patient participation (Steinman et al 2011). 
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Figure 2.10: Paradigm for primary, secondary and tertiary hearing preservation as intervention 
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2.10 REFLECTIONS FROM THE LITERATURE 
 
The literature review provides a theoretical framework for this study.  The study 
investigated the following two hypotheses. No published studies directly address the 
issue of MDR-TB treatment-related hearing loss and the impact of HIV on hearing 
impairment incidence in an HIV high prevalence setting. Although there is some 
evidence that HIV, or even anti-retroviral drugs, could cause hearing loss there is no 
consensus on the magnitude. The literature review suggests that many drugs may 
have synergistic effects that potentiate ototoxicity among patients receiving MDR-TB 
treatment.  
 
2.11 CONCLUSION  
 
Irreversible hearing loss related to treatment regimens in MDR-TB is common and 
various studies conducted in different continents reveal that unless there changes to 
the current regimen, the incidence of MDR-TB treatment related hearing loss will 
continue to increase. Various studies identify some risk factors but no uniform 
guidelines exist for prevention and monitoring of hearing loss in MDR-TB patients. 
The  ASHA (1997) recommendations for establishment of ototoxicity monitoring 
programs are largely unimplemented in resource-limited settings as evidenced  from 
the literature. The NSM provides a model nurses and doctors treating patients with 
MDR-TB to facilitate conservation of hearing as part of preservation of the 
wholeness of the individual so that his or her participation and place in the family, 
community and society can be preserved using prevention as an intervention (three 
levels). Neuman Systems model also provides a framework for development of the 
best practice guidelines for monitoring and prevention of hearing loss related to 
MDR-TB treatment in Swaziland  
 
The next chapter discusses the research design and methods to investigate the 
incidence of hearing loss among MDR-TB patients in Swaziland. It also provides a 
framework for the development of best practice guidelines for prevention and 
monitoring hearing impairment in the patients on treatment for MDR-TB. 
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                                               CHAPTER 3 
 
RESEARCH DESIGN AND METHODS  
 
 
3.1 INTRODUCTION 
 
“Every successful research project requires two things: a meaningful research 
question and an appropriate way to answer that question”  
 
-(Morgan 2013:59) 
 
The purpose of the current chapter is to provide the practical and relevant details of 
how the study‘s intentions were realised. The study intentions (purpose and 
objectives), as stated on page 8, influenced and shaped the research design and 
methods. Whereas research design refers to the broader plan for management of 
the study, encompassing plans for data collection, utilisation, measurement and 
analysis, the research methods refers to data collection using the specific 
instruments and techniques to  achieve the outcomes of the study (Curtis & Drennan 
2013a:131, Mouton 2001:55-56). The details of data collection and analysis, study 
population and sample, sampling techniques, research instruments, and measures 
taken to ensure validity and reliability, and the ethical considerations are presented.  
 
3.2 RESEARCH DESIGN   
 
Research design refers to the structure of an enquiry. Research design plays a 
central role in ensuring that the study minimises the chance of drawing incorrect 
causal inferences from data. In addition, it ensures that the evidence collected 
enables the researcher to answer questions, and/ or to test theories, as 
unambiguously as possible.   Research design also specifies direction for 
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procedures in the study design (Lincoln, Lynham & Guba 2011).  
 
3.2.1. Quantitative research designs  
 
According to (Krauss 2005:759), quantitative research on how we acquire knowledge 
(epistemology) is closely linked to the philosophy and study of reality (ontology) and 
the specific practices to acquire knowledge (methodology)  Quantitative research 
designs aim to produce findings that are: objective, reliable, valid, and reproducible, 
and associated with an objectivist ontology, a positivist epistemology, and use of 
quantitative methods (Curtis & Drennan 2013a:133).   In order to determine 
incidence of SNHL in MDR-TB patients, determine the risk factors and the time to 
hearing loss, the current study used analytical study design, which falls under the 
quantitative research design. Donmoyer (2008) refers to quantitative research as 
approaches to empirical inquiry that collect, analyse and display numerical data in 
numerical rather than narrative form. 
 
The following factors influenced the choice of the quantitative design: 
  
 In epidemiology and statistics, analytical observational studies draw 
inferences about the possible effect of exposure or treatment. The researcher 
observes what happens to people under exposure conditions that have been 
self-selected or have been determined by influences outside the control of the 
researcher. The researcher can choose what exposures to study, but does 
not influence them.  Observational studies can either be descriptive studies 
that describe how things are; or analytical, in that they are set out to test 
hypotheses predicting an association between the two, an exposure and the 
independent variable (AFMC Primer on Population Health, [Sa]; Curtis & 
Drennan 2013c). The latter suited this study. The aim of the current study was 
to determine whether there was a relationship between hearing loss and 
duration on MDR-TB treatment, and whether HIV status of the patients 
influenced the incidence of hearing loss, and hence suited the study design as 
an observational analytical study.   
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 This study sought to understand the relationships, type of the relationships, 
and quantify the strength of the relationships, akin to correlational studies 
(Grove, Burns & Gray 2013:87). In order to establish such associations, a 
deductive approach was necessary (Curtis & Drennan 2013a:134).  A 
literature search preceded the choice of theoretical concepts and theories 
most relevant to the causes of hearing loss in MDR-TB patients and the 
hypotheses developed. A quantitative design was the best option for the 
hypothetico-deductive approaches.  
 
 Time was a variable in this study. In order to analyse time-to-event, an 
analytical survey approach using multiple timed data collection points was 
necessary. Repeated measurements of hearing sensitivity at timed intervals 
during follow up on the patients who initiated treatment within the prescribed 
period were necessary for the derivation of time to hearing loss from initiation 
of MDR-TB treatment. This type of longitudinal data collection, requiring 
collection of data from the same unit at two or more different points in time is 
one of the quantitative methods that can suggest the direction of cause and 
effect associations(Curtis & Drennan 2013d:178; Mathew & Farewell 
2007:160; Todem 2007). 
 
 The common characteristic of this study population was enrolment into MDR-
TB treatment. The objectives of the study necessitated the gathering of data 
in form of numbers to enable evidence be presented in quantitative form on 
the study cohort. Cohort studies are typically quantitative and collect empirical 
data. While experiments can provide empirical data, in this study, observation 
was the source of the empirical data (Donmoyer 2008:2-3).   
 
The differentiating characteristic between observational and experimental study 
designs is that, in the latter, the presence or absence of an intervention defines the 
groups. In an observational study, the investigator does not intervene but simply 
―observes‖ and assesses the strength of the relationship between an exposure and 
health outcome variable, that is, observe and measure the effects on disease rates 
of exposures of interest as they occur in the target population (Song & Chung 
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2010:2232-42). On the other hand, experimental designs have an intervention and 
control arm. To describe and measure the degree or association (or relationship) 
between the exposure and the health outcome of interest in analytical studies, 
investigators use the correlational statistics (Creswell 2012). Therefore, results of the 
current study were analysed to produce quantifiable, statistical data to shed more 
light on such cause-and-effect relationships between independent variables and 
SNHL related to MDR-TB treatment (Polit & Beck 2008:338).  
  
3.2.2. Cohort study design  
  
A cohort study design is one of the three observational analytical study designs, the 
other two being, cross-sectional studies and case control studies. However, the 
cohort studies and case-control studies can aid in evaluating associations between 
diseases and exposures. As in other cohort studies, the identification, and 
establishment of the exposure was done before the outcome, and hence the 
temporal framework was used to assess causality. Cohort studies yield the more 
reliable results in observational epidemiology when compared to case control 
studies. They are used in epidemiology  to describe the distribution of disease 
incidence, and prevalence of disease or health outcomes, and the exposure-disease 
association (Hseih, Feng & Wang 2007). Cohort studies collect data through 
longitudinal research. Ruspini (2003:182-88) characterises longitudinal research in 
which: (1) data are collected for two or more distinct periods; (2) the respondents or 
cases analysed are the same, or at least comparable, from one period to the next; 
and (3) the analysis involves some comparison of data between or among periods. 
The longitudinal studies have the ability to collect data over a period, and hence 
monitor and record change in life events. By recording events over time, longitudinal 
studies are better placed to disentangle temporal and sequential occurrence and 
facilitate understanding of causal mechanisms and relations (Curtis & Drennan 
2013d:178, Ruspini 2003:182-88).  
 
In the study, the main variable that was uniquely different among the study 
respondents was HIV status. Hence, in the current study, the ―exposed‖ cohort was 
constituted by the HIV positive group while the ―unexposed‖ cohort was composed of 
the HIV negative group making it possible to compare the rate and risk hearing loss 
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between the HIV exposed and the HIV unexposed which was expressed by the 
proportions as cumulative incidence relative risk. 
The cohort study design was relevant to the study as follows: 
 
i) The cohort studies are able to measure the risk of disease in the exposed 
and the unexposed. While all the patients were exposed to second line 
MDR-TB drugs, the study measured risk of hearing loss in the HIV positive 
(exposed) and in the HIV negative (unexposed) in order to compare the 
risk ratio for SNHL. The temporal sequence between putative cause and 
outcome in prospective cohorts is usually clear; and  
ii) Investigation of multiple outcomes that might arise after a single exposure 
is possible with cohort studies. The study had potential to document 
multiple outcomes such grade of hearing loss, change medications 
because of adverse drug reactions, other incidental complications 
associated with hearing loss. 
 
The limitations of cohort studies include:  
 
i) Sensitivity to selection bias due to drop outs and loss to follow-up of cases 
and controls whereby the validity of the study can seriously be affected by 
the differential losses to follow-up between those exposed and unexposed 
because of the bias in results that this causes;  
ii) Over time, the exposure status of study respondents can change, for 
instance, the HIV status changes from negative to positive during the 
study; 
iii) Confounding and bias and hence need to control for potential confounding 
at the design stage and in the analysis; and 
iv) Prospective cohorts can be expensive and time consuming because of the 
long-time of follow-up and if the condition is rare, a large group of people 
have to be followed up.  
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3.2.3. Case-cohort design 
 
The current study also adopted a nested case-cohort design where, instead of 
obtaining the exposure information on all the individuals constituting the 
denominators in the exposed and unexposed cohorts on on-going basis, the data 
was only continuously collected on a sample of the cohort save for the hearing 
sensitivity. This innovative design uses a sub sampling technique in survival data for 
estimating relative risk of disease in the cohort study without collecting data from the 
entire cohort.  
 
Data from all respondents becoming cases (case sample) and a randomly selected 
sample of the cohort (referred to as; reference cohort, reference sample, sub cohort, 
or control- cohort or control group) are used in the study.  The sub cohort may 
contain some cases (see Figure 3.2). The purpose of the reference sample is to 
estimate the relative size of the exposed and the unexposed components of the 
source population (the proportion of the exposed in the source population at the 
beginning of the cohort). The case-cohort allows efficient analysis where the 
population size is large to collect detailed data on all the respondents. Thence, the 
sub cohort is selected from the original sample at entry and data was analysed only 
on all the members of the sub cohort and all the cases. Case-cohort studies can be 
thought of as nested with the cohorts of the exposed and unexposed people, hence 
as nested from the source population (Kulathinal, Karvanen, Saarela & Kuulasmaa 
2007; Pfeiffer et al 2005:982; Zhang, Schaubel & Kalbfleisch 2011:18).  
 
Benefits of case-cohort design as applied to the study include: 
 
i) the selected sub-cohort was able to serve as a comparison group for multiple 
endpoints (Kang & Cai 2009:887);  
 
ii) Given that, at baseline, all cohort member information was collected rather 
than only that from sub cohort, analysis can be performed on the full cohort 
(Breslow, Lumley, Ballantyn, Chambless & Kulich 2009). 
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3.3 RESEARCH METHOD  
 
A research method is a general framework guiding a research project and methods 
that are used to tackle different research questions. It involves the specific forms of 
data collection, analysis, and interpretation that researchers propose for their studies 
(Creswell 2014:17). Quantitative research methods were used to collect data and 
analyse the problem. Methodological standards adhered to in order to assure that 
the evidence provided is reproducible and reliable knowledge, included: sampling, 
measurement validity, internal validity and external validity.   
 
3.3.1 Population 
 
A population is a complete set of people with a specialised set of characteristics and 
a sample is a subset of the population.  However, there are three closely linked types 
of population in a study, and these are target, study and sample population.  
 
3.3.1.1. Target population 
 
In the current study, the target population and hence the group to whom 
generalisation is intended were all the individuals on MDR-TB treatment in 
Swaziland. Any inferences from a sample only refer to this defined population from 
which the sample was properly selected (Banerjee & Chaudhury 2010:60-65).  
 
The main characteristics of interest to the researcher that defined the target 
population in the current study was that all these patients were using aminoglycoside 
treatments for MDR-TB. Swaziland has a high MDR-TB/HIV capita burden setting, 
albeit the population of about 1.2 million inhabitants. The HIV prevalence is 31% 
among 18-49 year olds (Bicego et al 2013) and among MDR-TB patients, the HIV 
prevalence was about 75% of the patients. In 2010, the nationally representative 
drug resistance study found that MDR-TB is also prevalent with 7.7% of the new TB 
cases (NTC) patients and 33.9% of previously treated TB cases (PTC) having MDR-
TB.  HIV co-infection is independently associated with MDR-TB (Sanchez-Padilla et 
al., 2012:32-33).  At the time of cohort enrolment (November 2012-December 2013), 
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a total population of 353 MDR-TB patients were initiated on treatment, constituting 
the target population.  
 
3.3.1.2 Study population 
 
The study population is the subset of the target population available for the study. In 
the current study, the accessible population was that of the individuals who enrolled 
into MDR-TB treatment at the MDR-TB treatment sites in Swaziland. Before 
selecting the health facilities relevant to be included in the study, health facilities 
offering MDR-TB treatment were visited to ascertain enrolment practices of MDR-TB 
patients, patient loads, and availability of audiology services for MDR-TB patients 
and willingness of the MDR-TB health facilities to participate in the study. One health 
facility has audiology services on site and the other sites receiving outreach services 
form the department of ENT.  The findings showed that all the six MDR-TB treatment 
sites were clustered into three: TB hospital in Manzini was linked with Piggs Peak 
Hospital in the Hhohho region, Mankayane Hospital in Manzini region was linked to 
MSF comprehensive clinic in Manzini, and Nhlangano MDR-TB centre in Shiselweni 
linked to Matsajeni MDR-TB treatment site. The Lubombo region did not have an 
MDR-TB treatment site at the time of the study commencement, and hence its 
patients managed at the TB hospital.   
 
The TB hospital in Manzini had a national representation with patients visiting from 
all the other regions and had onsite audiology services.  
 
3.3.1.3 Sample population 
 
Due to practical reasons and creditable data management, it was not possible to 
study all the patients from the six MDR-TB sites. The derivation of the sample 
population was done in two stages.  
 
 Study sites: The TB hospital and Piggs Peak hospital were selected to 
participate in the study in a two stage multistage sampling method. The 
sampling frame was consisted of all patients in the master MDR-TB register 
maintained at the TB and Piggs Peak hospitals. All patients referred for 
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treatment at these two sites were included in the sampling frame (Curtis & 
Drennan 2013d:181).  
 
 Study cohorts: patients enrolled into the study were categorised and followed 
based on HIV status. The HIV positive patients constituted in the HIV exposed 
cohort and the HIV negative patients constituted the unexposed cohort. All the 
patients received injectable MDR-TB TB medication during the study. The 
internal comparison group of the HIV negative patients was used because its 
characteristics were mostly similar to the exposed group.  In addition, using 
an internal comparison group was the most feasible approach to testing the 
hypothesis evaluating incidence of hearing loss in the HIV positive and HIV 
negative MDR-TB patients and would make follow up more feasible (Purty 
2011:176).  
 
The primary objective of the analysis of the cohort data was to compare the 
occurrence of hearing loss in the HIV positive (exposed) and the HIV negative 
(unexposed), and the occurrence of the outcome measured using incidence 
rates and the relationship between the exposure and the outcome quantified 
using the relative difference between the rates. 
 
3.3.1.2 Sampling  
 
Sampling is the process of selecting a group of respondents for a study in such a 
way that the individuals represent the larger group from which they were selected 
(Curtis & Drennan 2013a:135-136). Probability sampling was considered ideal for 
this study because it increases the likelihood of obtaining samples that are 
representative of the population. In a random sample, each individual in the 
population of interest has an equal likelihood of selection. The rationale of sampling 
is selecting a representative subset of the population because it is impractical and 
very costly to survey the whole population (Curtis & Drennan 2013d:180). Hence, 
selection of the sample is done according to specific criteria.  
 
In first stage of the multistage sampling, two health facilities were selected out of the 
six facilities providing MDR-TB treatment in Swaziland (see section 3.3.1.1.3). In the 
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second stage of the multistage sampling the sample from the sample was selected 
from the available lists. The listing of all patients enrolled at the two health facilities 
was done.  All consecutive patients fulfilling the eligibility criteria, attending the 
participating MDR-TB sites between November 2012 and December 2013, and 
registered for MDR-TB treatment were approached for enrolment into the study. 
According to Polit and Beck (2008:338) eligibility criteria as is that which designates 
the specific attributes of the target population by which people are selected for the 
study.  This study used the following criteria to select the study population at the 
study sites: 
 
i) Patients who were diagnosed with MDR-TB (bacteriologically or clinically on 
empirical criteria) between November 2012 and December 2013 (13 months); 
ii) Patients who had been notified of the intention to start them on MDR-TB 
treatment;  
iii) Patients who were free of the outcome of interest (hearing loss) at the 
beginning of the study;  
iv) Had not initiated on MDR-TB treatment or had initiated on treatment within a 
period of less than 72 hours; 
v) Were males and females aged 15 -65 years; 
vi) Clinically stable; and 
vii) Consented to the study or, in case of minors, where the guardian has 
consented to enrolment in the study and assent from the minor obtained.  
 
The following exclusion criteria applied for non-eligibility:  
 
i) Patients with serious forms of drug resistance like extremely resistant drug 
resistant TB (XDR-TB) and totally drug resistant TB (TDR-TB) because these 
posed extremely serious infection control risk to the data collectors. These 
patients also have very high mortality rates and hence are unsuitable for long 
term follow up; 
ii) Very sick patients and patients with pre-existing psychiatric conditions and 
dementia;  
iii) Patients with pre-treatment clinical assessment of infective pathology in ear; 
iv) Patients with pre-existing sensori-neural hearing loss (prevalent hearing loss). 
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The schematic in Figure 3.1 shows the steps in sampling included in the 
identification of the target population, identification of the study population, and the 
selection of the sample.  
 
Figure 3.1: Study Population Selection and Follow up 
 
In order to nest the case cohort study, two distinct samples comprised the study 
cohorts. (i) The random subsample of the original cohort (sub-cohort), selected 
independently of the definition of cases of hearing loss (respondents developing the 
event of interest) and, (ii) respondents outside the sub cohort developing hearing 
loss (respondents outside the sub cohort developing event of interest) during the 
follow up (Kulathinal et al 2007). The full cohort observation conducted from 
November 2012 to October 2014 identified respondents who developed hearing loss, 
that is, the cases. The cases emerged from the full cohort (that is from both in and 
out of the sub-cohort); while the controls were respondents in the sub-cohort, who 
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were not cases. 
In this study, the following notation are used:  
N = the size of the sampling frame 
n = the size of the sample 
nc =the size of the full cohort C 
nsc = the size of the sub-cohort SC 
E = respondents developing hearing loss in the Event subset E 
d the size of the set E respondents of hearing loss with the event E 
f = n/N = the sampling fraction. 
 
By definition, all of the respondents in E are in C. The union of (i) and (ii) is referred 
to as the case-cohort set (Kulathinal et al 2007). Detailed data was collected only for 
cases experiencing the event of interest in a cohort and for members of a randomly 
selected sub-cohort. 
 
3.3.1.2.1 Sub Cohort Selection process 
 
Use of simple random sampling techniques achieved the sub cohort sample from the 
full cohort.  A simple random sample is a subset of a statistical population in which 
each member of the subset has an equal probability of being chosen and simple 
random sample is meant to be an unbiased representation reflecting characteristics 
of a group (Mathew & Farewell 2007:3). The calculated size of the sub cohort was 
obtained randomly using random numbers generated from an internet based 
software  developed by Social Psychology Network (Social Pyschology Network, 
[Sa]). Source: http://www.randomizer.org/form.htm Retrieved 14 Nov 2012. Random 
numbers were allocated to the respondents with the registration serial number 
matching the random number.    
3.3.1.3 Ethical Issues related to sampling 
 
Before and during the conduct of the study, ethical considerations were adhered to in 
order to protect the rights of the respondents. These included the respect for the 
human person, who has the right not to be injured or mistreated, right to give 
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informed, un coerced consent to participate in a particular piece of research, the right 
to privacy, and the right to confidentiality and/or anonymity, commonly summarised 
as the ethical principles of: autonomy, justice, beneficence and non-maleficence 
(Curtis & Drennan 2013f:77-85). 
 
3.3.1.3.1 Research approval 
 
When the proposal was fully developed, the researcher applied to the Department of 
Health Studies of the University of South Africa (UNISA) for ethical clearance 
(Annexure C1)(University of South Africa, 2015:71-74). Once approval was received 
from UNISA, the proposal was submitted to the Swaziland Ministry of Health (MOH) 
Scientific and Ethics committee for country level approval (Annexure C2) and a 
research reference number (Creswell 2014a:95).  Approval was also obtained from 
the Ear Nose and Throat department of Mbabane National Referral hospital and the 
National Tuberculosis hospital (Annexures C3 and C4).  
 
3.3.1.2.2 Respect for the human person 
 
It is the duty of the research team not to expose the research respondents to 
significantly burdensome, unreasonable, known or predictable risks (Curtis & 
Drennan 2013f:81). As the duty of the researchers, the respondents were provided 
with the information on the purpose, procedures and rights, risks, discomforts and 
constraints of participation in the study.  The research assistants were trained to 
provide adequate information to all prospective eligible patients. The information 
sheet and consent form provided information on the researcher, sponsoring 
institutions, purpose of the study, benefits of participating, notation of the risks to the 
respondent, assurance of withdrawal anytime and provided names of persons to 
contact if questions arose (see Annexure B1).   
 
3.3.1.3.2 Voluntary informed consent 
 
Informed and voluntary consent was sought from each of the study respondents 
(Annexure B1).  Informed consent refers to the respondents being fully aware of the 
research they are involved in (Boynton, 2005:91). As autonomous beings, individuals 
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have the right to make decisions about themselves and their life. Participation in the 
study was voluntary. The study respondents were adequately and properly informed 
about the nature and the extent of the proposed participation in the study, including 
information that their participation, responses, results of the medical examination 
would be sued for purposes identified in the study only. Before enrolment into the 
study, the following steps were taken to ensure that their participation was not only 
informed, but also voluntary: 
 
 The capacity to understand the information that was being provided, the 
implications of their participation and that they had the cognitive ability to 
exercise consent (Curtis & Drennan 2013f:79). This was also embedded 
inclusion and exclusion criteria; 
 The participants were free form coercion (Creswell 2014:97). The 
respondents were assured that they had the right to refuse participation 
and that would not affect care provided in any way. The study respondents 
were also made aware of their right to withdraw from the study at any time 
without any jeopardy to their medical care as well as the right not to 
respond to any question of their choice or partake any procedure.   
 Patients who initially consented to the study but found not to be eligible 
after the preliminary evaluation were given the reasons for removal from 
the study.  
 In order to include minors in the study, the minor secured the informed 
consent of the guardian in addition to assent.   
 
3.3.1.3.3 Anonymity and Confidentiality 
 
Research subjects need to know that they will not be identified through the research 
and that their information is going to be private and remain anonymous in a study in 
order to be protected from unwarranted risk of personal information becoming 
publically available(Boynton 2005:101). Respondents‘ responses were obtained in 
private and medical examinations such as audiometry and biophysical 
measurements were conducted in private.  They were assured that their identity and 
personal information would not be divulged, except for medical care purposes and 
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only to their physicians, and that the data handling and storage processes would 
protect anonymity and confidentiality (Curtis & Drennan 2013f:81). Respondents 
were also assured that the researcher would not reveal potentially identifying 
information and materials when presenting the research findings. The research 
assistants were also trained to provide privacy and keeping research information 
confidential according to the established procedures.  
 
3.3.1.3.4 Justice 
 
The principle of justice can be viewed as having two components:  i) fair treatment in 
research activity, including fairness to the least advantaged who should be benefited 
rather than forgotten, and ii) participation without exclusion based on vulnerability or 
vulnerable persons taken advantage of with enrolment into research which is not 
responsive to their health needs. All groups in the socio and economic structure 
were eligible to partake in this study. There were no grounds for discrimination and 
denial of enrolment because of belonging to one group of the other.  The hard-to-
reach category or had limited resources to participate in the follow visits to the 
hospital during the data collection period were supported with transport 
reimbursements. The age group 15-18 participated in the study based on assent 
provided by them in addition to the guardian‘s consent.  The risk of selection bias 
and error were dealt with through rigor in defining the target population, inclusion of 
all cases meeting the eligibility criteria, not omitting ―hard to find or potential non-
adherent‖ persons. The study assistants were provided with skills to increase 
acceptance rate and lower dropout rate, and the following measures were 
implemented to minimise loss to follow up and hence compromise the sample 
representativeness: 
 
Respondents likely to be lost (planning to move or were non-committal) 
were provided with additional counselling to stay in touch;  
 
 Information to allow future tracking  was collected including subject's 
contact information such as physical addresses and telephone numbers. 
During follow-up, periodic contact was made by telephone; 
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 Transport allowance provided for those having challenges to return for 
appointments ensured that respondents returned for appointments.  
 
3.3.1.3.5 Beneficence and non-maleficence 
 
Article 5 of the World Medical Association declaration of Helsinki of 1964 (as 
amended in Fortaleza, Brazil in 2013) declares that medical progress is based on 
research that may involve human subjects. Similarly, however, article 7 articulates 
the need for medical research to be subjected to ethical standards that promote and 
ensure respect for all human subjects and protect their health. In the same vein, risk 
must be minimised, monitored and documented according to article 17 (World 
Medical Association, 1964, 1975, 1983, 1989, 1996, 2000, 2002, 2004, 2008, 2013).  
The two principles of beneficence (do good) and non-maleficence (do no harm) 
require that health practice and research fulfil the duty of doing good, preventing 
harm, as well being vigilant.  While the current study did not pose significant 
discomfort, risk and burden on the respondents, it is important that scientific studies 
benefit the patient directly and/or society as a whole (WMA, 2013). 
 
In summary, the researcher took the necessary steps to address the ethical 
principles in general but also during sampling in the following manner: 
 Ensuring that the selected research question was legitimate, an hence it was 
not a waste of time and that the design would answer the research question; 
 Self-identification of the researcher, and assurance to the effect that the 
researcher was not responsible for the clinical care of the patients and hence 
minimising the fear that refusal to participate in the study would adversely 
affect the patients care; 
 Providing clear information and guidance as to the purpose of the study  and 
information on the potential inconvenience and risks;  
 Adequately addressing anonymity and confidentiality of the respondents; 
 Ensuring that there was no discrimination in the selecting of study 
respondents. 
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3.3.1.4 Sample 
 
3.3.1.4.1 Sample Size considerations 
 
According to (Faber & Fonseca 2014:27-9), the purpose of estimating the 
appropriate sample size is to produce studies capable of detecting clinically relevant 
differences,  protection of human subjects and good stewardship of fiscal, physical 
and staff resources. The reasons for performing sample size calculations in the 
planning phase of a study were: 
 
i) to assure confidence in the study results and conclusions; 
ii) ensure that the study is adequately powered because inadequately-powered 
studies are waste resources and have ethical considerations to the study 
respondents, given that they may not produce clinically meaningful results; 
iii) achieve adequate power to enable the testing hypothesis testing; 
iv) facilitate development of sound evidence for the best practice guidelines given 
that inadequately powered may produce results that are unable to alter clinical 
practice.   
 
According to Grove et al (2013:704) power is the probability that a statistical test will 
detect a significant difference or relationship that exists, and in so doing, the capacity 
to correctly reject a null hypothesis. A number of factors affect power of the study: α, 
β, effect size, variability (baseline incidence), n 
 
 The level of significance (α) is the probability of a Type I error.  The 
researcher is willing to accept a 5% level of risk of declaring the null 
hypothesis false when it is actually true. 
 The effect size (β) is the deviation from the null that the researcher wishes to 
be able to detect.  The researcher powered the study so as to be able to 
detect a relative risk of two or greater. 
 Design effect (DEFFs) is the effect of a non-simple random sampling that 
needs to be accounted for by the researcher because of the risk of 
misestimating the effects and increasing the probability of type 1 errors. 
Without correcting for design effects, standard errors could be 
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underestimated, leading to significant tests that are inappropriately sensitive 
(Osborne 2013:74). 
 
Two sample sizes were calculated: 
 
a) the sample size of the study cohort, Lwanga and Lemeshow (1991:18-19);  
b) the sample size for the case cohort, Kubota and Wakana (2011:279).  
 
They provided minimal sample sizes of 81 for the full cohort and 20 for the sub 
cohort. 
 
3.3.1.4.2 Assumptions of sample size calculation for the full cohort 
 
Because of lack of studies with incidence rates in Africa, the current study assumed 
incidence MDR-TB related hearing loss of 20% among the HIV negative patients 
based on the prevalence reported in the literature for studies in the United Kingdom 
and India (Bisht &Bist, 2011:255-9; Bitner-Glindzicz & Rahman 2007:784-5; Blakley, 
Hochman, Wellman, Gooi & Hussain 2008-3; Bloss et al 2010:275; Duggal & Sarkar 
2007:1-7; Sturdy et al 2011:1815). The study assumed the incidence for MDR-TB 
treatment induced hearing loss was double (40%) among HIV positive patients (lack 
of studies of MDR-TB treatment related hearing loss in HIV positive patients).  
 
According to Lwanga and Lemeshow (1991:18-19) hypothesis testing for two 
incidence rates in cohort studies can be derived from the sample size formula: 
  
  {       
  
    
  
√[    )   )        √[    )      ) }
 
       )
        Equation 1 
 
Where k is a ratio of the sample size for the second group of respondents (HIV 
positive) and the first group (HIV negative).  
 
Hence, assuming the null hypothesis of no difference between the incidence 
between the exposed (HIV positive) and the unexposed (HIV negative), the following 
information was assumed: 
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Test value in the difference in incidence… ……………………………………………0 
Anticipated incidence rates (20% among HIV negative and 40% among HIV 
positive)...20% 
Level of significance ……………………………………………………………………5% 
Power of the test………………………………………………………………………80% 
Alternative hypothesis………………………………………………………………      
Duration of study…………8 months follow up during the injectable phase of 
treatment 
The minimum sample size per group (HIV positive and HIV negative) was 28 
according to the tables (Lwanga &Lemeshow, 1991:80) assuming sample size ratio 
of 1.  
 
However, given the high HIV rates in the target population are 75% HIV positive to 
25% HIV negative, the number per group was adjusted to reflect a ratio of HIV 
prevalence in MDR-TB patients which stands at 3:1 (HIV+: HIV- = 3:1). The adjusted 
minimum sample size for the study was 112. Although the rule of thumb for lost to 
follow up not to exceed 20%, we provided for 30% attrition rate in the study because 
of high mortality among MDR-TB patients and hence the adjusted the sample size 
was 149 respondents (Song & Chung 2010). 
 
3.3.1.4.3 Assumptions of sample size calculation for the sub cohort 
 
In order to determine the adequacy of sample size for case cohort study,  the 
formula proposed by Kubota and Wakana which derives the sample size calculation 
for case cohort studies from formula of the sample size of the cohort study was used 
(Kubota & Wakana 2011:279). Kubota and Wakana (2011:279) proposed a sample 
size formula for the case-cohort study for a binary exposure variable with the 
exposed respondents (N1) and total respondents (N) in the entire cohort for the case-
cohort study with the same α, β, K, RR and P0 as full cohort. 
 
                 (1) 
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N is full cohort (112) and N1full number exposed (84),  m is the ratio of the number of 
respondents in the sub cohort to the expected number of cases(0.5)  in the entire 
cohort and K ratio of unexposed to  exposed (0.5). The value of m was assigned by 
the researcher as 0.5 and the required size of the sub cohort, n, is 
 
               (2) 
 
Assuming m as 0.5; PD as 20% (Duggal, 2007) and N as 112 
The calculated Sub cohort sample size n=20 
 
3.3.1.4.4 Description of final sample 
 
A study sample is chosen from the study population. In the current study, the study 
sample was the group of patients attending two of the six MDR-TB treatment sites 
from November 2012 to December 2013.  One hundred and ninety-four (194) 
respondents were evaluated for eligibility and of these 173 fulfilled the inclusion 
criteria and were enrolled into the study. Figure 3-3 summarises time of the baseline 
assessment in relation to commencement of MDR-TB treatment.  About 84% had 
pre-treatment assessments and 9% assessment within 72 hours and 7.5 % within 4-
7 days of initiation on treatment. A small proportion had the pre-treatment 
assessment after the recommended 72 hours cut-off but hearing status was still 
within normal range at the time of the baseline audiology. 
 
 
 
Figure 3.2: Pre-treatment baseline assessment (number of days of treatment at 
baseline audiological evaluation) 
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Study enrolment Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 3.3: Subject enrolment and follow-up flow chart sub cohort and non-sub cohort 
subject 
 
3.3.2 Data Collection 
 
3.3.2.1 Data collection approach and method 
 
The WHO defines data collection as an ongoing systematic collection, analysis, and 
interpretation of health data necessary for designing, implementing, and evaluation 
of public health programs(World Health Organization, [Sa]-a). On the other hand, 
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Grove et al (2013:690) define data collection as the systematic gathering of 
information relevant to the research purpose or specific objective, question of 
hypothesis. In the current study, quantitative methods were used to collect numerical 
data or data that could be converted into numbers using a longitudinal survey 
method.  The data required was collected on a number of variables that would be 
used to describe the incidence patterns, and predict the time-to-hearing loss among 
the cases.  
  
Advantages of longitudinal surveys: 
 
 As an observational study with the aim of understanding cause-effect 
relationships, determination of sequencing and timing can be done readily, 
using this method. Prospective data collection also reduces recall bias and 
allows examination of expected and unexpected outcomes (Curtis & Drennan 
2013d:178).   
 Quantitative data collection methods product results that are easy to 
summarise, compare and generalise.  
 The longitudinal survey method enables the determination of incidence, risk 
ratio and time-to-event analysis (see section 3.2.2)(Curtis & Drennan 
2013b:19). According to Singer and Willet (2003), in the framework for 
investigating event occurrence, identify three methodological features:  
 
 a well-defined ―event‖ whose occurrence is being explored;  
 a clearly defined ―beginning of time‖; and  
 a substantially meaningful metric for clocking time. In line with 
the above criteria; the event being investigated was hearing 
loss; the beginning time was assessed for each individual MDR-
TB patient at the entry of the cohort (recruited between 
November 2012-December 2013); and the metric for clocking 
time was the monthly follow up during the intensive phase of 
treatment until exit of the cohort.   
Based on the above considerations for cohort studies, collection of socio-
demographic information and risk factors, HIV status, determinants and risk factors 
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in the previous medical, family and occupational history as well as biophysical 
characteristics was conducted. The method also enabled the follow up of self-
selected cohorts to the HIV positive (exposed) or HIV negative (unexposed).  The 
metric for clocking time was the monthly follow up during the intensive phase of 
treatment until exit of the cohort.  The longitudinal survey also enabled recording of 
repeated measurements of hearing sensitivity and to collect and record event 
occurrence up to eight months (injectable phase of treatment) and determine 
occurrence of hearing loss as the outcome of interest (hearing loss).  
  
The key disadvantage of longitudinal studies is that they are expensive and 
possibility of missing data due to loss to follow up is high. These challenges have the 
potential of cause threats to internal validity. Section 3.4 explains the measures that 
were used to minimise any threat to internal and external validity. 
 
3.3.2.2 Development and testing of Face-to-Face Interviewer-administered 
questionnaire 
 
3.3.2.2.1 Defining Face-to-Face Interviewer-administered questionnaire 
 
According to the SAGE Dictionary of Social Research Methods, a questionnaire is, ― 
A set of carefully designed questions given in exactly the same form to a group of 
people in order to collect data about some topic(s) in which the researcher is 
interested‖ (McLean 2006). Face-to-face Interviewer-administered standardised 
questionnaire were administered by the researcher/ research assistant in the 
hospital setting in a private space to consenting patients.  
 
The Wikipedia, however, includes other prompts in the definition - ―a questionnaire is 
a research instrument consisting of a series of questions and other prompts for the 
purpose of gathering information from respondents‖ (Wikidepia., ibid-c). While some 
researchers reserve this term exclusively for self-administered or postal 
questionnaires, others would include interview schedules (personally administered 
face-to-face) under the general rubric of ‗questionnaire‘. The researcher used the 
latter definition (Curtis & Drennan 2013d:183).  
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Advantages of face-to-face interviewer administered questionnaires include: 
 
 The questionnaire format and sequence is the same for all although pre-
determined, no directive prompts maybe used. 
 The interviewer is able to build rapport and confidence with the respondent  
 Observation of body language is possible and enable clarification where the 
respondent does not seem to understand 
 Interviewer structured interviews/ questionnaires are a useful tool to obtain 
information from disabled respondents or those who are unable to read. 
 
The disadvantages of the face-to –face interviewer-structured interviews include: 
 
 Could be time consuming and may involve travel of either the respondent or 
the research assistant. 
 Could be more costly than questionnaires sent through the post or 
administrated online 
 
3.3.2.2.2 Developing the Face-to-Face Interviewer-administered questionnaire 
 
In the formulation of the questionnaire, the researcher complied with the following 
best practices for developing questionnaires: 
 
 The questions were arranged in a set format, measuring separate variables 
and some aggregated into either a scale or index; 
 Open-ended questions were used for the respondent to formulate their own 
answer while the closed-ended questions were used to enable respondents to 
pick an answer from a given number of options, and having standardised 
answers that make it simple to compile data; 
 In order to address a limitation with questionnaires where the respondents 
must be able to read the questions to respond appropriately to the limitation, 
conducting face-to-face questionnaire administration was done as a mitigation 
measure. In addition, translation of the questionnaire into SiSwati made it 
easier for some patients who can read the local language.  
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3.3.2.2.3 Pilot Study 
 
Grove, Burns and Gray (2013:523) define a pilot study as a smaller version of a 
proposed study conducted to develop or refine methodology such as treatment, 
instrument or data collection.  Hence a pilot study was conducted with a subset of 
the respondents (Sproull 2004). The purpose of the pilot study was to replicate the 
large study, as a trial, to test the consent forms, data collection forms and 
questionnaires and recruitment process, and to identify if there was need to alter the 
big study based on the pilot study (Curtis & Drennan 2013d:185).   
 
According to Curtis and Drennan (2013d: 185), the following rationale is provided for 
pilot studies:  
 
 development of rigorous data collection tool and evaluation of workability; 
 development and pre-testing questionnaires and other instruments; 
 to establish validity, reliability, practical utility and issues affecting 
respondents‘ response;  
 identification of logistical problems that could mar data collection.  
 evaluating data analysis techniques;  
 establishing communication networks with key stakeholders, and  
 determination of resources are needed for the main study.  
 
Thirty respondents for the pilot study were recruited in the same way as the 
proposed study and respondents completed the same informed consent and 
instrumentation procedures. The primary feasibility outcomes of the pilot were: 
 
 establish the recruitment rates of the study patients,  
 establish the informed consent rates,  
 determine follow-up return rates for the first three months of follow-up period, 
formulate a questionnaire that is clear and comprehensible, and   
 establish adequacy of data handling system.  
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The secondary feasibility outcomes were optimised human resources for the study 
and establishment of an external quality assurance.  
 
Summary of the results of the pilot  
 
 Assessment of the methodological quality, validity, reliability of the measurement 
instruments and data management was conducted during the pilot. The 
questionnaires were easy to complete consistently, and there was evidence of 
difficult questions that needed to be modified. The calibration of the audiometers was 
immediately verified and all audiometers, tympanometers and otoscopes were 
validated and the produced reproducible measurements, passing internal quality and 
external quality assessments. HIV exposure was assessed by a documented result 
of an HIV test obtained according to the national algorithm.  
 
Training to support research and data entry assistants to assure consistency across 
the data collectors and reliability of data collected and entered was over a three-day 
period. On-going support provided post training ensured that the research assistants 
became proficient within two weeks. The test-retest by the same and/or different 
data collectors was consistent. A change to patient flow was necessary after the 
analysis of pilot data. The systems for managing longitudinal files were available but 
strengthened. A ―cross-sectional" file was also maintained where the longitudinal 
data had been cleaned. 
 
3.3.2.3 Types of data collection instruments 
 
Questionnaires and audiograms were used for data collection in this study. 
 
3.3.2.3.1 Questionnaire 
 
 The structured questionnaire was divided into the following sections: 
 
a) The first section comprised the biographic data, medical information and 
lifestyle characteristics: 
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 the socio-demographic and patient characteristics data including 
patient‘s age, gender, and region of origin, educational 
achievement, employment, profession and job types as well as 
marital status, race and religious affiliations.   
 relevant medical information including concurrent medical 
conditions such as hypertension, diabetes mellitus, HIV/AIDS, 
cancer as well as any medical treatments for these conditions as 
applicable.  
 data on life style characteristics such as history and quantity of 
smoking, drinking alcohol, exercise, and daily fluid and water intake.  
 
b) The second component of the questionnaire captured responses from self-
assessment of  the following variables:  
 
 hearing acuity and history of hearing problems in the family and by 
the patient, as well as physical assessments like external and 
middle ear examinations,  
 audiometric screening hearing status,  
 clinical measurements such as blood pressure, temperature, 
weight, and height for calculation of body mass index and hydration 
status. The physiological assessment was used to determine the 
participant's health status prior to and during the study.  
 results of laboratory tests including HIV sero-status, blood 
chemistry tests including random blood glucose, haemoglobin A1c, 
serum urea, creatinine, electrolytes, and liver function tests.  
  
3.3.2.3.1 Collection of audiometry results using Audiograms 
 
Hearing sensitivity results from audiometry were recorded in both the graphic and 
tabular audiograms. The audiogram is a picture of how a person hears at a given 
place and time under given conditions. Graphic representation is probably the most 
common form for reporting pure tone, audiometric results. The American Speech-
Language-Hearing Association recommends a set of symbols to allow for efficient 
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and uniform transfer of information using audiometric symbols(American Speech-
Language-Hearing Association 1990, 2002-129; British Society of Audiology- 
2011:22-23). Audiometric symbols are used to record the results of conventional 
pure tone threshold audiometry and the audiogram to describe the hearing of a 
person for the various frequencies tested (Figure 3.5 and Figure 3.6). An audiogram 
maybe used to calculate the amount of hearing handicap a person has. In addition, it 
may be used as a tool to determine the cause of a person‘s hearing loss (Frank 
2007).   
 
 
Figure 3.4 Hearing loss grading;           Figure 3.5 Normal Audiogram 
  
Audiograms are graphic presentations shown as a grid with frequency, in Hertz (Hz), 
represented logarithmically on the abscissa and hearing level (HL), in decibels (dB), 
represented nearly on the ordinate. 
  
3.3.2.4 Data collection process  
 
3.3.2.4.1 Questionnaire administration  
 
Two locations were selected for administration of the face-to-face Interviewer-
administered questionnaires; one in each of the study sites near the audiology room. 
For each of the consenting respondents, the research assistant or audiologist filled in 
the general questionnaires and audiologist administered questionnaire filled in by the 
audiologist in a private setting within the hospital. On average completion of both 
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questionnaires lasted about 20-25 minutes. The completed questionnaires were then 
kept in individual respondents longitudinal files, secured together with the consent 
form.  Results of the audiological evaluation and audiometric tests were also added 
to the respondents which were then stored away in a lockable cupboard accessed 
only by the researcher and research assistants. At the end of follow up of each 
patient, files were checked for completeness before being transported to the 
researcher‘s office data entry into a password-protected computer. In the 
researcher‘s office, files were stored under lock and key, and accessible only to the 
researcher. 
 
3.3.2.4.2 Ear, Hearing health and sensitivity screening  
 
 Case history was obtained including history of hearing loss, unilateral hearing loss, 
sudden or rapid progression of hearing loss, unilateral tinnitus, acute or chronic 
dizziness, recent drainage from the ear(s), and/or pain or discomfort in the ear(s), 
recreational noise exposure, family history and exposure to ototoxic drugs was the 
first hearing health screening activity.  
 
3.3.2.4.3 Ear examination 
 
Ears (auricle, ear canal, and eardrum) were examined visually using an otoscope 
(see Figure 3.7):  
 
 to identify abnormalities requiring alternate audiometric procedures or could 
influence the results obtained; and  
 to identify conditions requiring medical referral. Patients with cerumen 
impaction were assisted through cerumen management (ASHA 1997).   
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Figure 3.6 Picture of an Otoscope 
 
3.3.2.4.4 Tympanometry/Acoustic immittance measurement  
   
Acoustic impedance is a collective term that refers to measurements of eardrum 
compliance. There are two types of acoustic impedance measures: tympanometry 
and acoustic reflex testing. In the current study, the function of the middle ear was 
tested using tympanometry. Tympanometry tests the mobility of the eardrum, from 
which information regarding the function of the middle ear system can be inferred. A 
picture of a tympanometer is shown in Figure 3.7. 
 
 
 
Figure 3.7: Picture of a Tympanometer 
 
a. Diagnostic audiometry 
 
An audiometer (see Figure 3.8) was used to obtain air conduction thresholds on all 
examinees.  The audiometry protocol tested the participant‘s hearing threshold (in 
decibels, dB) at six frequencies in a soundproof room (see Figure 3.9).  Baseline 
measurements were taken pre-treatment of within 72 hours of treatment. Follow up 
audiometry was done either two weekly or monthly.  
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Figure 3.4: Picture of an Audiometer 
b. Audiometry testing environment 
 
Figure 3.5 Testing environment-Sound proof booth at the national TB Hospital 
 
A patient was instructed to respond in a specified manner (conventional audiometric 
techniques) each time auditory stimuli are perceived. Pure tone signals are then 
presented to each ear through earphones and the intensity of the signals is varied 
until the level is identified at which the person is just able to hear the sound. After the 
baseline measurements, the hearing status is measured periodically during follow up 
at specified periods: month 1, 2… month N… Hearing loss was graded according to 
the WHO grading: 0-25 dB Normal hearing; 26-40 dB Slight/Mild hearing loss; 41-60 
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dB Moderate hearing loss; 61-80dB severe hearing loss; and 81+ dB Profound 
hearing loss. 
 
Instructions to respondents 
 
Instructions were as follows: 
 
“I am going to test your hearing by measuring the quietest sounds that you 
can hear. As soon as you hear a sound 
(tone), press the button (or raise your 
finger). Keep it pressed (or raised) for as 
long as you hear the sound (tone), no 
matter which ear you hear it in. Release the 
button (or lower your finger) as soon as you 
think you no longer hear the sound (tone). 
Whatever the sound and no matter how 
faint the sound, press the button (or raise 
your finger) as soon as you think you hear 
it, and release it (or lower it) as soon as you 
think it stops.” 
False Responses: false responses may be 
of two types: (a) false positive, a response 
when no tone is present; or (b) false 
negative, no response to a tone that the audiologist believes to be audible to the 
participant. Either type complicates the measurement procedure. Reinstruction was 
done reduce the occurrence rate of either type.  
3.3.2.4.5 Audiometry results recording 
 
Pre-treatment diagnostic audiology was conducted to document baseline pure tone 
average (PTA) for conventional frequencies, (PTA 250Hz-4000Hz) as well as high 
frequency averages (PTA 4000-8000K) using a conventional audiometer.  Recording was 
done in a graph that shows the audible threshold for the standardised frequencies 
  
 
Figure 3.10 Audiometric test being 
conducted 
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call and audiogram. Audiograms were used to record hearing status of each of the 
two ears for each patient at baseline (pre-treatment or within 72 hours after start of 
MDR-TB treatment) and during the scheduled follow up hearing evaluation. For each 
ear tested, results of the hearing threshold (in decibels) at frequencies of: 250 hertz; 
500 hertz; 1 000 hertz; 2 000 hertz; 3 000 hertz; 4 000 hertz; 8 000 hertz were 
recorded.  Standard symbols were used for recording hearing sensitivity, which was 
shown as a grid with frequency, in Hertz (Hz), represented logarithmically on the 
abscissa, and hearing level (HL), in decibels (dB), represented nearly on the ordinate 
(ASHA, 1990: 32-35).   
 
3.3.2.4.6 Hearing loss case definition 
 
In order to define a case of hearing loss and to grade the extent of the hearing loss, 
the pure tone averages at baseline were compared with follow up hearing sensitivity 
pure tone averages. Significant threshold shifts during the follow up were used to 
define a case of SNHL. According to WHO, hearing sensitivity is graded as follows: 
0-25 dB Normal hearing; 26-40 dB Mild hearing loss; 41-60 dB Moderate hearing 
loss; 61-80 dB severe hearing loss; 81+ dB Profound hearing loss. However, based 
on threshold shift criteria, a case of hearing loss was confirmed when baseline 
measurements  were compared with follow up measurements and ototoxicity defined 
as any of: i) a 20 dB decrease at any one frequency, ii) a 10 dB decrease at any two 
adjacent frequencies (American Speech-Language-Hearing Association 1994:11-
19). 
 
3.3.2.4.7 Results confirmation 
 
A person was considered at risk of incident hearing loss during the follow-up period if 
the Pure-Tone average (PTA) 0.5–4 kHz in the better ear was ≥26 dB HL). The 
incidence of any level of hearing loss was defined as a PTA0.5–4 kHz ≥26 dB HL, mild 
hearing loss as PTA 0.5–4 kHz≥26 to 40 dB HL, and moderate hearing loss as PTA0.5–4 
kHz>≥41 to 60 dB. Respondents with hearing loss at baseline were considered at risk 
of progression of hearing impairment if the PTA0.5–4 kHz in the better ear was ≥26 dB 
HL. Progression of hearing impairment was defined as a PTA0.5–4 kHz at follow-up that 
was >20 dB HL than at baseline at a single frequency or 10 dB in each of the 
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adjacent frequencies. Low-frequency hearing loss was defined as a PTA 0.5, 1, 2 kHz 
≥26 dB HL in the better of the two ears. Conventional frequency hearing loss PTA 
0.25, 0.5 1, 2, 4 kHz ≥26 dB HL. High-frequency hearing loss was defined as a PTA 4, 8-
kHz≥26 dB HL in the better of the two ears. The audiometric ISO values calculated as 
an average of 250, 500, 1000, 2000 and 4000 Hz in the better ear (Mitchell et al 
2011). 
 
3.3.2.4.8 Interventions post audiometry for patients with early hearing loss 
 
A referral for hearing amplification was made if no response is observed at any 
frequency in either ear.  The referral involved counselling regarding hearing 
impairment and recommendations for further management.  
 
 
 
Figure 3.11: Respondents’ recruitment, data collection, and follow-up process 
 
All data was checked for completeness and doubly entered into ©Microsoft Office 
Access 2013 database (Microsoft Corporation 2013 (15.0.4420.1017) by trained data 
capturers. Errors and disparities between the databases were rectified before that 
DATA ANALYSIS AND REPORT WRITING 
2 WEEKLY; MONTHLY OTOTOXICITY AUDIOLOGICAL MONITORING 
SUB COHORT CASES NON SUB COHORT CASES CASES  
FULL BASELINE AUDIOLOGICAL EVALUATION, BASELINE LABOARTORY TEST 
FULL  COHORT SUB COHORT NON SUB COHORT CASE SAMPLE 
GENERAL QUESTIONAIRE COMPLETED 
AUDIOLOGICAL SCREENING QUESTIONAIRE AUDIOLOGY SCREENING EXAMINATION 
INFORMED CONSENT 
IF AGREE, EVALUATED FOR ELIGIBILITY IF GUARDIAN AGREES FOR MINOR, ASSENT SOUGHT 
DRUG RESISTANT TUBERCULOSIS PATIENTS IDENTIFIED FOR INITIATION OF TREATMENT 
BACTERIOLOGICAL CONFIRMATION CLINICAL DECISION  
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was exported to Microsoft® Excel® (version 14.4.7), SPSS version 17 and 
STATA/MP (StataCorp LP, Texas, USA) version12 where data cleaning was done by 
the principal investigator before statistical data analysis commenced.  
 
3.3.2.5 Ethical considerations related to data collection 
 
The principles of autonomy, beneficence, non-maleficence, and justice were 
explained in section 3.3.1.3. Data collection is a critical point in the study process 
and has some ethical considerations that needed to be taken into account:  
 Obtaining permission from the institution where the data were to be 
collected.  Management of the institutions was briefed about the study and 
formal approval was granted prior to the commencement of the study 
(Annexure C).  
 Obtaining permission for data collection from the clinical staff and from the 
patients. The respondents were provided with information on the purpose, 
procedures and rights and other information as part of the ethical 
considerations of autonomy, justice, beneficence, and non-maleficence 
(see details in section 3.3.1.3).  
 Guaranteeing appropriate behaviour from the researchers during the data 
collection period. 
 In line with the principle non-maleficence, the potential risks and 
discomforts/constraints were explained to the respondents. While no 
significant psychological or social risks were anticipated to occur, other 
forms of inconvenience that were likely. Respondents were informed of 
potential discomfort,   embarrassment, mild fatigue, anxiety, or frustration 
while completing the items in the questionnaires or undergoing 
procedures, as well as their right to skip any questions that they did not 
wish to answer without having to explain their response for non-response.  
 
 The respondents were informed of their right if any unforeseen risks are 
noted, to notify the principal investigator and/or Swaziland Scientific and 
ethics committee.  
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 Benefits: For some respondents, completing the questionnaires and 
participating in the research could have provided an opportunity for them 
think about their overall well-being in a more concentrated structured 
manner. Some would potentially benefit from close monitoring of their 
hearing status because of the possibility of earlier detection of ototoxicity 
and action to preserve hearing but, for others, there may not have been 
direct benefits from participating in this study. 
 
3.3.2.5.1 Involvement of Audiologist, Statistician, Clinicians, Nurses and the 
Researcher 
 
The researcher was responsible for the overall supervision and coordination; 
collection of data, safety and confidentiality of all data collected, management of the 
data derived from ototoxicity monitoring training all personnel involved in data 
collection, data entry and data analysis. The audiologist participated in the designing 
and implementing the audiology procedures and in the design and implementation of 
ototoxicity monitoring protocol. She administered the monitoring test(s), interpreted 
audiometry results and participated in the follow-up management when clinically 
significant, especially when handicapping degrees of hearing loss were detected. 
The Audiologist received technical supervision from the Otorhinolaryngologist at the 
national referral hospital and from the researcher who is also a physician. Quality 
assurance was done in collaboration with the audiology department at the University 
of Pretoria. The statistician was involved in the calculation of sample size, 
development of the data analysis plan and detailed data analysis. The clinical team 
of doctors and nurses were involved in referring patients for the study, following 
recommendations by the audiologist to prevent aggravation of hearing loss, and 
referring cases of hearing loss to the audiologist for rehabilitation. 
 
3.3.3 Data Analysis 
 
Data analysis is the process of developing answers to questions through the 
examination and interpretation of data.  The basic steps in the analytic process 
consist of identifying issues, determining the availability of suitable data, deciding on 
which methods are appropriate for answering the questions of interest, applying the 
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methods and evaluating, summarizing and communicating the results.  In this 
section, the study hypothesis and objectives are recapped because they influence 
the analysis plan. The study design allows for three major analytic approaches, 
namely: analysis as a cohort study, analysis as a case-cohort study and analysis as 
a nested case control. Data analysis was done per objective and the main analysis 
methods used were: 
 
 Descriptive analysis; 
 Explanatory analysis of longitudinal data; 
 Predictive analysis of survival data; 
 Hypothesis testing. 
 
a. Descriptive analysis 
 
The first objective was analysed using descriptive data analysis to address each sub 
problem statistically using measures of central tendency (mean, standard deviation 
and median) calculated from the continuous data. The following rates and 
proportions were also calculated:  
 
i) Incidence rate presented as the number of new cases of hearing loss per 1 
000 person-days observation; 
ii) Incidence odds presented as the ratio of number of people who developed 
hearing loss (outcome) to the number of people who do not experience the 
event;  
iii) Risk ratio or Relative risk presented as ratio of the incidence rate of hearing 
loss among those who are HIV positive and HIV negative respondents 
(Mathew & Farewell 2007:263-281); 
iv) Cumulative incidence (incidence proportion) was presented as an estimate of 
the risk that a person will develop hearing loss during a specified period of 
time and calculated as the number of new cases of hearing loss that develop 
in a population at risk during the follow-up time interval. Cumulative incidence 
allowed the researcher to predict risk of a hearing impairment over 8 months 
of MDR-TB treatment for patients.  
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 Explanatory Analysis 
 
Explanatory analysis was conducted for the second and third objective.  Analytic 
tests were applied and statistical methods were used to establish the risk factors and 
determinants for hearing loss among the cases.  Risk factors are variables with a 
lower likelihood of a positive outcome and higher likelihood of undesirable outcomes; 
while determinants are any variable that affect the frequency with which disease 
occurs in the community. Measures of association were used to identify relationships 
between the dependent variable and one or more variables and statistics used to 
measure the relationship when it exists. The Spearman rank-order correlation 
coefficient (Spearman rho) was used to measure the strength of a monotonic (in a 
constant direction) association between level hearing impairment and risk factors 
measured in the ranked scale. The 2 × 2 (‗two-by-two‘) table used to analyse data 
with two levels of exposure (HIV exposed, not exposed), and the chi-square test for 
association (contingency) used to measure for association between two categorical 
variables and the significance of the association (Haug 2007). Logistic regression 
modelling was applied to remove the confounding effect in an estimate of the 
association and to identify significant factors (Mathews & Farewell 2007:263; 
(Bednarczyk & McNutt, 2007). The results were reported by relative risk with 95% 
confidence intervals. 
 
The endpoint of interest was hearing loss at the end of the time of follow up logistic 
regression and the proportional hazards regression used to study the effect of HIV 
and ARV on hearing status among patients receiving MDR-TB treatment. The 
covariates considered as indicator variables X1 = 1; if the patient has a positive HIV 
status and 0 otherwise, and two indicators for level of immune suppression, X2 = 1 
for CD4 levels less than 200, X2 = 0 otherwise, and X3 = 1 for CD4 levels above 500, 
X3 = 0 otherwise. The lowest CD4 level was the reference group. We also used the 
covariates indicators related to ARV treatment. We considered the indicator 
variables X4 = 1; if the patient has a positive HIV status and on ARV and 0 otherwise 
(Larsen 2005:1049-55; Kulathinal et al 2007; Mathews & Farewell 2007:152-159; 
Grimes 2002a: 248-52). 
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b. Predictive analysis and Survival data analysis 
Objective 4 was achieved by analysis of time- to- event and to prediction probability 
of hearing loss after survival after time t. Through the calculation of the median and 
the interquartile range, the researcher was able to assess the optimal frequency for 
audiologic testing for monitoring of patients on MDR-TB treatment in Swaziland. 
Proportional hazards regression, using the Cox regression, was used to model the 
incidence or hazard rate with adjustment to the standard partial likelihood. The 
hazard function is the probability that if a person survives to t, they will experience 
the event in the next instant. Data from the study was used to analyse earliest time 
for the event in order to recommend how frequently conducting audiology testing 
should be done to prevent the hazard of hearing impairment (Onland-Moret et al 
2007:350; Kalbfleisch & Lawless 1988:149; Barlow 1999:1165; Mathews & Farewell 
2007:263).  
 
c. Hypothesis testing 
 
Study hypothesis 1: 
 
The incidence ratio of sensorineural hearing loss during the intensive 
phase of MDR-TB treatment increases proportionally with the duration 
of treatment. 
 
If incidence ratio of sensorineural hearing loss is stated as a/b 
and the duration of treatment is stated as d  
The study hypothesis can be stated as a/b ∞ d 
 
Null hypothesis 1: 
“There is no relationship between the incidence of hearing loss among 
MDR-TB patients on MDR-TB treatment and the length of treatment 
during the intensive phase of MDR-TB treatment”  
 
Likewise, the null hypothesis can be stated as a/b not ∞ d 
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Study hypothesis 2 
 
MDR-TB patients living with HIV infection have a higher incidence ratio 
of sensorineural hearing loss than HIV negative MDR-TB patients 
during the intensive phase of MDR-TB treatment. 
 
 If the Incidence ratio of SNHL in HIV positive MDR-TB patients =    
 And If the Incidence ratio of SNHL in HIV negative MDR-TB patients =   
 Then study hypothesis can be restated as………………….      
 
Null hypothesis 2: 
 
“There is no difference in the incidence ratio of sensorineural hearing 
loss in MDR-TB patients living with HIV and MDR-TB patients who are 
HIV free during the intensive phase of MDR-TB treatment. 
 
 If the Incidence ratio of SNHL in HIV positive MDR-TB patients =    
 And If the Incidence ratio of SNHL in HIV negative MDR-TB patients =   
 Likewise the null hypothesis can be restated as………………….      
 
d. Grading evidence and best practice guidelines 
 
Objective 5 aimed at assessing the existing literature and existing guidelines in order 
to develop best practice guidelines for prevention of aminoglycoside induced hearing 
loss. Mold (2003:131-134) defines best practices research as a systematic process 
used to identify, describe, combine, and disseminate effective and efficient clinical 
and/or management strategies developed and refined by practicing clinicians.  The 
literature review for development of best practice guidelines analysed the following:  
 
 definition of ―best‖ based on values and standards; 
 identification and evaluation of potentially effective methods; 
 combination of most-effective methods, and testing of combined methods 
requiring methodological assessment of quality of the included studies, from 
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design, conduct and analysis as well as evaluation of the overall strength of 
that body of evidence (Harbour & Miller 2001:334-6; Polit & Beck 2008:348; 
Rehfuess & Akl 2013:1-5). Polit and Beck (2008) Identify 7 levels of evidence-
based practice:  
 
o Level 1: Systematic reviews of randomised and non-randomised 
clinical trials 
o Level 2: Single randomised and non-randomised clinical trials 
o Level 3: Systematic review of correlational and observational 
studies 
o Level 4: Single correlational and observational studies 
o Level 5: Systematic review of descriptive, qualitative, and 
physiologic studies 
o Level 6: Single descriptive, qualitative, and physiologic studies 
o Level 7: Opinions from authorities, and expert committees. 
 
 
3.4 INTERNAL AND EXTERNAL VALIDITY OF THE STUDY 
 
3.4.1 Internal Validity of the Study 
 
In scientific research, researchers try to establish as to whether one can draw 
meaningful and useful inference from the scores of the instrument (Creswell 
2014:160). According to Curtis and Drennan (2013a: 136), internal validity refers to 
whether an instrument used in a study actually measures what it purports to 
measure. Lavrakas (2008: (1-4) on the other side refers to internal validity as the 
extent to which methodological research design used by the researcher is able to 
provide empirical data to test possible cause-effect relationship between the 
dependent and independent variables. Traditional forms of validity that can be 
applied to the instrument, the questionnaire are: 
 
 Content validity identified as the extent to which the questions are 
representative of what is known about the specific topic,  
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 Criterion validity identified as the relationship between scores on the 
questionnaire and their correlation with an independent criterion 
 Construct validity which refers to the attributes which underlie series of scaled 
measurements, that is do the items in the tool measure hypothetical 
constructs or concepts (Curtis & Drennan 2013a:136, 2013d:186; Donmoyer 
2008, Lavrakas 2008).  
 
In the current prospective cohort study, the potential threats to internal validity could 
arise from the following (Lavrakas 2008): 
 
 The selection of the subjects to constitute different comparison groups in the 
study. If there is no controlled effort for random assignment of subjects to 
make the groups similar, the basis to draw valid inference about the causes of 
any observed difference between two populations is limited). In this study, we 
had internal controls. Although they self-selected on the basis of no HIV, all 
the other characteristics between the two groups were similar; 
 Differential history effect causing observed differences among the 
respondents in the dependent variable. Hence, in other words, because of 
previous exposure the possibility that something in the past other than the 
independent variable may influence dependent variable.  In the current study, 
previous exposure to second line anti-TB medicines used in the treatment of 
MDR-TB was taken into account. This history did not appear to be different 
between the HIV positive and HIV negative patients. 
 Changes in the measurement instrument between the pre and post-period in 
wave panel studies can influence the observed changes in the dependent 
variable. The observed changes in the dependent variable of interest could 
solely be due to changes in the instrument in the post period as opposed to 
the real changes in the groups attributable of the intervention effect. In the 
current study, the same instrument was used consistently throughout the 
observation time.  
 Mortality may undermine the research designs ability to support case-effect 
reasons especially if subjects were not randomly allocated in the current 
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study, mortality occurred during the follow up period but the proportion was 
less than 10% and occurred in both the exposed and unexposed cohorts. 
 
In summary, the instrument's internal validity was addressed in the following ways: 
 
i) A panel of experts in the area reviewed the content of the questionnaires to 
validate the questions. The experts included an Audiologist, an 
Otorhinolaryngologist, and a Senior Medical Officer managing MDR-TB and 
they provided independent views on the content.  
ii) Interviews with a sub sample of the MDR-TB patients (population of interest) 
through a pilot study to further strengthen the validity of the instrument.  The 
results of the pilot are presented in section 3.4.5. 
iii) The questions chosen were a culmination of review of the literature and 
examination of what is known on the topic of MDR-TB treatment related 
hearing loss.  
iv) Additionally, through the above three approaches, content validity was 
established. Patients were requested to provide self-reported assessment 
hearing sensitivity as part of the hearing health screening in the pre-
intervention period. Qualitative measures of hearing loss were compared with 
audiometry measures and this helped in the determination of whether the results 
accurately predicted what audiometer (instrument's) results would be 
expected to predict. Through this approach, criterion and predictive validity 
was achieved (Curtis & Drennan 2013c:223-227; Donmoyer 2008). 
 
3.4.2 External Validity of the Study  
 
Conversely, external validity (which also is referred to as generalisability) refers to 
the likelihood that a study's findings will apply to the larger population represented by 
the study's sample (Kalaian & Kasim 2008). However, measuring a construct by 
means of an instrument, in the case of this study, a questionnaire, always poses a 
problem of validity because constructs cannot be measured directly (Gallestey 
2008:1071-74). Gallestey (2008:1071) posits that validity can be assessed on two 
grounds, theoretical (thorough examination of  the contents of the instrument so as 
to verify if it reflects the meaning attached to the construct it is intended to measure), 
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and empirical (which entails a careful testing of the properties that should respond in 
practice to the meaning).  That is, the ontological and methodological dimensions. 
The study was based on probability sampling and the construction of the sampling 
framework ensured that sample size was large enough to overcome type 2 statistical 
error. The study also addressed the following potential threats to external validity that 
were likely to causes of a limitation to generalisation include: 
 
 Sample characteristics: The sample was selected through multistage 
sampling, and all consecutive patients attending the treatment sites had an 
equal chance of being included in the study. The biographic characteristics 
closely matched those of the target population. 
 Setting characteristics: The settings included an urban setting with referral 
of patients from all over the country, but also a rural hospital setting to 
reflect the general settings in the country. The intervention delivery 
methods were harmonised and synchronised at all the study sites and 
competencies of the personnel conducting the recruitment and testing of 
hearing sensitivity were the same at the study sites 
 Temporal characteristics: The time variable was considered in the study. 
For instance, recruitment of the cohort was continuously done over 13 
months. That type of enrolment overcomes the threat of seasonal 
fluctuations in any of the parameters 
 Research study awareness and pre-testing effects:  the Hawthorne effect 
or reactivity of respondents knowing that they are involved in a study can 
have potential impact on performance, achievement, attitude, behaviour. 
Most of the variables collected in the study, were not dependent on the 
variables listed in the previous paragraph. The measurements were rather 
objective. Audiometry is a behavioural test but measures were put in place 
to identify malingerers. In addition, ABR test was conducted, as an 
additional test to pure tone audiometry once there was a suspicion of 
―faking‖ responses. 
 Multiple treatment interferences:  the researchers worked closely with the 
management of the study sites to minimise any possibility of multiple 
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treatments, hearing sensitivity testing, and management algorithms‘ 
interferences.   
 High dropout rates attrition, in cases where individuals who drop out might 
have specific characteristics that are different from individuals who remain. 
Attrition rates were kept low and hence this was not a major problem in 
this study. Special training of the research assistant to motivate patients, 
provision of transport re-imbursement for patients who were likely to miss 
appointments and short text message reminders helped to reduce attrition. 
 Low response rates where there could be considerable effects due 
individual‘s nonresponse to certain items on the questionnaire: Out of the 
194 patients approached for eligibility, 173 agreed to participate in the 
study. The response rate was actually much higher than we have 
anticipated being 50-70%. 
 
In summary, the study addressed those weaknesses by: 
 
 Ensuring that the sample is a representative of the target population. 
Respondents were selected from the largest MDR-TB treatment site with a 
national representation of patients attending the facility.  
 The optimisation of statistical considerations in the calculation of sample size 
to achieve very high power for the study to increase the chances of 
generalizability. 
  
3.4.3 Reliability  
 
Another aspect of quantitative research related to validity is reliability. Reliability is 
viewed as a property of the instruments (for example, tests and observation 
schedules) that quantitative researchers used to measure the phenomena they are 
studying (Curtis & Drennan 2013c:314-322; Donmoyer 2008). An instrument is 
considered reliable if it consistently produces the same results when administered to 
the same or comparable individuals. Reliability was assured by the use of the 
standard operating procedures for the equipment including daily calibrations and 
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quality control manoeuvres. Translation of the questionnaires into SiSwati is another 
measure that the researcher took into consideration to ensure reliability.  
 
 A pilot test of procedures, equipment, and questionnaires was done as 
reported in section 3.3.1 and 3.4.5.  Procedure manuals detailing each step 
were used and staff involved in the study were trained. Scheduled progress 
meetings were conducted and troubleshooting was done timeously.  
 Hearing sensitivity measurements were conducted using pure-tone 
audiometer as recommended by the guidelines American Academy of 
Audiology (Durrant 2009:4), American National Standards Institute (ANSI 
2004a, 2004b), the American Speech-Language-Hearing Association 
(ASHA1994:11-19, 2002, 2005) and the British Society of Audiology (BSA 
1988). Hearing evaluation with pure-tone stimuli has shown good sensitivity 
and specificity in identifying hearing losses exceeding a predetermined 
screening level and in ruling out hearing losses for individuals having 
thresholds better than the selected screening criterion.   
 The main potential confounders were identified prior to the study. However, 
the researcher dealt with those discovered later during the data collection. 
Methods used to eliminate confounders included restriction in participation in 
the study; stratified analysis within strata of the cofounding variable (for 
example, age) and intent-to treat analysis to address drop out and non-
compliance. 
 Information Bias (Error or bias in measurements) minimised strict observance 
of diagnostic criteria; testing for inter and intra observer variability; and 
implementing regular quality assurance procedures to ensure that there is no 
―drift‖ in the precision of the results (Enarson et al 2001:97-104). The 
exposure variables were defined apriori to make sure they are clear, specific, 
and measurable.   
 The physician, audiologist and statistician, and other interested parties were 
invited to review the data collection tools, ensure content validity, and 
measurements were standardised for the exposed and unexposed.  
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3.4.4 Quality Control 
 
Other quality control procedures were conducted at all different facets and stages of 
the study, and these included: 
 review of sample selection procedures,  
 supervision of interviewing,  
 random checks that interviews have actually taken place,  
 compliance with proper standards in recruitment and training of personnel, 
continual review, verification, and evaluation that all procedures and 
processes correspond to the study design. 
 Training: Research assistants were trained for two weeks in the standard 
operating procedures of the study: basics in research methods, basics of 
research ethics, data collection, data entry, how to ensure data quality, 
actions to enhance adherence and reduce missing data. The audiologist also 
had an additional one-week attachment to the audiology-training centre at the 
University of Pretoria. 
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3.5 SUMMARY OF THE RESEARCH DESIGN AND METHODS 
 
The table 3.1 summarises the research design and methods framework. 
 
Table 3.4  Research design and methods summary framework 
 
Research Question 
i) What is the incidence of hearing loss among patients 
enrolled in the MDR-TB treatment programme in 
Swaziland? 
ii) Is there a difference in the incidence of SNHL, time to 
SNHL and risk factors in HIV positive and the HIV negative 
patients on MDR-TB treatment?  
iii) How can best practices for prevention and monitoring of 
MDR-TB treatment related hearing loss be developed? 
Time Line 
2011 
 
 
      
2014 
Problem Statement 
The internationally recommended MDR-TB treatment 
regimens are complex and use aminoglycosides and 
polypeptide antibiotic injections that have known to be 
ototoxic. 
There is paucity of data on impact of HIV infection on the 
incidence of hearing loss related to MDR-TB treatment. 
From existing studies, the influence HIV infection on 
incidence hearing loss in general is disputed. There is 
paucity of data for development of guidelines. 
There are no guidelines for prevention and monitoring 
SNHL in MDR-TB patients; and the guidelines from WHO 
do not provide details on what should be done, how and 
when. There is a need for best practice guidelines for 
monitoring and preventing MDR-TB treatment related 
hearing impairment, but there is empirical evidence. 
Research design and Methods 
1. Quantitative, 2. Analytical/Observational 3.  Prospective 
cohort and Case-cohort, 4 Longitudinal data collection. 
Areas Studied 
1. Medical history, family history, socio-demographic 
characteristics, Life style characteristics 2. Baseline and 
monthly hearing sensitivity testing during intensive phase of 
MDR-TB treatment, 3. Key laboratory data.  
Data Collection 
1. Questionnaires, 2. Physiobiological Assessments, 3. 
Medical records.  
Data Analysis 
1. Descriptive, 2. Explanatory, 3 Predictive analysis of 
longitudinal data regression analysis, 4. Survival 
distribution. 
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3.6 CONCLUSION 
 
In conclusion, this chapter presented a detailed description of the research design 
and methodology used for the study, focusing on the prospective cohort design and 
longitudinal data collection. Chapter four will present the findings and provide a 
response to the problem statement and other research questions presented in 
chapter 1.  
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                                CHAPTER 4 
 
ANALYSIS AND PRESENTATION OF RESULTS 
 
4.1 INTRODUCTION 
 
In Chapter 3, the research design and methods for the study and the plan for the 
analysis of data were discussed. Chapter 4 presents the results of the research 
conducted from August 2012 and October 2014.The presentation of the results is 
divided into five sections, closely linked to the study objectives. 
 
In Sections A to F, results of the research are presented. The socio-demographic 
data are presented first, characterising the study respondents according to their age 
profile, level of educational attainment, occupational profile, past medical history and 
their clinical profiles. Section 1 covers the results of the descriptive and explanatory 
analysis.  The incidence of hearing loss is presented first followed by the bivariate 
and multivariate analysis of risk factors for hearing loss associated with MDR-TB 
treatment.  Results of the impact of HIV on hearing loss are presented next followed 
by the presentation of the time-to-event data, predictive analysis, and survival data 
analysis. Finally, the results of the hypothesis testing are presented.  The logistic 
regression statistical model, cox proportional hazards regression, log rank tests, and 
Kaplan Meier survival curves are also represented.  
 
4.2 DATA MANAGEMENT AND ANALYSIS 
 
Data management is a process by which the required data are acquired, validated, 
stored, protected, and processed, and by which its accessibility, reliability, and 
timeliness is ensured to satisfy the needs of the data users (Business dictionery, 
[Sa]). Data management consists of: 
 
 data capture which refers to any process that converts the information 
provided by a respondent into electronic format (Canad 2013), and  
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 data cleaning, which is the process of preventing and correcting these errors. 
Common tasks in data cleaning include record matching, deduplication, and 
column segmentation, identified and managed through a variety of analytical 
techniques (Osborne 2013). 
 
The data were entered into the electronic form using an MS Access database by two 
trained research assistants /data clerks. The data were checked for completeness 
and errors, and finally cleaned before analysis.  
 
Data analysis is the process of developing answers to questions through the 
examination and interpretation of data (Canada 2013). Data analysis as the process 
of reducing, organising and giving meaning to data. Data analysis involves 
systematically applying statistical and/or logical techniques to describe and illustrate, 
condense and recap, and evaluate data and transforming raw data into usable 
information (Grove et al 2013; Polit & Beck 2008:725) Data were analysed using 
STATA software (Texas, USA).  In the current study, data analysis was conducted to 
achieve the objectives of the following objectives set for the research to: 
 
 Establish the incidence of hearing loss among DR TB patients receiving DR-
TB treatment in Swaziland. 
 Identify risk factors for hearing loss associated with DR-TB treatment. 
 Determine the extent to which HIV/AIDS influences the incidence of hearing 
loss in MDR-TB patients in Swaziland. 
 Assess time-to-hearing loss and recommend the optimal frequency for 
audiology testing for monitoring of patients on DR-TB treatment in Swaziland. 
 Develop best practice guidelines for prevention and monitoring MDR-TB 
related hearing loss in Swaziland. 
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4.3 RESEARCH RESULTS 
 
SECTION A 
 
4.3.1 Socio-demographic characteristics of the respondents 
 
4.3.1.1  Age of respondents  
 
The ages of the respondents ranged from 15 years to 68 years. The mean age was 
33.9 years (95% CI: 32.1-35.7).  More than half of the respondents (52%) were 34 
years or younger.  The mean age in the male was higher at 36.4 years (95%CI: 33.7-
38.9) compared with the mean age in females which was 31.9 years (95% CI 29.6-
34.7) (p value 0.0062). Table 4.1 provides the details of the age breakdowns. 
 
Table 4.1: Age distribution of the study respondents 
Age categories Frequency Percentage 
15-19 (1) 04 2.37% 
20-24 (2) 18 10.65% 
25-29 (3) 36 21.30% 
30-34 (4) 33 19.53% 
35-39 (5) 36 21.30% 
40-44 (6) 17 10.06% 
45-49 (7) 06 3.5% 
50-54 (8) 10 5.92% 
55-59 (9) 09 5.45% 
60+   (10) 04 2.37% 
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4.3.1.2 Item 2: Gender  
 
Data from one hundred and seventy-three (173) respondents were analysed.  
Seventy-eight respondents (45%) were males and 95 females (55%). See Figure 4.1 
for the details. 
 
 
 
Figure 4.1: Frequency of respondent’s gender 
 
4.3.1.3 Item 3: Nationality and Race 
 
The majority of the respondents, 169 (97.6%) were black Swazis, while the white 
Swazis constituted 2 (1.68%) and black Africans of other nationalities, 2 (1.68%) as 
shown in Figure 4.2. 
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Figure 4.2: Nationality of respondents  
 
4.3.1.4 Item 4: Respondent’s Region of origin  
 
The respondents from Manzini region constituted 71 (41%) of the study respondents. 
Respondents for Lubombo region constituted 51 (30%) and Hhohho 43 (25%) as 
shown in Figure 4.3. Respondents from Shiselweni region were the least  7 (4%). 
There were fewer respondents from Shiselweni because there is an MDR-TB 
treatment facility serving catchment area that covers most of the region. The two 
respondents who reported their ethnicity as black African did not state their 
nationality and region of origin.    
Except for Hhohho region, there were more female respondents than males in each 
of the regions as displayed in Figure 4.3. 
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Figure 4.3: Region and gender of the respondents 
 
4.3.1.5 Item 5: Respondent’s highest educational attainment 
 
About 59 (34%) of the respondents had completed secondary education, 40 (23.1%) 
completed tertiary education, and 39 (22%) had some secondary education. Only 
about 2 (1%) had no formal education (See Figure 4.5).  Respondents from either 
Hhohho or Manzini were more likely to be more educated than those from either 
Lubombo or Shiselweni were (p value = 0.014). In addition, the male respondents 
were more likely to be more educated than female counterparts (p value = 0.014). 
This compares well with the country‘s literacy level. Swaziland has a total adult 
literacy rate of 87.8% (UNICEF 2013). 
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Figure 4.4: Highest level of education attained by respondents by gender 
 
4.3.1.6 Item 6 and 7: Employment status and profession (Job type) 
 
Seventy (40%) of the respondents were in employment at the time of the study. Fifty 
eight (58) (33.5%) respondents had not had a job in the past year, and about 
17(10%) were minors. The highest proportion of the respondents, 52 (30.2%), were 
in the unskilled manual category and 34(19.6%) had a professional managerial/ 
clerical job. Respondents employed in the mining sector or working as machine 
operators constituted eight (4.6%) of the study sample. Only one (0.6%) respondent 
was from the music/sound industry. Nineteen respondents did not indicate 
profession. See the details in Table 4.2  
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Table 4.2: Employment status and profession of the respondents 
Variable Sub categories Frequency Percentage 
Employment Currently employed 70 40.5% 
Not employed within the last 
12 months 
58 33.5% 
Not employed for more than 
12 months 
25 14.5% 
Minor 17 10% 
No answer 3 1.8% 
Profession/ Job 
type 
Professional/technical 
Managerial 
34 19.7% 
Clerical 12 6.9% 
Sales and Service 20 11.6% 
Skilled Manual 15 8.6% 
Unskilled Manual 52 30.1% 
Mining/Machine operators 8 4.6% 
Sound technicians/ Music 01 0.6% 
Agriculture 01 0.6% 
Scholars 06 3.5% 
No answer 19 10.4% 
 
4.3.1.7 Item 8: Marital Status 
 
The married respondents plus respondents living together constituted about 85 
(50%) of the sample. However, there was almost equal numbers of the married and 
never married among the respondents, 79 (46%) and 76 (44%) respectively as 
shown in Figure 4.6. 
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Figure 4.5: Respondents’ marital status 
 
4.3.1.8 Item 9: Religious affiliation of respondents 
 
The Zionist religion constituted the largest religious affiliation among the respondents 
39 (22.5%) followed by the Charismatic Christians, 36 (20.8%) and the Pentecostals, 
30 (17.3%) with 9 (5.2%) who had no religious affiliation as shown in Table 4.3. 
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SECTION B  
 
4.3.2 Clinical characteristics and history of treatment among the 
respondents 
 
4.3.2.1 Item 10: History of TB disease and comorbidity 
 
In response to the question on history of TB disease and comorbidity, of the 173 
respondents, 44 males and 51 females (55%) had a previous history of TB 
treatment.  
 
 
 
 
 
 
 
 
Table 4.3: Religious affiliation of the respondents 
Religious affiliations  of the 
respondents 
Frequency  Percentage 
Protestant/Anglican 8 4.6% 
Roman catholic 10 5.8% 
Charismatic 36 20.8% 
Pentecostal 30 17.3% 
Apostolic 21 12.1% 
Methodist 15 8.7% 
Seventh Day Adventist 02 1.2% 
Zionist 39 22.5% 
No Religion 09 5.2% 
Other 03 1.8% 
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Figure 4.6: History of tuberculosis treatment (frequency and percentage) 
 
4.3.2.2 History of Streptomycin use for TB treatment 
 
A total number of 7 males and 11 females (18%) were treated with streptomycin for a 
previous episode of tuberculosis as reflected in Figure 4.7 and Table 4.5. 
 
 
 
Figure 4.7: History of tuberculosis treatment with streptomycin (frequency and 
percentage) 
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Table 4.4: Clinical Characteristics (history of TB disease and exposure to TB 
treatment) (N=173) 
Variables Sub category   Frequency Percent 
Previous TB 
treatment 
(n=173) 
No History  76 43.93% 
History present  95 54.9% 
History Unknown  02 1.16% 
Previous TB episode 
(n=146) 
Drug Susceptible   59 40.1% 
Retreatment (D-S)  86 58.90% 
DR-TB case  01 0.68% 
Previous 
Streptomycin 
No history   149 89.2% 
Previous treatment   18 10.8% 
DR-TB at enrolment Presumed  21 12.21% 
Confirmed  148 86.05% 
Unknown  3 1.73% 
 
4.3.2.3 Item 11: HIV status of respondents  
 
The majority 136 (79%) of the study patients were HIV positive and 37(21%) HIV 
negative. One hundred and thirty-four 134(98.5%) were aware of their HIV status at 
the time of enrolment and 133 (97.8) were taking HIV treatment (see Figure 4.8 and 
4.9).  
 
 
    
  Figure 4.8: HIV sero-status of the respondents (frequency and percentage) 
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Female respondents were more likely to be HIV positive than male respondents 
were (p value = 0.044). Age group was significantly associated with HIV status (p 
value = 0.000). The prevalence of HIV was highest age group 40-44 years, followed 
by 30-34 years age group and 35-39 years age group. 
 
 
 
Figure 4.9: HIV sero-status of the respondents by gender 
 
4.3.2.4 Item 12: Comorbid conditions (other than HIV) 
 
Five (3%) respondents had high blood pressure and all were female but only one 
was on medication for hypertension. There were four (2.3%) respondents with 
diabetes mellitus and they were all male but only two (2) were on anti-diabetic 
treatment. Four (2.3%) patients had known renal disease (2 males, 2 females). 
Please see table 4.6 for details. 
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Table 4.5: Clinical Characteristics (concurrent comorbidities) 
Variables Sub category Frequency Percent 
HIV status (n=173) Negative 39 22.54% 
Positive 134 77.26% 
On ART (HIV 
Pos)(n=134) 
 
Not on ART 01 0.7% 
ART 133 99.3% 
Diabetes Mellitus 
(n=173) 
No DM 169 97.69 
DM present 04 2.31% 
Comorbid with Renal 
Disease (n=173) 
No Renal Disease 169 97.69% 
Renal Disease 04 2.31% 
Cardiovascular disorder 
(n=173) 
No CVD 170 98.27% 
CVD 03 1.73% 
   
Hypertension 9173) 
 
No HT 168 97.1% 
Hypertensive 05 2.9% 
    
CD4 Count  
 (n=173) 
<200 cells/ml 151 87.28% 
 200-500 cells/ml 8 4.62% 
 >500 cells/ml 5 2.57% 
 Not taken 9 4.98% 
 
4.3.2.5 Item 13: Clinical symptoms and concurrent medications  
 
The five commonest presenting symptoms and signs of MDR-TB reported by the 
respondents at baseline assessment as shown in Table 4.7 were: 
i) weakness and/or fatigue (95%); 
ii) night sweats (92%); 
iii) chest pain (91%);  
iv) loss of appetite (86%); and  
v) weight loss (85%)  
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Table 4.6: Clinical symptoms at the diagnosis of MDR-TB reported by the respondents  
Symptoms at 
diagnosis 
Sub 
category 
Frequ
ency 
Percent 
(%) 
Symptoms at 
diagnosis 
Sub 
category 
Frequ
ency 
Percent 
(%) 
High grade 
fever 
No 135 78.3% Loss of appetite No 24 13.7% 
Yes 38 21.97%  Yes 149 86.3% 
Low grade 
fever 
No 85 49.13% Nausea/Vomiting 
(n=173) 
No 146 84.3% 
Yes 88 50.87%  Yes 27 15.6% 
Night Sweats No 14 8.09% Visual 
problems(n=173) 
No 165 95.38% 
 Yes 159 91.91%  Yes 08 4.62% 
Unproductiv
e Cough 
No 72 41.62% Dyspnea(n=173) No 131 75.72% 
Yes 101 58.38%  Yes 42 24.28% 
Productive 
Cough 
No 103 59.54% Headache v No 77 44.51% 
Yes 70 40.4%  Yes 96 55.49% 
Heamoptysis No 149 86.13% Hearing loss 
(n=173) 
No 173 100% 
 Yes 24 13.87%  Yes 0 0% 
Chest pain 
(n=173) 
No 15 8.7% Weight loss 
(n=173) 
No 27 15.61% 
 Yes 158 91.33%  Yes 146 84.39% 
Weakness/Fa
tigue(n=173) 
No 08 4.62% Thirsty (n=171) No 132 75.78% 
Yes 165 95.3%  Yes 39 24.22% 
Diarrhea 
(n=173) 
No 164 94.8% Loss of 
appetite(n=173) 
No 24 13.7% 
 Yes 09 5.2%  Yes 149 86.3% 
Nausea/Vomi
ting (n=173) 
No 146 84.3%     
Yes 27 15.6%     
 
4.3.2.6 Item 14: Medications used by the respondents 
 
One hundred and seventy two (99.4%) respondents were on treatment using the 
national standard regimen for MDR-TB during the intensive phase of treatment is 8 
Km-Lfv-Cs/Tr-Ethio-PZA-PAS. One (0.6%) patient received amikacin instead of 
kanamycin. One hundred and thirty three (76.9) HIV positive respondents also 
received ART. In addition, however, five (2.8%) respondents were on paracetamol 
as depicted in Table 4.8. 
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4.3.2.7 Item 15: ARV medications used by respondents 
 
Respondents who were HIV positive also received antiretroviral medicines for 
treatment of HIV in addition to the medications for MDR-TB.  The majority of the HIV 
positive respondents were on a Tenofovir based regimen 101 (59%), followed by the 
Zidovudine based regimen 19 (11%), Abacavir based regimens 4 (6%) and the 
Stavudine based regimens 4 (1.3%). One hundred and twenty (70.2%) HIV patients 
were on Efavirenz and only 10 (5.6%) on Nevirapine. 
 
Table 4.7: MDR-TB and ARV prescriptions for respondents  
Name of Medication  Frequency Percentage 
 
MDR-TB regimen at enrolment    
Kanamycin No 03 1.73% 
 Yes 170 98.27% 
Amikacin No 172 99.42% 
 Yes 01 0.58% 
Ethionamide No 03 1.73% 
 Yes 170 98.27% 
Para Aminosalicylic Acid No 76 43.93% 
 Yes 97 56.07% 
Pyranazinamde No 06 3.47% 
 Yes 167 96.53% 
Terizidone  No 0  
 Yes 173  
Levofloxacin No 03 2.17% 
 Yes 170 98.27% 
HIV Treatment regimen    
    
Zidovudine None 154 89.00% 
 Yes 19 11.00% 
Tenovir None 72 42.8% 
 Yes 101 59.2% 
3TC None 42 24.28% 
 Yes 131 75.72% 
Stavudine None 169 97.69 
 Yes 04 1.31  
Nevirapine  None 163 94.2% 
 Yes 10 5.58% 
Abacavir None 167 96.00% 
 Yes 06 4.00% 
Efavirenz None 51 21.9% 
 Yes 122 70.2% 
Other medications    
    
Concurrent Paracetamol None 168 97.11 
 Yes 05 2.89% 
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SECTION C  
 
4.3.3 Life style and physical characteristics 
 
4.3.3.1 History of smoking among respondents 
 
While the 155 (89.6%) respondents did not smoke, three (2%) were current smokers 
and 12 (7%) were previous smokers. Current smoking was referred to as currently 
smoking or stopped smoking less than 6 months while previous smokers were 
defined as those who had not smoked for at least 6 months after quitting smoking. 
See table 4.10 for further details.  
 
 
 
Figure 4.10: History of smoking among the respondents  
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4.3.3.2 Drinking Alcohol 
 
The majority of the respondents, 135 (78%) reported no history of drinking alcohol. 
Three respondents, all males, were current drinkers. Twenty-six (26) males and six 
females (18.5%) were previous drinkers.   See Figure 4.11. 
 
 
 
 
Figure 4.11: History of drinking alcohol among the respondents (frequency 
and percentage) 
 
4.3.3.3 History of exercise 
 
Only 17 (9.8%) of the study respondents reported involvement in regular exercise 
prior to their illness (at least once or twice a week). Women were not likely to engage 
in any form of exercise or exercise less than once a month (p value = 0.010). See 
table .4.12 
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Figure 4.12: Frequency of exercise among the respondents 
 
4.3.3.4 Ear health (History of ear infections and conductive hearing 
loss) 
 
The baseline assessment of hearing health showed that 28(16.2%) of the 
respondents had a history of ear infection. 
 
Table 4.8: Ear Health (history of ear infections and conductive hearing loss) 
 
Variables  Frequency Percent (%) 
History Ear Infection None 137 79.91% 
Childhood 09 5.20% 
Adult 19 10.89% 
unknown 08 4.62% 
Baseline conductive 
hearing loss 
 
Normal 168 97% 
Conductive 5 3%  
7, 4% 
40, 23% 
3, 2% 
14, 8% 
109, 63% 
Frequency of Exercise (N=173)  
Unknown
Occasionally
Twice/Week
Once/week
Less than once a week
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4.3.3.5  Fluid consumption among the respondents 
 
Men were more likely to consume more fluids than women (p value 0.040) were 
overall, 80(46.2%) of the study respondents reported that they consumed at least 1-2 
litres of fluids per day. 
 
4.3.3.6 Hydration status of the respondents 
 
The majority 114(66%) of the patients were dehydrated at the time they were 
enrolled into MDR-TB management (see Figure 4.13) 
 
 
 
Figure 4.13: Hydration status of respondents at baseline 
  
At least 21(12%) of the respondents were exposed to noise at the work place and 
58(33%) during leisure. Men were more likely to be exposed to noise at the work 
place and during leisure than women were (p value = 0.002). 
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Figure 4.14: Exposure to noise by respondents at baseline 
 
 
4.3.3.7: Baseline body temperature of the respondents 
 
 
 
Figure 4.15: Body temperatures of the respondents at baseline 
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4.3.3.8 Baseline weight 
 
The modal weight band of the respondents was 50-59k kg while the baseline 
average weight was 51.7kg (95% CI: 49.16-54.40). See table 4.10 and Figure 4.16.  
 
Table 4.9 Baseline weight bands of the respondents (N=161) 
 
  Weight bands Frequency Percent 
Baseline weight  35-49 50 31.01% 
 50-59 64 39.71% 
 60-69 31 19.21% 
 70-79 11 6.83% 
 80-96 5 3.11% 
 
 
 
 
Figure 4.16: Boxplots for the baseline weight of respondents in kilograms 
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SECTION D   
 
4.3.4 Incidence of hearing loss 
 
In this cohort study, the research aimed to determine incidence of hearing loss and if 
an association exits between the exposure to HIV infection (as well as other risk 
factors) and hearing loss incidence. Hearing loss was analysed as a categorical 
outcome (hearing loss; no hearing loss). However, incidence rates calculated as 
continuous variable. The Table 4.11 shows the incidence rates of high frequency 
hearing loss. 
 
Table 4.10 Incidence rates per 1 000-person days at risk 
Factor Sub category High frequency 4 and 8 kilohertz 
Rate per 1000 
person days 
Confidence 
Intervals  
P value 
Gender Male 5.2 3.9-6.8 0.03 
 Female 3.3 2.4-4.4  
Age Group 15-29 2.8 1.9-4.2 0.02 
 30-49 4.5 3.5-5.9  
 50-69 7.0 4.2-11.9  
Profession/ 
 
Agriculture/ other  1.6 0.37-3.8 0.006 
 Manual Workers (skilled and 
unskilled) 
4.2 2.9-5.8  
 Office (Managers and Clerical) 5.0 3.7-6.8  
 Machine operators, Miners 
and drivers 
9.7 5.1-18.7  
 Scholars and pupils  2.4 0.6-9.8  
Dyspnoea 
present 
No 3.5 2.8-4.5  
 Yes 7.4 5.0-10.9  
Noise 
exposure 
Not sure  4.7 3.6-6.1 0.02 
 At work 6.4 3.6-11.2  
 During leisure 2.8 1.9-4.1  
BMI Normal 4.0 3.0-5.4 0.009 
 Under weight 8.0 5.4-11.9  
 Overweight 0 -  
Haemogloblin 11+ 3.4 2.4-7.6 0.002 
 08-11 5.1 3.4-7.6  
 <08 12.3 5.9-25.8  
Creatinine Normal 3.9 3.1-5.1 0.04 
 High 8.0 4.4-14.5  
 Low 2.5 0.6-10.1  
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SECTION E 
 
4.3.5  Associations of high frequency hearing loss 
Table 4.11: Bivariate Analysis (Associations with high frequency hearing loss)  
Variable Counts No Hearing 
Loss 
Hearing 
Loss 
P value 
Gender (n=159) Male 23 51 0.02 
Female 42 43 
Age (n=159) 15-29 29 25 0.02 
30-49 33 55 
50-69 03 14 
Job type (n=159) Miner/Machine operator/ Sound or 
music Operator 
0 9 0.003 
Office based (Manager/clerical) 21 41 
Manual (skilled/unskilled) 25 34 
Agriculture/Other 12 05 
Dyspnoea of 
admission 
(n=159)  
Dyspnoea absent at initiation of 
treatment 
56 69 0.054 
Dyspnoea present at initiation of 
treatment 
09 25 
Noise Exposure 
(n=159) 
Not sure 31 56 0.078 
At work 05 12 
During Leisure 29 26 
   
Rifampicin 
Resistant (n=144) 
No Rifampicin Mono-Resistance at 
initiation of treatment 
16 16 0.278 
Rifampicin Mono-Resistance at 
initiation of treatment 
44 68 
Pre-treatment 
hydration status 
(n=102) 
Not hydrated 25 40 0.145 
 Dehydrated 33 36 
Haemoglobin 11+ 33 36  
 08-11 9 24  
 <08 01 07  
Creatinine Normal 40 60 0.19 
 High 2 11  
 Low 2 2  
BMI Normal 27 42 0.018 
 Underweight 5 1  
 Over weight 1 3  
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Temporal associations of hearing loss and several independent variables were 
explored (see table 4.12) 
  
4.3.6 Risk factors for hearing loss 
 
4.3.6.1 Univariate Analysis of risk factors for high frequency hearing loss 
 
On univariate regression analysis, the following were risk factors for DR TB 
treatment related sensorineural hearing loss (see Table 4.13): 
 
 being  of male gender (p value =0.033),  
 poor baseline hydration status  at the start of MDR-TB treatment (p value 
=0.012),  
 use of Abacavir as backbone in the ART regimen in MDR-TB (p value = 
0.017)   and  
 low of <8 g/dl baseline HB (p value <0.001), low BMI (p value =0.003), 
presence of dyspnoea at the start of treatment (p value < 0.001 ) were found 
to be risk factors for high frequency hearing loss. 
 
4.3.6.2 Multivariate Analysis of risk factors for high frequency hearing loss 
 
On the Cox regression model, the following variables were dropped: education, 
religion, noise, body-mass index, regimen for HIV, religion, and CD4 count. Variables 
retained in the model with statistically significant relationship with high frequency 
hearing loss were as follows and Table 4.13 contains the details: 
 
 Compared to agriculture as a day-to-day employment, the hazard ratio of high 
frequency hearing loss was 4.2 times in the Miners/machine Operators and 
Sound Industry (HR: 5.4, CI 1.2-24.03, p value =0.024) 
 Patients who had dyspnoea at initiation of MDR-TB treatment were 3.4 times 
likely to develop high frequency hearing loss (HR: 3.4, CI 1.8-6.3, p value 
=0.000).  
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 Low baseline haemoglobin was a risk factor for hearing loss (p value<0.01). 
Patients with HB 8-11 g/dl and those with HB less than 8g/dl were 2 times and 
8.5 times respectively more likely to develop hearing loss compared to those 
with HB above 11g/dl (p value <0.01). See table 4.13. 
.  
Table 4.12: Non HIV related Risk measurements for high frequency hearing 
loss continued 
 
Variable (Ref group) Univariate Analysis 
Crude HR 
P-value Multivariate P-value 
Gender:  Male 
 Female 
1.00 
0.64  (0.42- 0.96) 
- 
0.033 
- 
0.69 (0.37-1.2) 
 
0.23 
Baseline Hydration: Normal 
Dehydrated 
1.00 
1.87  (1.14- 3.003) 
- 
0.012 
  
Job type: Agric/other 
Office based (Manager/clerical) 
Miner/Machine operator/ Sound 
or music Operator 
Manual (skilled/unskilled) 
Scholar 
  1.00 
3.07 (0.68-13.8) 
 
5.4 (1.2-24.03) 
4.7 (0.74-30.0) 
4.7 (0.56-3.6) 
 
0.143 
 
0.024 
0.099 
0.155 
Night sweats:  No  
  Yes 
1.00 
0.57 (0.29-1.14) 
-- 
0.112 
  
Hydration:  Normal 
 Dehydrated 
1.00  
1.35 (0.87-2.10) 
-- 
0.18 
  
Baseline BMI:  Normal 
Underweight 
1.00 
2.14 (1.29- 3.35) 
-- 
0.003 
  
Dyspnoea: Absent 
Present 
1.00 -- 1.00 
3.4 (1.8-6.3) 
 
0.000 
Baseline creatinine: Normal 
Abnormal 
1.00 
1.81 (0.84-3.90) 
-- 
0.13 
  
Baseline Hb level: 11+ 
8-11 
<8 
1.00 
1.78 (0.96- 3.17) 
5.02 (2.17- 11.64) 
-- 
0.07 
<0.01 
1.00 
1.98 (1.11-3.55) 
3.8 (3.33-21.64) 
 
0.02 
0.000 
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4.4 HIV and Hearing loss 
 
4.4.5 HIV and hearing loss  
 
4.4.5.1 Association of HIV and Hearing loss 
 
Of the three HIV related parameters measured in the current study, only ARV 
regimen was associated with MDR-TB treatment related hearing loss (p value 
=0.017), compared to HIV status and HIV treatment (Figure 4.14). 
 
Table 4.13: Association of HIV parameters and hearing loss 
 
variable Sub categories Number with 
no hearing loss 
Number with 
hearing loss 
P value 
HIV status (n=159)  Negative  16 20  Fischer‘s 
exact 
0.62 
Positive 49 74 
HIV treatment 
(n=163) 
Yes [(HIV +)] 44 84 0.491 
No [HIV (-)] 15 20 
ARV regimen 
(n=125) 
TDF Based 40 52 0.017 
AZT Based 4 14 
D4T based 4 0 
ABC based 0 5 
 
 
4.4.5.2 Risk measurements by HIV  
 
Males are worse off than females and there is no distinct difference by HIV status.  
The incidence rate among the HIV positive patients was 4.2/1 000 person days (CI: 
3.4-5.3) and for HIV negative patients, 3.6/1 000 person days (CI: 2.4-5.7).  ART 
regimen containing Abacavir (ABC) backbone has survival distributions that were 
statistically different (see Table 4.14). 
171 
 
 
Table 4.14: Risk measurements for High frequency hearing loss and HIV 
Variable (Ref group) Incidence ratio   P-value 
Gender:  Male 
 Female 
1.00 
0.58  (0.39- 0.89) 
- 
0.01 
HIV: negative 
Positive 
1.00  
NRTI backbone: TDF based 
AZT/d4T based 
ABC based 
-- 
1.12 (0.60- 2.07) 
3.53 (1.37- 9.09) 
-- 
0.72 
0.01 
CD4 count:  <200 
200-500 
>500 
1.00 
1.76 (0.64-4.82) 
2.90 (0.91- 9.30) 
-- 
0.28 
0.07 
NRTI backbone: TDF based 
AZT 
d4T based 
ABC based 
-- 
1.37 (0.76- 2.49) 
0 
3.29 (1.28- 8.40) 
-- 
0.294 
0 
0.013 
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4.5 SURVIVAL DISTRIBUTION AND TIME TO HEARING LOSS 
 
4.5.1 Time to hearing loss by socio demographic characteristics 
 
4.5.1.1 Gender and Age: Survival analysis and time-to-hearing loss 
 
Males had worst survival distribution compared females and age group 50-69 years 
and also had poorer survival when compared to the younger age groups as shown in 
Figure 4.17 and 4.18. The median failure time among males was 94 days and 80 
days among females (see table 4.15) 
 
 
 
Figure 4.17: Hearing loss distribution by gender 
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Figure 4.18: Hearing loss distribution by age group (right) 
 
4.5.1.2 Time to hearing loss by Job type 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: Hearing loss survival and job type  
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Figure 4.20: Hearing loss survival and noise exposure  
 
4.5.2 Time to hearing loss by HIV variables 
 
4.5.2.1 HIV status 
 
No distinct difference by HIV status was observed in survival distribution (p value 
=0.59). See Figure 4.21. The time to hearing loss was 84 days in both HIV positive 
and HIV negative respondents (Table 4.15). 
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Figure 4.21: Survival distribution of hearing loss by HIV status 
  
 
4.5.2.2 Time to hearing loss by status of ARV treatment 
 
However, when survival by ART regimen were compared using NRTI backbone, 
there was statistical significance among the regimens. Patients on Abacavir had a 
higher failure rate when compared to TDF based regimen as shown in Figure 4.22.  
The median time to hearing loss in respondents 104 days  on ABC, 100 days for 
those on AZT and 83 days for those on TDF (see Table 4.15 for details) 
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Figure 4.22: Survival distribution of hearing loss by NRTI ARV base (right) 
 
4.5.3 Time to hearing loss by clinical parameters 
 
4.5.3.1 Time-to-hearing loss between Body mass index and Haemoglobin 
 
Underweight patients and patients with low haemoglobin level failed at faster rates 
than normal patients with normal BMI did (p value=0.01) and haemoglobin level 
above 11 g/dl (p value <0.01). See Figure 4.23 and 4.24.  
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Figure 4.23: Survival distribution of hearing loss by body mass index  
 
Respondents with HB less than 8g/dl had the mean time hearing loss of 142 days 
compared to respondents with HB between 8 and 11g/dl of 98 days and HB more 
than 11g/dl of 160 days. See Table 4.24 
 
 
 
Figure 4.24: Survival distribution of hearing loss by haemoglobin (HB) level 
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4.5.3.2 Time to hearing loss and dyspnoea 
 
Presence of dyspnoea is associated with higher rates of failure when compared with 
absence of dyspnoea at the start of treatment (p value <0.01) – see Figure 4.25. 
 
 
 
Figure 4.25: Hearing loss distribution by dyspnoea 
 
4.5.3.3 Time to hearing loss and hydration status 
  
Figure 4.26: Hearing loss survival distribution by hydration status 
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Table 4.15: Median and mean times to hearing loss 
Median time to failure: 84 days (IQR: 54.5- 147); Mean: 103.9 (sd: 67.2) 
Variable No. of events Median (IQR) Mean(s.d.) 
Gender:  Male 
Female 
53 
47 
94 (49- 160) 
80 (57- 126) 
108.5 (72.3) 
98.7 (61.3) 
Night sweats:  No 
Yes 
12 
88 
83 (54.5-149) 
84 (54.5- 147) 
105.3 (72.5) 
103.7 (66.9) 
Baseline Hb:  >11 
8-11 
<8 
17 
8 
5 
147 (83- 213) 
86.5 (55- 144.5) 
44 (34- 56) 
144.1 (71.2) 
103 (70.0) 
51.2 (27.4) 
Bas.hydration:   Normal 
Dehydrated 
41 
44 
97 (72- 174) 
66 (39.5- 112.5) 
114.8 (63.5) 
87.1 (63.7) 
CD4 count:  <200 
200-500 
>500 
90 
4 
2 
83.5 (51- 151) 
79 (44- 109) 
164.5 (97- 232) 
104.7 (68.7) 
76.5 (38.6) 
164.5 (95.5) 
NRTI backbone:  TDF 
AZT 
D4T 
ABC 
60 
13 
0 
4 
83 (56- 151.5) 
100 (59- 160) 
---- 
104.5 (59- 125) 
106.9 (71.3) 
118.5 (65.4) 
---- 
92 (47.1) 
Weight category: <50 
50-<60 
60-<70 
70+ 
31 
40 
19 
8 
83 (58- 117) 
81 (47.5- 147) 
94 (43- 170) 
109 (76- 146.5) 
100.2 (63.9) 
101.2 (68.8) 
105.1 (66.9) 
113.1 (60.5) 
Productive cough:  No 
Yes 
61 
39 
104 (58- 177) 
68 (42- 98) 
119.4 (71.7) 
79.7 (51.7) 
HIV test result:  Neg 
Pos 
21 
79 
84 (35- 151) 
84 (56- 147) 
97.8 (67.8) 
105.5 (67.4) 
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                   CHAPTER 5 
 
DISCUSSION OF RESULTS 
 
5.1 INTRODUCTION 
  
The previous chapter presented the findings of the empirical study. Chapter 5 
discusses the results based on the analysis of data. Chapter 5 discusses the 
descriptive statistics such as age, gender, region of origin, education, profession, 
occupation marital status, and religious affiliation, and the inferential statistics.   
 
5.2 DISCUSSION OF THE DESCRIPTIVE STATISTICS 
 
5.2.1 Socio-demographic characteristics of the respondents 
 
5.2.1.1 Gender  
 
The findings of this study indicate that there were more female respondents 95 
(55%) than the males 78(45%) reflecting a sex ratio of male: female of 0.82. This is 
similar to the results from the Swaziland Demographic and Health Survey (SDHS) of 
2007 that showed that there were 53 females to every 43 male citizens in Swaziland, 
giving a sex ratio of 1:1.14, that is 88 men to 100 women (Central Statistics Office 
(CSO) [Swaziland] and Macro Inc, 2008:9). The statistics also reflect the health 
seeking behaviour for TB services. For instance, the 2009 National Tuberculosis 
Control Programme annual report indicates that 55% of clients receiving HIV testing 
were females and 45% males (NTCP 2009:28).  
 
5.2.1.2 Age  
 
According to the results, the age of the respondents ranged from 15 years to 68 
years. The mean age was 33.9 years. Fifty two percent of the sample was 34 years 
or younger. This is in line with Swaziland‘s demographic and health survey of 2007 
which found that Swaziland‘s population was young, with 44 percent of the total 
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population under 15 years of age, and less than 4 percent is 65 years or older 
(Central Statistics Office (CSO) [Swaziland] and Macro Inc, 2008:9).   
 
5.2.1.3 Respondent’s Region of origin and nationality 
 
The respondents from Manzini region constituted 41% the study respondents. 
Respondents for Lubombo region constituted 30% of the respondents and Hhohho 
25%. Respondents from Shiselweni region constituted the least proportion of (4%). 
There were fewer respondents from Shiselweni because there is an MDR-TB 
treatment facility serving catchment area that covers most of the region (Swaziland 
Ministry of Health 2010:28).   According to the results, there were more female 
respondents than males in each of the regions with the exception of Hhohho region. 
The reason for this finding is not clear.  In addition, the majority of the respondents, 
97.6% (169) were black Swazis, while the white Swazis constituted 1.68% (02) and 
black Africans of other nationalities, 1.68% (02).  This picture reflects the hospitality 
of Swaziland where the country is multi-cultural, with almost 4% are white Swazis or 
black Africans from other African countries. 
 
5.2.1.4 Respondent’s highest educational attainment 
 
This study revealed that educational levels of respondents ranged from no formal 
education to tertiary education. Fifty-nine respondents (34%) had completed 
secondary education, 40 (23.1%) completed tertiary education, and 39 (22%) had 
some secondary education. Only 2 respondents (1%) had no formal education. The 
findings from the study compare well with the country‘s adult literacy rate estimated 
at 87.8% (UNICEF 2013). Education is a key determinant of the lifestyle and status 
an individual enjoys in a society. Studies have consistently shown that educational 
attainment has a positive effect on health behaviours and attitudes.  
From the data, a regional pattern of the educational attainment shows that 
respondents from either Hhohho or Manzini were more likely to be more educated 
than respondents from either Lubombo or Shiselweni (p value = 0.014). These 
findings are consistent with the results of the SDHS of 2008. According to the SDHS, 
across the regions, men and women in Manzini are better educated than those in 
other regions, and likewise men and women in Lubombo are the least educated 
182 
 
(Central Statistics Office (CSO) [Swaziland] and Macro Inc, 2008:11). The SDHS 
also showed that educational attainment is positively related to the wealth status of 
the household and Manzini and Hhohho are the most endowed regions in the 
country, and among the four regions, households in Manzini and Hhohho are more 
likely to fall in the highest wealth quintile than those living in the other regions 
(Central Statistics Office (CSO) [Swaziland] and Macro Inc, 2008:23). In addition, the 
male respondents were more likely to be more educated than female counterparts 
were (p value = 0.014). Although the results from the general population showed 
slight differentials between sexes in the levels of education attained, with men 
generally having higher educational levels (Central Statistics Office (CSO) 
[Swaziland] and Macro Inc, 2008:11).  
 
5.2.1.5 Employment status and profession (Job type) 
 
Only 40% of the respondents were in employment at the time of the study. About half 
of the respondents had not had a job in the past year. These results mirror the 
population level findings of the SDHS of 2008 (Central Statistics Office (CSO) 
[Swaziland] and Macro Inc, 2008:23) where 40% (versus 40% in this study) of the 
population had current employed and 50% did not have employment in the 
preceding 12 months (versus 48.0% in this study). In this study, about 10% were 
minors. According to the results, the highest proportion of the respondents, 30%, 
were in the unskilled manual category and 19% had a professional 
managerial/clerical job. Respondents employed in the mining sector or working as 
machine operators constituted 4.6% of the study sample and those in the 
sound/music industry constituted 1%. In comparison to the findings of the SDHS, 
with six occupational categories under which those currently employed: professional, 
technical, and managerial; clerical; sales and services; skilled manual; unskilled 
manual; and agricultural, the results are contrary. In the SDHS, the  majority of 
currently employed women worked in sales and services (56 percent) and for the 
men were evenly employed in sales and services and as skilled manual labourers 
(29 percent and 32 percent, respectively). Some professions expose the population 
to excessive noise, and unless noise levels are controlled or the workers wear 
protective gear, such employees will be at risk of noise induced hearing loss that can 
potentiate ototoxic hearing loss. 
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5.2.1.6 Marital Status and religious affiliations. 
 
According to the findings of  this study, the combination of the marrieds and those 
living together constituted about 50% of the respondents in the sample, reflecting an 
almost even distribution with the never married among the respondents, 79 (46%) 
and 76 (44%) respectively. The Zionist religion constituted the largest religious 
affiliation among the respondents at 22.5% (39) followed by the Charismatic 
Christians, 20.8% (36) and the Pentecostals, 17.3% (30). The SDHS also found that 
the Zionist religion  was the largest religious affiliation in Swaziland at 37%(Central 
Statistics Office (CSO) [Swaziland] and Macro Inc, 2008:28) 
 
5.2.2 Clinical parameters of the respondents 
 
5.2.2.1 HIV status and comorbid conditions among respondents  
 
One hundred and thirty six (78%) of the study patients were HIV positive and 37 
(22%) HIV negative. One hundred and thirty-four (99%) respondents were aware of 
their HIV status at the time of enrolment and 133 (98%) respondents were taking HIV 
treatment.   The very high number of HIV positive respondents was expected given 
that Swaziland has the highest HIV prevalence in the world, at 26% in the age group 
15-49 years (Central Statistics Office (CSO) [Swaziland] and Macro Inc, 2008). 
Tuberculosis is also often associated with HIV. The finding that 78% of the 
respondents were HIV positive confirms the impact of HIV on tuberculosis incidence 
(Lawn, Bekker, Middelkoop, Myer & Wood 2006:1040; Wells, Cegielski, Nelson, 
Laserson, Holtz, Finlay, Castro & Weyer 2007:S86). Routine MOH statistics show 
that the prevalence of HIV among TB patients is 80% (Swaziland Ministry of Health 
2010:23). Female respondents were more likely to be HIV positive than male 
respondents with (p value = 0.044). The results reflect the national picture.  A recent 
population-based study where measures of HIV prevalence were produced and 
compared against similarly measured HIV prevalence estimates from the 2006-7 
SDHS showed an HIV prevalence of 39% among females aged 18-49 years and 
24% among males of the same aged group (Bicego et al 2013).  
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Multiple morbidities (MM) are common in patients with MDR-TB increasing 
complexity and the impact on health services, providers and patients, and 
opportunities for chronic diseases screening in a population linked to care. In one 
study, 22.6% of the patients in a high HIV/TB setting presented with MM (Oni, 
Youngblood, Boulle, McGrath, Wilkinson & Levitt 2015:1). In this study, MM were 
found as follows: i) five respondents (3%) had high blood pressure and all were 
female but only one was on medication for hypertension; ii) four respondents (2%) 
had diabetes mellitus and they were all male but only two were on anti-diabetic 
treatment; and iii) four patients (2%)  had known renal disease (2 males, 2 females). 
Diabetes Mellitus is one of the commonest co-morbidity in patients with tuberculosis. 
(Kang, Kim, Jo, Kim, Park, Kim, Kim, Lee, Lee, Park, Koh, Kim & Shim 2013:472).  
Other respiratory conditions may also exist although this study did not find any, and 
the functional status may require additional rehabilitation (Godoy, Mello, Lopes, 
Costa, Guimaraes, Pacheco Castanho & Menezes 2012:1949).  
 
Because of the MM, respondents who were HIV positive also received antiretroviral 
medicines for treatment of HIV in addition to the medications for MDR-TB.  The 
majority of the HIV positive respondents were on a Tenofovir based regimen (59%), 
followed by the Zidovudine based regimen (11%), Abacavir based regimens (06%) 
and the Stavudine based regimens (04%). One hundred and twenty (122) HIV 
patients were on Efavirenz and only 10 on Nevirapine. Current WHO guidelines 
recommend that patients on rifampicin should not receive Nevirapine because of the 
drug-to- drug interaction and bioavailability of Nevirapine when co-administered with 
anti-TB medicines (World Health Organization 2014a). The reduction of nevirapine 
concentrations with concomitant rifampicin is greater than with Efavirenz, particularly 
during the lead-in dose period when subtherapeutic concentrations occur in the 
majority of TB patients (Maartens, Decloedt & Cohen 2009). The number of 
respondents on Nevirapine was lower than anticipated because MDR-TB regimen 
does not contain rifampicin as efavirenz is preferred to Nevirapine (Bonora & Di Perri 
2008:306).  
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5.2.2.2 Life style characteristics: smoking and drinking  
 
The majority of the respondents 155 (89.6%) did not smoke, three were current 
smokers and 12 were previous smokers. Current smoking was defined as currently 
smoking or stopped smoking less than 6 months while previous smokers were 
defined as those who had not smoked for at least 6 months after quitting smoking. 
Smoking impacts treatment outcomes like bacteriological conversion during 
treatment (Magee, Kempker, Kipiani, Tukvadze, Howards, Narayan & Blumberg 
2014:1) and some studies suggest that second smoke could be associated with 
hearing loss (Fabry , Davila, Arheart, Serdar, Dietz, Bandiera & Lee 2011:82-5; 
Lalwani, Liu & Weitzman 2011b:655). Strict prevention of children exposure to 
second-hand smoke should be encouraged by every means because of its impact on 
hearing which could be augmented when ototoxic drugs are administered (Talaat, 
Metwaly, Khafagy & Abdelraouf 2014:46-9).  
 
The majority of respondents, 135 (78%) reported no history of drinking alcohol. 
Three respondents, all males, were current drinkers. Twenty-six (26) males and six 
females were previous drinkers (18.5%).   This finding raises concern as all patients 
on medication are advised not to take alcohol. Moreover, an association of drinking 
and hearing loss has been reported in students (Li, Zhang, Li & Guo 2014:1499).  
 
5.2.2.3 Exposure to noise among respondents 
 
In this regard, the results show that at least 46% of the respondents had noise 
exposure at the work place or during leisure.  This is likely to impact on the incidence 
of hearing loss given that noise is a well-known risk factor for noise induced hearing 
loss. Noise potentiates aminoglycoside induced hearing loss (Li &Steyger 2009b:26-
32). Men were more likely to be exposed to noise at the work place and during 
leisure than women were (p value = 0.002). The possible explanation is that men are 
likely work with machines, in the mines or sound industry that exposes them to 
excessive noise.  
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5.2.2.4 Weight of respondents 
 
The modal weight band of the respondents was 50-59k kg while the baseline 
average weight was 51.7kg (95% CI: 49.16-54.40).  
 
5.2.2.5 History of Exercise among respondents 
 
Only 10% of the study respondents reported involvement in regular exercise prior to 
their illness (at least once or twice a week). Women were not likely to engage in any 
form of exercise or exercise less than once a month.   
 
5.3 DISCUSSION OF INFERENTIAL STATISTICS  
 
5.3.1 Incidence of hearing loss 
 
The first objective of the study was to establish the incidence of hearing loss among 
MDR-TB patients in Swaziland. According to the study results, the majority of the 
patients developed hearing loss as follows: overall 94 respondents out of 159 (60%); 
74 out the 123 (60.1%) of the HIV positive respondents and 23 out of 37 (55.6%) the 
HIV negative respondents respectively developed hearing loss  during the injectable 
phase of DR-TB phase. The incidence of hearing loss among male was higher than 
females (p value=0.03), among those exposed to noise at work than the exposed 
during leisure (p value=0.02), and in those with job type of a miner, a machine 
operator or driver.  
 
The incidence of hearing loss in this study is similar to what falls within the range of 
other studies within the southern Africa region. Van der Walt et al (2013) report a 
hearing loss of 38.9% in South Africa. On the other hand, two studies in South Africa 
have reported slightly different incidences. Ramma and Ibekwe respectively (2012) 
reported an incidence rate of 47% in South African patients in Cape Town, while  
Harris et al (2012) reported incidences of 40% among HIV negative patients and 
70% among HIV positive patients in Mpumalanga. In Botswana, Modongo (2014:1) 
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found hearing loss incidence of 62%  among study respondents on MDR-TB in a 
retrospective study.  .  
While other studies in the literature do not provide for incidence rates, this study 
results indicate a general crude incidence rate for high frequency hearing loss 
(HFHL) of 4.1/1 000 person days of observation (CI 3.3-5.0/1 000).    The incidence 
rate among the HIV positive patients was 4.2/1 000 person days (CI: 3.4-5.3) and for 
HIV negative patients, 3.6/1 000 person days (CI: 2.4-5.7).  
 
Incidence of hearing loss was a result of direct measurement of hearing sensitivity, 
and incident cases defined the comparisons between the baseline and follow-up 
audiometry based on criteria for defining cases found in section 3.3.2.7.  It is 
important to note that usually it is the frequencies of 250-8 000 Hz that are used in 
hearing sensitivity testing because that is the range representing most of the speech 
spectrum, although the human ear can detect frequencies from 20-20 000 Hz.   
 
Studies show that early ototoxicity corresponds with damage to hair cells in the basal 
region of the cochlea, where higher frequency sounds are processed. Animal studies 
have also shown that ototoxic damage progresses from high to low frequencies. 
Testing for high frequency hearing sensitivity was prioritised because it tests the 
highest audible frequencies within the speech range; allows for early detection of 
ototoxic changes and the detection of hearing changes before the lower frequencies 
necessary for understanding speech are affected (Audiology 2009; Fausti, Henry, 
Schaffer, Olson, RH. and WJ., 1992:1026-32; Fausti et al 2005:52). 
 
This paragraph puts the discussion in the preceding paragraph in context. High 
frequency hearing loss affects a person‘s ability to hear the consonant sounds of F, 
S, T, and Z, differentiating words that sound alike, especially words that contain S, F, 
SH, CH, H, TH, T, K or soft C sounds, and higher octaves, like a woman‘s or a 
child‘s voice, or a bird chirping. Therefore, loss of hearing in those frequencies 
makes the sounds harder to discern although they can hear vowels well (Berke 
2014:[Sa], Crawford, 2012:[Sa]). On the other hand, low frequency hearing loss 
makes it difficult for the individual to hear sounds in frequencies 2 000 Hz and below 
although they may still hear sounds in the higher frequencies (Berke 2014:[Sa]). Due 
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to that, people with low frequency hearing loss can still understand human speech 
well.  
Audiograms were used to record hearing sensitivity of the respondents in this study 
and provide a good indication of the degree of hearing loss with pure tones. 
However, they do not provide details on the person's ability to understand speech. 
An innovative technique; ―the speech banana", superimposes the audiograms over a 
mapped conversational speech on an audiogram (the "speech banana"), and 
provides more information to interpret the results (Figure 5.1).  Figure 5.1 shows that 
vowels fall in the "louder" ranges, and they lie lower on the chart. On the other hand 
consonants are higher-pitched than vowels, and they lie more to the right on the 
chart, higher on the chart and in the lower decibel ranges (Constantine 2011). 
Furthermore, Figure 5.1 portrays a normal sloping to profound hearing loss in the left 
ear and moderate to severe hearing loss in the right ear. In this regard, the patient 
can hear no conversation in the right ear. The left ear, however, hears all but the 
soft, upper frequency consonants 
 
 
Figure 5.1: Speech banana superimposed on an audiogram showing different 
hearing losses in the left and right ears  
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On the contrary, Figure 5.2 shows bilateral mild sloping to profound hearing loss in a 
child. With only a few consonant and vowels sounds audible, this child would miss 
most of the distinguishing speech features. 
 
 
Figure 5.2: Speech banana superimposed on an audiogram showing similar 
bilateral hearing losses in the left and right ears  
 
5.3.2  Risk factors for high frequency hearing loss 
 
As part of explanatory analysis of this study, statistical methods utilised temporal 
associations to establish the risk factors and determinants for hearing loss among 
the cases.  According to WHO: 
 
“A risk factor is any attribute, characteristic, or exposure of an individual that 
increases the likelihood of developing a disease or injury” 
 
-(World Health Organization, [Sa]-b) 
 
Risk factors are variables with a lower likelihood of a positive outcome and higher 
likelihood of undesirable outcomes. In order to establish whether an association 
exists or not between hearing loss and the independent variable, Chi square 
statistics as the measure of association. High frequency hearing loss was the 
dependent variable and the independent variables were characteristics in the socio-
demographic, clinical or lifestyle profiles of the respondents.  
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According to the results of the study, on bivariate analysis, Age group (p 
value=0.02), gender (p value =0.2), job type (p value =0.003), ARV regimen (p value 
=0.004), Haemoglobin level (0.039) and body mass index (0.018) were significantly 
associated with hearing loss.   
 
The association between age and hearing loss is documented. Patients who 
developed auditory toxicity were significantly older (p value =0.01) in a randomised 
trial (Gatell, Ferran, Araujo, Bonet, Soriano, Traserra & SanMiguel 1987:1383). It 
appears that damage is more significant in the elderly who may have fewer hair cells 
at the beginning of treatment or lower endogenous protective mechanisms than 
other individuals with compromised auditory function (Rybak 2007:364, Rybak & 
Whitworth 2005:1313). On the contrary, a study in Cape Town on cochlea-vestibular 
clinical and audiometric findings among XDR and MDR-TB patients did not find an 
association with age and sex (Ramma & Ibekwe 2012).  
 
The association between gender and hearing loss as been documented. A study in 
Iran found the hearing loss among men was higher than among women (Javadi et 
al., 2011:905).  In this study, all the diabetic patients developed hearing loss, all of 
whom where female respondents.  It appears that the development of hearing loss 
was more associated with the existence of diabetes mellitus (DM). No statistically 
significant association between hearing loss and DM was found because of the small 
sample. Suboptimal glycemic control was also associated with a nearly threefold 
increased risk of high-frequency hearing impairment (Akinpelu et al 2014:767; 
Bainbridge & Cowie 2009; Oh et al 2014; Sogebi 2013:244).  It is postulated that 
some of the mechanisms by which hearing is affected in diabetic patients include 
thickened vessels of the stria vascularis and the internal auditory artery, as well as 
demyelination of the eighth cranial nerve (Carrasco et al 1990:411; de Moraes 
Marchiori et al 2006:533). 
 
While there was an association between hearing loss and dyspnoea and noise 
exposure, the association was not statistically significant for either, (p value =0.054) 
for dyspnoea on admission and (p value =0.078) for noise exposure respectively.  
The implications of this finding although not statistically significant, that whenever 
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hazardous noise exists in the workplace, patients on MDR-TB treatment are 
vulnerable to the additive effect of the aminoglycosides. To this end, measures are 
required to reduce noise levels as much as possible to protect exposed workers. 
Measures are also required to monitor the effectiveness of hearing loss prevention 
programmes at the workplace because noisy environments potentiate susceptibility 
to noise induced cochlear damage (Fausti et al 2005) .  
 
The mechanism for noise induced hearing loss and/or potentiation of aminoglycoside 
SNHL is that excessive sound (unprotected exposure above 95dBA) damages the 
hair cells and the blood supply in the cochlea, (Dobie, 2008:565,  2005a:630; 
Rabinowtz 2012:14; Thurston 2013:367). The damage may directly result from the 
noise, or indirectly from very high levels of continuous sound, that causes 
vasoconstriction of the vessels of the stria vascularis in the cochlea blood supply. 
This renders the hair cells relatively anoxic and thus secondarily damaged. The 
amount and type of direct hair cell damage depends on the intensity of the sound 
and level of damage due to aminoglycosides and noise exposure will increase 
hearing thresholds, resulting in threshold shifts toward higher values (poorer hearing) 
(Li & Steyger 2009a:26-32).    
 
The results of the study show that occupation/job type are associated with SNHL. 
The explanation for such association of job type and hearing loss is not very clear. 
One study in the gold mines found that patients had a higher occurrence of hearing 
loss than the controls from non-gold mines. However, patients with multiple 
treatments for TB were at even a higher risk  (Brits, Strauss, Eloff, Becker & 
Swanepoel 2011). A study in US marines and other trades suggests that excessive 
noise exposure and lack of hearing protection and the major risk factors to hearing 
loss difference across occupations (Abel 2005:1128). Hence, these statistically 
significant results could point to men‘s risk behaviour of exposure to unprotected 
noise at work in mining, undocumented genetic predisposition or other risk factors 
that are associated with the male gender. These are collaborated by findings in a 16 
year cohort study that documented changes to hearing acuity that exceeded 15 dB 
at high frequencies in 42.8% of men and 27.7% of women (Marlenga, Berg, 
Linneman, Wood, Kirkhorn & Pickett 2012:479). Analyses of risk factors for NIHL 
showed that risks increased in association with higher levels of the most common 
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recreational and occupational noise sources, as well as chemical exposures with 
ototoxic potential. Use of hearing protection and other safety measures, appeared to 
offer some protection hearing conservation programmes should focus on a broader 
range of exposures, whether in occupational or non-occupational settings, and some 
priority exposures could include gunshots, chainsaws, power tools, smoking and 
potentially some chemical exposures (Marlenga et al 2012). 
 
Reasons for low haemoglobin being associated with hearing loss are not clear. The 
possibility of anoxia to the hair cells in the cochlea. In a study to investigate effect of 
blood parameters in patients on Cisplatin (an anti-cancer ototoxic medicine) found 
that decreased serum albumin level, haemoglobin level, red blood cell count, and 
haematocrit were associated with an increased likelihood of significant hearing loss 
during chemotherapy (Blakley, Gupta, Myers & Schwan 1994:541).  
 
5.3.3 Univariate regression analysis for risk factors for high frequency 
hearing loss 
 
In addition to bivariate analysis, the results of the univariate regression analysis 
indicated that the following were risk factors for DR TB treatment related 
sensorineural hearing loss. 
  
 being  of male gender (p value =0.033),  
 poor baseline hydration status  at the start of MDR-TB treatment (p value 
=0.012),  
 use of Abacavir as backbone in the ART regimen in MDR-TB (p value 
=0.017),   and  
 low of <8 g/dl baseline HB (p value <0.001), low BMI (p value =0.003), 
presence of dyspnoea at the start of treatment (p value < 0.001 ) were found 
to be risk factors for high frequency hearing loss. 
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5.3.4 Multivariate analysis for risk factors for high frequency hearing loss 
 
The Cox regression model was used to control for confounders. According to the 
study results, the following variables were dropped: education, religion, noise, body-
mass index, regimen for HIV, religion, and CD4 count. Variables retained in the 
model with statistically significant relationship with high frequency hearing loss were 
as follows: 
 
 Compared to agriculture as a day-to-day employment, the hazard ratio of high 
frequency hearing loss was 4.2 times in the Miners/machine Operators and 
Sound Industry (HR: 5.4, CI 1.2-24.03, p value =0.024) 
 Patients who had dyspnoea at initiation of MDR-TB treatment were 3.4 times 
likely to develop high frequency hearing loss (HR: 3.4, CI 1.8-6.3, p value 
=0.000).  
 Low baseline haemoglobin was a risk factor for hearing loss (p value<0.01). 
Patients with HB 8-11 g/dl and those with HB less than 8g/dl were 2 times and 
8.5 times respectively more likely to develop hearing loss compared to those 
with HB above 11g/dl (p value <0.01).  
 
5.3.5 Salient features of the results 
 
In this study, 172 respondents were on Kanamycin as the injectable aminoglycoside 
and only one respondent on Amikacin, hence unable to compare types of drugs as 
risk factor for hearing loss. However, it appears that studies where amikacin was the 
predominant drug, incidence of SNHL was higher as reported in Javadi et al, 2011;  
Modongo et al, 2014 Sturdy et al (2011).  This study found bacteriological status of 
confirmed Rifampicin resistance on GeneXpert was associated with MDR-TB 
hearing loss (p value= 0.078) but not a statistically significant risk factor. In children, 
bacteriological confirmation was a risk factor for hearing loss (Seddon et al 
2013:320).  
 
This study further revealed that no respondents had a family history of hearing loss. 
However, genetic predisposition and family history of ototoxicity has been implicated 
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in predisposing certain individuals to future ototoxicity (Jing et al 2014). Sickle-cell 
disease also predisposes to a significant incidence of sensorineural hearing loss 
(SNHL) in SCD patients (36.95%), although the patients maybe clinically 
asymptomatic (Al Okbi et al 2011:392).  The mechanism for this seems to be linked 
to ischaemia (Przewozny, Gasecki, Narozny & Nyka 2008:745).  Przewonzy et al 
(2008:745) found that the highest risk for hearing loss in a group of patients 
experiencing the early stage of ischemic stroke were age above 60 years, male 
gender, bilateral ischaemic focuses and arterial hypertension. 
 
5.3.6 HIV and High frequency hearing loss  
 
5.3.6.1 Incidence of Hearing loss and HIV serostatus, ART treatment and 
level of immunosuppression.  
 
In this study, while the general incidence in the sample was 94 out of 159 (60%). The 
incidence of SNHL among the HIV positive patients was 60.1%, while it was 55.6% 
among the HIV negative patients.  The incidence rate was  4.2/1 000 person days  
(CI: 3.4-5.3) among the HIV positive respondents and for HIV negative respondents,  
it was 3.6/1 000 person days (CI: 2.4-5.7).  While there was preponderance by HIV 
positive respondents for SNHL, there was no statistical difference in the hazard rates 
(p value =0.59). In South Africa, 70% of  the HIV positive patients  MDR-TB patients 
developed SNHL compared 40% HIV negative MDR-TB patients (Harris et al 
2012:363). In Botswana, while bivariate analysis of data indicated an association 
between HIV infection and SNHL, among MDR-TB  association disappeared after 
adjusting for confounders (Modongo et al 2014).  
 
Studies suggesting the association between hearing loss and the HIV status, level of 
immune suppression and ARV have been inconclusive. While one study to detect 
differential HIV effects for Low-frequency pure-tone average (LPTA) at 250, 500, 
1000, and 2000 Hz and high-frequency PTA (HPTA) at 3000, 4000, 6000, and 8000 
Hz found poorer low frequency and high frequency hearing in HIV positives than HIV 
negative adults (Torre, Hoffman, Springer, Cox, Young, Margolick & Plankey 2014a). 
On the contrary, another study on distortion product acoustic emissions, found that 
poorer cochlear function was not associated with HIV status (Torre, Hoffman, 
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Springer, Cox, Young, Margolick & Plankey 2014).  This has led some scientists to 
postulate that the changes that HIV/AIDS patients might have in the conventional 
audiological assessment and high frequency audiometry may suggest involvement of 
both the peripheral and central auditory pathways (Assuiti et al 2013:248-255).. 
 
According to the results of this study, ARV regimen was associated incidence with 
MDR-TB treatment related hearing loss (p value =0.017).   
 
ART regimen containing abacavir (ABC) back bone, has survival distributions that 
were statistically significant.  
 
There are some postulations that ARVs could be ototoxic; and if used in combination 
with aminoglycoside antibiotics used in the treatment of MDR-TB, the possibility of 
additive ototoxic is high. This study investigated the association between the co-
administration of ART and MDR-TB treatment and hearing loss in order to determine 
the additive ototoxicity between aminoglycoside and ARV and abacavir containing 
regimens were shown to be associated with hearing loss. Khoza-Shangase 
(2011:145-53) shows statistically and clinically significant association was obtained 
for distortion product otoacoustic emissions (DPOAEs) among patients on HAART, 
particularly at high frequencies suggesting subclinical hearing loss on DPOAEs 
although they had normal pure tone function after six months of follow up. Van de 
Walt et al (2013) found that HIV-infected per se, did not predispose a patient to 
experience severe adverse drug reactions (SADRs) including sensorineural hearing 
loss for patients on MDR-TB treatment. Their study confirms that the rate and range 
of SADRs amongst HIV-infected ART naive and uninfected patients are similar. In 
fact, HIV-uninfected cases experienced slightly more, (1.35) serious adverse drug 
reactions on average, compared to the 1.25 in HIV-infected cases (Van der Walt et 
al 2013). Schouten found no association between NRTI with hearing in a prospective 
study (Schouten et al 2006). 
 
The study investigated the impact of CD4 on MDR-TB treatment related hearing loss 
(MDR-TB-TR-HL). Because number of cases were CD4 taken during this period was 
very low, the study did not analyse those data during the development of this report, 
and hence we cannot ascertain whether there is/no association.  A study by Van der 
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Westhuizen, Swanepoel de, Heinze and Hofmeyer (2013) on audiological and 
ontological manifestations in adults with HIV, found a general increase in SNHL that 
becomes statistically significant towards the advanced stages of HIV disease 
progression when compared to the HIV negative.Thus, it is plausible that the HIV 
infection by itself does not lead to a higher risk of developing hearing loss but is likely 
associated with other factors that, by themselves or in combination increase the 
patient‘s risk of AG- induced hearing loss. 
 
5.4 SURVIVAL ANALYSIS AND TIME TO HEARING LOSS 
 
In 1964, Gerald Caplan introduced the trilogy dealing with prevention and control of 
mental disorders. He introduced the concepts of primary, secondary and tertiary 
prevention whereby primary, secondary and tertiary prevention programmes focus 
on different aspects of the natural history of disease, while program planning, staffing 
and staff training are discussed from a standpoint of prevention (Caplan 1964). In its 
application to the subject of interest in this study, primary prevention aims at 
inhibiting the development of hearing loss before it occurs, ideally, either through 
preventing MDR-TB or avoidance of ototoxic medications in the management of 
MDR-TB. Time to hearing loss is an important variable in secondary prevention that 
aims to identify and detect hearing loss in its earliest stages before it is noticeable, 
when it is possible to prevent progression or minimise complications. Screening for 
the earliest signs of decrease in hearing sensitivity achieves secondary prevention 
and the time to hearing loss is useful in determining optimum intervals for screening 
for ototoxicity.  The results were presented using survival distribution in Chapter 4 
and are discussed in this section. Where it is not possible to prevent or ameliorate 
hearing loss, the purpose of tertiary prevention is to improve the quality of life for 
people by rehabilitation (therapy to restore functionality and self-sufficiency) among 
people already affected by a disease in order to mitigate catastrophic outcomes 
(Caplan 1964) 
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5.4.1 Survival analysis and time-to-hearing loss 
 
The life table, survival distribution, and Kaplan-Meier survival function estimation are 
all descriptive methods for estimating the distribution of survival times from a sample. 
Survival analysis offers regression models for estimating the relationship of (multiple) 
continuous variables to survival times. In this study, we used the cumulative 
proportion surviving (survival function). This is the cumulative proportion of cases 
surviving hearing loss up to the respective interval. Since the probabilities of survival 
are assumed independent across the intervals, the probability is computed by 
multiplying out the probabilities of survival across all previous intervals (Rich, Neely, 
Paniello,Voelker, Nussenbaum & Wang 2010:4) . The resulting function is also called 
the survivorship or survival function. The researcher started by calculating the 
median survival time. This is the survival time at which the cumulative survival 
function is equal to 0.5 (50th percentile).  The 50th percentile (median) for the 
cumulative survival function is usually not the same as the point in time up to which 
50% of the sample survived, given that censoring, is observations prior to this time. 
In general, the median time to high frequency hearing loss (high-tone average 4 and 
8kHz) was 84 days (IQR=55-157 days) for middle frequency hearing loss  frequency 
(the pure-tone middle-tone average; 0.5, 1,2 and 4 kHz)  the median time was 98 
days (60-158 days).   No studies were found in literature to have investigated this 
construct.  
 
Typically, survival analysis is linked to the hazard rate defined as the probability per 
time unit that a case that has survived to the beginning of the respective interval will 
fail in that interval. Specifically, it is computed as the number of failures per time 
units in the respective interval, divided by the average number of surviving cases at 
the mid-point of the interval.  
 
In this study we used Kaplan-Meier Product-Limit Estimator to estimate the survival 
function directly from the continuous survival or failure times (Rich et al 2010:331-6) . 
Multiplying out the survival probabilities across the "intervals" (i.e., for each single 
observation) gives us the survival function: 
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S(t) = j
t
= 1 [(n-j)/(n-j+1)]
( j )
  
Where: 
S(t) is the estimated survival function,  
n is the total number of cases, and, 
 denotes the multiplication (geometric sum) across all cases less than or equal 
to t; 
 (j) is a constant that is either 1 if the j'th case is uncensored (complete), and 0 if it 
is censored.  
- (Kaplan & Meier 1958) 
 
5.4.1.1 Gender: Survival analysis and time-to-hearing loss 
 
The results from the analysis of the study showed that males have a high hazard 
rate for SNHL than the females and hence worse off survival for high frequency 
hearing loss while on MDR-TB treatment than females (p value=0.03). There are no 
previous studies from the literature to explain the observed difference.  
 
5.4.1.2 Age: Survival analysis and time-to-hearing loss 
 
The results also indicated that the age group 50-69 years had poorer survival when 
compared to the younger age groups (p value =0.02).  While some of the literature 
collaborates this finding, the finding has not been consistent across all studies. 
Presbycusis is proposed as one of the mechanisms (Langer et al 2013:458; Mudd 
2012)  
 
5.4.1.3 Survival analysis and the Clinical parameters 
 
Survival analysis for key clinical parameters mirrors the findings discussed in Section 
5.3.2. No distinct difference by HIV status was observed in survival distribution (p 
value =0.59). However, when survival by ART regimen were compared using NRTI 
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backbone, there was statistical significance among the regimens. Patients on 
Abacavir had a higher failure rate when compared to TDF based regimen.  
 
Underweight patients and patients with low haemoglobin level fail at faster rates than 
normal patients with normal BMI (p value=0.01) and haemoglobin level above 11 g/dl 
(p value <0.01).  The explanation is provided in section 5.3.2. 
 
Presence of dyspnoea is associated with higher rates of failure when compared with 
absence of dyspnoea at the start of treatment (p value <0.01 
 
5.4.2 Time to event analysis and optimal frequency for audiology  
 
The diagnosis of hearing loss occurred at a median time of 84 days (IQR, 54.5- 120 
days) in those confirmed by audiogram. This is the first prospective study to date to 
examine meticulously the time it takes for persons on MDR-TB treatment to develop 
hearing loss.  
 
5.5 HYPOTHESES TESTING 
 
5.5.1 Interpreting the Hypothesis  
 
Table 5.1 Interpreting Results of Hypothesis 
P-
value 
Interpretation 
P< 
0.01  
Very strong evidence against H0  
 P < 
0.05  
Moderate evidence against H0  
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Study hypothesis 1: 
 
The incidence ratio of sensorineural hearing loss during the intensive 
phase of MDR-TB treatment increases proportionally with the duration 
of treatment. 
 
If incidence ratio of sensorineural hearing loss is stated as a/b 
and the duration of treatment is stated as d  
The study hypothesis can be stated as a/b ∞ d 
 
Null hypothesis 1: 
“There is no relationship between the incidence of hearing loss among 
MDR-TB patients on MDR-TB treatment and the length of treatment 
during the intensive phase of MDR-TB treatment”  
 
Likewise, the null hypothesis can be stated as a/b not ∞ d 
 
Study hypothesis 2 
 
MDR-TB patients living with HIV infection have a higher incidence ratio 
of sensorineural hearing loss than HIV negative MDR-TB patients 
during the intensive phase of MDR-TB treatment. 
 
 If the Incidence ratio of SNHL in HIV positive MDR-TB patients =    
 And If the Incidence ratio of SNHL in HIV negative MDR-TB patients =   
 Then study hypothesis can be restated as………………….      
 
 
The results show that other factors influenced incidence of MDR-TB related 
hearing loss than the length on MDR-TB treatment.   
Conclusion: the results of the study fail to reject the null hypothesis 1. 
 
 
201 
 
Null hypothesis 2: 
 
“There is no difference in the incidence ratio of sensorineural hearing 
loss in MDR-TB patients living with HIV and MDR-TB patients who are 
HIV free during the intensive phase of MDR-TB treatment. 
 
 If the Incidence ratio of SNHL in HIV positive MDR-TB patients =    
 And If the Incidence ratio of SNHL in HIV negative MDR-TB patients =   
 Likewise the null hypothesis can be restated as………………….      
 
 
Based on Figure 5.1 Incidence ratio of hearing loss among the HIV positive 
MDR-TB patients is not statistically significant from the incidence ratio of 
SNHL among the HIV negative respondents. P value =0.59 
 
Conclusion: the results of the study fail to reject the null hypothesis 2. 
 
 
5.6 SUMMARY AND CONCLUSION 
 
This study reveals that the MDR-TB treatment-related high frequency hearing loss in 
Swaziland is one of the highest in the region. Of 159 respondents, 94 developed 
high frequency hearing loss. Total observation time was 22 032-person.  The 
findings are in consonance with the findings in other parts Southern Africa. In 
Botswana, Madongo et al (2014) reports an incidence of 62%, while in South Africa, 
Harris and others (2012) report a hearing loss incidence of 57%. Risk factors for 
development of hearing loss were male gender, occupation as a miner, low 
haemoglobin level, HIV treatment with Abacavir regimen and presentation with 
dyspnoea. The median time for development of hearing loss ranged from 54.5 days 
to 147 days.   
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CHAPTER 6 
  
DEVELOPMENT OF BEST PRACTICE GUIDELINES TO MONITOR 
AND PREVENT HEARING LOSS RELATED TO DRUG RESITANT 
TUBERCULOSIS TREATMENT 
 
6.1 INTRODUCTION 
 
Guidelines are “systematically developed statements to assist practitioner and 
patient decisions about appropriate health care for specific clinical circumstances‖ 
 
- (Shekelle, Woolf, Grimshaw, Schunemann & Eccles 2012).   
 
Good guidelines serve as a quality improving strategy but barriers to implementation 
must be removed for guidelines to be successful (Wallen, Mitchell, Melnyk, Fineout-
Overholt, Miller-Davis, Yates & Hastings 2010). The previous chapter discussed the 
findings and conclusions drawn from the analysis of the empirical study. In this 
chapter, best practice guidelines to monitor and prevent hearing loss related to DR-
TB are developed.  The chapter starts with the background and the theoretical 
framework underpinning this study. Subsequently, the justification for the 
development of the best practice guidelines and the development of the best practice 
guidelines in order prevent permanent hearing loss through raised awareness, 
monitoring, and prevention of ototoxicity.   
 
In chapters 4 and 5, the study results revealed that patients on MDR-TB treatment in 
Swaziland are at risk of developing permanent sensorineural hearing loss. In 
chapters 1 and 2  this study also revealed that there are no clear best practice 
guidelines  available to the various cadres of health care workers involved in the 
management of MDR-TB patients, hospital managers involved in the allocation of 
resources and the affected patients and their families.  In South Africa, a recent 
study revealed that 80-100% of the health care workers managing TB did not inquire 
about family history of hearing impairment and that 74% of the health care workers 
lacked awareness about ototoxicity and hearing loss associated with MDR-TB 
203 
 
treatment (Khoza-Shangase 2013:2140). Yet loss of hearing can be one of the most 
catastrophic adverse drug reaction experienced by patients. Hearing loss refers to 
any reduction of, or difficulties with hearing. Hearing loss is caused by dysfunctions 
anywhere along the auditory pathway. There are three general categorisations of 
hearing loss:  based on where in the ear the impairment is located (the type of 
hearing loss), the severity of the impairment that affects a person‘s hearing 
sensitivity (the degree of hearing loss), and which ears are affected (the 
configuration or laterality of the hearing loss). In South Africa,  the finding in the 
study referred to earlier that only 9% of the health care workers provided information 
on ototoxicity monitoring to their patients and lack of  awareness on their role or that 
of the audiologist in monitoring ototoxicity was partly due to lack of guidelines and 
protocols. 
 
The situation in Swaziland concerning ototoxicity monitoring is not much different 
from that in South Africa. This current study found lack of guidance at the MDR-TB 
treatment sites on how to assess patients for hearing loss and what to do to 
minimise hearing loss in their patients. The proposed best practice guidelines are for 
various cadres of health care workers involved in the management of MDR-TB 
patients and hospital managers. The best practice guidelines will service as a road 
map to guide nurses, doctors, audiologists, hospital managers, pharmacists and 
policy makers in determining the appropriate course of action when faced with the 
need to address conserve hearing loss in patients on MDR-TB.  
 
 
6.2 BACKGROUND OF THE STUDY  
 
The development of the best practice guidelines addresses the fifth objective of the 
research study that investigated the incidence of MDR-TB treatment related hearing 
loss in Swaziland and best practices to monitor and prevent hearing loss related to 
DR-TB treatment. Best practice guidelines are systematically developed statements 
to assist practitioner and patient decisions about appropriate health care (Shekelle et 
al 2012).  Good guidelines serve as a quality improvement strategy (Wallen et al 
2010:2761). 
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Tuberculosis (TB) is a major threat to public health, with a global incidence of 
approximately nine million, and a mortality rate of over one million per year (WHO 
2013). In 2012, some 3.6% of newly diagnosed TB cases and 20% of those 
previously treated for TB had MDR-TB, translating to a global burden of 450,000 
cases of MDR-TB. With increased use of molecular diagnostic tools (Al-Ateah, Al-
Dowaidi & El-Khizzi 2012; Bodmer & Strohle 2012; Cauda 2014; Feasey, Banada, 
Howson, Sloan, Mdolo, Boehme, Chipungu, Allain, Heyderman, Corbett & Alland 
2013) and availability of second line TB medicines, a larger proportion of MDR-TB 
patients are being treated (World Health Organization 2011c).  
 
The injectable aminoglycoside and polypeptide antibiotics used in the treatment of 
MDR-TB can cause ototoxicity and irreversible sensorineural hearing loss (SNHL) in 
some patients which may even progress after treatment has been completed (de 
Jager & van Altena 2002; Seddon et al 2013). 
 
Adult onset of SNHL is associated with disability and psychosocial effects, as well as 
reduced productivity and quality of life (Shield 2006). For example, affected 
individuals may have difficulty participating in social activities, enjoying music, 
speech discrimination and localizing sounds (Gates Mills 2005). Increased emotional 
dysfunction, depression, and social isolation have also been reported for all age 
groups (Boi, Racca, Cavallero, Carpaneto, Racca, Dall' Acqua, Ricchetti, Santelli & 
Odetti 2012; Skrbic, Milankov, Veselinovic & Todorovic 2013; Southall, Gagne & 
Jennings 2010; Southall, Jennings & Gagne 2011). Figure 6.1 presents a schematic 
on consequences of hearing loss on the victims. 
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Figure 6.1: Consequences of hearing loss. 
Source: Adapted from Acoustical Society of America 133rd Meeting Lay Language Papers: URL: 
https://acoustics.org/pressroom/httpdocs/133rd/2paaa2.html (Accessed April 19, 2015) 
 
The World Health Assembly resolutions of 1985 and 1995 called on member 
countries to develop strategies for prevention of hearing loss. According to the World 
Health Report of 2003, adult onset hearing loss was the second leading global cause 
of Years Lived with Disability (YLDs) in 2000 (Mathers et al 2010). Early detection 
and rehabilitation may prevent hearing loss and reduce YLDs. This study found 
easily modifiable risk factors of MDR-TB treatment-related hearing loss and these 
provide the basis of the best practice for use by clinicians and health care staff in 
resource-limited settings.  
 
 
6.3 THEORETICAL UNDERPINNING OF THE GUIDELINES 
 
The theories underpinning this study are discussed briefly here as they have been 
dealt with in Chapters 1 and 2. Refer to Figure 6.2 and 6.3. 
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Figure 6.2:The Neuman Systems model 
Source: (Freese & Lawson 2010) 
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Figure 6.3 Enhanced ADR monitoring framework 
Source: Steinman. 2011. J Am Geriatr Soc. 59(8): 1513–1520. 
 
Briefly, the study framework by Neuman‘s System model of nursing (NSM) provides 
a useful best practice model for monitoring and prevention of sensorineural hearing 
loss (SNHL) in MDR-TB patients in the following manner (Geib, 2010, Neuman, 
2002).  
 
 First, according to the model, medical and nursing goals are guided by the 
development of comprehensive diagnoses, determination of appropriate 
interventions, evaluation of outcomes, and mitigating possible harm. The 
patients and caregivers form a partnership relationship to negotiate desired 
outcome goals of optimal health retention, restoration and maintenance.  
 
 Second, multiple factors in the medical, work, family, and developmental 
history of the patient, as well as the pathophysiology and sociocultural realm 
influence the incidence of SNHL.  From a hearing preservation perspective, 
the model suggests that clinical and nursing interventions occur through three 
prevention modalities based on Caplan‘s concept of level of prevention 
(Caplan, 1964). Caplan described three levels of prevention for mental 
disorders but these are now widely applied to other disease conditions as well 
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and these are primary, secondary, and tertiary prevention.  WHO guidelines 
for ototoxicity prevention outline some of the actions for primary, secondary 
and tertiary prevention as illustrated in Figure 6.1 (Olusanya et al 2014b; 
World Health Organization 2006). 
 
 Three, the clinical care of MDR-TB starts with assessment of the patient‘s 
physiological, psychological, developmental, socio-cultural and spiritual 
background, in order to conceptualise and analyse the patient‘s system, and 
to apply appropriate diagnosis, treatment goals and interventions. When 
SNHL is inevitable, mobilisation of external resources for assisted hearing, 
family and community support, and understanding may promote rehabilitation 
and function, as well as physiological and psychological health.  
 
 
Table 6.1: WHO framework for hearing loss primary, secondary, and tertiary 
prevention 
 
 Primary Secondary Tertiary  
Ototoxicity Avoidance of ototoxic drugs 
or only rational and 
prescribed use, use of 
antioxidants 
Early detection 
and prompt 
management 
Fitting of hearing devices 
(hearing aids, cochlear 
implants, etc.), hearing 
rehabilitation, training in sign 
language and special or 
inclusive education. 
 
Exposure 
to 
excessive 
and/or 
prolonged 
noise 
Education, hearing 
conservation, enforceable 
regulations 
Fitting of hearing devices 
(hearing aids, cochlear 
implants, etc.), hearing 
rehabilitation, training in sign 
language and special or 
inclusive education. 
 
 
In this study, NSM in nursing practice is complemented by the Enhanced Monitoring 
Framework (EMF) for monitoring adverse drug reactions proposed by (Steinman et 
al 2011:1513-20). According to Steinman et al (2011:1513-20), team-based 
approaches for patient management are emphasised, integrating monitoring ADRs in 
clinical practice, use of health information technology and systems redesign ( Figure 
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6.3). Key activities include tracking of laboratory tests, timely notification of physician 
of critical results, use of risk assessment tools and enhanced patient participation 
(Steinman et al 2011).  
 
According to the enhanced monitoring framework, instead of the patient presenting 
with signs and symptoms and/or a disease diagnosis and the physician consulting 
evidence and guidelines in the prescribing process as in traditional method, the 
physician should consider medication prescribing is viewed as an ongoing process 
that begins rather than ends at the initial prescribing decision. Care quality is judged 
in part on the quality of monitoring for drug side effects, effectiveness, adherence, 
and therapeutic necessity, and whether the clinician makes appropriate changes to 
address any problems that are detected (Steinman et al 2011). In the context of 
hearing preservation, the framework puts teamwork, baseline assessments and 
continued monitoring, and documentation at the centre of prevention efforts for the 
permanent SNHL.  
 
 6.4 RATIONALE FOR THE BEST PRACTICE GUIDELINES 
 
6.4.1 Monitoring ototoxicity and prevention of hearing loss 
 
Audiologic monitoring for ototoxicity may be performed for two purposes according to 
the (American Academy of Audiology 2009): 
 
 early detection of changes to hearing status attributable to enable changes to 
be made to the drug regimen, and 
 audiologic intervention when hearing impairment has occurred.  
 
Health care practitioners must be aware of their roles and responsibilities in hearing 
preservation. Early intervention then becomes the responsibility of all health care 
practitioners through the implementation of primary, secondary and tertiary 
prevention. It is important to standardise the assessment of hearing for patients 
being treated for MDR-TB in the country. Such an approach improves clinical case 
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management. Standardisation includes the schedule and duration of testing as well 
as the testing methodology.  
 
 
6.4.2 Enabling patients to report hearing loss  
 
Health care practitioners must assist patients and their families to maintain effective 
communication where hearing loss occurs, particularly when speech frequencies are 
lost. Khoza-Shangase (2013: 2140-43) found that only 9% of health care 
practitioners inquired or provided information on ototoxicity and hearing loss.  
 
 
6.4.3 Planning resources and ensuring availability of tools and resources for 
hearing screening and screening strategies 
 
Audiometry is the preferred method for hearing assessment in adults and older 
children (Seddon et al 2012:1277). Testing is conducted in a sound-proof room or 
booth with headphones placed over the patient's ears. Frequencies tested are in the 
range of 125 to 8 000 Hz. Audiometry requires patient co-operation and 
concentration and is therefore appropriate for adults and children over 5 years of age 
with normal development. For those unable to co-operate with testing, it may be 
necessary to assess the patency of the neuronal auditory circuit and that involves 
measuring otoacoustic emissions (OAEs), which are small sounds continuously 
produced by a functioning cochlea.  
 
In low resource settings, other available screening techniques for testing hearing 
sensitivity include physical diagnostic tests, such as the whispered voice, finger rub, 
and watch-tick tests (bearing in mind that many modern watches no longer audibly 
tick); single-question screening or longer patient questionnaires; and handheld 
audiometers.  
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6.4.4 Standardizing the categorisation of Hearing Loss 
 
The World Health Organisation (WHO) defines disabling hearing impairment in 
adults as a permanent unaided hearing threshold level (average for frequencies 0.5, 
1, 2, 4 kHz) for the better ear of 41 dB or greater (WHO 2001). In children under 15 
years of age, disabling hearing impairment is defined as permanent unaided hearing 
threshold level (average for frequencies 0.5, 1, 2, 4 kHz) for the better ear of 31 dB 
or greater. However, many other standards are different.    
 
The WHO also classifies hearing impairment into five grades in better ear and 
provides qualitative description (Olusanya 2008; Olusanya et al 2014b).  
 
 Grade 0 is No impairment; 25 dB or better refers to no or very slight hearing 
problems.  
 Grade 1 refers to slight impairment, and 26 - 40 dB the person is able to hear 
and repeat words spoken in normal voice at 1 metre. Counselling and hearing 
aids may be needed.   
 Grade 2 is moderate impairment with a 41 - 60 dB range, and the person is 
able to hear and repeat words using a raised voice at 1 metre and hearing 
aids are usually recommended.  
 Grade 3 is severe impairment with a threshold of 61 - 80 dB, and the person 
is able to hear some words when shouted into the better ear and certainly, 
hearing aids are needed. If not available, lip-reading and signing should be 
taught.  
 Grade 4 is profound impairment including deafness and a threshold of 81 dB 
or greater. The person is unable to hear and understand even a shouted 
voice. Hearing aids may help understanding words but additional rehabilitation 
is needed, lip-reading, and sometimes signing may be essential.  
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6.4 PROCESS OF DEVELOPING THE GUIDELINES 
 
This section discusses the steps followed in the development of the best practice 
guidelines to monitor and prevent hearing loss related to MDR-TB treatment. In Step 
1, the researcher drew evidence for the formulation of the guidelines from the 
summary and conclusions of this study finding. In Step 2, the researcher also 
consulted key stakeholders through meetings during which findings from the 
literature review were presented.   
 
Two models influenced the process of developing guidelines, namely: ―A guideline 
on guideline development‖ (Ansari & Rashidian 2012) and a model developed in 
Eccles et al (2012) for developing clinical practice guidelines. This process is 
outlined below: 
 
1. Defining the purpose and scope of the best practice guidelines; 
2. Review of the findings of the empirical study; 
3. Review of the literature; 
4. Development of the first draft of the guidelines; 
5. Establishment of the guidelines development group (GDG); 
6. GDG review, discuss, reach consensus on first draft of guidelines and provide 
inputs. Revised guidelines produced; 
7. Seek inputs from the reference group; 
8. Present to stakeholders and validate the guidelines. 
 
The details of the application of the process for the development of best practice 
guidelines are discussed in this section (see 6.5.1-6.5.8) 
 
6.5.1 Defining the purpose and scope of the best practice guidelines 
 
The purpose was established and scope developed by the researcher. Details are 
found in section 6.6.1 
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6.5.2 Review of the findings of the empirical study 
 
The findings of this study are compiled and details are found in Section 6.6.2 of this 
thesis. 
  
6.5.3 Review of the literature 
 
Appraisal of the existing literature was conducted on an ongoing basis and details 
are found in Section 6.6.3 of this thesis. 
 
6.5.4 Development of the first draft of the guidelines 
 
The first draft of the guidelines was developed and shared with the guidelines 
development group for inputs. Details are outlined in Section 6.6.4 of this thesis. 
 
6.5.5 Establishment of the guidelines development group (GDG) 
 
The GDG worked on the draft guidelines over a couple of months, consulting widely 
and providing input into the best practice guidelines. The GDG consisted of ENT 
surgeon, audiologist, and audiology technician clinicians and clinical Advisors. 
 
6.5.6 GDG review, discuss, reach consensus on first draft of guidelines and 
provide inputs. Revised guidelines produced 
 
Consensus was achieved on the key guidelines before they were shared with the 
guidelines reference group. 
 
6.5.7 Seek inputs from the reference group 
 
The Reference group consisted of persons familiar with the subject matter and 
external to the GDG. Feedback from the GDG was incorporated into the draft prior to 
sharing with the stakeholder. However, the process of feedback remained open until 
the finalisation of the best practice guidelines. 
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6.5.8 Present to stakeholders and validate the guidelines 
 
The draft of best practice guidelines were presented to 50 stakeholders on the 23 
April 2015. Input was received and incorporated. 
 
 
6.5 THE APPLICATION OF THE PROCESS FOR THE 
DEVELOPMENT OF BEST PRACTICE GUIDELINES  
 
6.6.1 Defining the purpose and scope of the best practice guidelines for the 
monitoring and prevention of hearing loss associated with MDR-TB 
treatment 
 
6.6.1.2 Explanation of best practice guidelines and the purpose  
 
As defined in 6.1; best practice guidelines assist practitioner and patient decisions 
about appropriate health care for specific clinical circumstances‖ (Shekelle et al 
2012).  A best practice is a method or technique that has consistently shown results 
superior to those achieved with other means, and used as a benchmark. In addition, 
a "best" practice can evolve to become better as improvements are discovered. Best 
practices are used to maintain quality as an alternative to mandatory legislated 
standards and can be based on self-assessment or benchmarking (Bogan & English 
1994). However, in clinical practice, a best practice guideline can be referred to as a 
clinical practice guideline, which is a document with the aim of guiding decisions and 
criteria regarding diagnosis, management, and treatment in specific areas of 
healthcare. Best practice guidelines are based on an examination of current 
evidence within the paradigm of evidence-based medicine (Medicine 2011; The 
Agree Collaboration 2003; Wikidepia). Guidelines are viewed as useful tools for 
making care more consistent and efficient and for closing the gap between what 
clinicians do and what scientific evidence supports (Burgers et al 2003). 
 
 
215 
 
6.6.1.3 Scope of the best practice guidelines 
 
The main purpose of the best practice guidelines is to present a solution-focused 
effective and efficient approach towards early detection, management, and 
prevention of hearing loss among TB patients on MDR-TB treatment.   
 
6.6.1.4 Potential users of the guidelines 
 
The best practice guidelines have been primarily developed for health care 
personnel who are involved in managing TB patients such as the nurses, clinicians, 
doctors, and audiologists.  The secondary target will be the managers of the health 
facilities, policy and decision makers that develop strategic interventions and 
policies; mobilise resources and are actively involved in monitoring and quality 
assurance of TB programs as well as improved access to quality patient care. Lastly, 
the guidelines will target patients who access TB treatment services to create 
awareness and information that will foster measures and positive behaviours for 
hearing preservation.  
 
6.6.1.5 Objectives of the best practice guidelines 
 
The overall objective of the best practice guidelines was to raise awareness of the 
adverse effects of ototoxic MDR-TB drugs to enable early detection and prevention 
of SNHL. The use of guidelines will assist making of better decisions for clinical 
management of patients and improvement in the evidence used for policy planning 
and the data for the advancement science.  
 
The best practice guidelines will: 
 
 Strengthen institutional capacity towards preventing deafness and hearing 
loss among TB patients 
 Provide focused practice guidelines for early identification, diagnosis and 
treatment of causes of hearing loss and deafness among TB patients on 
MDR-TB treatment by health care practitioners. 
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 Create awareness on the magnitude of ototoxicity caused by MDR-TB drugs 
in order catalyse early detection and prevention of hearing loss among health 
care practitioners.  
 
6.6.1.6 Expected Benefits  
 
Effective utilisation of these best practice guidelines is intended to generate the 
following benefits: 
 
 Availability of various high quality services for prevention, early identification, 
treatment, referral, rehabilitation for hearing impairment and deafness among 
TB patients right from community based health care facilities to national 
referral hospitals. 
  
 Awareness creation among the health practitioners on the early detection, 
management, and prevention of hearing loss among TB patients. 
 
 Increased capacity building of health workers to ensure better care regarding 
early detection, management, and prevention of hearing loss among TB 
patients.   
 
 
6.6.2 Review of the findings of the empirical study 
 
According to this study, the generation of current evidence on ototoxicity and best 
practices provides a framework for contextualised best practice guidelines. In 
Chapters 4 and 5, very high incidence of MDR-TB treatment-related SNHL became 
evident.  In a study of 159 patients treated for MDR-TB observed for 22,032 person 
days, 94 (60%) developed high frequency hearing loss. The incidence rate in the full 
cohort was 4.1/1 000 person days of observation. Among the HIV positive patients 
the incidence was 4.2/1 000 person days (CI: 3.4-5.3) and for HIV negative patients, 
3.6/1 000 person days (CI: 2.4-5.7).  Time-to-hearing loss analysis results were 
presented in Chapters 4 and 5, providing a basis for recommendation of audiometric 
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testing frequency. As stated in Sections 4.3.5  and 4.3.6 hearing loss was associated 
with male gender, age group, Abacavir containing ARV regimen, job type of a 
miner/machine operator or taxi driver, low haemoglobin level,  and low body-mass 
index (0.018).  While there was an association of dyspnoea on admission and noise 
exposure, the associations were not statistically significant, their pointers for 
modifiable risk factors.  Table 6.4 presents the summary of the best practice 
guidelines and the basis for the recommendation from the study and from the 
theoretical frameworks. 
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6.6.3  Summary of best practice guidelines and application of the evidence 
 
6.6.3.1 Best practice guidelines for prevention, treatment and management of hearing loss 
 
Best Practice Guidelines Study Findings Elements of NSM and EMF 
Guideline 1: Drug Resistant Tuberculosis 
(DR-TB) treatment sites should establish an 
ototoxicity-monitoring programme. Where 
audiology services cannot be provided on site, 
there should be a functional referral system in 
place. 
 
-High incidence of SNHL among study respondents (60% of 
respondents developed SNHL 
-Lack of ototoxic monitoring programs at MDR-TB treatment 
centres.  
-Data collection for the study at sites without audiology 
services was through outreach programs 
NSM: Six phases of the Nursing 
process are required for holistic care: 
assessment, diagnosis, identification of 
outcomes, planning, implementation, 
evaluation 
EMF: All HCW should be involved in 
monitoring ADRs 
Guideline 2: All health care workers, 
administrators, and managers have delineated 
roles and responsibilities for implementing 
programmes focused on prevention, treatment, 
and management of hearing loss among DR-
TB patients.   
 
The pilot study revealed that there was a lack of awareness 
about audiological monitoring of treatment as part of quality 
care. Guidelines for roles and responsibilities were non-
existent. HCWs were lacking in awareness of the role of the 
audiologist as part of the team providing care.  Acceptance of  
routine monitoring audiology at the hospital was a quality 
improvement project 
1. Nursing processes: Planning and 
evaluation 
 
Nursing goals  
Guideline 3: All patients with DR-TB should 
have a thorough assessment of risk factors for 
hearing loss prior to exposure to second-line 
anti-TB medications.  
 
Baseline assessments showed that some respondents have 
pre-existing hearing losses.  
Conductive hearing loss due to wax impaction and due to 
middle ear infection was alleviated promptly through pre-
treatment assessment.  Family risk factors for hearing loss 
can also be assessed 
Nursing diagnosis 
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Guideline 4: Each DR-TB treatment site, and 
dependent ‗baby‘ facilities, should have a 
system for monitoring ototoxicity through 
pharmacovigilance protocols and tools. 
Pharmacovigilance monitoring should be used 
as a basis for informed medical decision-
making, especially where there is observed 
change in hearing thresholds.  
 
A high burden of incident hearing loss was revealed by the 
study. 
Health facilities were lacking tools and protocols for hearing 
loss referrals between the main treatment centre and the 
feeder health facilities and yet timely assessment is of 
essence if interventions are going to have an impact on 
hearing conservation 
Lack of tools to capture modifiable risk factors 
NSM 
Six phases of the Nursing process:  
-planning,  
-implementation,  
-evaluation 
 
6.6.3.2 Best practice guidelines for procedures conducted by health care providers 
 
Best Practice Guidelines Study Findings Elements of NSM and EMF 
Guideline 5: All DR-TB patients enrolled into 
care should have a pre-treatment assessment 
and baseline audiometry conducted prior to 
initiating treatment, or within 72 hours of the 
first dose of an aminoglycoside or polypeptide 
antibiotic. For facilities without audiology 
services, patients should be referred to an 
audiologist at an audiometry centerwithin two 
days. 
 
It is a best practice to establish a baseline for 
hearing sensitivity for future reference and 
comparison. MDR-TB treatment is associated 
with threshold shifts and significant threshold 
shifts require changes in the dosing and/or 
drug regimen in order to preserve hearing. 
Timing of hearing loss ranges from anywhere 
within the first month to post treatment. The 
median range of time to hearing loss ranged 
from 54.5 days to 147 days. 
Nursing  assessment and diagnosis 
Guideline 6: At initiation of MDR-TB treatment, 
all modifiable risk factors for hearing 
This study found that the following modifiable 
factors need to be addressed with a possibility 
Nursing  assessment and diagnosis 
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impairment (dehydration, renal insufficiency, 
dyspnoea and fever) should be addressed 
prior to administration of aminoglycosides or 
polypeptide antibiotics.  
 
of reducing the incidence of hearing loss  
-Improving hydration status 
- attending to dyspnoea 
- attending to low haemoglobin level 
-excluding and attending to pre-existing 
conductive hearing loss 
-attending to pre-existing diabetes 
Guideline 7: All DR-TB patients should receive 
regular scheduled two-weekly audiometry 
during the first 60 days of treatment and, 
thereafter, monthly assessment throughout the 
injectable phase of treatment. Urgent 
evaluation should be arranged whenever a 
patient reports decreased hearing sensitivity. 
 
More than 25% of respondents who developed 
hearing loss did so within the first 2 months. 
The median time to hearing loss ranges from 
54.5 days to 147 days (median is 84 days). 
More frequent testing improves the chances of 
early intervention soon after detection of 
ototoxicity 
Nursing  assessment and diagnosis 
Guideline 8: Audiometry should be conducted 
at least once within six months after 
completion of injectable MDR-TB treatment. 
 
Hearing loss is progressive. Patients hearing 
loss grades worsening during follow up in the 
study 
Nursing goals and outcomes 
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6.6.3.3 Best practice guidelines for documentation and record keeping 
 
Best Practice Guidelines Study Findings Elements of NSM and 
EMF 
Guideline 9: All health care workers should be trained in 
documentation and record keeping of adverse drug reactions. 
Proactive targeted observation (and recording), analysis and 
action are central to the hearing loss prevention programme. 
 
Incident cases were identified  
through thorough record keeping 
Early and proactive interventions for 
Secondary and tertiary prevention 
depend to targeted observation and  
analysis of records recording 
Nursing evaluation 
 
 
6.6.3.4 Best practice guidelines for public health actions 
 
Best Practice Guidelines Study Findings Elements of NSM and EMF 
Guideline 10: The public should be provided 
with appropriate evidence based documentation 
and clear guidelines for early detection of 
hearing loss among DR-TB patients, including 
risks arising from abuse or improper use of 
ototoxic drugs. 
 
High incidence of hearing loss among MDR-TB 
patients 
Nurse-client relationship 
Guideline 12: Information and educational 
materials should be used to provide correct and 
Some respondents declined enrolment into the 
study because of fear of hearing loss. Some 
Nurse-client relationship and 
nursing goals and outcomes. 
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accurate information on ototoxicity in a simple 
and engaging way. 
 
defaulted their medication based on the fear for 
SNHL 
Client system extends to family 
and community 
Guideline 13: Regulation and legislation should 
be implemented to ensure that only appropriate 
health care workers conduct prescription and 
administration of ototoxic medication.  
 
Aminoglycosides used in MDR-TB management 
are ototoxic and should be used judiciously 
Previous exposure increases risk for SNHL 
during MDR-TB treatment 
Nurse-client relationship and 
nursing goals and outcomes. 
Client system extends to family 
and community 
Guideline 14: Wherever possible, DR-TB 
patients with hearing impairment should be 
provided with or referred for hearing aids early 
enough to prevent deterioration of hearing. 
 
Hearing aids reduce progression of hearing loss 
Health care workers need to discuss potential 
hearing loss with patients so that patients are 
clear on what to do should they start 
experiencing hearing loss 
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6.6.4 Review of existing literature 
 
The WHO estimates that around 360 million people suffer from disabling hearing loss worldwide. In 1995, the World Health 
Assembly developed guidelines to address this burden. These guidelines may be applied to address MDR-TB-related hearing loss, 
where increasing use of MDR-TB treatment is likely to increase the prevalence of hearing loss (Olusanya et al., 2014a). The high 
incidence of hearing loss associated with MDR-TB treatment was also in Botswana (62%), Iran (71%) and South Africa (40% and 
57%) (Harris et al., 2012, Modongo et al., 2014, Seddon et al., 2013, Van der Walt et al., 2013). Lower incidence has been reported 
in the United Kingdom (18%), and in the Netherlands (18%) (de Jager &van Altena, 2002, Sturdy et al., 2011).  
 
6.5.1.1 Interpretation of Evidence in the development of best practice guidelines  
 
This study utilised the US Preventive services task force (2014) Guide to clinical preventive services framework (US Preventive 
services task force, 2014 #842) for describing the quality of the evidence. The USPSTF is an independent panel of experts in 
prevention and primary care that evaluates available evidence and makes recommendations about clinical preventive services, 
including screenings, counseling, and preventive medications. The Task Force determines whether or not the evidence supports 
providing a clinical preventive service in primary care settings to people without symptoms. For a service to be recommended, the 
evidence must show that the potential benefits of providing that service outweigh the potential harms. The grade linked to each 
recommendation reflects both the magnitude of net benefit and the strength and certainty of the evidence supporting the provision 
of a specific preventive service. These grades translate to practice guidance for clinicians: high priority, medium and low. 
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Table 6.2 Levels of Certainty concerning quality of evidence/ service 
 
Level of Certainty Description 
High The available evidence usually includes consistent results from well-designed, well-conducted studies in representative 
primary care populations. These studies assess the effects of the preventive service on health outcomes. This conclusion 
is therefore unlikely to be strongly affected by the results of future studies. 
Moderate The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in 
the estimate is constrained by such factors as:  
 The number, size, or quality of individual studies. 
 Inconsistency of findings across individual studies. 
 Limited generalizability of findings to routine primary care practice. 
 Lack of coherence in the chain of evidence. 
As more information becomes available, the magnitude or direction of the observed effect could change, and this change 
may be large enough to alter the conclusion. 
Low The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of:  
 The limited number or size of studies. 
 Important flaws in study design or methods. 
 Inconsistency of findings across individual studies. 
 Gaps in the chain of evidence. 
 Findings not generalizable to routine primary care practice. 
 Lack of information on important health outcomes. 
More information may allow estimation of effects on health outcomes. 
Source: (USPSTF 2014:99) 
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6.6.5 Recommendations and summary of evidence 
 
Table 6.3: Guidelines, summary of the evidence and recommendations for implementation of prevention and monitoring 
strategy for hearing loss associated with MDR-TB. 
 
GUIDELINE SUMMARY OF EVIDENCE FROM THE REVIEW OF 
LITERATURE AND THE STUDY FINDINGS ON WHICH THE 
BEST PRACTICE GUIDELINES ARE BASED 
RECOMMENDATIONS FOR IMPLEMENTATION  
1. Drug Resistant Tuberculosis 
(DR-TB) treatment sites should 
establish an ototoxicity-
monitoring programme. Where 
audiology services cannot be 
provided on site, there should 
be a functional referral system 
in place. 
 
Strong recommendation, 
high quality evidence 
 
Situation: Hearing loss is an important public health concern with 
substantial economic and societal costs. The incidence of hearing 
loss associated with MDR-TB treatment in Swaziland is high and 
there are no monitoring and prevention systems in place. 
Solution:  
 Audiometric monitoring for ototoxicity is primarily 
performed for early detection of changes to hearing status 
when it is possible to institute interventions to prevent 
further deterioration of hearing.  
 The current preferred method for testing hearing is 
audiometry for adults and older children (those able to 
cooperate with testing). 
The responsibility for hearing loss monitoring and its prevention is 
currently undefined. 
 Early intervention is the responsibility of all health care 
workers through implementation of primary, secondary 
The Drug Resistant Tuberculosis (DR-TB) treatment 
sites should:  
 Plan resources to ensure availability and utility 
of audiology equipment, forms of requesting for 
audiology services and human resources for 
hearing screening. 
 Establish ototoxicity monitoring and prevention 
services to: identify ototoxicity; enable timely 
identification of at-risk patients; provide pre-
treatment counselling regarding potential 
ototoxic effects; take valid baseline measures 
(pre-treatment or early in treatment); conduct 
monitoring evaluations at sufficient intervals to 
document progression of hearing loss or 
fluctuation in sensitivity; and conducts follow-up 
evaluations to determine post-treatment effects. 
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and tertiary prevention. 
Health care workers and authorities are unclear about appropriate 
interventions for patients presenting with deteriorating or loss of 
hearing. 
 Early detection enables audiology intervention when 
hearing impairment has occurred.   
 
(Audiology, 2009, Seddon et al., 2012)).  
 Establish a referral system for every patient to 
receive baseline audiometry where audiometry 
services cannot be provided on site. 
 Establish supportive hearing programmes to 
assist patients with communication in the event 
of loss of speech frequencies.  
 
2. All health care workers, 
administrators and managers 
have delineated roles and 
responsibilities for 
implementing programmes 
focused on prevention, 
treatment and management of 
hearing loss among MDR-TB 
patients.   
 
 
Strong recommendation, 
Low quality evidence 
Interdisciplinary collaboration may lead to improvements in health 
care access, outcomes of health care, and satisfaction of health 
care workers and their patients. Interdisciplinary collaboration 
may also improve recruitment and retention of health care 
workers and communication.  
Clear definitions of providers‘ roles and expectations with regard 
to shared care are essential in order to reduce the possibility of 
ambiguity and misunderstanding regarding protocols, procedures, 
responsibility and authority (Paquette-Warren et al 2004). In an 
ototoxicity monitoring and prevention programme: 
 Audiologists should be responsible for establishing the testing 
protocol, patient testing, interpretation and management of 
data derived from monitoring and prevention programmes. 
They should also be responsible for follow-up management 
when hearing loss is clinically significant. 
 Pharmacists should be responsible for storing and dispensing 
DR-TB treatment sites should: 
 Establish a multi-disciplinary approach to 
monitoring and prevention of hearing loss among 
patients on MDR-TB treatment. The physician, 
audiologist and occupational therapist should 
provide leadership in championing the balance 
between pursuing cure and ensuring quality of life 
is maintained. 
 Develop a chart showing the roles and 
responsibilities of all health worker cadres in the 
prevention, detection, and management of 
ototoxicity among MDR-TB patients. Delineated 
responsibility and improvement of communication 
among the health care workers will ensure that 
each cadre fulfils a defined role in primary, 
secondary and tertiary prevention.  
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MDR-TB drugs, providing non-prescription drugs, health care 
aids and devices, and providing patients and health care 
workers with information related to drug use. Together with 
audiologists and doctors, pharmacists‘ should develop risk 
assessment tools and monitor implementation of 
pharmacovigilance tools.  
 Doctors should be responsible for the assessment of the 
physical and mental health of patients, including establishing 
a diagnosis, initiating treatment and preventing disease or 
disability where possible. More generally, doctors should be 
responsible for overall patient wellbeing, and for managing 
the implementation and running of the ototoxicity programme.  
 The laboratory staff should be responsible for interpreting 
tests, including critical values of certain risk factors, and for 
notifying doctors where an abnormality is detected in order to 
prevent or mitigate further hearing loss.  
 Nurses should be responsible for health promotion, and for 
assessing the adequacy of patient care. They should be 
involved in the provision of supportive, preventive, 
therapeutic, palliative and rehabilitative care, in order to 
optimise patient function. Nurses should also conduct pre-
treatment assessments, be involved in the management of 
modifiable risk factors and support patients with 
communication difficulties. 
 Engage health care administrators and managers 
in ototoxicity monitoring and prevention 
interventions in order to improve patient quality of 
life and outcomes increase advocacy and the 
provision of resources, and promote an enabling 
environment. 
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(Atun et al., 2010, Audiology, 2009)Paquette-Warren et al 2004). 
3. All patients with MDR-TB 
should have a thorough 
assessment of risk factors for 
hearing loss prior to exposure 
to second-line anti-TB 
medications.  
 
 
Strong recommendation,  
High quality evidence 
 
 While aminoglycoside antibiotic administration is the most 
important risk factor for the development of MDR-TB treatment 
related hearing loss, several factors may potentiate this risk. 
These factors are modifiable and non-modifiable, and may be 
cumulative.  
 Documented risk factors include: familial and genetic 
predisposition of the patient, especially in patients with 
genetic mutations of genes coding mitochondrial 12S RNA, 
such as A1555G and T1095C and so on, exposure to noise 
during aminoglycoside treatment, cumulative dosage of 
aminoglycosides, previous exposure to aminoglycosides, 
age of the patient (especially extreme ages), existence of 
renal dysfunction and chronic renal disease, and the 
presence of hypertension and other systemic disorders.  
 Concurrent exposure to other ototoxic drugs, such as loop 
diuretics, platinum-based antineoplastic drugs, salicylates 
and NSAIDs, anti-malarial drugs (especially quinine), is also 
associated with increased risk of hearing loss.   
 In Swaziland, additional risk factors include dyspnoea, use of 
abacavir for treatment of HIV in MDR-TB patients and job 
type.  
(Harris et al., 2012, Hirose &Sato, 2011, Kim , Xue &Du, 2006, 
Nitz , Kontopantelis , Bielack , Koscielniak , Klingebiel , Langer 
DR-TB treatment sites should:  
 Conduct a thorough assessment of risk factors for 
hearing loss prior to exposure to second-line anti-
TB medications. Assessments should include: 
family history of hearing impairment; occupational 
and recreational exposure to noise; use of other 
ototoxic medications; previous recurring inner ear 
infections; familial predisposition and genetic 
factors; and systemic diseases (for example, 
diabetes)  
 Implement appropriate monitoring of patient 
hearing on the basis of their risk assessment  
 Provide pre-initiation counselling for patients, 
including information on MDR-TB treatment, and its 
benefits and side effects 
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&Paulides, 2013, Xiong et al., 2010). 
 
4. Each DR-TB treatment site, 
and its ‗baby‘ facilities, should 
have a system for monitoring 
ototoxicity through 
pharmacovigilance protocols 
and tools.  Pharmacovigilance 
monitoring should be used a 
basis for informed medical 
decision-making, especially 
where there is observed 
change in hearing thresholds  
 
Strong recommendation,  
High quality evidence 
 
Health care workers and health facilities do not adequately report 
adverse drug reactions. 
 Early detection and monitoring of ototoxicity can reduce the 
impact of hearing loss.  
 In the event of deterioration in hearing sensitivity during 
MDR-TB treatment, treatment modification can prevent 
further hearing loss. 
 If hearing sensitivity is not impaired during treatment, no 
changes are required, though monitoring for delayed 
changes in hearing sensitivity should continue. 
 Monitoring provides an opportunity for counselling and 
rehabilitation during and after treatment. 
 Monitoring provides the basis for informed medical decision-
making. 
 
 
(Lopez-Gonzalez et al 2009; Wilmington, Konrad-Martin, Helt, 
Dille, Gordon & Fausti 2011:248; WHO 2005:7).   
 
 
 
 Establish a reporting system to enable 
documentation of hearing loss frequency and 
magnitude, as well as the impact of adverse 
events. 
 Early detection of hearing loss should be linked to 
risk reduction strategies for adverse drug reactions 
WHO grades for hearing impairment should be 
incorporated in the pharmacovigilance tool. 
  
5. All DR-TB patients enrolled Baseline testing establishes whether patients have any pre- DR-TB treatment sites should ensure that:  
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into care should have a pre-
treatment assessment and 
baseline audiometry conducted 
prior to initiating treatment, or 
within 72 hours of the first dose 
of an aminoglycoside or 
polypeptide antibiotic. For 
facilities without audiology 
services, patients should be 
referred within two days. 
 
Strong recommendation,  
High quality evidence 
 
existing hearing impairment and enables comparison with 
subsequent tests during DR-TB treatment.  
 Audiologic monitoring for ototoxicity is performed for early 
detection of existing impairment and changes to hearing 
sensitivity, enabling audiologic intervention when hearing 
impairment occurs. Thresholds for acceptable versus 
unacceptable hearing loss should be defined and used to 
prompt intervention. The thresholds are; 26-40 dB Mild 
hearing loss; 41-60 dB Moderate hearing loss; 61-80 
dB severe hearing loss; 81+ dB Profound hearing 
loss. 
 Significant threshold shift criteria for a case of hearing 
with follow up compared with baseline measurements 
and ototoxicity defined as any of: i) a 20 dB decrease 
at any one frequency, ii) a 10 dB decrease at any two 
adjacent frequencies (American Speech-Language-
Hearing Association., 1994; Audiology, 2009). 
 
 
 All DR-TB patients enrolled into care should 
undergo pre-treatment assessment and baseline 
audiometry prior to initiating treatment, or within 72 
hours of the first dose of an aminoglycoside or 
polypeptide antibiotic.  
 For facilities without audiology services, ensure 
referral to appropriate facilities within 2 days.  
 
 
6. At initiation of MDR-TB 
treatment, all modifiable risk 
factors for hearing impairment 
(dehydration, renal 
Aminoglycosides and polypeptide antibiotics are ototoxic, 
affecting both vestibular and cochlear function of the inner ear 
through damage to the sensory neuroepithelium of the inner ear. 
The risk of ototoxicity is increased in the presence of modifiable 
DR-TB treatment sites should: 
 Ensure risk factors for hearing impairment are 
addressed prior to administration of 
aminoglycosides or at the earliest opportunity. 
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insufficiency, dyspnoea and 
fever) should be addressed 
prior to administration of 
aminoglycosides or polypeptide 
antibiotics.  
 
Strong recommendation,  
High quality evidence 
 
risk factors such as transient renal dysfunction, dehydration, 
smoking, job type and exposure to noise.  
(Gopinath et al 2010; Harris et al 2012). 
 
 Ensure patients are hydrated and do not have any 
other conditions that have been known to 
accelerate ototoxicity among MDR patients. 
 Ensure patients are apyrexic. Pyrexic patients 
need stabilisation prior to MDR-TB treatment. 
 Use patient history, weight and age to inform anti-
TB drug regimen. 
 Provide patient counselling about drug adherence, 
and how to cope with MDR-TB treatment, as well 
as information on the benefits and side effects of 
relevant drugs. 
 
 
 
 
7. All MDR-TB patients should 
receive regular scheduled two-
weekly audiometry during the 
first 60 days of treatment, and 
thereafter monthly assessment 
throughout the injectable phase 
of treatment. Urgent evaluation 
should be arranged whenever a 
patient reports decreased 
Most MDR-TB-associated hearing loss observed in Swaziland 
occurs within 60 days of receiving ototoxic drugs. More frequent 
assessments of hearing during this period is therefore critical. 
 When audiologic monitoring detects hearing impairment or 
changes to hearing status, medical and audiologic 
interventions and rehabilitation may prevent disabling hearing 
impairment and disability (Duggal & Sarkar 2007; Seddon et 
al 2012). 
 
All MDR-TB patients receiving aminoglycosides or 
polypeptide antibiotics should have regular scheduled 
audiometry. DR-TB treatment sites should:  
 Ensure audiometry is conducted at the beginning of 
treatment and is repeated at regular two-weekly or 
monthly intervals 
 Audiometry tests should be conducted every two 
weeks during the first 60 days of treatment and 
monthly throughout the injectable phase of 
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hearing sensitivity or 
symptoms such as tinnitus 
or vertigo. 
Strong recommendation,  
High quality evidence 
 
treatment. Urgent evaluation should be arranged 
whenever a patient reports decreased hearing 
sensitivity (see Guideline 4). 
 Audiometry results should be compared with 
baseline results in order to determine whether there 
has been a significant threshold shift/change. 
 If high-frequency hearing loss is detected, the 
offending drug should be stopped or dose reduced.  
It may be possible to stop the drug before hearing 
loss involves frequencies required for speech, 
without impairing successful treatment. However, 
where hearing loss has been reported, the health 
practitioner should consider the following; 
o Reducing the frequency of the drug 
administration to 5 times or even 3 times per 
week from daily dosing. 
o Lowering the drug dosage if this does not 
compromise the regimen. 
o Discontinuing the drug if this will not 
compromise the regimen. 
o Prescribing an alternative treatment regimen 
with less ototoxic medications when early 
SNHL is detected. 
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8. Audiometry should be 
conducted at least once within 
six months after completion of 
injectable MDR-TB treatment 
 
Strong recommendation,  
High quality evidence 
 The degree of hair cell damage in the organ of Corti
1
 and 
hearing loss is directly proportional to drug dosage.  
 Association of hearing loss with treatment duration and total 
aminoglycoside dosage has been reported. Aminoglycosides 
may persist in the inner ear tissues for more than six months, 
therefore patients may continue to be susceptible to 
ototoxicity long after completion of treatment. 
 Continuation of monitoring beyond the duration of drug 
treatment is therefore required.  
 Among adults and children, hearing impairment associated 
with aminoglycosides can develop after the aminoglycoside 
has been stopped ((de Jager & van Altena 2002; Seddon et al 
2012). 
DR-TB treatment sites should ensure that:  
 Patients who received aminoglycosides or 
polypeptide antibiotics should undergo audiometry 
within six months of  completing injectable MDR-TB 
treatment 
 If new hearing loss is detected, patient should be 
referred to audiologic services. 
 
9. All health care workers 
should be trained in 
documentation and record 
keeping of adverse drug 
reactions. Proactive targeted 
observation (and recording), 
analysis and action are central 
to the hearing loss prevention 
Among the public and health care professionals there is limited 
awareness about the effects of anti MDR-TB antibiotics, loop 
diuretics and some NSAIDs on hearing. 
 Health care workers who are aware about ototoxicity may not 
be familiar with the fact that each phase of the ototoxicity 
programme generates its own form of records, and the 
information from the various records must be considered in 
order to evaluate the effectiveness of the hearing loss 
All DR-TB treatment sites and non DR-TB sites should 
ensure that:  
 There is a system for recording and reporting 
ototoxicity, and that health care workers receive 
appropriate training in order to use it. Training 
should specifically enable healthcare workers to use 
records that the system generates. For an 
ototoxicity prevention programme, all health care 
                                            
1 The organ of Corti comprises both outer and inner hair cells. There are approximately between 15,000 and 16,000 of these hair 
cells in one ear (Plewes 2006).  Inner hair cells are the mechanoreceptors for hearing: they transduce the vibration of sound into 
electrical activity in nerve fibres, which is transmitted to the brain and perceived as hearing 
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programme. 
Strong recommendation,  
High quality evidence 
 
prevention programme.  
 Some of these records may be occupationally relevant. Not 
all health care workers will be familiar with the requirements 
for ototoxicity monitoring. 
 Health care workers may not be aware of the tools used to 
detect and monitor hearing loss among MDR-TB patients, 
nor of the relevant protocols where hearing loss is detected. 
There is therefore a need for training. 
 
(Coleman, Fernery & Evans 2011:371-7). 
workers should be trained in documentation and 
record-keeping of adverse drug reactions, including 
ototoxicity.  
 Records should be examined and analysed on a 
regular basis.  
 The recording system for monitoring adverse drug 
reactions should define the variable being 
monitored, the system to be used to monitor, and 
reliability of recording, continuity and threshold for 
actions.   
 
 
10. The public should be 
provided with appropriate 
evidence-based documentation 
and clear guidelines for early 
detection of hearing loss 
among MDR-TB patients, 
including risks arising from the 
abuse or improper use of 
ototoxic drugs 
Strong recommendation,  
High quality evidence 
 
 The general public are largely unaware that medications, 
such as anti MDR-TB antibiotics, loop diuretics and some 
NSAIDs, can cause transient or permanent hearing loss. 
    Occupational noise and social noise can potentiate hearing 
impairment in patients receiving MDR-TB treatment. 
Protective equipment, where  available, is not always 
available or acceptable to the workforce or the public. It is 
therefore recommended that noise should be reduced and/or 
avoided. 
   Public awareness campaigns reduced ototoxicity in studies 
conducted in China and South Africa. 
The Ministry of Health through the national TB 
programme should: 
 Sensitize the health care providers to increase 
awareness of the risks associated with abuse or 
improper use of ototoxic drugs, drug dosage and 
duration of drug treatment  
 Create public awareness materials on hearing loss 
and prevention strategies. 
 Address the problem of work place and social noise 
including provision of protectors, and reducing noise 
and noise exposure where possible.  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(WHO 1994 WHO 1997). 
11. Professional education and 
training should be tailored to 
the needs of all categories of 
health care worker, taking into 
account  roles and 
responsibilities  
Strong recommendation,  
Low quality evidence 
 Lack of trained personnel to carry out audiometric testing is a 
significant challenge to the development of hearing 
conservation programmes during MDR-TB treatment. 
 
 Several cadres of health care worker have a role in 
monitoring and prevention of ototoxicity. Professional 
education and training therefore needs to be tailored to the 
needs of each cadre, based on their roles and responsibilities.  
 
(Seddon et al 2012). 
 General practitioners, clinicians, nurses, 
audiologists, pharmacists and community health 
care workers should be informed about the potential 
for particular drugs to cause ototoxicity, possible 
interactions of these drugs, and ototoxicity 
prevention and early detection strategies. 
 Beyond training, sensitization of health care 
workers should be conducted through information 
brochures and campaigns.  
 
 Experienced and qualified personnel should 
conduct in-service training and experiential learning 
on ototoxicity in order to increase awareness of 
health care workers about ototoxicity. 
12. Information and educational 
materials should be used to 
provide correct and accurate 
information on ototoxicity in a 
simple and engaging way.  
Strong recommendation, 
high quality evidence 
 
Although a significant proportion of hearing loss among patients 
with MDR-TB is associated with anti-TB drugs, environmental 
chemicals such as organic solvents, asphyxiant gases, 
pesticides, and heavy metals may also play a role. The public 
may not be aware of these ototoxic agents, nor of their role in 
protecting themselves and their family members from them.  
Evaluation of individuals who have had environmental ototoxic 
exposures and noise-induced hearing loss can help in making 
 Appropriate information dissemination material 
should be made available in health care centres, 
hospitals, schools, colleges and other public places 
concerning risk factors for ototoxic hearing loss.  
 
236 
 
decisions regarding the potential ototoxicity of exposure to an 
unknown chemical agent or preceding noise-induced hearing 
loss. 
(Audiology, 2009, Rybak & Ramkumar 2007; Rybak 1992). 
13. Regulation and legislation 
should be implemented to 
ensure that prescription and 
administration of ototoxic 
medications are conducted only 
by appropriate health care 
workers  
Strong recommendation, low 
quality evidence 
 Local data is lacking to increase awareness of the decision 
makers on the impact of hearing loss.  
 Our study on the incidence of MDR-TB related hearing loss in 
Swaziland provides data that can be used to develop 
measures for prevention and to mobilise funds for further 
research towards better MDR-TB treatment, as well as 
rehabilitation of those with hearing loss. 
 Various studies have revealed that in most developing 
countries there are no restrictions concerning access to 
ototoxic dugs. In Swaziland, a recent study conducted among 
pharmacists by the pharmacist at the TB hospital and 
Management Science of Health (MSH) revealed that it is 
possible to obtain prescription drugs, including 
aminoglycosides, without a prescription. 
 
(Olusanya 2013; Smith 2005). 
 There should a deliberate effort to raise awareness 
about ototoxic hearing loss among of decision 
makers through sharing of evidence and best 
practices. 
 Decision makers should be lobbying health facility 
managers for funding to provide hearing aids, and 
for decentralisation of audiology services. 
 
14. Wherever possible, MDR-
TB patients with hearing 
impairment should be provided 
with or referred for hearing aids 
 Audiologic rehabilitation, that is, the process of providing 
training and treatment to improve hearing, is necessary for 
those who develop hearing impairment.  
 Hearing rehabilitation services focus on adjusting to hearing 
To mitigate the social and economic impact of MDR-TB 
hearing loss, wherever possible, persons with drug 
induced hearing impairment should be provided with 
aids early enough to prevent deterioration of hearing.  
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early enough to prevent 
deterioration of hearing 
 
Strong recommendation,  
High quality evidence 
 
loss, optimizing use of hearing aids, exploring assistive 
devices, managing conversations and other hearing 
strategies, and encouraging patient to exert control of 
communication.  
According to the WHO, the grade of hearing impairment is as 
shown but disabling HL starts at grade 2 
 0 – No impairment: 25 dB or better (better ear) 
 1 – Slight impairment: 25 dB or better (better ear)   
 2 – Moderate impairment: 41-60 dB (better ear)   
 3 – Severe impairment: 61-80 dB (better ear)   
 4 – Profound impairment including deafness: 81 dB or 
greater (better ear).   
 
(Olusanya et al 2014b) 
 For Grade 2 hearing loss, counseling and potential 
interventions including hearing aids may be required 
by the patient.  
 For Grade 3 hearing loss, hearing aids are usually 
recommended.  
 For Grade 4 hearing loss, hearing aids are required, 
however if these are not available, lip-reading and 
signing should be taught.  
 For profound hearing loss, hearing aids may help the 
patient to decipher speech. Additional rehabilitation 
may be needed, and supporting the patient to develop 
lip-reading and signing skills is essential. 
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Roles and Responsibilities of health Care workers  
Table 6.4: Stakeholder roles and responsibilities for prevention, treatment, and management of 
hearing loss 
 
STAKEHOLDER ROLES AND RESPONSIBILITIES 
Policy makers  Carry out advocacy, communication and social mobilisation (ACSM) to 
bring about policy reforms and the development of institutional structures 
to support hearing loss programmes for MDR-TB patients.  
 Create a policy environment & mobilise resources for the implementation 
of effective TB programmes to reduce the number of MDR-TB cases. 
 Support the implementation of surveillance programmes to manage 
ototoxicity among MDR-TB patients. 
 Provide guidance concerning the improvement of hospital facilities and 
services to meet the needs of TB patients with hearing loss. 
Hospital 
administrator/ 
senior medical 
officers and 
matrons  
 Provide resources to strengthen the implementation of programmes to 
prevent, treat and manage hearing loss among MDR-TB patients. 
 Implement on-site surveillance to ensure health care facilities are 
adequately detecting and managing hearing loss among MDR-TB 
patients. Health care facilities should conduct initial and ongoing 
evaluations for each patient regarding the reduction risks of ototoxicity 
among MDR-TB patients.   
 Develop a facility-specific plan for the reduction of hearing loss among 
MDR-TB patients, informed by surveillance data findings. This plan 
should include standard operating procedures for staff to implement in 
the event of hearing loss. 
 Ensure sufficient funding is allocated from the annual facility budgets to 
support MDR-TB hearing loss programmes. 
 Purchase appropriate drugs, commodities and supplies. 
 Establish a patient records management system. 
 Ensure sufficient and appropriately trained health care workers are 
employed to run high quality services.  
 Establish health care facility networks and a referral system.  
Health practitioners 
(doctors, clinicians 
and other 
specialists) 
 Carry out diagnostic tests and examine patients for symptoms.  
 Identify co-morbidities and medical, pathophysiological, psychological 
and sociocultural risk factors for hearing loss. 
 Monitor treatment adherence and audiometric testing.  
 Refer patients for hearing screening and audiometry.  
 Prescribe appropriate drugs and inform patients of  adverse drug effects 
 Educate the community on early detection of hearing loss and the 
availability of treatment and rehabilitation for hearing impairment among 
MDR-TB patients. 
 Refer patients with hearing loss to Ear, Nose and Throat doctors and 
audiologists for appropriate treatment, including hearing aid provision and 
fitting, cochlea implant surgery and rehabilitation. 
 Complete patient records.  
Nurses  Educate patients and the community on early detection of hearing loss 
and the availability of  treatment and rehabilitation for hearing impairment, 
through health education talks and community awareness campaigns.  
 Participate in the diagnosis and management of patients with MDR-TB. 
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 Identify cases of hearing loss and refer patient for further assessment.  
 Provide treatment for common ear conditions, including cerumen 
impaction and acute suppurative otitis media, with guidance from doctors.  
 Distribute ear-drops and other medications as instructed by doctors. 
 Provide counselling to patients on the side effects of drugs, and how to 
cope with hearing loss. 
 Complete appropriate registers and clinical records for TB patients.  
Audiologists  Establish and in collaboration with doctors and administrators manage 
MDR-TB hearing loss programmes, including in-service education and 
interpretation of hearing test results. 
 Advocate for and supervise hearing loss programmes.  
 Design, implement and coordinate occupational and community hearing 
loss prevention programmes, which should  include: assessment of  
individual exposure to  ototoxic agents; identification and reduction of 
exposure to noise; education for employers and employees; screening for 
hearing loss; recommendations for treatment; and counselling for use of 
hearing protection. 
 Train and supervise non-audiologists involved in monitoring audiometry in 
the health care setting.  
 Conduct screening, diagnostic tests and follow up audiometry, using 
baseline audiometry results to identify significant threshold shifts. 
 Provide preventive, promotive, curative, medical and social rehabilitative 
services.  
 Make recommendations to prescribing doctors concerning patient 
treatment. 
 Conduct surveillance and maintain patient records.  
 Manage hearing loss that is not medically treatable by and prescribing 
amplification and/or assistive listening devices, and supporting the patient 
and their family in accessing counselling and developing communication 
strategies. 
 Provide information to patients regarding treatment and rehabilitation in 
the event of hearing loss. 
Pharmacy  Lead the pharmacovigilance teams, monitor adverse drug reactions and 
develop risk assessment tools. 
 Dispense medication and check drug doses are correct.  
 Identify potential drug interactions and prevent adverse effects.  
Laboratory staff  Conduct tests to identify patient risk factors for ototoxicity, including renal 
function tests, blood glucose tests.  
 Manage lab tracking systems for tests are early notification of critical 
abnormal results for example, creatinine clearance values. 
Patients  Monitor hearing and present early to an appropriate facility if hearing 
deteriorates.  
 Voice their concerns and questions about the hearing loss prevention 
programme and MDR-TB treatment more generally. 
 Comply with guidelines on how to prevent hearing loss. 
 Communicate information about MDR-TB treatment related hearing loss 
to other patients and the community at large, and help to inform and train 
their colleagues in the use of occupational hearing protection. 
 Approach programme facilitators (health care workers) and their 
employers to report any health and safety concerns. 
 Adhere to treatment advice on prevention of further damage. 
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Community based 
workers and family 
members  
 Educate patients and the community on early detection of MDR-TB-
related hearing loss, as well as available treatments, through health 
education talks and community awareness campaigns.  
 Support and counsel patients on MDR-TB treatment to ensure risks are 
managed. 
 Support patient with hearing loss to accept their disability and maintain 
communication through the use of lip reading and sign language. 
 Identify hearing loss in the elderly and enable them to access suitable 
management or rehabilitation. 
 
Table 6.5: Procedures for health care workers during pre-treatment assessment 
Step  Action Description Responsibility 
1  Assessing patient risk 
of hearing loss prior to 
initiation on MDR-TB 
treatment 
The health practitioner is expected to: 
 Take the patient‘s history of exposure 
to loud noises or ototoxic agents, 
including: occupational exposures; 
previous recurring middle ear 
infections; familial predisposition and 
genetic factors; and certain systemic 
diseases, such as diabetes, 
hypertension, chronic kidney disease 
and sickle cell disease. 
 Most at risk people are those that work 
in noisy places for prolonged periods 
(more than 8 hours at noise levels 
>85dB or for more than 1 hour at noise 
levels >95dB(Audiology, 2009)). 
 High risk occupations include machine 
operators, industrial workers and those 
working in the music industry (for 
example, disco jockeys). 
 Assess patients‘ previous exposure to 
aminoglycosides.  
 Counsel patients with pre-existing 
vestibulo-cochlear impairment on the 
potential risks of MDR-TB treatment, and 
gain  informed consent prior to drug 
treatment. 
 Conduct tests to assess and document 
patients‘ physical state, including 
hydration status, temperature, and 
presence of absence of dyspnoea.  
 Optimise and stabilise patient physical 
state before initiating aminoglycosides 
Nurse 
2  Ear examination, 
hearing screening and 
diagnostic audiometry 
for hearing sensitivity  
 Conduct a pre-treatment audiometry at 
initiation of MDR TB treatment to assess 
baseline hearing sensitivity and the need 
for further hearing tests. 
Audiologist 
3  Recommendations for 
MDR-TB treatment  
 Recommendations should be informed by 
the pre-treatment assessment results, 
including patient fit and readiness to 
commence MDR-TB treatment.  
Doctor or 
audiologist 
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Step  Action Description Responsibility 
4  Patient counselling 
and consent to 
commence treatment 
 Provision of pre-initiation counselling to the 
patient, including information about the 
type of treatment, its benefits and likely 
side effects. 
 Consenting the patient to commence 
treatment.  
Nurse 
 
Table 6.6: Procedures for health care workers at initiation of the patient on MDR-TB treatment 
Step  Action Description 
1 Preparation for treatment  Ensure the patient is well hydrated and does not have 
any conditions known to accelerate ototoxicity  
 Ensure patients are apyrexic and observations are  
stable prior to drug administration.  
2 Determination of the 
regimen 
 Determine an appropriate regimen based on the patient‘s 
history, weight and age.  
 
3 Patient counselling on 
adherence  
 Provide patient counselling on drug adherence, and how 
to cope with the drug treatment, including its benefits and 
likely side effects.  
 
Table 6.7: Procedures for health care workers for monitoring patients on MDR-TB treatment 
Step  Action Description 
1  Patient review and 
monitoring as 
recommended by the 
guidelines  
 Review patients progress on the MDR-TB treatment. 
 If decreased hearing sensitivity is reported patients 
should be referred for audiometry. 
 Compare results from follow-up audiometry with the 
baseline results. 
2  Monitor hearing loss  Diagnose hearing loss when one of the following criteria 
are met: (i) ≥20 dB decrease at any one test frequency, 
(ii) ≥10 dB decrease at any two adjacent frequencies, or 
(iii) loss of response at three consecutive frequencies 
where responses were previously obtained. Apparent 
changes should be compared to baseline 
measurements, and confirmed by repeat testing, 
generally within 24 hours. 
 Communicate results of audiology monitoring to patients 
and other health care workers. 
 Ensure that the drug dosage administered is appropriate 
for weight and age, as toxicity increases with both. 
 
3   If ototoxicity and/or hearing 
loss is detected 
Consider: (i) reducing the frequency of drug 
administration to three to five times per week; (ii) 
lowering the dose of the suspected agent if this can be 
done without compromising the regimen; or  (iii) stopping 
the drug before hearing loss progresses to the 
frequencies needed for speech communication. 
Caution: 
 Hearing loss is generally not reversible 
 The risk of further hearing loss should be weighed 
against the risk of stopping the drug 
 Monitoring serum drug concentrations is essential 
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4  If there is significant 
irreversible hearing loss  
 Refer patient for rehabilitation and counselling. 
 
 
Table 6.8:  Procedures for health care workers post-MDR-TB treatment 
Step  Action Description 
1  Post treatment 
evaluation 
 Given that aminoglycosides remain in the cochlea 
long after cessation of treatment, patients should be 
monitored for hearing loss  every six months in the 
first year after completion of MDR-TB treatment. 
2  If new onset hearing 
loss is detected 
 Refer to specialist services such as hearing aid fitting 
as appropriate.  
 
6.7 SUMMARY AND CONCLUSIONS 
 
The World Health Organization defines disabling hearing impairment in adults as 
permanent hearing threshold level of 41 decibels or greater. At this level of impairment, 
most people can only distinguish words spoken at one metre if they are spoken in a raised 
voice. Hearing impairment/loss and deafness due to ototoxicity is associated with MDR-TB 
treatment and is generally irreversible but avoidable in some instances within the health 
care system. In the management of MDR-TB, injectable aminoglycosides are the cause of 
hearing impairment from ototoxic damage. Health workers need to be aware of modifiable 
determinants of ototoxicity, which can be derived from the family and medical  history 
including family  susceptibility to hearing loss, socio-demographic characteristics such as  
patient age and general health, current and previous drug exposure characteristics such 
daily drug dosage, duration and route of ototoxic drug administration; length of exposure to 
ototoxic drugs. Awareness about MDR-TB related hearing loss is low, and there are no 
global guidelines for monitoring and prevention of ototoxicity to assist countries with largest 
burden of MDR-TB and burgeoning MDR-TB treatment programs to prevent this type 
hearing loss.  The ―Best practice guidelines for preventing hearing loss in patients on 
treatment for drug resistant tuberculosis in Swaziland provides a comprehensive guide to  
setting up an ototoxicity monitoring program, key outputs of the program and outlines how 
monitoring and prevention activities should be conducted. It includes guidelines for 
assessing patient risks and major determinants of ototoxicity, prior to initiation on TB 
drugs, as well as surveillance during and after treatment.  
The next chapter provides a conclusions, limitations, and recommendations from the study 
to develop the best practice guidelines. 
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CHAPTER 7 
SUMMARY, CONCLUSIONS, LIMITATIONS AND 
RECOMMENDATIONS OF THE STUDY  
 
7.1 INTRODUCTION 
 
This chapter presents the major conclusions of the study, discusses the limitations, and 
suggests recommendations for practice and further research.  The World Health 
Organization defines disabling hearing impairment in adults as a permanent hearing 
threshold level of 41 decibels or greater. At this level of impairment, most people can only 
distinguish words spoken at one metre if spoken in a raised voice. Hearing impairment and 
deafness due to ototoxicity are important and common side effects of DR-TB treatment.  
Hearing loss due to ototoxicity is generally irreversible but avoidable in some instances, 
through prevention and rational use of the ototoxic drugs within the health care system. 
Injectable aminoglycosides are the most common cause of hearing impairment from 
ototoxic damage amongst TB patients. Health workers need to be aware of modifiable 
determinants of ototoxicity, which can be derived from the family and medical  history 
including family  susceptibility to hearing loss, socio-demographic characteristics such as  
patient age and general health, current and previous drug exposure characteristics such 
daily drug dosage, duration and route of ototoxic drug administration; length of exposure to 
ototoxic drugs. There are no global guidelines for monitoring and prevention of ototoxicity 
to assist countries with the largest burdens of DR-TB and burgeoning DR-TB treatment 
programmes. Existing guidelines are largely inadequate and lack explicit clinical guidance. 
 
The conclusions are presented according to the aim and objectives of the study. The 
purpose of the study was to improve monitoring and prevention of hearing loss in MDR-TB 
patients in Swaziland and thereby develop best practice guidelines for monitoring and 
prevention of hearing loss associated with MDR-TB treatment in Swaziland. The best 
practice guidelines would contribute to strengthening institutional capacity towards 
preventing hearing loss among MDR-TB patients by enabling early identification, 
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diagnosis, and mitigation interventions.  The overall aim of the study was to explore and 
determine the incidence of hearing loss, calculate the incidence ratios, determine the 
extent to which HIV influences the incidence of hearing loss, determine the risk factors and 
analyse the time to hearing loss related to MDR-TB treatment. To do this, the following 
primary research questions emerged: 
 
 What is the incidence of hearing loss among drug resistant TB patients receiving 
DR-TB treatment in Swaziland? 
 What are the risk factors for hearing loss associated with DR-TB treatment?  
 How does HIV/AIDS influence the incidence for hearing loss among patients 
receiving DR-TB treatment in Swaziland? 
 What is the mean of hearing loss free survival time and what is the optimal 
frequency for audiology testing for monitoring of patients on DR-TB treatment in 
Swaziland to enable early prompt detection of ototoxicity? 
 How can best practices for monitoring and prevention of MDR-TB treatment related 
hearing loss be developed?  
 
To support exploration of the research questions, this study had five objectives addressed 
as follows. The first objective focused on establishing the incidence of hearing loss among 
drug resistant TB patients receiving DR-TB treatment in Swaziland. Chapters 4 and 5 
presented and discussed the results in detail. The risk factors for hearing loss associated 
with DR-TB treatment in Swaziland were analysed and results presented in Chapters 4 
and 5 in response to objective 2 of the study. Results for objective three, whose focus was 
to  determine the extent to which HIV/AIDS influenced the incidence of SNHL and 
objective 4 which sought to determine the time-to-hearing loss were also presented in 
chapters 4 and 5.  The last objective focused on developing best practice guidelines for 
monitoring and prevention of hearing loss associated with MDR-TB treatment in Swaziland 
and the best practice guidelines are presented in Chapter 6.  
 
Additionally, however, the study also tested two study hypotheses: 
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Study hypothesis 1: 
 
The incidence ratio of sensorineural hearing loss during the intensive phase 
of MDR-TB treatment increases proportionally with the duration of treatment. 
 
Study hypothesis 2 
 
MDR-TB patients living with HIV infection have a higher incidence ratio of 
sensorineural hearing loss than HIV negative MDR-TB patients during the 
intensive phase of MDR-TB treatment. 
 
The results of the hypothesis testing are presented in Chapter 5. 
 
 
7.2 RESEARCH DESIGN AND METHODS 
 
This was a quantitative observational correlational prospective cohort study with a nested 
case-cohort study. The results of the empirical study were used to develop draft best 
practice guidelines, which were presented to key informants, guidelines development 
committee and to stakeholders for validation.  
 
The empirical study was conducted between November 2012 and October 2014 and the 
findings used to answer the research questions posed at the beginning of the study. By 
answering the research questions, the researcher was able to build a local evidence base 
to inform the best practice guidelines the empirical study was conducted in a high HIV and 
TB prevalence setting and the study population consisted of MDR-TB patients attending 
MDR-TB treatment sites for their treatment initiation and monthly treatment follow up. The 
researcher enrolled a cohort of 173 respondents who were followed up until when they 
hearing loss developed, completed 8 months of the intensive phase of DR-TB treatment, 
or were lost to follow up. Data was collected using longitudinal data collection method for 
the monthly measurement of hearing sensitivity using pure tune audiometry and laboratory 
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parameters, analysis and interpretation statistical measures by exposure to HIV and other 
risk factors and characteristics using STATA statistical software. Results were presented 
using tables, graphs (see Chapter 4), and discussed in chapter 5. The Cohort design 
allowed for the determination of incidence; accurate relative risk (risk ratio) estimation; 
inference to the temporal relationship; time-to-event analysis for development of hearing 
impairment; and quantification of risk factor‘s effect on hearing loss and optimised 
information bias through unambiguous identification of study population. 
 
While some existing international guidelines provided recommendations to conduct 
audiometry to monitor hearing loss, no clear guides were provided on the ―how‖ and the 
―who‖. Key evidence for the formulation of the guidelines arose from the summary of the 
literature review and findings of an empirical study conducted by the researcher (2012-
2014).  Stakeholder involvement comprised many separate meetings and platforms to 
present the findings from critical appraisal of the literature and the empirical study and 
enrich the draft. 
 
 
7.3 THEORETICAL MODEL 
 
The study is based on the application of Neuman‘s Systems model. The model provides a 
comprehensive flexible holistic and system based perspective for nursing and health care 
for patients being treated for MDR-TB. Developed by Betty Neuman, the Neuman‘s 
System model is a nursing theory based on following key concepts:  
 
 the client system (which maybe an individual, family group or community); 
 interacting variables of the client system which are the physiological, psychological, 
spiritual, developmental and sociocultural; 
 client‘s response to actual or potential environmental stressors (internal, external 
and created environments), the reaction to it, and reconstitution factors that are 
dynamic in nature (Freese & Lawson 2010; Geib 2010:237).   
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 emphasis on prevention, as intervention for retention, attainment, and maintenance 
of optimal client system wellness; and  
 The purpose of the nurse is to retain of the client system's stability through the three 
levels of prevention.  
 
Primary prevention to protect the normal line and strengthen the flexible line of defence. 
Primary prevention relates to good clinical practice that is applied in client assessment and 
intervention, in identification and reduction of possible or actual risk factors. Secondary 
prevention to strengthen internal lines of resistance, reducing the reaction, and increasing 
resistance factors. Secondary prevention also relates to symptomatology following a 
reaction to stressor, appropriate ranking of intervention priorities and treatment to reduce 
their noxious effects. Tertiary prevention to readapt and stabilise and protect reconstitution 
or return to wellness following treatment. Tertiary prevention also relates to adjusted 
processes taking place as reconstitution begins. 
 
Betty Neuman Systems model provides a comprehensive, flexible, holistic, and system-
based perspective for medical practice including monitoring and prevention of hearing loss 
for patients on MDR-TB treatment. It also provides a structure for critical thinking (an active 
process that guides action). It also guides a framework for the development of 
comprehensive diagnoses, determination of appropriate interventions and evaluation of 
outcomes as part of the nursing diagnosis, treatment goals, and Outcomes. The review of 
the literature revealed the four paradigms of Neumann Systems model. 
 
i) The person is viewed the human being as well as a total person, as a client system, 
and the person is a layered multidimensional being physiological (physicochemical 
structure and function of the body); psychological (has mental processes and 
emotions); has relationships and social/cultural expectations and activities; has 
spiritual beliefs and undergoes processes related to development over the lifespan. 
ii) The environment: the model considers the environment with the totality of the 
internal and external forces (intrapersonal, interpersonal, and extra-personal 
stressors) which surround a person and with which they interact at any given time). 
 
 
248 
 
iii) Health, whereby the model equates health to wellness where the condition in which 
all parts and subparts (variables) are in harmony with the whole of the client and the 
client system moves toward illness and death when more energy is needed than is 
available;  
iv) Medical practice/nursing- giving a unique profession that is concerned with all of the 
variables, which influence the response a person might have to a stressor, a person 
is seen as a whole, and it is the task of nursing to address the whole person. The 
expected actions are those that will assist individuals, families and groups to 
maintain a maximum level of wellness, and the primary aim is stability of the 
patient/client system, through nursing interventions to reduce stressors by the use 
of primary, secondary, and tertiary interventions. 
 
7.4 SUMMARY AND INTERPRETATION OF RESEARCH FINDINGS 
 
The findings of the study from the two phases are summarised and presented according to 
the study objectives. 
 
7.4.1 Establish the incidence of hearing loss among drug resistant TB 
patients receiving DR-TB treatment in Swaziland  
 
The study revealed that sixty-percent of the patients developed high frequency hearing 
loss. The incidence rate among the HIV positive patients was 4.2/1 000 person days (CI: 
3.4-5.3) and for HIV negative patients, 3.6/1 000 person days (CI: 2.4-5.7). The incidence 
is similar to Botswana (62%) and South Africa (47%).  
 
7.4.2 Determine the risk factors for hearing loss associated with DR-TB 
treatment 
 
The study validated findings by Wu and others who have also shown that HIV prevalence, 
and length of treatment were not significant factors for hearing loss (Wu et al 2013).  
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7.4.3 Determine the extent to which HIV/AIDS influenced the incidence of 
hearing loss related to MDR-TB treatment in Swaziland 
 
The study found that HIV infection was not an independent risk factor for hearing loss in 
MDR-TB patients. However, use of certain ARVs especially Abacavir containing regimens 
predisposed an individual to a higher odd of hearing loss. 
 
7.4.4 Determine the optimal frequency for audiology testing for monitoring of 
patients on DR-TB treatment in Swaziland  
 
This is the first prospective study to date to examine meticulously the time it takes for 
persons on MDR-TB treatment to develop hearing loss. We found that the median time to 
high frequency hearing loss was 84 days with a range from 54.5 days to 147 days. The 
respondents were followed up at 22,032 person days.  
 
7.4.5 Develop best practice guidelines for the monitoring and prevention of 
hearing loss related to MDR-TB treatment 
 
These best practice guidelines are expected to assist in decision-making during clinical 
management of patients, and policy planning and key objectives of the best practice 
guideline are to:  
 
1. To raise awareness of the adverse effects of ototoxic MDR-TB drugs to enable early 
detection and prevention of SNHL; 
2. To facilitate early identification, diagnosis and treatment of hearing loss and 
deafness among TB patients as a result of ototoxicity; 
3. To strengthen institutional capacity towards preventing SNHL deafness and hearing 
loss among MDR-TB patients; 
4. To provide guidelines for rehabilitation and psychosocial support to affected 
patients; 
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The best practice guidelines were grouped into three thematic areas: 
 
 Guidelines for prevention, treatment, and management of hearing loss comprising 
establishing an ototoxicity-monitoring programme. Involving all health care workers, 
health care administrators with clears and delineated roles assessing risk factors to 
hearing loss prior to exposure to second-line anti-TB medications. And a system for 
monitoring of ototoxicity through pharmacovigilance protocols and tools.   
 
 Guidelines for procedures to be conducted by health care providers encompassing 
baseline audiometry conducted prior to initiating treatment, or within 72 hours of the 
first dose of an aminoglycoside or polypeptide antibiotic, addressing all modifiable 
risk factors for hearing impairment (dehydration, renal insufficiency, dyspnoea, and 
fever) their correction prior to administration of aminoglycosides or polypeptide 
antibiotics, scheduling  audiometry 
 
 Guidelines for Documentation and Record Keeping encompasses guidelines for 
training in documentation and record keeping of adverse drug reactions. 
 
 Guidelines for Public Health Actions which encompasses Guidelines for 
communication strategy and public education for the public, professional education 
and training health care workers as well as and engagement of policy makers for 
appropriate regulatory and legislation framework  
 
Hypothesis testing 
 
The study failed to reject both hypothesis stated at the beginning of study. 
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7.5 CONCLUSIONS 
 
The study found a very high incidence of hearing loss associated with MDR-TB treatment.  
It also highlighted modifiable and non-modifiable risk factors for DR TB treatment related 
sensorineural hearing loss, as follows on univariate and bivariate analysis.  
 
 being  of male gender (p value =0.033),  
 poor baseline hydration status  at the start of MDR-TB treatment (p value =0.012),  
 use of Abacavir as backbone in the ART regimen in MDR-TB (p value =0.017),   
and  
 low of <8 g/dl baseline HB (p value <0.001), low BMI (p value =0.003), presence of 
dyspnoea at the start of treatment (p value < 0.001 ) were found to be risk factors 
for high frequency hearing loss. 
 
On multivariate analysis, and after controlling for confounders the following variables 
showed a very high hazard rates:  
 
i) compared to agriculture as a day-to-day employment, the hazard ratio of high 
frequency hearing loss was 4.2 times in the Miners/machine Operators and 
Sound Industry (HR: 5.4, CI 1.2-24.03, p value =0.024); 
ii) Patients who had dyspnoea at initiation of MDR-TB treatment were 3.4 times 
likely to develop high frequency hearing loss (HR: 3.4, CI 1.8-6.3, p value 
=0.000) and  
iii) Low baseline haemoglobin was a risk factor for hearing loss (p value<0.01). 
Patients with HB 8-11 g/dl and those with HB less than 8g/dl were 2 times and 
8.5 times respectively more likely to develop hearing loss compared to those 
with HB above 11g/dl (p value <0.01).   
iv) The median time to hearing loss was 84 days (IQR 54.5 -147)  
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7.6 RECOMMENDATIONS 
 
Based on the results of the study, the following recommendations are presented: 
 
 There is a need for the establishment of string pharmacovigilance systems to 
document and quantify all drug induced adverse events. The MDR‐TB best practice 
guidelines therefore recommend careful and systematic monitoring of patients to 
help prevention as much possible hearing loss as a result of ototoxicity. Monitoring 
should include comprehensive patient assessment of risks and major determinants 
of ototoxicity, before they are initiated on the drugs, surveillance of proper dosage 
and duration, as well as assessment of symptoms.  Wherever possible, audiometry 
should be carried out periodically for high risk TB patients. 
 
 .Adoption and effective utilisation of the best practice guidelines in Swaziland, which 
then is expected to generate the following benefits: 
 
1. Availability of local community-based and national centralized services for 
prevention, early identification, treatment, referral and rehabilitation for MDR-
TB treatment-related SNHL and deafness  
2. Reduction in the incidence, severity and extent of MDR-TB-related hearing 
impairment. 
3. Improved service network and referral system  
4. Increased awareness of ototoxic MDR-TB drug side effects among health 
workers, including how to detect, manage and prevent them 
5. Increased capacity of health workers to improve the quality of care for 
affected patients.   
 
 Training and capacity building of health workers on the rational use of ototoxic 
drugs among TB patients remains critical to prevent the inappropriate and in 
discriminatory use of these drug by health workers managing TB patients. This 
 
 
253 
 
training should be given continuously as part of their continued professional 
development. 
 The public should be made aware of the adverse effects and potential damage 
some TB drugs may have on their hearing to help them report any effects that could 
be noticed among TB patients. Production of education materials with a clear 
message would go a long way in acquainting the public on the hazards of ototoxic 
drugs among TB patients. 
 
 Investments in need technology for alleviating loss is urgent.  Exciting possibilities 
have been report in Nature through the use of stem cell and gene therapy and the 
possibility that auditory function can be restored or at least maintained reveals the 
need for more research in this area (Muller & Barr-Gillespie 2015). 
 
 New drugs that are safe and of a shorter duration are also urgently required. 
However in the meantime, national governments should strongly consider the use of 
new and repurposed drugs that have less impact on hearing to be utilised for 
patients with risk factors that cannot be modified.  The notion of use of the 
repurposed drugs may provide hope for the multitudes in dare need of MDR-TB 
treatment but without its ADRs such as irreversible hearing loss. 
 
 Given the inadequate accessibility to audiometry screening in low resource settings, 
mobile devices such as smart phones can be used for initial screening of hearing 
loss` prior to referral to hearing sensitivity testing centres.  
 
Further research is required into the following areas: 
 
 Linkage between ototoxicity and vestibulotoxicity; 
 Impact of an ototoxicity programme on the reduction in the incidence of hearing 
loss; 
 Experiences and needs of patients experiencing hearing loss; 
 Effectiveness of an assisted hearing programme for MDR-TB patients; 
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 Perceptions of family members on hearing loss in family members experiencing 
hearing loss and their role as hearing relatives in promoting communication; 
 Impact of newer drugs with less ototoxic effects and the repurposed drugs on 
hearing loss. 
 
7.7 CONTRIBUTIONS OF THE STUDY 
 
The key contributions of the study can be summarised as: generation of local evidence, 
sensitisation of clinicians, policy makers and managers about hearing loss, development of 
best practice guidelines that have been adopted from the MOH, policy advocacy and 
identification of areas for further research. 
 
This study was conducted at a time when the rate of MDR-TB is increasing in Swaziland, 
and globally, at alarming rates and the threat of further resistance projected unless several 
interventions to control the epidemic were put in place, including development of new and 
safer drugs. The rapid scale-up of current treatments is associated hearing loss related to 
MDR-TB and the increasing interest in the area reveals that hearing loss is more 
widespread than previously thought. Moreover, while tuberculosis itself is a cause, 
sometimes it has catastrophic financial consequences to individuals and families. Patients 
and families need protection against the additional potential catastrophic psycho-
socioeconomic impact of adult onset hearing loss through better monitoring and prevention 
strategies, and assisted hearing technologies as part of the MDR-TB treatment package. 
Raising awareness about this required generation of local evidence. It must be pointed out 
that the study generated new data to fill specific knowledge on hearing loss associated 
with MDR-TB treatment. Beyond raising awareness and sensitisation of health cares for 
engagement, the knowledge generated has many other potential applications such 
advocacy for enabling policies and resources, exposing need gaps in knowledge and 
hence the identification of further areas of research and the development of guidelines, 
protocols and job aides for health care workers. The findings can also be used as a 
motivation tool for health care workers‘ engagement in the monitoring of patients for 
hearing loss and in the provision of timely intervention to avert the potential psychological, 
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physical, social and economic consequences of hearing loss. Loss of hearing is a silent, 
destructive condition that contributes to immense human suffering and globally is a huge 
contributor to years lived with disability.   
 
The possible implications of the study include the following: 
 
 Improving Clinical Practice, Patient care and Quality of life. According to the 
Institute of Medicine, clinical practice guidelines are defined as ―…statements that 
include recommendations, intended to optimise patient care, that are informed by a 
systematic review of evidence and an assessment of the benefits and harms of 
alternative care options‖.  Accordingly, guidelines have two parts: i) a systematic 
review of the existing evidence from studies, in response to a clinical question in 
mind, considering the strength of the evidence on which clinical decision-making for 
that condition is based as the basis of the guideline. And ii), a set of 
recommendations, involving both the evidence and value judgments regarding 
benefits and harms of alternative care options, addressing how patients with that 
condition should be managed, everything else being equal (Consensus report, 
institute of medicine. Clinical practice guidelines we can trust. March 23, 2011, 
2011). This study contributes to the call made by Sturdy and others, who have 
studied hearing loss and anti-MDR-TB treatments,  for better clinical data to inform 
guidelines for monitoring hearing loss related to MDR-TB treatment (Sturdy et al 
2011). The study also translates the evidence into practice guidelines in line with 
what Davies et al (2008:29), Dulko (2007:29), Herdeiro, Polonia et al (2004:483-9), 
Ploeg, Davies, et al (2007:2010-9) and Tanenbaum (2005:163-73) have posited that 
the goal of research evidence is to change the practitioners‘ behaviour by bridging 
the distance from research to practice and securing a central place for research in 
the consulting room. The results of the study demonstrate a high burden of hearing 
loss among MDR-TB patients is Swaziland. While there is no difference in the 
incidence of hearing loss between HIV negative and HIV positive patients, the study 
time-to-event analysis shows that HIV positive patients develop hearing loss sooner 
than the negative counter parts. There is need for more aggressive monitoring in 
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people living with HIV for hearing sensitivity, but this needs to be preceded with 
otologic and tympanometric examinations to rule out other middle ear conditions 
that are associated with HIV.  Given a lack of guidelines, this leads to unregulated 
practice and missed opportunities for better patient care. As a product of the study, 
best practices have been developed, and thus provide a basis for implementing 
standardised monitoring practices to improve quality of patient care and minimise 
variations in service delivery. 
 Raising awareness on the need for pharmacovigilance system for all adverse drug 
reactions:  The study provides evidence of the big problem facing patients on MDR-
TB treatment in Swaziland and the need to urgently institute measures for 
pharmacovigilance. WHO has recommended implementation of pharmacovigilance 
by all countries but this has lagged behind in Swaziland (World Health Organization 
2011c). The results of the study were used to sensitise stakeholders on hearing loss 
monitoring and need for pharmacovigilance. Renewal of interest in 
pharmacovigilance is a critical contribution of the study and the potential result is 
envisaged as imparting positive attitude of managers towards availing of resources 
and tools for monitoring all the ADRs related to MDR-TB treatment.  
 Awareness of the need to provide Counselling and support to patients and families 
The study corroborates the findings by Groce and others that the deaf in Swaziland 
face communication problems with health care workers and are more likely to be 
misinformed about HIV prevention measures. Therefore, for families of the people 
with hearing loss, sign language and communication skills for patients and 
significant others needs to be taught. Collaboration with sign language 
organisations to train staff at the MDR-TB treatment sites becomes an essential 
package of the community linkages component of MDR-TB care.  
 Guidance to Policy makers and health planners: This research documents the 
quantifiable outcomes of a standardised intervention and enables evidence based 
planning and a basis for construction of a hearing health policy for MDR-TB 
patients. Policy makers and health planners will be able to use the evidence to 
create an enabling environment for early intervention and data for planning 
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procurement hearing aid services/ assisted listening devices, rehabilitation and 
reintegration of cases of hearing impairment and family counselling and education.  
 
7.8 STUDY LIMITATIONS 
 
Data in a longitudinal study is more likely to be incomplete and of poorer quality because 
of the frequency of loss to follow up and missing data. In this study, although it was the 
doctors and patients made decisions on the next appointment, appoint schedules were 
tracked by the study team. Sometimes the treatment follow-up appointment dates and the 
audiology follow-up appointment conflicted. To avert any potential threat to the validity of 
the study strategies to ensure adequate follow up for audiometry appointments were 
devised. Follow up was done telephonically through short text messages (sms) or voice 
reminders and transport re-imbursements were made follow up reminders. 
 
The findings in this study are representative of incidence of hearing loss for the 8 months 
when patients were on the intensive phase of treatment during which, aminoglycoside 
antibiotics are a key medicine. Some studies shown evidence of progressive ototoxic 
effects even after the stoppage of the offending drug (Seddon , Thee , Jacobs , Ebrahim , 
Hesseling &Schaaf, 2013a). The eight months follow up period however, represents the 
current WHO recommended duration for injectable aminoglycosides.  The findings from 
this study, therefore, cannot, be extrapolated for the entire MDR-TB treatment period of 24 
months. 
 
In order to determine the incidence of hearing loss, repeated audiometry testing of 
respondents over time was conducted. Repeated measures can also lead to confounding 
due to learning effects. The audiology team was aware of this and hence exercise extra 
caution. Where indicated, non-behavioural testing methods using of ABR studies were 
conducted to negate this effect.  
 
One of the main weaknesses for observational studies is confounding and measures were 
undertaken to minimise consequences of confounding. . Given that the researcher does 
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not allocate exposure there is always a possibility that known and unknown potential 
confounders that influence outcome and hence lead to bias. Therefore, in this study, a 
priori identification of potential confounders was done and unknown confounders dealt with 
immediately they were discovered, during the data collection or analysis. Techniques such 
as restriction of participation in the study and stratified analysis within strata of the 
cofounding variables (for example age) were used.. 
 
Despite the limitations, the findings from the study are reliable and valid 
 
7.9 CONCLUDING REMARKS 
 
According to the WHO, multidrug resistant tuberculosis MDR-TB is a global health security 
risk and carries grave consequences for those affected and WHO therefore called for 
MDR-TB to be addressed as a public health crisis in 2013.  Prevention of MDR-TB is the 
first priority, while scaling up rapid testing, detection of all MDR-TB cases and prompt 
access to appropriate MDR-TB care and preventing transmission of MDR-TB through 
appropriate infection control are the next priorities.  Currently use of ototoxic medications 
in the treatment regimens adversely affects quality of life of patients during treatment and 
in the post treatment period and associated mortality due to poor adherence to MDR-TB 
treatment.  
 
Hearing loss remains an invisible and unrecognised public health issue with grave social, 
psychological, and economic consequences.  Currently, guidelines for early detection and 
management to halt further deterioration of hearing sensitivity for patients on MDR-TB 
treatment in the low and middle-income countries that bear the greatest brunt of MDR-TB 
to deal are lacking. Existing guidelines are largely inadequate and clinicians do not give 
adequate guidance on what to do when and how. While the best practice guidelines 
developed in this study will go a long way in assisting health care workers in Swaziland 
improve practice in dealing with hearing health of MDR-TB patients, the ultimate goal 
should be replacing the aminoglycosides in the MDR-TB regimen. In the meantime, 
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advocacy should be stepped up for the use new and repurposed drugs like Bedaquline 
and Delaminad for treating patients at high risk for MDR-TB treatment related hearing loss. 
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ANNEXURE B 
ANNEXURE B1: QUESTIONNAIRE 1: GENERAL QUESTIONAIRE 
BEST PRACTICE GUIDELINES TO MONITOR AND PREVENT DRUG RESISTANT TUBERCULOSIS 
TREATMENT RELATED HEARING IMPAIRMENT 
Respondent’s Number……………..  ..Date………………………………. Treatment 
facility…………………..  
Office Use 
 
SECTION A: RESPONDENT’S DEMOGRAPHIC CHARACTERISTICS  
 
Please indicate the appropriate option in the shaded box adjacent to the option  
1. Age(at last birthday)   
15-19 years 1 
20-24 years 2 
25-29 years 3 
30-34 years 4 
35-39 years 5 
40-44 years 6 
45-49 years 7 
50-54 years 8 
55-59 years 9 
60-64 years 10 
65+ 11 
 
2. Gender  
Male=1  Female=2  
 
3. Nationality and Race  
Swazi: Black of African 1 Swazi: Caucasian/White 2 Other Nationality: Black 
of African 
3 
Other nationality: 
Caucasian/White 
4 Other Nationality: other 
race than any of above 
   
         
4. Region  
Hhohho 1 Manzini 2 
Lubombo 3 Shiselweni 4 
Does not know 5   
Respondent’s Number……………..  .. Treatment facility…………………..  
         
 3 
 
5. Highest level of education  
No Education 1 Some Primary school 2 
Completed Primary school (7th 
Grade) 
3 Some Secondary School 4 
Completed secondary school (5th 
Grade) 
5 Tertiary education 6 
Do not know/ missing  99    
 
6. Employment Status  
Currently employed (did work in past 1 month: includes those on leave, sickness, 
regularly employed 
1 
Not employed in the last 12 months 2 
Not employed for more than 12 months 3 
Minor (Child) 4 
Does not know 99 
 
 
7. Profession  
Professional/Technical/Managerial 1 Clerical 2 
Sales and services 3 Skilled Manual 4 
Unskilled manual 5 Mining/ machine operator 6 
Sound technician/music industry 7 Agriculture 8 
Others 9   
         
8. Marital Status  
Never married 1 Married 2 Living together 3 
Divorced/separated 4 Widowed    
 
9. Religious affiliation   
Protestant/Anglican 1 Roman Catholic 2 Charismatic 3 
Pentecostal  4 Apostolic 5 Methodist 6 
Seventh Adventist 7 Zionist church 8 None 9 
Other  10     
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Respondent’s Number……………..  .. Treatment facility…………………..  
SECTION B: Treatment       
HISTORY OF TREATMENT FOR PREVIOUS TB DISEASE 
10.  Has the patient ever received medication for TB disease in the past?      
0 No 1 Yes    99 Unknown (If no, skip to #13)                                              
11. If the patient was treated for TB please indicate date and type of Tuberculosis 
the patient was treated for during first episode of tuberculosis:   
                       11 a) Date: -- 
              11b) Type: 1Drug susceptible TB (New); 2Drug susceptible TB (Retreatment/ 
previously treated); 3Drug Resistant TB                                                                                    
If the patient was treated for TB more than once in the past, please 
indicate date and type of Tuberculosis the patient was treated for during second 
episode of tuberculosis:   
                       11 c) Date: -- 
              11d) Type: 1Drug susceptible TB (New); 2Drug susceptible TB (Retreatment/ 
previously treated); 3Drug Resistant TB                                                                                          
 
 
12. Was patient ever treated with streptomycin during any of the previous 
episode(s) of tuberculosis treatment?  0 No   1 Yes                                                                             
 
13. Please indicate when TB treatment with streptomycin started and for how long:          
Streptomycin start          --      Duration of Streptomycin:   1 One month or 
less; 2 between one and Two months inclusive; 3 More than 2 months             
CLINICAL SYMPTOMS AT MDR-TB DIAGNOSIS 
 
14. At the time of diagnosis of Drug Resistant, please indicate which of the 
following symptoms where present 
  1. High-grade fever ( 38.0 C)        0 No   1 Yes  9.     Diarrhea   0 No   1 Yes  10q.  
  2. Low-grade fever (37.0 - 37.9 C)  0 No   1 Yes  10.   Loss of appetite   0 No   1 Yes          
  3. Sweats                                          0 No   1 Yes  11.  Nausea/vomiting  0 No   1 Yes          
  4. Dry cough                                     0 No   1 Yes  12.   Visual problems   0 No   1 Yes          
  5. Productive cough                          0 No   1 Yes  13.   Dyspnea           0 No   1 Yes          
  6.  Blood spitting                                0 No   1 Yes  14.  Headache            0 No   1 Yes          
  7. Chest pain                                    0 No   1 Yes   15.  Hearing loss         0 No   1 Yes          
  8.  Weakness                                   0 No   1 Yes   16.   Weight loss           0 No   1 Yes     
Respondent’s Number……………..  .. Treatment facility…………………..  
   
17. Thirsty and Drinking a lot of water   0 No   1 Yes     18.   Other (specify)……… 0 No   1 Yes 
  19   Other (specify)……… ………0 No   1 Yes    20.   Other (specify)……… 0 No   1 Yes 
14b. At the time of diagnosis of Drug Resistant, please indicate if this was confirmed or presumed 
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DR-TB:                                                                                                                                                
1Presumed MDR-TB 2 Confirmed DR-TB                                                                          
14C. At the time of bacteriological confirmation of Drug Resistant TB, please indicate if the Drug 
susceptibility testing (DST) indicated revealed the following confirmation of DST:                     
1Isoniazid Mono-Resistant DR-TB (IMR) 2 Rifampicin Mono-Resistant DR-TB (RMR)  
3Isoniazid &Rifampicin Resistant DR-TB (MDR) 4 Second Line Resistant (either FLQ or SL 
Aminoglycoside DR-TB (Pre-XDR)  
 
 
 
HIV SEROLOGY RESULTS AT INITIAL DIAGNOSIS OF THIS TB EPISODE 
15.  HIV test results              0  Negative     1  Positive                                                     
                                                                                            99  Not taken    
16. Date of HIV test at initial diagnosis of this episode:   -- dd-mm-yyyy                                   
Date Unknown  
 16a. Absolute CD4 count                                                                                    
              
                                                                       1 < 200   
                                                                 2    200-500     3 > 500 
                                    4    Not taken (if not taken, tick & skip to #24c)      
                                                                 
             16c.   The date of absolute CD4 count --       Unknown 
                                                                                d  d      m   m     y    y    y    y 
             16d. Is the patient currently taking HIV treatment?       1   No treatment                
                                                                                                    2   Antiretroviral therapy                                                                                                    
                                                                                                    99   Unknown 
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17. MDR-TB TREATMENT REGIMEN: 
K C A S Ehtio PAS Cs Ter   
 
18. Date when the current DR-TB treatment regimen prescribed (DATE of THIS MDR REGIMEN):            
-- 
                                                                                                                                                                     d  d   m  m   y  y  y  y                                                                                        
  
19. Date when drugs were received and patient started treatment (START DATE of THIS MDR 
REGIMEN):            -- d  d   m  m   y  y  y  y                                                                                                                                                                              
 
 A. Drug B. Status C. Start Date            D.  Frequency  
of dose (#days/wk)    
E.  Dose (mgs) 
1 KANAMYCIN   0 No   1 
Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
2 CAPREOMYCIN 0 No   1 
Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
3 AMIKACIN 0 No   1 
Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
4 ETHIONAMIDE 0 No   1 
Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
5 CYCLOSERINE 0 No   1 
Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
6 TERIZDONE 0 No   1 
Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
7 LEVOFLOXACIN 0 No   1 
Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
8 PAS 0 No   1 
Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
9 PYRAZINAMIDE 0 No   1 
Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
10 Other 1: If other, 
please specify 
 -- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
11 Other 2: If other, 
please specify 
 -- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
                                                        
 
20.  Duration on the MDR-TB 
injectable drug at baseline 
evaluation 
 
Pretreatment 1 Treatment  < 72 hours 2 Treatment 4-7 days 3 
Treatment 8-14 days 4 Treatment  15-21 days 5 Treatment 22-28 days 6 
Other (specify) 7     
      
21. Duration on the MDR-TB injectable drug at Follow up evaluation (see follow up sheet) 
Section C: Medical History 
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21. Does you suffer from (ever been diagnosed) any of the following conditions? 
Condition Status Duration of 
condition 
Treatment 
 
Duration on 
treatment 
  Mont
hs 
Year
s 
 weeks Mon
ths 
Year
s 
1 High blood pressure  0 No   1 Yes           0 No   1 Yes             
2 Diabetes Mellitus 0 No   1 Yes           0 No   1 Yes             
3 Cardiovascular 
disease 
0 No   1 Yes           0 No   1 Yes             
4 Renal  disease 0 No   1 Yes           0 No   1 Yes             
5 HIV/AIDS 0 No   1 Yes           0 No   1 Yes             
6 Cancer(specify) 0 No   1 Yes           0 No   1 Yes             
7 Persistent fever 0 No   1 Yes           0 No   1 Yes             
8 Kaposi Sarcoma 0 No   1 Yes           0 No   1 Yes             
9 Hepatic disease                       0 No   1 Yes           0 No   1 Yes             
1
0 
Silicosis    0 No   1 Yes           0 No   1 Yes             
1
1 
Other 0 No  1 
Yes          
  0 No   1 Yes             
1
2 
Other 0 No  1 
Yes          
  0 No   1 Yes             
1
3 
Other 0 No  1 
Yes          
  0 No   1 Yes             
 
22. Are you currently using or used the following medications in the last 2 
weeks for treatment of any of the above conditions? 
 B. Drug B. Status C. Start Date            D.  Frequency  
of dose (#days/wk)    
E.  Dose (mgs) 
1 Furosemide 
(oral)   
0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
2 Furosemide 
(Inj) 
0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
3 erythromycin 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
4 Clarithromycin 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
5 Azithromycin 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
6 Paracetamol 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
7 Aspirin        0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
8 Insulin 0 No   -- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
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1 Yes          
9 Oral 
hypoglycaemics  
0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
10 Other 1 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
11 Other 2 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
 
 
Respondent’s Number……………..  
 
23. Kaposi Sarcoma Treatment 0 No   1 Yes    Start Date --      
                                                                                                  
 
 C. Drug B. Status C. Start Date            D.  Frequency  
of dose (#days/wk)    
E.  Dose 
(mgs) 
1 Kaposi Sarcoma 
Treatment 
0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
2 Doxorubicin 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
3 Daunorubicin 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
4 Bleomycin 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
5 Vinblastine 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
6 Vincristine 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
7 Other 1 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
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24.  ARV  Treatment 0 No   1 Yes     Start Date --      
 
 A. Drug B. Status C. Start Date            D.  Frequency  
of dose (#days/wk)    
E.  Dose (mgs) 
1 AZIDOVUDINE 
(AZT) 
0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
2 TENOFOVIR 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
3 3TC 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
4 STAVUDINE 
(D4T) 
0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
5 NEVIRAPINE 
(NVP) 
0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
6 NEVIRAPINE 
(NVP) PMTCT 
0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
7 EFERVIRENZ 
(EFV) 
0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
8 OTHER 1 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
9 OTHER 2 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
10 OTHER 3 0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
11 EFERVIRENZ 
(EFV) 
0 No   
1 Yes          
-- 
dd -   mm -   yyyy                                                                      
7 D 5 5  3 3        . 
 
25. Any  ear infections/ disease  
Childhood 1 Adolescent 2 Adult 3 
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Section C Life Style and Physical parameters 
26. Do you smoke?   
Current (even if stopped within last 6 months) 1 
Previous( stopped at least 6 months ago) 2 
Never smoked 3 
27. For current smoker, how many  sticks do you smoke per 
day 
 
<2 per day 1 
3-15 per day 2 
>15 per day 3 
28.  Do you drink alcohol?   
Current (even if stopped within  last 6 months) 1 
Previous (stopped at least 6 months ago) 2 
Never drunk 3 
29. From question 22, if  current drinkers indicate drinks per 
week 
 
<7 per week 1 
8-14 per week 2 
>15 per week 3 
30. Please indicate how much water and Fluids you take per day(minus alcohol)  
Less than 500ml per day 1 501-1000ml per day 2 
1001-2000ml per day 3 2001-3000ml per day 4 
3001-4000ml per day 5 4001-5000ml per day 6 
5000+ ml per day 7   
31. Please indicate commonest  source of the fluids you take   
Water  1 
Juice  2 
Bottled beverages 3 
32. Please indicate level of physical exercise you are engaged in  
Yes regularly exercise > 2 times weekly 1 
Yes at least Once a  week 2 
Occasionally exercise at least Once a month 3 
Less than once a month/None 4 
Other (specify) 5 
33. Are you exposed to noise of more than 1 hour at work or leisure activities     
Yes, at work 1 
Yes, during leisure 2 
Not applicable 3 
34. Biometry and Physical parameters      
    
  
DATE 
-
-  
WEIGH
T (Kg) 
HEIGHT (m
2) 
(children at 
follow up) 
Body 
TEMP 
(
0
C) 
BMI 
(Weight/Height
2 
) 
BLOOD 
PRESSURE 
(Systolic/diastoli
c) mmHg 
HYDRATIO
N STATUS 
(Normal) 
Audiometry 
summary 
Baselin
e 
Values 
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ANNEXURE B 2 
 
QUESTIONNAIRE 2: HEARING LOSS SCREEN AND AUDIOLOGICAL TESTING 
QUESTIONNAIRE 
 BEST PRACTICE GUIDELINES TO MONITOR AND PREVENT DRUG RESISTANT 
TUBERCULOSIS TREATMENT RELATED HEARING IMPAIRMENT 
Respondent‘s Number……………..  
 Date……………………………….. 
 Office Use 
            
# ____________________________________   Date: 
_____________________       
Date of Birth   Age  Gender M_____ F______ 
      
Examiner ____________________________________________  
 Date of Calibration        
            
  Self-Assessment of Communication for Prevalent Hearing loss   
        
Please respond by circling the appropriate number ranging from 1 to 5, for the following 
questions. If you have a hearing aid, please fill out the form according to how you 
communicate when aid is not in use.         
1 = almost never (or never); 2 = occasionally (about one-quarter of the time); 3 = about half 
of the time; 4 = frequently (about three-quarters of the time); 5 = practically always (or 
always).            
Various Communication Situations  
1. Do you experience communication difficulties in situations when speaking with one other 
person? (For example:       
at home, at work, in a social situation, with a waitress, a store clerk, a boss, etc.)  
         
1 2 3 4 5        Q 1=    
    
2. Do you experience communication difficulties in situations when conversing with a small 
group of several persons? (For example: with friends or family, co-workers, in meetings or 
casual conversations, over dinner, or while playing cards, etc.).    
        
1 2 3 4 5        Q2=    
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3. Do you experience communication difficulties while listening to someone speak to a large 
group? (For example, at church or in a civic meeting, in a fraternal or women's club, at an 
educational lecture, etc.)          
1 2 3 4 5        Q3=    
   
4. Do you experience communication difficulties while participating in various types of 
entertainment? (For example: TV, radio, plays, night clubs, musical entertainment, etc.) 
           
1 2 3 4 5        Q4=    
    
5. Do you experience communication difficulties when you are in an unfavorable listening 
environment? (For example:  at a noisy party, where there is background music, when riding 
in an auto or a bus, when someone whispers or talk from across the room, etc.)  
      
  1 2 3 4 5                                                                                                       Q5=  
6. Do you experience communication difficulties when using or listening to various 
communication devices? (For  example: telephone, telephone ring, doorbell, public address 
system, warning signals, alarms, etc.)       
  
1 2 3 4 5        Q6=    
    
Feelings about Communication 
 
7. Do you feel that any difficulty with your hearing limits or hampers your personal or social 
life?         
1 2 3 4 5        Q7=    
    
8. Does any problem or difficulty with your hearing upset you?    
        
1 2 3 4 5        Q8=    
    
Other People 
9. Do others suggest that you have a hearing problem?     
       
1 2 3 4 5        Q9=     
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10. Do others leave you out of conversations or become annoyed because of your hearing?
          
1 2 3 4 5        Q10=    
            
      
11. Raw Score __________(total of circled numbers; normal range: 10–18)  
                                                                                      Q11=   
    
Score Interpretation (Schow, Smedley, & Longhurst, 1990):     
       
Raw score Handicap range _____________________     
        
10–18 Normal-no handicap _____________________     
        
19–26 Slight handicap ______________________     
         
27–38 Mild-moderate handicap __________________    
        
39–50 Severe handicap  __________________    
       
          
Case History- Circle most appropriate 
12. Do you think you have hearing loss?      Yes No
      
13. Have hearing aids ever been recommended for you    Yes No
      
14. Is you hearing better in one ear       Yes No
      
 If yes, which ear   Right          Left   
       
15. Have you ever had sudden deterioration in hearing    Yes No
      
16. Do you have ringing or noises in the ears     Yes No
      
17. Do you consider diuzzines to be a problem     Yes No
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18. Have you had recent drainage from your ears     Yes No
      
 If yes, which ear   Right                              Left   
       
19. Do you have pain or discomfort in your ears    Yes No 
     
20. Have you ever received medical consultation for any ear related problems?  
  Yes No      
             
Visual/otoscopic examination 
        
21. Otoscopic examination (baseline)       
      
1 External appearance of the pinna                     Tick (add comments if necessary) 
 Normal, 
              Malformations,  
              Inflamed          
   
2 External auditory meatus  
                              Normal   
                               Inflamed          
    
  Occluding Wax         
     
  Foreign body          
    
  Pus discharge          
    
  Other (specified)         
     
3 Appearance of tympanic membrane 
                     Normal          
   
  Dull            
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  Opacified          
    
  Retracted,          
    
  Bulging          
   
  Redden          
    
  Air-fluid level          
    
  Scarred          
    
  Perforated          
    
4 Tympanic membrane light reflex  
               Present          
    
  Absence          
    
  Deranged          
    
5 Status of media ear (if OM perforated)  
               Normal          
    
  Inflamed          
    
  Discharge present         
     
  other           
   
         
22. a) Refer for cerumen management __________________________ 
b) Refer for medical Management_____________________________ 
            
   
23. Screening Pure Tone Screen (25dB HL) (R=Response; NR=No Response) 
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Frequency   1000  2000  4000    
    
Right Ear              
    
Left Ear              
    
Hearing Disability  Preesent? (tick one)      Yes No
      
        
24. Type of Hearing impairment                                                                                           
         
 Sensorial 1         
    
 Conductive 2         
    
 Mixed          3         
    
 Other (Specify)          
     
            
         
25. Further Action: (Tick as appropriate)                                 Yes       No
      
 Medical Examination                       Yes No
      
 Cerumen Management       Yes No
      
 Counsel                                   Yes No
      
 Audiologic evaluation                      Yes No
      
 Include in the study cohort       Yes No
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26. See audiogram for summary of the results from audiometry testing 
 
27. Hearing status                                                                        Q27=   
            
0-25 dB= Normal hearing;         
       
      
26-40 dB= Slight hearing loss;        
       
         
41-60 dB =Moderate hearing loss;        
        
            
     
60-80 dB = severe hearing loss;        
       
            
   
        
81+ dB =Profound hearing loss.        
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Follow up sheet: Respondents #............................; Health Facility…………………………………………………. 
1. Please indicate date of the follow Biometric and audiometric findings.   
 Follow 
Up # 
DATE 
- -  
WEIGHT 
(Kg) 
HEIGHT (m
2) 
(children 
at follow up) 
Body TEMP 
(
0
C) 
BMI 
(Weight/Height
2 
) 
BLOD PRESSURE 
(Systolic/diastolic) 
mmHg 
HYDRATION 
STATUS 
(Normal) 
Audiometry 
summary 
1         
2                
3                
4                
5                
6                
7         
8         
9         
10         
11         
12         
13  
 
      14  
 
      
 2 
 
 Follow 
Up # 
DATE 
- -  
WEIGHT 
(Kg) 
HEIGHT (m
2) 
(children 
at follow up) 
Body TEMP 
(
0
C) 
BMI 
(Weight/Height
2 
) 
BLOD PRESSURE 
(Systolic/diastolic) 
mmHg 
HYDRATION 
STATUS 
(Normal) 
Audiometry 
summary 
15  
 
      16  
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2. Please indicate date AND intervention if any during the follow up period 
1 Developed hearing loss; date -- dd-mm-yyyy   
2 Drug adjustment recommended; date -- dd-mm-yyyy   
3 Dose adjustment recommended; date -- dd-mm-yyyy   
4 Hearing aids prescribed; date -- dd-mm-yyyy   
5 Hearing aids fitted; date -- dd-mm-yyyy   
6 Patient trained on sign language; date -- dd-mm-yyyy   
7 Patient’s family counseled on hearing loss; date -- dd-mm-
yyyy   
8 Patient’s family trained on sign language; date -- dd-mm-yyyy   
9 Other Intervention (Specify)……….. ………………………………..; date -
- dd-mm-yyyy   
 
3. For patients develop hearing loss, please indicate period on treatment and date of 
follow up 
 
Treatment  1 week 
-  
1 Treatment  2 weeks-
 
2 Treatment  3 weeks -
 
3 
Treatment  4 
weeks- 
4 Treatment  5 weeks-
 
5 Treatment  6 weeks-
 
6 
Treatment   7 
weeks- 
7 Treatment  8 weeks-
 
8 Treatment  9  weeks-
 
9 
Treatment  10 
weeks- 
10 Treatment  11 
weeks- 
11 Treatment  12 weeks-
 
12 
Treatment  13 
weeks- 
13 Treatment  14 
weeks- 
14 Treatment  15 weeks-
 
15 
Treatment  16 
weeks- 
16 Treatment  17 
weeks- 
17 Treatment  18 weeks-
 
18 
Treatment  19 
weeks- 
19 Treatment  20 
weeks- 
20 Treatment  21 weeks-
 
21 
Treatment  22 
weeks- 
22 Treatment  23 
weeks- 
23 Treatment  24 weeks-
 
24 
Treatment  25 
weeks- 
25 Treatment  26 
weeks- 
26 Treatment  27 weeks-
 
27 
Treatment  28 
weeks- 
28 Treatment  29 
weeks- 
29 Treatment  30 weeks-
 
30 
          
4. For patients who die while on treatment, please indicate date of exit from cohort (period 
on treatment at date of death) 
 
Treatment  1 week 
-  
1 Treatment  2 weeks-
 
2 Treatment  3 weeks - 3 
Treatment  4 
weeks- 
4 Treatment  5 weeks-
 
5 Treatment  6 weeks- 6 
Treatment   7 
weeks- 
7 Treatment  8 weeks-
 
8 Treatment  9  weeks- 9 
Treatment  10 1 Treatment  11 weeks- 1 Treatment  12 weeks- 1
 2 
 
weeks- 0  1  2 
Treatment  13 
weeks- 
1
3 
Treatment  14 weeks-
 
1
4 
Treatment  15 weeks-
 
1
5 
Treatment  16 
weeks- 
1
6 
Treatment  17 weeks-
 
1
7 
Treatment  18 weeks-
 
1
8 
Treatment  19 
weeks- 
1
9 
Treatment  20 weeks-
 
2
0 
Treatment  21 weeks-
 
2
1 
Treatment  22 
weeks- 
2
2 
Treatment  23 weeks-
 
2
3 
Treatment  24 weeks-
 
2
4 
Treatment  25 
weeks- 
2
5 
Treatment  26 weeks-
 
2
6 
Treatment  27 weeks-
 
2
7 
Treatment  28 
weeks- 
2
8 
Treatment  29 weeks-
 
2
9 
Treatment  30 weeks-
 
3
0 
          
5. For patients who are lost to follow up, please indicate date of exit from cohort (period 
on treatment at date of confirmed lost to follow up) 
 
Treatment  1 week 
-  
1 Treatment  2 weeks-
 
2 Treatment  3 weeks - 3 
Treatment  4 
weeks- 
4 Treatment  5 weeks-
 
5 Treatment  6 weeks- 6 
Treatment   7 
weeks- 
7 Treatment  8 weeks-
 
8 Treatment  9  weeks- 9 
Treatment  10 
weeks- 
1
0 
Treatment  11 weeks-
 
1
1 
Treatment  12 weeks-
 
1
2 
Treatment  13 
weeks- 
1
3 
Treatment  14 weeks-
 
1
4 
Treatment  15 weeks-
 
1
5 
Treatment  16 
weeks- 
1
6 
Treatment  17 weeks-
 
1
7 
Treatment  18 weeks-
 
1
8 
Treatment  19 
weeks- 
1
9 
Treatment  20 weeks-
 
2
0 
Treatment  21 weeks-
 
2
1 
Treatment  22 
weeks- 
2
2 
Treatment  23 weeks-
 
2
3 
Treatment  24 weeks-
 
2
4 
Treatment  25 
weeks- 
2
5 
Treatment  26 weeks-
 
2
6 
Treatment  27 weeks-
 
2
7 
Treatment  28 
weeks- 
2
8 
Treatment  29 weeks-
 
2
9 
Treatment  30 weeks-
 
3
0 
 
ALLOCATION OF FINAL HEARING ASSESSMENT OUTCOME 
 
6. Please indicate date AND final audiometric outcome at the end on follow 
up period (completion of intensive DR-Treatment/ injection phase or at 
loss to follow up or at death) 
Final Audiometric Outcome Grading Intervention (if any) Date of recording 
out come 
0  Patient did not develop 
Hearing loss 
 0 Normal Hearing  weeks of 
follow up 
 
  
1 Patient developed 1 Mild HL   
 3 
 
Hearing loss  weeks of follow up 
2 Mod HL 
 weeks of follow up 
 
3 Mod-Severe HL 
 weeks of follow up 
 
4 Severe HL 
 weeks of follow up 
 
5 Profound HL 
 weeks of follow up 
 
3 Patient was LOST to 
Follow up  before HL could 
be detected 
 0 Normal Hearing  weeks of 
follow up before lost to follow up 
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ANNEXURE B3 
 
 B3 THE PILOT STUDY CHECKLIST 
Dimension and Aspect tested 
Aspects tested for feasibility 
What is the anticipated number of patients that can be included in the study? 
How many of the potential patients satisfy the inclusion and exclusion criteria?  
Will the eligible respondents consent to receive monthly or two weekly audiometric 
follow up for 8 months of treatment on injectable antibiotics because some patients 
prefer to receive injections at home or at a clinic closest to them rather than the 
hospital? 
Why may some respondents not want to take part or what are the reasons for drop out? 
Are all medical files or information from other data sources retrievable? 
Can all measurements be easily implemented and are they not too bothersome for the 
research respondents? 
Is it possible to the implement the intervention and/or study in a setting that did not 
have audiology services before and there were no dedicated staff for audiology 
services beyond the outreach services? 
How much time does the measurement of hearing status procedure take, and how 
many patients can be assessed per day? 
Aspects tested for methodological quality that were piloted 
Are the measurement instruments valid? 
Are the measurements reproducible: Are the research assistants performing the 
measurements in exactly the same way? 
Was exposure (to HIV) being properly measured? 
Aspects related to data management that were tested 
How much support does the data collector need to accurately document the study 
related data? It is important during the data collection phase that the data continue to 
be collected accurately and in a standardised fashion. 
Were the multiple measurements and calibration immediately verified, consistent?  
Were multiple testing (test-retest by the same and/or different data collectors) and, 
calibration consistent? 
Were questionnaires completed consistently and were there difficult questions that 
need to be modified? 
Did the analysis of pilot data necessitate modifications to the test protocol, 
modifications in the number of respondents to be tested per day, or modifications in 
patient flow? 
Are the systems sufficient for managing longitudinal files? 
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ANNEXURE C 
CONSENT FORM TO PARTICIPATE IN RESEARCH STUDY 
University of South Africa 
Respondent’s Number……………..   Date……………………………….. 
 Office Use 
 
Dear participant, you are being asked to participate in a research study. Below her are the 
details about the research study. 
 
1. Title of Research:  BEST PRACTICE GUIDELINES TO MONITOR AND PREVENT HEARING 
IMPAIRMENT AMONG PATIENTS RECEIVING DR-TB TREATMENT IN SWAZILAND 
 
2. Investigator's Name: Dr. Samson Haumba,  
 
3. Research Entity: University of South Africa 
 
4. Consenting for the Research Study:  
This is an important document. If you sign it, you will be authorizing the University South 
Africa and its researchers involve you as a respondent for a research study. You should take 
your time and carefully read it. 
 
5. YOUR RIGHT TO PRIVACY AND CONFIDENTIALITY: 
Very specific information on your right to privacy and the confidentiality of the use and 
disclosure of your personal health information can be found at the end of this consent form. 
We need your authorisation to use and disclose the health information that we may collect 
about you during this research study. To be in this research study you must read and sign the 
authorisation of this consent form. 
 
6. PURPOSE OF RESEARCH: 
The purpose of this study is to determine incidence ratio and risk factors for MDR-TB 
treatment hearing loss; establish duration from treatment initiation to hearing loss; develop 
a local evidence base for development of best practice guidelines for monitoring hearing and 
prevention of MDR-TB treatment related hearing loss; and guide local policy for integrating 
hearing loss monitoring and prevention as integral part of the overall MDR-TB treatment 
strategy. You are being asked to participate in this study because you are on anti TB 
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medication. This research project is being conducted in partial fulfillment of the 
requirements for the degree of Doctor of Literature and Philosophy and you have been 
asked to take part in this study because you meet criteria for participation in this study.  
 
7. PROCEDURES:  
 
If you agree to take part in this study: 
You will be asked to complete a set of questions that we ask about your health. This study is 
limited to completing these self-report questions, conducting a hearing measurement using 
an audiometer and taking all the relevant medical tests normally requested in management 
of TB or MDR-TB. All questionnaires will be destroyed after the completion of this study. 
 
8. RISKS AND DISCOMFORTS/CONSTRAINTS: 
Significant psychological or social risks are not anticipated to occur to you. You may 
experience slight discomfort such as embarrassment, mild fatigue, anxiety, or frustration 
while completing the items in the questionnaires. You may skip any questions that you do 
not wish to answer. The questions have been selected and arranged in a manner that will 
help complete them relatively quickly. If for any reason you decide that you do not want to 
participate in the study, you may withdraw from the study at any time.  
 
9.  UNFORSEEN RISKS: 
Participation in this study may involve unforeseen risks. The study investigators do not 
anticipate any unforeseen risks to you in taking part in this study. If any unforeseen risks are 
noted, the Office of Secretary of the Scientific and Ethics committee in the Ministry of Health 
will be notified.  
 
10. BENEFITS: 
For some respondents, completing these questionnaires might provide an opportunity to 
think about their overall well-being in a more meaningful manner. For others, there may be 
no direct benefits from participating in this study. It is anticipated that frequent monitoring 
of your hearing status during the study is a good and recommended practice for all patients 
on injectable drugs used in the treatment of multi drug resistant TB and may be beneficial to 
you. It is also anticipated that the results from this study will be used for the common public 
health good of all patients. 
 
11. ALTERNATIVE PROCEDURES/TREATMENT: 
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No alternative treatment is provided through this study. Only the treatment that will be 
prescribed by the doctors managing your condition will be provided to you. The alternative is 
not to participate in the study. 
 
12. REASONS FOR REMOVAL FROM STUDY: 
You may be required to stop the study before the end for any of the following reasons: 
a) Change in medical condition; 
b) If all or part of the study is discontinued for any reason by the sponsor, investigator, 
university authorities, or government agencies; or 
c) Other reasons, including new information available to the investigator or harmful 
unforeseen reactions experienced by the subject or other respondents in this study. 
 
13. VOLUNTARY PARTICIPATION: 
You understand that being in this study is voluntary. Your health care will not be affected in 
any way if you decline to be in or later withdraw from the study. Please contact Dr. Samson 
Haumba at telephone number (268) 7602-6400 if you have questions related to the study. 
 
14. IN CASE OF INJURY: 
If you have any questions or believe you have been injured in any way by being in this 
research study, you should contact Dr. Samson Haumba. However, neither the investigator 
nor University of South Africa will make payment for injury, illness, or other loss resulting 
from your being in this research project. If you are injured by this research activity, medical 
care including hospitalisation is available, but may result in costs to you or your insurance 
company because the University does not agree to pay for such costs.  
 
15. CONFIDENTIALITY AND PRIVACY: 
This section gives more specific information about the privacy and confidentiality of your 
health information. It explains what health information about you will be collected during 
this research study and who may use, give out and receive your health information. It also 
describes your right to inspect your medical records and how you can revoke this 
authorisation after you sign it. By signing this form, you agree that your health information 
may be used and disclosed during this research study. We will only collect information that is 
needed for the research study. Your health information will only be used and given out as 
explained in this consent form or as permitted by law. In any publication or presentation of 
research results, your identity will be kept confidential. 
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A. Health Information that will be collected: The following personal health information 
about you will be collected and used during the research study and may be given to others:  
Information about number of your status in decibel hearing, results of blood tests for liver 
function, renal function and blood sugar. 
B. Who will see and use your health information: The research study investigator and 
other authorised individuals involved in the research study will see your health information 
and may give out your health information during the research study. The authorised persons 
include the research investigator and the research staff and medical staff managing your 
condition. The institutional review board and their staff, and other people who need to see 
the information in order to conduct the research study or make sure it is being done 
properly might also see your information. 
C. Why your health information will be used and given out: Your health information will 
be used by the research investigator and other authorised individuals involved in the 
research study to evaluate the results of the study and to the medical staff managing your 
condition to manage your better. Your information may also be used to meet the reporting 
requirements of governmental agencies. 
D. If you do not want to give authorisation to use your health information: You do not 
have to give your authorisation to use or give out your health information. However, if you 
do not give authorisation, you cannot participate in this research study. 
E. How to cancel your authorisation: At any time you may cancel your authorisation to 
allow your health information to be used or given out by sending a written notice.  If you 
leave this research study, no new health information about you will be gathered after you 
leave. However, information gathered before that date may be used or given out if it is 
needed for the research study or any follow-up. 
F. When your authorisation ends: Your authorisation to use and give out your health 
information will end when the research study is finished. After the research study is finished, 
your health information will be maintained in a research database. The researcher shall not 
re-use or re-disclose the health information in this database for other purposes unless you 
give written authorisation to do so. However, Ministry of Health Scientific and Ethics 
committee and Institutional Review Board may permit other researchers to see and use your 
health information under adequate privacy safeguards. 
G. Your right to inspect your medical and research records: You have the right to look at 
your medical records at any time during this research study. However, the investigator does 
not have to release research information to you if it is not part of your medical record.  
 
16. CONSENT: 
• I have been informed of the reasons for this study. 
• I have had the study explained to me. 
• I have had all of my questions answered. 
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• I have carefully read this consent form, and have received a signed copy. 
• I authorise the use and disclosure of my personal health information as explained in this 
consent form. 
• I give my consent voluntarily. 
 
Subject or Legally Authorised Representative……………………………. Date……………. 
 
Investigator or Individual Obtaining this Consent……………………….. Date…………… 
 
 
Witness to Signature…………………………… Date………………………………….. 
 
 
Thank you, very much 
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ANNEXURE D: Supporting documents for guidelines development and 
dissemination. 
  
D1: invitation to participate in the validation of guidelines for monitoring and 
prevention of hearing loss related to MDR-TB treatment in Swaziland 
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Dissemination of the draft guidelines for monitoring and prevention 
of Drug induced Hearing loss among MDR TB patients 
Date: 22nd of April 2015 Time: 7:30 am – 9:30 am Venue: Royal Swazi Spa 
Programme Director: Dr Simetlane (Acting SMO, National TB Hopsital) 
Agenda 
 
 
Time Item Responsible 
7:20 – 
7:30 
Arrival and Registration 
 
Sikhumbuzo Simelane, 
Hellen Makhanya 
7:30 – 
7:35 
Opening Prayer  Sixolelwe Hlatshwayo 
7:35 – 
7:45  
Welcome remarks and Introductions Programme Director 
7:45 – 
7:55 
Introductory Remarks Programme Manager, 
NTCP 
7:55 – 
8:15 
Opening Remarks Director of Health Services, 
MOH 
8:15 – 
8:25 
Burden of Hearing Disability and services in 
Swaziland 
Eunice Haumba/ Nomsa 
Mabaso 
8:25 – 
8:45 
Presentation of Study findings: Incidence of drug 
induced Hearing Impairment in patients 
receiving MDR-TB treatment in Swaziland 
Samson Haumba/ Dr 
Simetlane 
8:45 – 
9:15 
Presentation of draft guidelines for monitoring 
and prevention of drug induced hearing loss 
 
Nomcebo Fakudze /Arnold 
Mafukidze 
9:15 – 
9:30 
Discussion and recommendations 
 
Deputy Director of Health 
Services, MOH  
 
